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Four different methods; molecular electrostatic potentials (MEPs), hydrogen-bond energies 
(HBE), hydrogen-bond propensities (HBP) and hydrogen-bond coordination (HBC) were used for 
mapping out the structural landscape of twelve pyrazole and twelve thiazole based molecules. In 
seven out of eight crystal structures obtained in pyrazoles, a combination of HBE and HBP 
predicted the experimentally observed synthons correctly. In all eight crystal structures obtained 
in thiazoles, the synthons were predicted correctly using all four methods.  
 
A series of co-crystallizations between twelve pyrazole with twenty carboxylic acids (240 
experiments), and twelve thiazole with twenty carboxylic acids (240 experiments) were carried 
out to build an experimental library that could be used for evaluating the ability of electrostatics, 
energies, propensities and molecular complementarity methods to rationalize the observed 
intermolecular interactions. The results suggested that a combination of electrostatics and 
molecular complementarity are essential for identifying the predominant molecular recognition 
events in the pyrazole based study, and methods such as MEPs, HBE, and HBP all predicted the 
observed synthons in co-crystals of the thiazole-based molecules. 
 
In order to examine competition between hydrogen and halogen bonds, and to synthesize ternary 
co-crystals, four thiazole based molecules were co-crystallized with 15 hydrogen-bond donors and 
one halogen bond donor resulting in new co-crystals in 44 out of 60 experiments, and the crystal 
structures of two ternary co-crystals were obtained.  
 
A series of eight unactivated and activated amide functionalized molecules were synthesized to 
establish a supramolecular halogen-bond hierarchy.  The positive electrostatic potential on the 
halogen atoms was enhanced through an sp-hybridized carbon and electron-withdrawing fluoro 
group(s) next to amide group. Tetraflourinated and iodoethynyl based molecules were identified 




In order to predict crystallizability of 83 drug-like molecules a molecule, logistic regression 
approach was employed using molecular descriptors such as molecular weight, rotatable bond, 
surface area, heteroatom, melting temperature, glass transition temperature, and molecular 
shape/volume. Four different models were developed, and the success rate was above 85% (using 
experimental DSC data for the crystallization classification). 
  
Finally, the solid-form landscape of urea was explored using full interaction maps (FIMs), and 
data from the CSD to develop optimum protocols for synthesizing co-crystals of this compound.  
As a result, 49 of 60 attempted reactions produced new co-crystals.  Moreover, the goal of reducing 
solubility and lowering hygroscopicity of the parent compound was achieved, which, in turn, offers 
new opportunities for a slow-release fertilizer with limited hygroscopicity thereby reducing many 
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Four different methods; molecular electrostatic potentials (MEPs), hydrogen-bond energies 
(HBE), hydrogen-bond propensities (HBP) and hydrogen-bond coordination (HBC) were used for 
mapping out the structural landscape of twelve pyrazole and twelve thiazole based molecules. In 
seven out of eight crystal structures obtained in pyrazoles, a combination of HBE and HBP 
predicted the experimentally observed synthons correctly. In all eight crystal structures obtained 
in thiazoles, the synthons were predicted correctly using all four methods.  
 
A series of co-crystallizations between twelve pyrazole with twenty carboxylic acids (240 
experiments), and twelve thiazole with twenty carboxylic acids (240 experiments) were carried 
out to build an experimental library that could be used for evaluating the ability of electrostatics, 
energies, propensities and molecular complementarity methods to rationalize the observed 
intermolecular interactions. The results suggested that a combination of electrostatics and 
molecular complementarity are essential for identifying the predominant molecular recognition 
events in the pyrazole based study, and methods such as MEPs, HBE, and HBP all predicted the 
observed synthons in co-crystals of the thiazole-based molecules. 
 
In order to examine competition between hydrogen and halogen bonds, and to synthesize ternary 
co-crystals, four thiazole based molecules were co-crystallized with 15 hydrogen-bond donors and 
one halogen bond donor resulting in new co-crystals in 44 out of 60 experiments, and the crystal 
structures of two ternary co-crystals were obtained.  
 
A series of eight unactivated and activated amide functionalized molecules were synthesized to 
establish a supramolecular halogen-bond hierarchy.  The positive electrostatic potential on the 
halogen atoms was enhanced through an sp-hybridized carbon and electron-withdrawing fluoro 
group(s) next to amide group. Tetraflourinated and iodoethynyl based molecules were identified 




In order to predict crystallizability of 83 drug-like molecules a molecule, logistic regression 
approach was employed using molecular descriptors such as molecular weight, rotatable bond, 
surface area, heteroatom, melting temperature, glass transition temperature, and molecular 
shape/volume. Four different models were developed, and the success rate was above 85% (using 
experimental DSC data for the crystallization classification). 
  
Finally, the solid-form landscape of urea was explored using full interaction maps (FIMs), and 
data from the CSD to develop optimum protocols for synthesizing co-crystals of this compound.  
As a result, 49 of 60 attempted reactions produced new co-crystals.  Moreover, the goal of reducing 
solubility and lowering hygroscopicity of the parent compound was achieved, which, in turn, offers 
new opportunities for a slow-release fertilizer with limited hygroscopicity thereby reducing many 
current problems of transport, handling, and storage of urea. 
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Glossary of terms 
• Hydrogen-bond propensity: A model to predict which donors and acceptors form hydrogen 
bonds in a crystal structure, based on the statistical analysis of hydrogen bonds in the 
Cambridge Structural Database (CSD). 
• Hydrogen-bond coordination: A model indicating how many hydrogen-bond interactions a 
donor and acceptor can have.  
• Hydrogen-bond energies: A term to calculate the interaction energies between a donor and 
acceptor.  
• Molecular electrostatic potentials: The molecular electrostatic potential (MEP) at a given 
point p(x,y,z) in the vicinity of a molecule is the force acting on a positive test charge (a proton) 
located at p through the electrical charge cloud generated through the molecules electrons and 
nuclei. 
• Synthon polymorphism: Synthon polymorphism in a molecule occurs when the primary 
synthons in the forms are different.  
• Logistic regression model: It is a statistical model that is usually taken to apply to a binary 
dependent variable.  It is used to estimate the probability of a binary response based on one or 
more predictor (or independent) variables (features).  
• Full interaction maps: The tool calculates regions around the molecule (maps) where 
chemical probe groups are likely to be found, based on pre-extracted Isostar interaction data 
from the CSD. The calculation procedure first identifies distinct functional groups in the 
molecules viewed, and then finds relevant interaction data in IsoStar. Next it pulls together the 
group-based interaction data and takes into account the environmental effects of combinative 




I would like to express my deepest gratitude to my advisor and mentor, Professor Christer Aakeröy 
for his tremendous support, patience and encouragement throughout my five years of Ph.D. at K-
State. His continuous motivation, selfless attention helped me to become a better presenter, public 
speaker, writer, and overall a better scientist. I am so thankful to you for giving me an opportunity 
to work with you and making me a strong, and confident individual.  
 
I would also like to thank my Ph.D. advisory committee; Professor Ryan Rafferty, Professor 
Tendai Gadzikwa, Professor Jennifer Anthony and Professor Vinod Kumarappan for their 
invaluable time and encouragement.   
 
I would also like to extend special thank you to Professor Eric Maatta for serving on my committee 
for three years and providing invaluable support and encouragement.  
 
I am very grateful to Dr. John Desper, Dr. Marijana Đaković and Dr. Abhijeet Sinha for solving 
all the crystal structures mentioned in this thesis and for always being very patient and helpful. A 
special thank you to Dr. Abhijeet Sinha for being such a great friend and always supportive and 
willing to help even when you were busy.  
 
I also want to acknowledge Dr. Yasmin Patell (for being very supportive and caring friend), Dr. 
Leila Maurmann (for helping me with NMR), Mr. Ron Jackson (for fixing broken instruments and 
talks), Mr. Tobe Eggers (for fixing broke instruments), Mr. Michael Hinton (for teaching me lab 
skills), Mr. Jim Hodgson (for fixing broken glassware), Ms. Mary Dooley, Ms. Kimberly Ross and 
Ms. Lisa Percival for making my research life smooth at K-State.  
 
A special thank you to my collaborators; Dr. Amy A. Sarjeant and Dr. Shyam Vyas, Dr. Jonas 
Nyman and Dr. Susan M. Reutzel-Edens. Thank you for your inputs, discussions and always 




I want to acknowledge Department of Chemistry at Kansas State University, ICL Innovation at 
Israel, Cambridge crystallographic database center (CCDC) and Eli Lilly and company for 
providing funding throughout my Ph.D.  
 
I would also like to thank Phi Lambda Upsilon (PLU), Graduate student council (GSC), and Indian 
Student association (ISA) for giving me an opportunity to serve the K-State community.  
 
A very special thank you to all the present and past Aakerӧy group members for always being 
there for me and I will always remember our wonderful memories for rest of my life. A special 
thank you to Dr. Tharanga Wijethunga for being very patient and helpful mentor, Dr. Sheelu 
Panikattu for helping me settle in K-State, Chamara, Janaka and Stefan for great classmates and 
labmates. Thank you to my two best friends in the Chemistry Department; Nandini and Ayyappan 
for always having my back, making me laugh and always there for me when I was down.  
 
My heartful gratitude to my parents for believing in me from day one and giving me this 
opportunity to study abroad. Your immense support, sacrifices and understanding has helped me 
overcome any obstacle in life and made me a better person. Thank you to my loving brothers and 
entire Sandhu family for showering your love and support from miles away. You are my strength 
and I wouldn’t have been able to finish my studies without your constant love.  
 
Lastly, I want to thank Rickey for loving and believing in me. Thank you Ravi, Veeru, Tayebeh 





To my Grandfather, parents and brother! 






Research carried out at Kansas State University for this dissertation led to the following 
publications in scientific journals:  
1. Sandhu B., Sinha A., Desper J., Aakeroy C., “Modulating physical properties of solid forms 
of urea using co-crystallization technology” Chem. Commun., 2018, Advance Article. 
2. Sandhu B., McLean A., Sinha A., Desper J., Sarjeant A., Vyas S., Reutzel-Edens S., Aakeroy 
C., “Evaluating competing intermolecular interactions through molecular electrostatic 





Chapter 1 - Introduction  
1.1 Crystal structure-property relationship 
“Structure Determines Properties”1 is a powerful concept in chemistry and plays an important role 
in all fields including environmental science, biology, biochemistry, polymer science, medicine, 
engineering, and nutrition.2 Crystallization performed under different conditions can yield crystals 
of different sizes and morphologies, thus providing a way of modifying particles to desired 
specifications. The structure of a compound including form, size, shape, conformation, functional 
groups, intermolecular interactions have the potential to impact the purification, solubility, 
chemical and physical stability, melting point, particle size and mechanical properties of a 
molecule of interest (Figure 1.1). The desired properties in a compound can be achieved via two 
ways: covalent modification to design and synthesize molecule with desired properties (covalent 
synthesis) or supramolecular synthesis via non-covalent interactions.  
 
Figure 1.1 Correlation of the melting points with the dicarboxylic acid chain length3 
 
 
1.2 Covalent chemistry vs supramolecular chemistry 
Covalent chemistry involves breakage or formation of a covalent bond to perform multi-step 
reactions, and to isolate intermediates and products with desired yield. Organic synthesis can be 
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studied over the years by organic chemists to better understand the structure, reactivity and reaction 
pathways (Scheme 1.1).4  
 
Scheme 1.1 Covalent vs supramolecular synthesis.  
 
Supramolecular synthesis on other hand is based on non-covalent interactions and is largely 
unexplored, compared to organic covalent synthesis. Supramolecular chemistry is defined as “the 
chemistry of molecular assemblies and of the intermolecular bond,” by Jean-Marie Lehn, who won 
the Nobel Prize in 1987 for his outstanding contributions to the field.5 It can be achieved by the 
use of reversible intermolecular interactions such as hydrogen-bonds, halogen-bonds, vander 
waals and π-π interaction. The strength of each interaction is given in Table 1.1.  
 
Table 1.1 Estimated strength of intermolecular interactions 
Types of interaction Strength 
(Kj/mol) 
Covalent  100-4400 
Hydrogen bond  10-70 
Halogen bond  5-180 
ᴨ- ᴨ 0-50 
Vander Waals  <5 
 
1.3 Supramolecular synthons 
 The design of organic crystals relies on the concept of Supramolecular synthons,6-7 a structural 
unit within a supermolecule which can be formed and/or assembled by known or conceivable 
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synthetic operations involving intermolecular interactions.6 These synthons defines the structure 
of a molecule.  However, robustness of these synthons is an issue because of weak, labile and 
deforming nature of non-covalent interactions. If a well-defined strategy is developed to generate 
robust synthons, then the protocol can be carried over from one molecule to another with 
generality. Supramolecular synthons are divided into two types; homomeric synthons (occurs 
within the individual molecules) are achieved by re-crystallization of individual molecules and 
heteromeric synthons (occurs between two different molecules) are achieved by co-crystallization 
of two or more molecules (Scheme 1.2).8-9  
 
Scheme 1.2 Supramolecular synthons  
 
1.4 Co-crystals 
The definition of a co-crystal is still under debate. Thus, for the scope of this dissertation, a co-
crystal will be defined as, solids that are crystalline single-phase materials composed of two or 
more different molecular compounds generally in a stoichiometric ratio.10-11 A co-crystallization is 
a deliberate attempt at bringing together different molecular species within one periodic crystalline 
lattice without making or breaking covalent bonds via heteromeric interactions.12  It is different from 
naturally occurring phenomenon called recrystallization in which homomeric interactions 
dominate in the crystal lattice (Scheme 1.2). The ability of a molecule to form a co-crystal depends 
on various factors, including the types of co-former, the stoichiometric ratio, the solvents, the 
temperature, the pressure, the crystallization technique, etc. Co-crystals have different crystal 
structures than the pure components, contain different intermolecular packing patterns, and as such 




Figure 1.2 Summary of synthetic method, supramolecular interactions and characterization 
method used to study co-crystals in this thesis.  
  
Co-crystal synthesis can be performed via several methods, including slow solvent evaporation, 
slurrying, liquid assisted grinding, melt (hot stage microscopy), solution crystallization and co-
sublimation techniques.13-16 Among these methods, liquid assisted grinding has been reported to 
be a cost-effective, green, and reliable method for discovery of new co-crystals as well as for 
preparation of existing co-crystals.17 The components in a co-crystal exist in a definite 
stoichiometric ratio, and assemble via non-covalent interactions such as  π-π stacking 
interactions,18 dipole-dipole interactions,19 halogen bonds,20 and hydrogen bonds.21 For this 
dissertation, only halogen and hydrogen bonds will be covered. The structure characterization of 
co-crystals can be done using infra-red spectroscopy, single crystal x-ray crystallography and 
powder x-ray diffraction and the physical properties using melting point apparatus, differential 




1.4.1 Hydrogen bonding 
A hydrogen bond (HB) is defined as “an attractive interaction between a hydrogen atom from a 
molecule or a molecular fragment, R−H⋯A in which R is more electronegative than H, and an 
atom or a group of atoms in the same or different molecule, in which there is evidence of  
bond formation”,25 Figure 1.3.  
 
Figure 1.3 A schematic of hydrogen-bonding  
 
Hydrogen-bonds represent one of the most studied intermolecular interactions in supramolecular 
synthesis, due to the strength and directionality of such interactions, when compared to many other 
intermolecular interactions. They are the basis of molecular recognition and are responsible for the 
generation of families of molecular networks with the same molecular components (single 
component crystals and their polymorphs) or with different molecular components (multiple 
component crystals or co-crystals) in the crystalline state (Figure 1.4).26   
 
Figure 1.4 An example of hydrogen-bonding in co-crystals 27  
 
An important milestone to determine the supramolecular synthons is the hydrogen-bond rules was 
proposed by Margaret C. Etter in 1991.28   
(1) All good acidic donors and acceptors in a molecule will be used in hydrogen bonding. 
(2) Six-membered intramolecular hydrogen bonds are preferred over intermolecular hydrogen-
bonds.  
(3) The best acidic donors and acceptors remaining after intramolecular hydrogen-bond will form 




1.4.2 Halogen bonding 
The definition of halogen bond (XB) states that, “A halogen bond R−X⋯A−Z occurs when there 
is evidence of a net attractive interaction between an electrophilic region on a halogen atom X 
belonging to a molecule or a molecular fragment R–X (where R can be another atom, including 
X, or a group of atoms) and a nucleophilic region of a molecule, or molecular fragment, A−Z”,29 
Figure 1.5.  
 
 Figure 1.5 A schematic of halogen-bonding  
 
Halogen bonding is a non-covalent interaction, electrostatic and directional in nature. It is 
comparable in strength to hydrogen-bonds (~5-180 kJ/mol) and has gained increasing importance 
in crystal engineering because of its strength and effectiveness as a structure-directing force. The 
strength of the interaction increases in going from chlorine to bromine to iodine depending on the 
polarizability of the halogen atom. An interesting feature of the halogen-bond is that the strength 
of this interaction can be effectively increased by “activating” the halogen atom (also called 
positive “σ-hole” activation) with electron withdrawing substituents (Figure 1.6). Literature has 
shown that by introducing an sp-hybridized carbon next to the halogen atom1 or by incorporating 
a fluorinated backbone2 next to the halogen atom, the molecular electrostatic potential that 







Figure 1.6 (a) Sigma hole on the halogen-bond donor (b) Activation of halogen-bond donors by 
fluorinating or introducing an sp-hybridized carbon.  
 
Figure 1.7 A halogen bond formed between 2,3,5,6-Tetramethylpyrazine and 1,4-bis(iodo)-
2,3,5,6-tetrafluorobenzene.32  
1.4.3 Applications of co-crystals  
Co-crystals have been used to develop new anticancer,33 antifungal,34 antiviral,35 
anticonvulsant,36 37 and antidepressant38 drugs with enhanced aqueous solubility.  The same type 
of technology has also been explored for improving energetic materials,39 enhancing 
agrochemicals and for stabilizing volatile chemicals.40   
 
1.4.3.1 Pharmaceutical co-crystals 
 
Co-crystals have been widely used in pharmaceutical industry to improve solubility, dissolution 
rates, stability and bioavailability. Several well-known commercial compounds have been targeted 
in cocrystal synthesis such as gabapentine,36 aspirin, norfloxacin,41 stanolone,37 caffeine, 
saccharine, efavirenz,42 and many others. An example of Figure 1.8 shows an increase in solubility 






Figure 1.8 Solubility profile of co-crystals of theophylline43  
 
1.4.3.2 Agrochemicals co-crystals 
The term ―agrochemical refers to a collection of chemicals (pesticides) such as fungicides, 
herbicides and insecticides or acaricides Agrochemicals are used to protect crops from pests and 
thus help improve the quality and quantity of crop production.  Two common agrochemicals; 
cyprodinil and terbuthylazine showed the potential to form co-crystals with a series of diacids. The 
co-crystals displayed melting points different from the parent active. In cyprodinil co-crystals, the 
solubility of the active could be altered using co-crystallization and a very good correlation 




Figure 1.9 (a) chemical structure of cyprodinil and (b) solubility profile of co-crystals of 
cyprodinil44 
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An energetic material is a reactive substance that releases great amount of potential energy upon 
explosion, also accompanied by the production of light, heat, sound, and pressure.45 Energetic 
materials include explosives, propellants and pyrotechnics.  Co-crystallization is proving to be a 
powerful tool for creating less-sensitive explosives, as well as modifying and optimizing other 
properties of energetic materials.39 While traditional strategies for energetic materials development 
have relied on the synthesis of novel energetic compounds and the optimization of their 
(polymorphic) solid forms, co-crystallization presents an elegant means to improve the 
performance of energetic materials without requiring new chemical synthesis.46 Few examples of 
energetic co-crystals includes HMX, CL-20, DADP where properties such as sensitivity, density, 
detonation velocity, and oxygen balance are altered (Figure 1.10). 
 
 
Figure 1.10 Detonation velocity and impact sensitivity of energetic-energetic co-crystal47 
 
1.4.4 Co-crystal prediction 
Co-crystal prediction has been reported to include the following steps: (1) determining whether a 
given set of two or more molecular components will undergo co-crystallization; (2) identifying the 
primary intermolecular interactions, or supramolecular synthons that will exist within a particular 
co-crystal structure. Both predictions are important form application stand point as co-crystals of 
APIs, agrochemicals, nutraceuticals and explosives represent a class of multi-component 
crystalline forms that are of interest for their advantageous physical properties and for intellectual 
property implications. The ability to predict a priori which compounds are likely to form co-
crystals with a given API would provide a complementary tool to experimental screening and 
ability to predict the primary intermolecular interactions in the co-crystal will prevent synthon 
crossover and synthon polymorphism. 
1.4.4.1 Current co-crystal screening prediction methods 
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Various approaches have been proposed in literature to elucidate the co-crystal screening outcome.  
Fabian employed molecular shape and polarity as benchmarks for predicting the formation of co-
crystals.48-49  Price and co-workers focused on lattice energy comparisons of co-crystals and pure 
components as a basis for predicting co-crystal formation,50 and Velaga suggested that drugs and 
co-formers with similar Hanson solubility parameters are likely to form co-crystals with each 
other.51  Jones and co-workers employed hydrogen-bond propensities as a way of quantifying 
homomeric and heteromeric interactions.52-54 Hunter et al. and Aakeroy et al. used a combination 
of experimentally derived parameters and electrostatic potential surfaces to predict co-crystal 
screen and supramolecular synthons in the solid as well as solution phase.55-59    Galek et al. 
demonstrated that hydrogen-bond propensity calculations,60-61  which rely on a statistical analysis 
of the occurrence of hydrogen bonds in relevant structures present in the Cambridge Structural 
Database,48, 62 could be used for predicting the outcome of co-crystallizations of the drug 
lamotrigine.63-64 Validation studies performed so far indicate that a combination of methods is 
valuable when performing a knowledge based co-former screen.65 
 
1.4.4.2 Current co-crystal synthon prediction methods 
Co-crystal design is aided by the use of statistical tools such as knowledge-based hydrogen-bond 
propensity calculations52-53 and computational methods such as molecular 
complementarity, 49ΔpKa calculations
66 and molecular electrostatic potential surfaces MEPS.58-59 
Despite the availability of such tools, and despite our evolving understanding of how molecules interact 
in the solid state, it still remains impossible to empirically and statistically predict the arrangement of 
individual or multiple molecules in a crystal lattice.67-68 Likewise, it is extremely difficult to empirically 
predict the formation of supramolecular synthons in cocrystals composed of molecules containing a 
broad range of functional groups.69  
In order to facilitate the design of cocrystals containing such complex entities, it will be necessary to 
considerably deepen our understanding of self-assembly processes in the solid state.70 The prediction 
method knowledge will then be applied to large, flexible drug like molecules to solve an important issue 




Crystallization is the physical transformation (phase transition) of a liquid, solution, or gas to a 
crystal, a solid with an ordered internal arrangement of molecules, ions, or atoms.71 It is different 
from amorphous materials, a solid that lacks the long-range order that is characteristic of a crystal 
(Figure 1.11).72  The generation of the first crystalline seed from which a molecule can be 
crystallized is one of the most important, and sometimes most difficult, tasks in drug development. 
Crystallization is critical in that it provides a path forward for product isolation from the final step 
of the synthetic process, as well as sets the physical properties underpinning drug substance 
performance in the drug product. The crystallization process consists of two major 
events, nucleation and crystal growth which are driven by thermodynamic properties as well as 
kinetics.73 
 
Figure 1.11 Properties of crystalline vs amorphous materials.74   
 
Crystal nucleation is the step where the solute molecules or atoms dispersed in the solvent forms 
stable clusters on the microscopic scale under the current operating conditions.75 These stable 
clusters then reaches a critical size to become a stable nuclei.76 The critical size is dictated by many 
experimental and environmental factors (temperature, pressure, solvent, supersaturation, etc.). It 
is at the stage of nucleation that the atoms or molecules arrange in a defined and periodic manner 




Figure 1.12 Schematics of crystal nucleation and crystal growth.79  
 
The crystal growth is the subsequent size increase of the nuclei that has achieved the critical cluster 
size (Figure 1.12).76 It is a dynamic process occurring in equilibrium where solute molecules or 
atoms precipitate out of solution, and dissolve back into solution. Supersaturation is one of the 
driving forces of crystallization, as the solubility of a species is an equilibrium process quantified 
by Ksp. Depending upon the conditions, either nucleation or growth may be predominant over the 
other, dictating crystal size.  
1.5.1 Why is prediction of crystallizability important? 
Predicting the crystallization propensity of drug-like molecules is one of the biggest challenges 
facing pharmaceutical scientists today. Specifically, understanding which molecules in a series of 
similar compounds will be the most difficult to crystallize would be extremely useful, as would 
any indication of the experimental conditions (such as temperature, solvent polarity, molar 
concentration, etc.) that might make crystallization take place more readily. There is also great 
interest in minimizing research and development costs, which are estimated to be about $1 billion 
per drug launch, taking about 6–10 years for drug development and only 10% of the compounds 
in development survive the efficacy and safety hurdles and become marketed drugs (Figure 1.13).80 
Therefore, predictions can save time, money and experimental efforts in both academic and 





Figure 1.13 Timeline of drug development process from synthesis to market stage81  
 
Different approaches have been taken in recent years to model and predict crystallization 
propensity. Machine learning approaches, statistical (random forest) modelling, DSC based 
heat/cool/heat methods have been employed to model and predict crystallizability in terms of 
giving single crystals suitable for X-ray diffraction.82 These varied approaches may not give a 
consistent picture of crystallizability, as the difficulty in nucleation does not necessarily correlate 
to slow crystal growth rates or poor crystal quality.83 More importantly, these approaches do not 
provide a path forward to overcome inherently poor crystallizability, i.e., crystallizing a molecule 
for the first time. Based on the information from various studies, it is concluded that combination 
of descriptors play an important role on the crystallization outcome. The following descriptors 
were considered important based on literature sources (Table 1.2).  
 
Table 1.2 Important descriptors and literature sources 
Important descriptors References 
Number of rotatable bond Florescence et. al,82 cooper et. al 84 
Molecular size Cooper et. al 84 
Molecular weight Taylor et. al 85 
Viscosity Taylor et. al 85 
Thermodynamics parameters Fischer et. al 86 
# of H-bond donors Fischer et. al 86 




1.6 Goals of the dissertation 
Discovering the right solid form with optimal chemical/physical properties is of paramount 
importance in academic and industry research. This thesis will focus on the validating the 
prediction methods such as hydrogen-bond propensity (HBP), molecular electrostatic potentials 
(MEPs), hydrogen-bond energies (HBE), and hydrogen-bond coordination (HBC) for 
supramolecular synthon predictions in the target molecules and co-crystals. The second goal of the 
thesis will be to predict co-crystal screening of a library of small rigid molecules using combination 
of prediction methods. This knowledge will then be transferred to predict the crystallizability of 
large, flexible drug-like molecules.   The basic concepts will then be used to alter bulk properties 
of functional materials in a desirable manner.  
This dissertation will focus on following goals; 
• Chapter 2 will focus on predicting the homomeric synthons in the twelve pyrazole molecules 
using four prediction methods: MEPs, HBE, HBP and HBC.   
• Chapter 3 will focus on comparing the prediction (using HBE and HBP) vs experimental (using 
FTIR) co-crystal screening results of twelve pyrazole molecules with 20 carboxylic acids. The 
second part of chapter will focus on the predicting the supramolecular synthons in the co-
crystals using MEPs, HBE, and HBP methods.  
• Chapter 4 will focus on predicting the homomeric synthons in the twelve thiazole molecules 
using four prediction methods: MEPs, HBE, HBP and HBC.   
• Chapter 5 will focus on comparing the prediction (using HBP) vs experimental (using FTIR) 
co-crystal screening results of twelve thiazole molecules with 20 carboxylic acids. The second 
part of chapter will focus on the predicting the supramolecular synthons in the co-crystals using 
MEPs, HBE, and HBP methods.87  
• Chapter 6 will apply both hydrogen and halogen bonding as synthetic tools to design binary 
and ternary co-crystals.   
• Chapter 7 will focus on developing a supramolecular hierarchy of activated amide containing 
halogen bond donors and co-crystallization to determine the strength of homomeric 
interactions in the target molecules.  
• Chapter 8 will focus on using a newly developed prediction tool to predict the crystallization 
propensity of drug like molecules with diverse functionalities.  
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• Chapter 9  will address the major challenges with 19th century molecule urea and ways to 
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Chapter 2 - Evaluating Homomeric Synthons in Pyrazole based 
molecules using Hydrogen-bond Energies and Propensities 
 
2.1 Introduction  
A common question in crystal engineering is, given a molecular structure, can we predict its crystal 
structure?1 The core of a crystal structure is the supramolecular synthon2-5 (introduced by G. R. 
Desiraju as a “structural unit within supermolecules which can be formed and/or assembled by 
known or conceivable synthetic operations involving intermolecular interactions”2) which 
encapsulates enough critical information so that it serves as a model for the entire crystal.6,7 So, 
the question is rather can we predict the supramolecular synthon given a molecular entity? 
Synthon prediction is a difficult task especially in molecules with multiple binding sites which 
often leads to synthon polymorphism8-10 or synthon crossover11 (Scheme 2.1).12 It is also difficult 
to predict synthons because of the complementary nature of certain functional groups and 
deviations in crystal structures from close packing. It also becomes more complicated in flexible 
molecules with large number of molecular conformations where both intra and intermolecular 
interactions are possible.  
Scheme 2.1 Schematics of using an in-silico approach for predicting synthons in a 
multifunctional molecule. 
The current methods for synthon predictions in organic molecules includes electrostatics, lattice 
energy predictions,14-16 focusing only on the thermodynamic (enthalpic) factors.17 For example, 
the preferred connectivity patterns in a molecule in the solid state can be determined using 
Margaret C. Etter rules which states that the best hydrogen bond acceptor binds to the best donor.18 
The ranking of best donor-acceptor can be determined using molecular electrostatic potential as 
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proposed by Aakeroy et.al.19 Hunter et al. has converted potentials into hydrogen-bond energies 
to determine the synthon preference in a multicomponent systems.20  
One way of accounting for kinetic factors is to analyze of a large amount of structural information 
encapsulated in the Cambridge Structural Database21 (CSD), the world’s repository of all 
published and patented small molecule crystal structures (900,000+). Of course, the crystal 
structure itself cannot provide information about kinetics of the seed formation and crystal growth, 
but it is, nevertheless, the final result of these processes. It is possible to suggest that if some 
structural array is abundant in a database, it may reflect thermodynamic stability of a given crystal 
packing array, as well as a kinetic preference of its formation. Therefore, this method used in 
conjunction with the electrostatics and energy may be useful in the predicting the outcome of 
supramolecular synthon in a complex multifunctional molecule. 
 
Scheme 2.2 Pyrazole molecules (P1–P12) employed in this study.  
 
In order to explore the structural landscape of a single molecule capable of forming a few specific 
and competing interactions, a library of pyrazole containing molecules (P1-P12) were synthesized 
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and explained, Scheme 2.2. Pyrazoles are reported to possess a wide range of biological activities 
such as anti-microbial, anti-fungal, anti-tubercular, anti-inflammatory, anti-convulsant, anticancer, 
anti-viral, and so on.22 The pyrazole-amide functionality is also present in some pharmaceutical 
related compounds such as Entrectinib, Graniseton, and Epirizol as well as antifungal compounds 
such as Furametpyr, Penthiopyrad and Tolfempyrad.23 Due to the presence of multifunctional 
groups, these molecules are always at risk of synthon polymorphism. Therefore, knowledge gained 
from a successful use of tools such as molecular electrostatic potentials, hydrogen-bond propensity 
and coordination, could have significant practical applications.  
 
 
Scheme 2.3 Representations of six postulated synthons in a generic pyrazole-amide; (a) synthon 
A, N-H (pyrazole)…N(pyrazole); (b) synthon B, N-H (pyrazole)…C=O(amide); (c) synthon C, 
N-H (amide)…N(pyrazole); (d) synthon D, N-H (amide)…C=O(amide), synthon E, 
NH(pyrazole)…N(aromatic) and synthon F, NH(amide)…N(aromatic).  (Y=H, CH3; X= methyl, 




The target molecules, P1-P12 can be divided into two groups: Group 1 (P1-P8) includes molecules 
with two donors (pyrazole NH and amide NH) and two acceptors (pyrazole N and carbonyl amide). 
In molecules P1-P8, four possible interactions based on two donors (pyrazole NH and amide NH) 
and two acceptors (pyrazole N and carbonyl C=O) can lead to four different synthons, scheme 3. 
The synthon A (NH (pyrazole)…N(pyrazole)) and synthon C (NH(amide)… N(pyrazole)) 
includes dimeric homo-synthon whereas synthon B (NH(pyrazole)…O=C(carbonyl)) and synthon 
D (NH(amide)…O=C(carbonyl)) include monomeric homo-synthon. It is likely that each 
molecule forms a combination of two synthons to satisfy all hydrogen-bond donors and acceptors 
and there are only two possibilities; Synthon (A+D) or synthon (B+C)). Group 2 (P9-P12) include 
molecules with two donors (pyrazole NH and amide NH) and three acceptor (pyrazole N, carbonyl 
C=O and pyridine N) groups. In additional to four synthons, synthon E 
(NH(pyrazole)…N(aromatic) and synthon F (NH(amide)…N(aromatic) are possible in group 2. 
Therefore, six different interactions are possible leading to six synthon possibilities; Synthon A-
F, (Scheme 2.3).   
 
The road map of this study is summarized in Scheme 3.4. We will use four different prediction 
methods; molecular electrostatic potentials (MEPs), hydrogen-bond energies (HBE), hydrogen-
bond propensities (HBP) and hydrogen-bond coordination (HBC) tools to determine the most 
likely synthon in the target molecules P1-P12 and compare our predictions with the experimental 
results. The overall goal is to develop robust and transferable protocols for identifying and 
predicting which hydrogen bonds are most likely to appear in homomeric molecular solids when 
there are numerous potential avenues for assembly, Scheme 2.1.       
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Scheme 2.4 The road map for synthon predictions 
 
The study is undertaken to address the following questions, 
1. Which method does a better job of predicting the synthon outcome in the target molecules; 
is it MEPs, HBE, HBP or HBC? 
2. Is a combination of prediction methods preferred over individual methods? 
3. Which synthon is the most optimal synthon in group 1 (P1-P8) and how does adding an 
acceptor group affect the choice of synthon in P9-P12.  
4. Which molecules have the risk of forming synthon polymorphs and which method is most 




2.2.1 General  
2-Amino-pyrazole, 2-amino-5-methyl-pyrazole, acetic anhydride, propionic anhydride and 
benzoyl chloride were purchased from Aldrich and utilized without further purification. Synthetic 
procedures and characterization of all molecules are provided in the Supporting Information (SI). 
Melting points were measured using Fisher-Johns melting point apparatus. 1H NMR data were 




2.2.2  Synthesis  
2.2.2.1 Synthesis of 3-acetamido-pyrazole, P124  
 
1H-pyrazol-3-amine (0.486 g, 5.85 mmole) was dissolved in 50 mL of distilled water. 
NaHCO3 (1.465 g, 17.4 mmole) was slowly added. Acetic anhydride (5ml) was 
then added dropwise and the resulting suspension was heated at reflux overnight. Then, the 
mixture was allowed to cool to room temperature and the solid obtained was filtered off and 
characterized as the title compound. After concentration of the filtrate, a second precipitate was 
obtained and also characterized as the title compound. 66% yield, m.p 218-220°C, 1H NMR (400 
MHz, DMSO-d6) δ ppm: 12.23 (br s, 1H), 10.42 (br s, 1H), 7.54 (br s, 1H), 6.44 (br s, 1H), 1.97 
(s, 3H). 
2.2.2.2 Synthesis of 3-acetamido-5-methyl-pyrazole, P2 
 
1H-pyrazol-5-methyl-3-amine (2.25 g, 2.30mmole) was dissolved in 20 mL of distilled water. 
NaHCO3 (5.8 g, 6.9 mmole) was slowly added. Acetic anhydride (8ml) was then added dropwise 
and the resulting suspension was heated at reflux overnight. Then, the mixture was allowed to cool 
down to room temperature and the solid obtained was filtered off and characterized as the title 
compound. 74 % yield, m.p. 215-218°C, 1H NMR (300 MHz, DMSO-d6) δ ppm: 11.89 (s, 1H), 
10.16 (s, 1H), 6.22 (s, 1H), 2.16 (s, 3H), 1.94 (s, 3H). 
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2.2.2.3 Synthesis of 3-propamido-pyrazole, P3  
 
3-amino-1H-pyrazole (0.486 g, 5.85 mmole) was dissolved in 10ml tetrahydrofuran in a 50ml 
round bottomed flask. 1 to 1.3 equivalence of propionic anhydride was added to the mixture and 
the resulting mixture was refluxed at 60-65 °C for 4 hours, monitored with TLC and after 
completion the excess solvent was removed by rotatory evaporation. The product was 
recrystallized from methanol to obtain the white solid as the pure product. Yield: 85%; mp 189-
190 ̊C, 1H NMR (δH; DMSO, 400MHz): 12.26 (s, 1H), 10.29 (d, 1H), 7.56 (d, 1H), 6.48 (d,1H), 
2.26 (q, 2H), 1.04 (t, 3H).  
 
2.2.2.4 Synthesis of 3-propamido-5-methyl-pyrazole, P424 
 
1H-pyrazol-5-methyl-3-amine (2.25 g, 2.30mmole) was dissolved in 20 mL of distilled water. 
NaHCO3 (5.8 g, 6.9 mmol) was slowly added. Propionic anhydride (10ml) was 
then added dropwise and the resulting suspension was heated at reflux overnight. Then, the 
mixture was allowed to cool down to room temperature and the solid obtained was filtered off and 
characterized as the title compound. 74 % yield, m.p. 189-190 ̊C, 1H NMR (400 MHz, DMSO-d6) 




2.2.2.5 Synthesis of 3-butyramido pyrazole, P5 
 
3-Aminopyrazole (0.499 g, 6.00 mmol) was dissolved in 30 mL of dichloromethane, 1.6 mL N-
methylmorpholine (14.6 mmol), and 1.49 mL butyryl chloride (14.0 mmol). After stirring for 16 
hours, the mixture was concentrated, and the residue was dissolved in 30 mL methanol.  Then, 7 
mL of 2.5M sodium hydroxide was added dropwise, followed by 10 mL of tetrahydrofuran. The 
mixture was allowed to sit for 15 minutes before being concentrated again and suspended in water. 
The tan precipitate was filtered, air dried, and finally recrystallized in methanol to yield white 
crystals. 66% yield, m.p. 130-141°C, 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.24 (1H), 10.26 
(1H), 7.55 (1H), 6.48 (1H), 2.24 (2H), 1.56 (2H), 0.88 (3H). 
 
2.2.2.6 Synthesis of 3-butyramido 5-methyl pyrazole, P6 
 
3-Amino-5-methylpyrazole (0.583 g, 6.00 mmol) was dissolved in 30 mL of dichloromethane, 1.6 
mL N-methylmorpholine (14.6 mmol), and 1.49 mL butyryl chloride (14.0 mmol). After stirring 
for 16 hours, the mixture was concentrated, and the residue was dissolved in 30 mL methanol.  
Then, 7 mL of 2.5M sodium hydroxide was added dropwise, followed by 10 mL of 
tetrahydrofuran. The mixture was allowed to sit for 15 minutes before being concentrated again 
and suspended in water. The tan precipitate was filtered, air dried, and finally recrystallized in 
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methanol to yield white crystals. ~70% yield, m.p. 184-189°C, 1H NMR (400 MHz, DMSO-d6) δ 
ppm: 11.90 (1H), 10.12 (1H), 6.25 (1H), 2.22 (2H), 2.17 (3H), 1.56 (2H), 0.87 (3H). 
 
2.2.2.7 Synthesis of 3-benzamido-pyrazole, P725  
 
To a solution of 2.49 g of 3-amino-1H-pyrazole in 150ml of dichloromethane, 8ml of n-
methylmorpholine and 8ml of benzoyl chloride were added at room temperature. After 16 hours 
of stirring, the mixture was concentrated, and the residue was dissolved in 150ml of methanol. An 
amount of 3.5 g of sodium hydroxide in 35ml of water was added dropwise and 100ml of THF 
was added to obtain homogenous solution. After 15 minutes under stirring, the solution was 
filtered to get rid of the solid and the solution was concentrated and the solid obtained was poured 
into water. The precipitate obtained was filtered and air-dried to obtain the pure product in 86% 
yield, m.p. 162-164 ̊C, 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.47 (s, 1H), 10.83 (s, 1H), 8.00 
(s, 1H), 7.66 (s, 3H), 7.50 (q, 2H), 6.63(s, 1H). 
 
2.2.2.8 Synthesis of 3-benzamido-5-methyl-pyrazole, P825 
 
To a solution of 2.49 g of 3-amino-5methyl-pyrazole in 150ml of dichloromethane, 8ml of n-
methylmorpholine and 8ml of benzoyl chloride were successfully added at room temperature. 
After 16 hours of stirring, the mixture was concentrated, and the residue was dissolved in 150ml 
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of methanol. An amount of 3.5 g of sodium hydroxide in 35ml of water was added dropwise and 
100ml of THF was added to obtain homogenous solution. After 15 minutes under stirring, the 
solution was filtered to get rid of the solid and the solution was concentrated and the solid obtained 
was poured into the water. The precipitate obtained was filtered and air-dried to obtain the pure 
product in 89% yield, m.p. 216-217 ̊C, 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.12 (s, 1H), 
10.67 (s, 1H), 7.98 (s, 1H), 7.53 (s, 3H), 7.48 (q, 2H), 6.40(s, 1H). 
 
2.2.2.9 Synthesis of 3-pyridyl-pyrazole, P9 
 
3-amino-1H-pyrazole (12mmol, 0.99g) was dissolved in 30 ml of acetonitrile. The resulting 
solution was treated with nicotinoyl chloride (12mmol, 1.70g) and triethylamine (2.0ml). The 
mixture was stirred at room temperature for 48 hours and monitored via TLC every 6 hours. Once, 
the reaction was completed, the organic phase was separated by filtration, washed with water and 
dried in air to get the white solid product. 84% yield, m.p. 226-227°C. 1H NMR (400 MHz, DMSO-
d6) δ ppm: 12.52 (s, 1H), 11.10 (s, 1H), 9.13 (s, 1H), 8.73 (s, 3H), 8.32 (s, 1H), 7.69(s, 1H), 7.53 
(s,1H) and 6.66 (s, 1H). 
 




3-Amino-5-methyl-pyrazole (12mmol, 1.69g) was dissolved in 20 ml of acetonitrile. The resulting 
solution was treated with nicotinoyl chloride (12mmol, 1.70g) and triethylamine (1.6ml). The 
mixture was stirred at room temperature for 48 hours. The mixture was stirred at room temperature 
for 48 hours and monitored via TLC every 6 hours. Once, the reaction was completed, the organic 
phase was separated by filtration, washed with water and dried in air to get the yellow solid product 
in 85% yield, m.p. 205-207°C. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.18 (s, 1H), 10.96 (s, 
1H), 9.11 (s, 1H), 8.72 (s, 1H), 8.30(s, 1H), 7.52(s, 1H), 6.41 (s, 1H) and 2.23 (s, 3H). 
 
2.2.2.11 Synthesis of 4-pyridyl-pyrazole, P11 
 
4-Amino-1H-pyrazole (12mmol, 0.99g) was dissolved in 20 ml of acetonitrile. The resulting 
solution was treated with nicotinoyl chloride (12mmol, 1.70g) and triethylamine (1.6ml). The 
mixture was stirred at room temperature for 48 hours. The mixture was stirred at room temperature 
for 48 hours and monitored via TLC every 6 hours. Once, the reaction was completed, the organic 
phase was separated by filtration, washed with water and dried in air to get the yellow solid 
product. 91% yield, m.p. 236-237°C. 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.55 (s, 1H), 11.17 
(s, 1H), 8.74 (s, 1H), 7.89 (s, 1H), 7.69 (s, 1H), 6.65(s, 1H). 
 




3-Amino-5-methyl-pyrazole (12mmol, 1.69g) was dissolved in 20 ml of acetonitrile. The resulting 
solution was treated with isonicotinoyl chloride (12mmol, 1.70g) and triethylamine (1.6ml). The 
mixture was stirred at room temperature for 48 hours. The mixture was stirred at room temperature 
for 48 hours and monitored via TLC every 6 hours. Once, the reaction was completed, the organic 
phase was separated by filtration, washed with water and dried in air to get the yellow solid product 
in 94%yield, m.p. 241-242°C. 1H NMR (400 MHz, DMSO-d6) δ ppm: 11.31 (s, 1H), 10.13(s, 1H), 
9.10 (s, 1H), 8.72 (s, 1H), 8.30(s, 1H), 7.83(s, 1H), 6.96 (s, 1H), 5.51 (s, 1H) and 1.32 (s, 3H).  
 
2.2.3 Molecular conformation analysis of P1-P12 
 
  
(a)Amide functionality (b) CSD structure analysis of amide 
conformation 
Figure 2.1 (a) Cis and trans amide functionality (both bonds are acyclic representing using symbol 
@) used to perform the torsion angle search. (b) Pie chart indicating number of structures with 
torsions for cis (yellow, ~32 structures, 0.5%) and trans (red, ~6303 Structures, 99.5%) 
conformations. 
 
A CSD database search was performed to determine whether the molecules with amide 
functionality occur as trans conformation or cis conformation. A total of 6335 structures was 
obtained and approximately 30 (0.5%) of these structures have the cis-amide conformation and 
about 6300 structures (99%) have trans-amide conformation, Figure 2.1.  Therefore, we 
determined the relative energy of all conformations with respect to most stable conformation with 











analysis). Geometry optimization was performed on each conformation of P1-P12 and the most 
stable conformation is given a value of 0 kJ/mol; all other conformations energies are presented 
relative to this, Table 2.1.   
Table 2.1 Energies of each trans amide conformation relative to most stable trans conformation 
is shown below in kJ/mol. The conformations with duplicate energies were ignored. Note: 
methyl-based target molecule conformations are not shown here. 
 Conformation 1 Conformation 2 Conformation 3 Conformation 4 Conformation 5 
P1 
  
   
ΔE (P1) 0 +50    







ΔE (P1) 0 0 +50 +50  
ΔE (P2) 0 +4 +50 +53  
P5 
 
   
  
ΔE (P1) 0 0 +2 +2 +3 





    
ΔE (P1) +50 +51 +52 +53 +54 
ΔE (P2) +50 +50 +52 +53 +55 
P7 
  
   
ΔE (P1) 0 +52    
ΔE (P2) 0 +51    
P9/P10 
 
   
 
ΔE (P1) 0 +4 +51 +55  
ΔE (P2) 0 +4 +51 +54  
P11 
  
   
ΔE (P1) 0 +52    





2.2.4 Molecular electrostatic potential (MEPs) calculations  
Molecular electrostatic potential surfaces (MEPS) of P1–P12 were generated with DFT B3LYP 
level of theory using 6-311++G** basis set in vacuum. All calculations were carried out using 
Spartan’08 software. All molecules were geometry optimized with the maxima and minima in the 
electrostatic potential surface (0.002 e/au isosurface) determined using a positive point charge in 
the vacuum as a probe. The numbers indicate the interaction energy (kJ/mol) between the positive 
point probe and the surface of the molecule at that particular point. The Etter’r rule based on 
electrostatic potentials was used to determine the best donor-best acceptor interaction.  
 
2.2.5 Hydrogen-bond energies (HBE) for synthon predictions  
The synthon predictions for pure compounds P1-P12 was made by calculating interaction energies 
to determine which of the three postulated synthons is most likely to appear in the crystal structures 
of the pure compounds. The hydrogen-bond parameters, α (hydrogen-bond donor) and β 
(hydrogen-bond acceptor) is determined using maxima and minima on the MEPS respectively 
(Equation 2.1 and 2.2), and the free energy of interaction is given by the product, -α β.20 The  
𝛼 = 0.0000162 𝑀𝐸𝑃𝑚𝑎𝑥2 + 0.00962𝑀𝐸𝑃𝑚𝑎𝑥                                                             (Equation 2.1) 
𝛽 = 0.000146 𝑀𝐸𝑃𝑚𝑖𝑛2 − 0.00930𝑀𝐸𝑃𝑚𝑖𝑛                                                                 (Equation 2.2) 
𝐸 = − ∑ 𝛼𝑖𝛽𝑗𝑖𝑗                                                                                              (Equation 2.3) 
 
Table 2.2 Electrostatics (in kJ/mol) and α and β values for P1-P12 calculated using equations 2.1 




















   
P1 210.00 2.73 255.00 3.51 -147.00 4.52 -198.00 7.57 
  
P2 205.00 2.65 244.00 3.31 -156.00 5.00 -202.00 7.84 
  
P3 206.00 2.67 252.00 3.45 -149.00 4.63 -195.00 7.37 
  
P4 200.00 2.57 242.00 3.28 -160.00 5.23 -199.00 7.63 
  
P5 207.00 2.69 253.00 3.47 -150.00 4.68 -196.00 7.43 
  
P6 201.00 2.59 242.00 3.28 -159.00 5.17 -199.00 7.63 
  
P7 196.00 2.51 255.00 3.51 -146.00 4.47 -191.00 7.10 
  
P8 189.00 2.40 244.00 3.31 -156.00 5.00 -195.00 7.37 
  
P9 209.00 2.72 250.00 3.42 -136.00 3.97 -179.00 6.34 -182.00 6.53 
P10 209.00 2.72 250.00 3.42 -132.00 3.77 -167.00 5.62 -174.00 6.04 
P11 190.00 2.41 240.00 3.24 -148.00 4.57 -173.00 5.98 -190.00 7.04 




2.2.6 Hydrogen-bond propensities (HBP) for synthon predictions  
To complement the electrostatic-based calculations, we used hydrogen-bond propensity 
calculations (CSD Version 5.38 and Mercury 3.9) to predict the synthons in the pure compounds 
P1-P12. Each compound was sketched and auto-edited, a careful selection of functional groups 
(Table 2.3) and training dataset (350-500) was made and the propensities were calculated with an 
ROC curve higher than 0.831 (“excellent discrimination”).  The propensity was used to determine 
the most likely synthon in these molecules.  
 
Table 2.3 Functional groups used to determine the hydrogen-bond propensities for the P1-P12 
target molecules.  The labels in the figures can be explained as follows:  Tn = atom makes n 
bonds, c = atom is cyclic,  = bond is acyclic, and Hn = n bonded hydrogen atoms.  
   
  
 
P1/P2 P3/P4/P5/P6 P7-P12 P1-P12 P1-P12 P9-P12 
 
 
2.2.7 Hydrogen-bond coordination (HBC) 
Because of the presence of multifunctional groups on each molecule, there is chance of synthon 
polymorphism and synthon crossover. Each molecule was run through a polymorph assessment 
analysis in the propensity tool and compared to experimentally obtained structure. In order to 
determine whether the target molecules P1-P12 have the chance to form synthon polymorphs, 
propensity-coordination analysis was performed on each molecule and the most optimal hydrogen-
bond motif was obtained.  
 
2.2.8 Crystal structures   
P1-P12 were kept in a vial for slow evaporation methanol solvent in order to obtain crystals 
suitable for single crystal X-ray diffraction. If suitable crystals were not obtained in methanol, then 
different solvents were tried to grow crystals.  The molecules were categorized into crystallizable 
or non-crystallizable based on slow evaporation method. DSC heat/cool/heat method was also used 
37 
 
to determine the crystallizability class of molecules.  X-ray experimental data and crystallographic 
data are given in the appendix D.  
 
Table 2.4 Experimental details of crystals obtained in this study 
 Molecules Solvent used Morphology Melting 
point 
Group 1 P1 Methanol Block, colorless 218-220 ̊C 
P2 Methanol Plate, colorless 215-218 ̊C 
P3 Methanol Plates, colorless 189-190 ̊C 
P4 Methanol Block, colorless 189-190 ̊C 
P5 Methanol Crystals not solved 130-141 ̊C 
P6 Methanol Crystals not solved 184-189 ̊C 
P7 Methanol Block, colorless 162-163 ̊C 
P8 Methanol Prism, colorless 217-218 ̊C 
Group 2 P9 Methanol N/A 227-228 ̊C 
P10 Methanol Block colorless 205-206 ̊C 
T11 Methanol Block colorless 236-237 ̊C 
T12 Methanol Crystals not solved 241-242̊C 
 
2.3 Results 
2.3.1 Conformational analysis 
Conformation analysis was performed using spartan 08’ software to determine all the possible 
conformations of each molecule and the relative energy of each conformation was calculated 
respective to the most stable conformation. Molecule P1, P2, P7, P8, P11 and P12 each has four 
possible conformations; P3, P4, P9, and P10 each has eight possible conformations, and P5 and 
P6 has ten conformations each.  
 
2.3.2 Molecular electrostatics potentials (MEPs) 
MEPs values for each donor group (pyrazole NH and amide NH) and acceptor group (pyrazole N, 
C=O amide for P1-P8 and additional acceptor as pyridine N for P9-P12) are presented in Figure 
2.2 and 2.3. The ranking of the acceptor sites and a donor site is established using molecular 
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electrostatic potential surfaces. Higher negative potential (indicated by red clouds) on the acceptor 
suggests better hydrogen-bond accepting ability and higher positive potential (indicated by blue 
clouds) on the donor suggests better hydrogen-bond donor ability. 
 
 
Figure 2.2 Electrostatic potentials values (in kJ/mol); a) P1 b) P2 c) P3 d) P4 e) P5 f) P6 g) P7 





Figure 2.3 Electrostatic potentials values (in kJ/mol); i) P9 j) P10 k) P11 and l) P12.  
 
2.3.3 Hydrogen-bond energies (HBE) 
The hydrogen-bond energies calculated for each individual (Table 2.5) and combination synthon 
are summarized in Table 2.6.  
 
Table 2.5 Hydrogen-bond energies (in kJ/mol) for each individual synthon for molecules P1-
P12. Synthon A and C are dimeric synthons; therefore, energies are presented for pairs of 
molecules.  
 
Synthon A Synthon B Synthon C Synthon D Synthon E Synthon F  
Monomeric Dimeric Monomeric Monomeric Dimeric Monomeric 
  
P1 -15.86 -31.71 -26.53 -12.37 -24.73 -20.69 
  
P2 -16.57 -33.14 -25.95 -13.27 -26.55 -20.79 
  
P3 -15.98 -31.95 -25.43 -12.35 -24.70 -19.66 
  
P4 -17.12 -34.25 -25.01 -13.44 -26.88 -19.63 
  
P5 -16.24 -32.49 -25.79 -12.57 -25.14 -19.96 
  
P6 -16.94 -33.88 -25.01 -13.38 -26.76 -19.75 
  
P7 -15.67 -31.35 -24.91 -11.21 -22.42 -17.81 
  
P8 -16.57 -33.14 -24.39 -11.99 -23.99 -17.65 
  
P9 -13.55 -27.10 -21.68 -10.78 -21.56 -17.24 -22.31 -17.75 
P10 -14.83 -29.66 -19.38 -11.04 -22.07 -14.42 -22.82 -16.98 
P11 -12.89 -25.78 -19.22 -10.25 -20.50 -15.29 -20.64 -16.41 
P12 -13.79 -27.58 -19.41 -10.98 -21.96 -15.45 -20.80 -16.56 
 















  Dimeric  Dimeric  Dimeric Dimeric     
P1 N/A -52.40 N/A -51.26 N/A N/A 
P2 N/A -53.93 N/A -52.50 N/A N/A 
P3 N/A -51.61 N/A -50.13 N/A N/A 
P4 N/A -53.88 N/A -51.89 N/A N/A 
P5 N/A -52.44 N/A -50.93 N/A N/A 
P6 N/A -53.63 N/A -51.77 N/A N/A 
P7 N/A -49.16 N/A -47.32 N/A N/A 
P8 N/A -50.80 N/A -48.38 N/A N/A 
AVG N/A -52.23 N/A -50.52 N/A N/A 
S.Dev N/A 1.67 N/A 1.81 N/A N/A 
P9 -44.85 -44.34 -43.87 -43.23 -39.55 -39.42 
P10 -46.64 -44.08 -44.89 -41.45 -37.24 -36.36 
P11 -42.19 -41.07 -41.14 -39.73 -35.93 -35.64 
P12 -44.14 -43.03 -42.76 -41.36 -36.25 -35.97 
AVG -44.46 -43.13 -43.17 -41.44 -37.24 -36.85 
40 
 
S.Dev 1.84 1.49 1.61 1.43 1.64 1.74 
 
2.3.4 Hydrogen-bond propensities (HBP) 
The propensities calculations consider all possible interactions between two donors (pyrazole NH 
and amide NH) and two acceptors (pyrazole N and C=O) resulting in four propensity numbers for 
P1-P8. In molecules with an additional acceptor group P9-P12, six different combinations of 
propensities are calculated. The propensity of individual and combination synthon is presented in 
Table 2.6 and Table 2.7.  
 
Table 2.7 Hydrogen-bond propensities for each individual synthon possible in molecules P1-
P12.  
 
Synthon A Synthon B Synthon C Synthon D Synthon E Synthon F 
P1 0.65 0.69 0.49 0.54 
  
P2 0.63 0.76 0.39 0.55 
  
P3 0.68 0.75 0.48 0.57 
  
P4 0.69 0.73 0.51 0.56 
  
P5 0.61 0.69 0.45 0.54 
  
P6 0.62 0.73 0.44 0.56 
  
P7 0.57 0.51 0.38 0.32 
  
P8 0.51 0.49 0.34 0.32 
  
P9 0.48 0.48 0.27 0.27 0.69 0.47 
P10 0.48 0.47 0.27 0.26 0.71 0.49 
P11 0.45 0.48 0.25 0.27 0.69 0.47 
P12 0.45 0.47 0.25 0.27 0.7 0.49 
 
Table 2.8 Hydrogen-bond propensities for combination synthons possible in molecules P1-P12. 















P1 N/A 0.35 N/A 0.34 N/A N/A 
P2 N/A 0.35 N/A 0.30 N/A N/A 
P3 N/A 0.39 N/A 0.36 N/A N/A 
P4 N/A 0.39 N/A 0.37 N/A N/A 
P5 N/A 0.33 N/A 0.31 N/A N/A 
P6 N/A 0.35 N/A 0.32 N/A N/A 
P7 N/A 0.18 N/A 0.19 N/A N/A 
P8 N/A 0.16 N/A 0.17 N/A N/A 
P9 0.23 0.13 0.19 0.13 0.19 0.23 
P10 0.24 0.12 0.19 0.13 0.18 0.23 
P11 0.21 0.12 0.17 0.12 0.19 0.23 




2.3.5 Hydrogen-bond coordination (HBC) 
The hydrogen-bond coordination tool was used to determine the coordination of each functional 
group which will guide us to determine which synthon is most likely to happen. The propensity-
coordination chart and the corresponding coordination for each hypothetical motif is shown in 





















(a) Propensity-coordination chart (b) Coordination table 
Figure 2.4 (a)Propensity-coordination chart of P1-P6 molecules and (b) coordination of each 



















Motif # Atom (D/A) 0 1 2 3 
III NH of pyrazole (d) 0.01 0.61 0.39 0.00  
NH of amide (d) 0.00 0.96 0.04 0.00  
N of pyrazole (a) 0.12 0.88 0.00 0.00  
O=C of amide (a) 0.02 0.74 0.23 0.01 
I NH of pyrazole (d) 0.01 0.61 0.39 0.00  
NH of amide (d) 0.00 0.96 0.04 0.00  
N of pyrazole (a) 0.12 0.88 0.00 0.00  
O=C of amide (a) 0.02 0.74 0.23 0.01 
II NH of pyrazole (d) 0.01 0.61 0.39 0.00  
NH of amide (d) 0.00 0.96 0.04 0.00  
N of pyrazole (a) 0.12 0.88 0.00 0.00  
O=C of amide (a) 0.02 0.74 0.23 0.01 
 
Motif # Atom (D/A) 0 1 2 3 
I NH of pyrazole 0.01 0.72 0.27 0.00  
NH of amide 0.02 0.95 0.03 0.00  
N pyrazole 0.17 0.83 0.00 0.00  
O=C amide 0.04 0.82 0.14 0.00 
III NH of pyrazole 0.01 0.72 0.27 0.00  
NH of amide 0.02 0.95 0.03 0.00  
N pyrazole 0.17 0.83 0.00 0.00  
O=C amide 0.04 0.82 0.14 0.00 
II NH of pyrazole 0.01 0.72 0.27 0.00  
NH of amide 0.02 0.95 0.03 0.00  
N pyrazole 0.17 0.83 0.00 0.00  




(a) Propensity-coordination chart (b) Coordination table 
Figure 2.5 Propensity-coordination chart of P7-P8 molecules and the coordination of each 






(a) Propensity-coordination chart (b) Coordination table 
Figure 2.6 Propensity-coordination chart of P9-P10 molecules and the coordination of each 




(a) Propensity-coordination chart (b) Coordination table 
Figure 2.7 Propensity-coordination chart of P11-P12 molecules and the coordination of each 
functional group in all predicted motifs. 
 
Motif # Atom (D/A) 0 1 2 3 
I NH of pyrazole (d) 0.00 0.62 0.38 0.00  
NH of amide (d) 0.02 0.95 0.03 0.00  
N of pyridine (a) 0.11 0.81 0.08 0.00  
N pyrazole (a) 0.40 0.60 0.00 0.00  
C=O amide (a) 0.17 0.80 0.03 0.00 
III NH of pyrazole (d) 0.00 0.62 0.38 0.00  
NH of amide (d) 0.02 0.95 0.03 0.00  
N of pyridine (a) 0.11 0.81 0.08 0.00  
N pyrazole (a) 0.40 0.60 0.00 0.00  
C=O amide (a) 0.17 0.80 0.03 0.00 
II NH of pyrazole (d) 0.00 0.62 0.38 0.00  
NH of amide (d) 0.02 0.95 0.03 0.00  
N of pyridine (a) 0.11 0.81 0.08 0.00  
N pyrazole (a) 0.40 0.60 0.00 0.00  




Atom (D/A) 0 1 2 3 
I NH of pyrazole (d) 0.01 0.83 0.16 0.00  
NH of amide (d) 0.01 0.96 0.03 0.00  
N of pyridine (a) 0.11 0.82 0.07 0.00  
N of pyrazole (a) 0.35 0.65 0.00 0.00  
C=O of amide (a) 0.19 0.78 0.03 0.00 
III NH of pyrazole (d) 0.01 0.83 0.16 0.00  
NH of amide (d) 0.01 0.96 0.03 0.00  
N of pyridine (a) 0.11 0.82 0.07 0.00  
N of pyrazole (a) 0.35 0.65 0.00 0.00  
C=O of amide (a) 0.19 0.78 0.03 0.00 
II NH of pyrazole (d) 0.01 0.83 0.16 0.00  
NH of amide (d) 0.01 0.96 0.03 0.00  
N of pyridine (a) 0.11 0.82 0.07 0.00  
N of pyrazole (a) 0.35 0.65 0.00 0.00  




2.3.6 Observed synthons in each crystal structure  
We were able to obtain crystallographic data for nine out of twelve molecules, P1-P12. P9 didn’t 
grow crystals suitable for single crystal x-ray diffraction studies. Our structure determination of 
P2 was consistent with the reported structure in the CSD(ARAGUV)26 and the crystal structure of 
P8 is also reported in the CSD (PESQEK)27.  The experimentally observed synthon in each crystal 
structure is shown in Figure 2.8 and Figure 2.9.  
 
 





Figure 2.9 Synthon (A+D) observed in crystal structure of P10 and P11.  
 
2.4 Discussion  
2.4.1 Molecular conformational analysis  
Molecular conformational analysis shows that the most stable conformation in each molecule 
has the amide functionality trans to each other and cyclic N group cis to the amide NH (Table 2.1). 
Additionally, in molecule P9 and P10, pyridine N is trans to the amide NH in the most stable 
conformation and the second conformation with pyridine N cis to amide NH is only ~4 kJ/mole in 
energy higher than the most stable conformation. Therefore, the main conformation in each 
molecule will have trans amide conformation as the most stable conformation. When compared to 
the experimental crystal structure, the trans amide conformation was indeed observed in all 
molecules. In the target molecule P11, second most stable conformation in which the pyridine N 
cis to the amide NH was observed, it is only ~4 kJ/mole higher than the most stable conformation 
where the pyridine N is trans to the amide NH. It is worth noting that the energy optimized 
conformations are not necessarily completely identical to those that may appear in the solid state, 
where a variety of close contacts and packing forces may distort some geometric parameters away 
from idealized gas phase values.  However, these idealized conformations are likely to be most 
relevant in the solution phase at the point when target molecules begin to recognize and bind to 




2.4.2 What are the preferred synthons?  
Four different methods (MEPs, HBE, HBP, and HBC) were used to predict synthons. For 
molecules P1-P8, Synthon (B+C) was predicted by all four methods. Also, synthon (A+D) was 
predicted by HBE and HBP method. For molecules P9-P12, Synthon (D+E) was predicted by 
MEPs and HBC. Synthon (B+F) was predicted by HBP and HBC. Synthon (A+F) was predicted 




Figure 2.10 Summary of synthons predicted in the target molecules, P1-P12.  
 
2.4.3 Molecular geometric complementarity  
Our next goal was to rule out any synthons which are unfavorable based on geometric constraints. 
Based on our CSD search, we found that dimeric synthon A is less likely to happen due to 
geometric constraint of NH(pyrazole)…N(cyclic) hydrogen-bond angle as being non-linear. 
However, monomeric synthon A is still a possibility 
 
2.4.4 Crystal structures  
The summary of synthons observed in each crystal structure is presented in Figure 2.11. Synthon 
(B+C) was observed in five out six crystal structures obtained in group 1. Synthon (A+F) was 
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observed in P10 and synthon (C+E) was observed in P11. In total, eight crystal structures were 
obtained, and synthon C was the most common synthon (in six out of eight crystal structures) 
followed by synthon B (five out of eight crystal structures). Synthon A is observed in two crystal 
structures as a dimeric synthon in P8 and monomeric synthon in P10.  
 
Figure 2.11 Summary of synthons observed in eight crystal structures obtained in this study.  
 
2.4.5 Predicted vs experimental comparison  
Group 1: In the crystal structures of P1-P4 and P7, both monomeric synthon B 
(NH(pyrazole)…C=O(amide)) and dimeric synthon C (NH(amide)…N(pyrazole)) were observed 
thus following Etter’s rule irrespective of substitution next to amide group or at the pyrazole ring. 
Therefore, in molecules P1-P6, five out of six times, synthon (B+C) is the dominant synthon as 
predicted by all three prediction methods. The best donor pyrazole NH binds to the best acceptor 
carbonyl oxygen (synthon B) and the second-best acceptor amide NH binds to the second-best 
acceptor pyrazole N (synthon C) as suggested by MEPs based on Etter’s rule. Dimeric synthon C 
is favored over synthon A in these molecules because the hydrogen bond angle in the former is 
linear compared to latter due to geometric complementarity. The observed synthon in the crystal 
structure of P1-P5 was predicted as the most preferred synthon by all four prediction methods; 
MEPs, HBE, HBP and HBC in the solid state informatic tools. The HBC results obtained by 
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importing the experimental crystal structure of P1 shows that the observed experimental motif 
matches with the predicted hypothetical motif I in this molecule, Figure 2.12.  
 
 
Figure 2.12 Polymorph assessment of P1 molecule indicating the most optimal hypothetical 
structure matches with the experimental structure.  
 
In P8, the pyrazole NH binds to cyclic N forming dimeric synthon A 
(NH(pyrazole)…N(pyrazole)) and the amide NH binds to carbonyl oxygen forming dimeric 
synthon D (NH(amide)…C=O(amide)). In one out of six crystal structures obtained, synthon 
(A+D) is the dominant synthon regardless of the geometric bias. It is not surprising to see such 
synthon as both hydrogen-bond energies and hydrogen-bond propensities predicted that either 
combination synthon (A+D) or (B+C) are possible.  
Based on HBC tool, the observed synthon in P8 doesn’t match with the most stable hypothetical 
structure indicating there is a possibility of polymorphism in this molecule. The most stable 
structure involves synthon (B+C) where NH(amide)…N(pyrazole) and 
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NH(pyrazole)…C=O(amide) hydrogen-bond interactions are present and it was predicted by all 
three prediction methods, Figure 2.13. 
 
Figure 2.13 Polymorph assessment of P8 molecule indicating the second hypothetical structures 
matches with the experimental structure. 
 
Group 2: When an extra acceptor group was added to the benzyl group, four new molecules were 
obtained; P9-P12. The crystal structures of P10 and P11 are reported in this study.  
In the crystal structure of P10, the amide NH binds to pyridine N forming synthon F 
(NH(amide)…N(Pyridine) and pyrazole NH binds to cyclic N forming monomeric synthon A 
(NH(pyrazole)…N(pyrazole)).  Therefore, synthon (A+F) is observed in P10. Synthon (A+F) was 
predicted by both HBE and HBP.  
In the crystal structure of P11, the amide NH binds to cyclic N forming dimeric synthon C 
(NH(amide)…N(pyrazole) and pyrazole NH binds to pyridine N forming synthon E 
(NH(pyrazole)…N(pyridine), therefore synthon (C+E) was observed. Synthon (C+E) was 
predicted by hydrogen-bond energy but not by MEPs, HBP or HBC.  
The HBC results of P10 and P11 shows that the experimentally observed synthon in these 
molecules matches with the hypothetical predicted motif II and there is chance of synthon 
polymorphism (Figure 2.14 and Figure 2.15). We haven’t performed experimental polymorph 




Figure 2.14 Polymorph assessment of P10 molecule indicating the experimental structure and 
more stable hypothetical structure. 
 
 
Figure 2.15 Polymorph assessment of P11 molecule indicating the experimental structure and 




2.4.6 Validation studies  
The comparison studies between the four predicted methods (MEPs, HBE, HBP and HBC) and 
experimentally observed results are mentioned here and tabulated in Table 2.9. In molecules P1-
P8 with two donors and two acceptor molecules, Synthon (B+C) as the most likely synthon was 
predicted by all four methods and in five out of six molecules (83%), synthon (B+C) was observed 
(4 out of 4 methods predicted correctly). In one molecule P8, synthon (A+D) was observed which 
was also predicted by HBE and HBP as the second possible synthon (2 out of 4 methods predicted 
correctly).  As the competition was increased by increasing the number of acceptor groups to three 
in molecules P9-P12 (two donors and three acceptors), synthon predictability became complex 
and it became difficult to predict the synthons because of the possibility of synthon crossover and 
synthon polymorphism. In molecule P10, synthon (A+F) was observed experimentally which was 
predicted correctly by HBE and HBP prediction methods (2 out of 4 methods predicted correctly). 
In molecule P11, synthon (C+E) was observed which was only predicted by HBE as the most 
stable synthon (1 out of 4 methods predicted correctly).  
 
Table 2.9 Summary of experimental vs predicted synthons in target molecules P1-P12 
 Experimental MEPs HBE HBP HBC 
P1 Synthon (B+C) Yes Yes Yes Yes 
P2 Synthon (B+C) Yes Yes Yes Yes 
P3 Synthon (B+C) Yes Yes Yes Yes 
P4 Synthon (B+C) Yes Yes Yes Yes 
P7 Synthon (B+C) Yes Yes Yes Yes 
P8 Synthon (A+D) No Yes Yes No 
P9 Didn’t crystallize N/A 
P10 Synthon (A+F) No Yes Yes No 
P11 Synthon (C+E) No Yes No No 
 
2.5 Conclusions  
The structural chemistry of twelve target molecules P1-P12 has been analyzed using MEPS, HBE, 
HBP and HBC as a way of predicting which intermolecular interactions are likely to appear in the 




Figure 2.16 A representation of health check on a molecule P8 to determine the synthons and 
risk of synthon polymorphism.  
 
1. In seven out of eight crystal structures obtained, a combination of HBE and HBP were the most 
effective prediction methods as they predicted the experimentally observed synthons correctly.  
2. These results indicate that combination of methods is preferred over individual molecules.  
3.  In group 1(P1-P8), Synthon (B+C) was the most optimal synthon (observed in five out of six 
crystal structures) compared to synthon (A+D) thanks to the geometric complementarity, 
MEPs and supramolecular chelating effect.28  However, when a strong acceptor group such as 
pyridine nitrogen was added as in P9-P12, synthon prediction became complex, so does the 
experimentally observed synthons. Synthon (A+F) and synthon (D+E) were the most optimal 
synthon in this category based on combination of atleast two prediction methods. In two crystal 
structures obtained, synthon (A+F) and synthon (C+E) were observed.  
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4. HBC was most effective in predicting the synthon polymorphs in this group of molecules. 
Three target molecules; P8, P10 and P11 have the risk of forming synthon polymorphs because 
the most optimal hypothetical synthon I is not observed in these molecules based on HBC tool.  
 
Four prediction methods used in this study are valuable tool to determine which synthon is likely 
to form in the crystal structure of a molecule and if the molecule is at a risk of synthon 
polymorphism. Therefore, a simple health check as shown in Figure 2.16 on these molecules using 
structural informatics tools such as MEPs, HBE, HBP and HBC for mapping out the structural 
landscape of these types of molecules will have significant practical applications in various fields.  
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Chapter 3 - Systematic Investigation of Knowledge based Prediction 
methods for Co-crystal Design in Pyrazoles 
3.1 Introduction  
The occurrence of polymorphism1-5 in solid-state chemistry is one reason behind the need for 
robust guidelines and for versatile and dependable practical supramolecular synthesis. A 
knowledge of connectivity pattern between given functional groups is useful in order to design a 
desired solid-state material and various prediction methods have been employed to determine the 
composition, multiple forms, synthons and properties of a chemical compound.  
 
 
Scheme 3.1. Scheme showing different prediction methods to determine the supramolecular 
synthon in the co-crystals of pyrazole based molecules.  
 
The preferred connectivity patterns in the solid state can be hypothesized using the Etter 
guidelines6 which states that the best hydrogen bond acceptor binds to the best donor and the 
ranking of best donor-acceptor can be determined using molecular electrostatic potential as 
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proposed by Aakeroy et.al.7 This connectivity pattern is also employed to predict the outcome of 
multicomponent systems such as co-crystals using interaction site pairing energies by Hunter 
et.al.8-9 Recently, Price et. al. have used lattice energy,10 Fabian et.al. have used molecular shape 
and polarity,11 Galek 12and jones et. al.13 have used hydrogen-bond propensities as a kinetic tool 
to quantify and predict the connectivity patterns.   
The geometric complementarity of the interacting species comes into play when the presence of 
multiple hydrogen bond functionalities in a molecule leads to multiple molecular recognition sites 
in the system.14,15  The molecular geometry of the co-former, along with the precise orientation of 
binding sites in the co-crystallizing agent, control the resulting supramolecular synthon in reliable 
manner in a competitive environment.16 Lehn et. al. has emphasized molecular recognition as a 
key component in the orientation/preorganization of binding sites to form synthons.17 Hamilton et. 
al. studied the molecular recognition in the solid state for series of amino-pyridine with rigid 
spacers towards carboxylic acids.18-19 They also emphasized that the directionality and orientation 
of two components involved in forming a co-crystal is a must to achieve the high yield 
supramolecular synthon.20  
Despite the recent advancement in the field, it is still difficult to use the specific intermolecular 
interactions to construct architectures with desired dimensionality and high reproducibility due to 
challenges associated with one-pot supramolecular synthesis, and the presence of multifunctional 
groups.21 These problems often lead to “synthon crossover”18 and “synthon polymorphism” 2, 4, 7 
in supramolecular synthesis due to reversible nature of weak hydrogen bonding.22 However, a 
good synthetic strategy can be built to obtain high supramolecular yields with desired motifs. 
These motifs should be dominant within the crystal structure in such a way that different 
substitutions on the individual covalent building block will form similar lattice structures. This can 
be achieved by using intermolecular interactions that are unlikely to interfere with one another 
which will lead to strong but also discriminating interactions in the solid state.23 Aakerӧy et al 
have used both hydrogen and halogen bonding to avoid synthon crossover in 2-aminopyrazine 
molecules based on electrostatics and geometric complementarity. They have also addressed the 
appearance of synthon crossover in a study done to predict synthon preference in hydroxy-benzoic 




Two different types of pyrazole based molecules were chosen for this study. Target molecules P1-
P6 has an alkyl next to the amide group, P7-P8 has a phenyl group and P9-P12 has a pyridyl 
nitrogen either at meta or para position (Scheme 3.1).  Molecules P2, P4, P6, P8, P10, and P12 
have a methyl group on the pyrazole ring. 
 
 
Scheme 3.2 Ten pyrazole based target molecules, P1-P12 split into two groups; group-1: without 
pyridyl, and group-2: with pyridyl.  
Twenty different carboxylic acids (10 diacids and 10 monoacids) were chosen as potential co-






   
Scheme 3.3 Twenty carboxylic acid co-formers (10 aliphatics and 10 aromatics).  
There are two donors (pyrazole NH and amide NH) and two acceptors (pyrazole N and carbonyl 
O) in P1-P8. There are three possibilities for the dicarboxylic acid to bind with P1-P8. The first 
possibility is the OH of acid binds to the pyrazole N via OH(acid)…N(pyrazole) and the carbonyl 
O=C of acid binds to pyrazole NH via NH(pyrazole)…O=C(acid), synthon I. The second 
possibility is that the OH of acid binds to the pyrazole N via OH(acid)…N(pyrazole) and the 
carbonyl O=C of acid binds to amide NH via NH(amide)…O=C(acid), synthon II. The third 
possibility is that the OH group of acid binds to O=C of target molecule via 
OH(acid)…O=C(amide) and the carbonyl group of acid binds to pyrazole NH of the target 
molecule via NH(pyrazole)…O=C(acid), synthon III. For P9-P12, an additional synthon is 
possible because of the presence of an additional acceptor group on each target molecule, the OH 
group of an acid can bind to pyridine N of target molecule via OH(acid)…N(pyridine), synthon 
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IV, therefore four different synthons are possible (synthon I, synthon II, synthon III and synthon 
IV) in P9-P12 (Scheme 3.4). Additional synthons are possible with aromatic acids that contains 
additional donor group such as hydroxyBA and aminoBA, Scheme 3.7.  
 
 
Scheme 3.4.  Four postulated heteromeric hydrogen-bond based synthons between P1-P12 and a 
carboxylic acid; (R1=H, CH3; R2= methyl, ethyl, or phenyl). 
 
In the work presented herein, first we want to determine if the chosen co-formers can break the 
homomeric interactions in P1-P12 and form heteromeric interactions to form co-crystals. Also, 
what is the effect of changing alkyl side to phenyl ring and pyridyl ring on the resulting co-
crystallization outcome? Can we predict the co-crystal outcome by already established prediction 
methods such as energies and propensities and is a combination of both methods useful in getting 




Scheme 3.5 Schematics of systematic investigation of knowledge based predictive methods for co-crystal 
screen.  
 
Second, we want to determine if we can systematically predict which synthon is more likely to 
occur in each of these target molecules. We want to examine the competition of two binding 
pockets (pyrazole NH and amide NH binding pockets) on the pyrazole molecules, P1-P8 to bind 
to a series of probe molecules containing carboxylic acid moieties and find out which of the three 
synthons; synthon I (using pyrazole binding pocket) or synthon II (using amide binding pocket) 
or synthon III (synthon crossover) is preferred in a competitive environment if a co-crystal is 
formed? Crystal structures containing two robust 𝑅2
2(8) based hydrogen-bond synthons; carboxylic 
acid---pyrazole (synthon I)18,19,20  and carboxylic acid---amide (synthon II) 6, 4 have shown 
excellent structural control when they are present independently (Scheme 3.6). The presence of all 
three functional groups (carboxylic acid, pyrazole and amide) in the same system can lead to 
competition between carboxylic acid for either pyrazole or amide as well as synthon crossover in 
P1-P8.  In fact, a comparatively less common carboxylic acid---pyrazole synthon-based crystal 
structures have been published even though the angle between N−H bond and the lone pair on the 





Scheme 3.6 Two robust hydrogen-bonded interactions; type I (carboxylic acid---amide) and type II 
(carboxylic acid---pyrazole) heterosynthons.  
 
There are no systems where functional groups required to form both carboxylic acid---amide and 
carboxylic acid---pyrazole heterosynthons are combined on the same molecular backbone. This 
motivated us to do a competitive study by combining two robust supramolecular synthons in the 
presence of multiple functional groups on the same backbone, thereby eliminating important issues 
such as solubility and stability of the neutral components. We increased the competition by 
including a well-known pyridine acceptor in P9-P12 to establish if the supramolecular chelate 
effect in hydrogen-bonding dominates the strong single point interaction of 
OH(acid)…N(pyridine). We also want to determine the role electrostatics, energies, propensities 
alone, geometric complementarity alone or combination of both on the outcome of co-crystal.  
The study is done to address following questions: 
1. Can we break homomeric synthons observed in P1-P12 and form heteromeric synthons 
with carboxylic acids? 
2. Can we predict the co-crystal formation of P1-P12 with 20 carboxylic acids? 
3. Which synthon is most favored in heteromeric systems and which method is most reliable 
for predicting the correct synthon? 
4. Is it electrostatics, propensity, energy, molecular complementarity or a combination of all 





Scheme 3.7 Six postulated heteromeric hydrogen-bond based synthons between P1-P12 and 
aromatic acids with an additional donor group (OH for hydroxyl and NH for amino substituents).  
 
3.2 Experimental section   
3.2.1 Materials  
The synthesis and characterization of P1-P12 is done in chapter 3. Carboxylic acids were 
purchased from commercial sources and used as received. Melting points were measured using a 
Fisher-Johns melting point apparatus. Solution 1H NMR data were collected in DMSO-d6 on a 
Varian Unity plus 400 MHz NMR spectrometer. IR spectra of co-crystal screening experiments 
were recorded with a Nicolet 380 FT-IR spectrometer using ATR (attenuated total reflection) 
technique and ZnSe as the crystal.  
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3.2.2 Molecular electrostatic potential (MEPs) calculations   
See section 2.2.4 for molecular electrostatic potential surfaces (MEPS) of P1–P12. The 
electrostatics potentials of 20 carboxylic acids (See appendix E for details) are presented in this 
study using same methodology described in section 2.2.4.  
 
3.2.3 Hydrogen-bond energies for predictions  
See section 2.2.5 for the hydrogen-bond energy calculation methodology. The synthon predictions 
for heteromeric synthons of P1-P12 was made by calculating interaction energies of the best donor 
of the acid with the best acceptor of the target and vice-versa.  
The Multi-Component Energy (MCE) score is calculated by subtracting the best energy of 
homomeric interaction from the best energy of heteromeric interaction. The best hetero/homo 
interaction is determined based Etter’s rule. Note that this calculation is different from Hunter’s 
calculations of virtual co-crystal screening. We have only considered best hetero and homomeric 
interactions of conventional hydrogen bond donors and acceptors (equation 3.1) whereas in 
Hunter’s calculations, all possible interactions in the homo and heteromeric systems are used for 
calculations.  
𝑀𝐶𝐸 𝑠𝑐𝑜𝑟𝑒 =  (
𝐸𝑛𝑒𝑟𝑔𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑒𝑠𝑡 
ℎ𝑒𝑡𝑒𝑟𝑜𝑚𝑒𝑟𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛
) − (
𝐸𝑛𝑒𝑟𝑔𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑏𝑒𝑠𝑡 
ℎ𝑜𝑚𝑜𝑚𝑒𝑟𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛
)           (Equation 3.1) 
 
 
3.2.4 Hydrogen-bond propensities for synthon predictions  
The hydrogen-bond propensities for P1-P12 when screened against 20 different co-formers were 
calculated and the Multi-Component score (MC score) was obtained by subtracting the propensity 
of the highest probability homo-interaction (pure components) from the propensity of the highest 
probability hetero-interaction (co-crystal) obtained from same propensity chart, Equation 3.2.  A 
positive MC score indicates that the hetero-interaction needed for co-crystal formation is favored, 
whereas a negative MC score indicates that homo-interactions are favored and therefore hydrogen-
bond directed co-crystallization is unlikely to occur.  
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𝑀𝐶𝑃 𝑠𝑐𝑜𝑟𝑒 =  (









)       (Equation 3.2) 
The functional groups of target molecules are listed in chapter 2 and the functional groups used 
for the acids are listed below in Table 3.1.  
 
Table 3.1 Functional groups used to determine the hydrogen-bond propensities for the six target 
molecules.  The labels in the figures can be explained as follows:  Tn = atom makes n bonds, c = 
atom is cyclic,  = bond is acyclic, and Hn = n bonded hydrogen atoms.  
   
  
 












3.2.5 Co-crystal screening and crystal growth  
P1-P12 were put through a co-crystal screen using liquid-assisted grinding (LAG) in a drop of 
methanol against ten aliphatic dicarboxylic acids and ten aromatic acids (Scheme 3.3).  In all 240 
reactions the reactants were mixed in stoichiometric ratios and the solid resulting from each 
reaction was characterized using IR spectroscopy to determine if a co-crystal had formed.  The IR 
analysis focused on the positions of readily identifiable vibrational modes (cf. O=C (amide), O=C 
(acid), etc) in the pyrazoles and acids, with the corresponding bands in the resulting solids.  Shifts 
greater than seven wavenumbers were taken as an indication of co-crystal formation.  In addition, 
the appearance of broad stretches around 2,300 cm-1 and 1,800 cm-1 as a result of intermolecular 
O-H…N hydrogen bonds, also support the formation of co-crystals since such interactions are not 
feasible in either of the pure compounds, see appendix C.  Subsequently, the mixtures obtained 
from the grinding experiments were dissolved in a minimum amount of methanol or nitromethane 
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(1–2 ml) and kept in a vial for slow evaporation in order to obtain crystals suitable for single crystal 
X-ray diffraction. X-ray experimental data and crystallographic data are given in the appendix D.  
 
Table 3.2 Experimental details of new co-crystal obtained in this study.  
 Ligands/co-crystal Ratio 
(A:D) 
Melting point Morphology 
1 P1-PentafluoroBA 1:1 106-107°C Colorless, blocks 
2 P2-Fum 2:1 232-235 °C Colorless blocks 
3 P2-Suc 2:1 228-230 °C Colorless plates 
4 P2-Adi 2:1 164-165 °C Colorless plates 
5 P2-Pim 2:1 198-200 °C Colorless prisms 
6 P3-3nitroBA 1:1 156-159 °C Colorless blocks 
7 P3-4AminoBA 1:1 140-142 °C Golden blocks 
9 P4-Fum 1:1 195-200 °C Colorless rhombohedra 
10 P4-Adi 2:1 245-250 °C Colorless blocks 
11 P4-PentafluoroBA 1:1 104-106 °C Colorless blocks 
12 P7-Sub 2:1 120-122 °C Colorless prisms 
13 P8-Sub 2:1 134-136 °C Colorless plates 
14 P8-Aze 2:1 120-125 °C Colorless needle 
 
This chapter is divided into two sections: 
1. Section 1 is focused on the prediction and experimental study of co-crystal screening of 
P1-P12 with 20 co-formers. 
2. Section 2 is focused on the prediction and experimental analysis of synthons in the co-
crystals of P1-P12 with 20 co-formers. 
 
3.3 Results 
3.3.1 Part 1: Co-crystal screening   
The study is divided into two groups: group 1 contains molecules with 2 donors and 2 acceptors; 
P1-P8 co-crystals (160 experiments). Group 2 contains molecules with 2 donors and 3 acceptors; 
P9-P12 co-crystals (80 experiments).   
 
3.3.1.1 Experimental co-crystal screening 
66 
 
The experimental screen produced co-crystals in 169 of the 240 experiments between P1-P12 and 
aliphatic diacids and aromatic monoacids. The results of the IR grinding screen are shown in Table 
3.3.   
Table 3.3 Attempted co-crystallizations using LAG (methanol) of P1-P12 with aliphatic and 
aromatic acids.  
  P1 P2 P3 P4 P5 P6 P7 P8  P9 P10 P11  P12 S.Y. 
Suc                       75% 
Adi                       75% 
Sub                       92% 
Seb                       83% 
Dod                       67% 
Fum                       83% 
Mal                       92% 
Glu                       92% 
Pim                       75% 
Aze                       83% 
 0/10 10/10 10/10 9/10 7/10 4/10 10/10 8/10 10/10 10/10 10/10 10/10  
3HydroxyBA                      50% 
4HydroxyBA                      50% 
3AminoBA                      83% 
4AminoBA                      42% 
3NitroBA                      100% 
4NitroBA                      42% 
BA                      83% 
4IodoBA                      17% 
4BromoBA                      25% 
PentaFBA         
 
            100% 
 6/10 7/10 7/10 4/10 5/10 4/10 6/10 6/10 7/10 8/10 5/10 6/10  
  6/20 17/20 17/20 13/20 12/20 8/20 16/20 14/20 17/20 18/20 15/20 16/20 169/240   
  30% 85% 85% 65% 60% 40% 80% 70% 85% 90% 75% 80% 70%  
 
3.3.1.2 Energies as prediction method for co-crystal screening 
The best hetero-meric interaction in P1-P8 molecules is OH(acid)…C=O (amide) and in P9-P12 
is OH(acid)…. N(pyridine). The best homomeric interaction in P1-P8 is 
NH(pyrazole)…C=O(amide) and in P9-P12 is NH(pyrazole)…N(pyridine).  The results of MCE 
are presented in Appendix G.  
3.3.1.3 Propensities as prediction method for co-crystal screening 
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Hydrogen-bond propensity calculations were performed on P1-P12 against 20 co-formers.  The 
two highest propensity donor-acceptor interactions were taken into account for homomeric 
systems in the target molecules: NH(pyrazole)….C=O(amide) for group P1-P12 and N-
H(pyrazole)N(pyridine) for group P9-P12. The two highest propensity donor-acceptor 
interactions were taken into account for hetero-meric systems: O-H(acid)O=C(amide) for group 
P1-P12 and OH(acid)…N(pyridine) for group P9-P12. An MCP score (as described in section 
4.2.4) is used to predict whether a reaction (in this case, co-crystal formation) will or will not take 
place when two reactants are combined. A summary of the multi-component hydrogen-bond 
propensity (MCP) screening results for P1-P12 with 20 co-formers is given in the Appendix G.    
 
3.3.2 Part 2: Synthon Prediction study  
3.3.2.1 Method 1: Electrostatics for synthon prediction in co-crystals  
In order to determine which synthon is more likely to form in the co-crystals, prediction studies 
were performed using electrostatics best donor binding to best acceptor rule. The different 









Synthon III Synthon IV 
Two-point 
interaction  
Synthon I Synthon I 
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Figure 3.1 Synthon prediction using electrostatics method for group 1 and group 2.  
 
3.3.2.2 Method 2: Energies for synthon prediction in co-crystals 
Hydrogen-bond energies of each synthon was calculated in each group and the average energy 
for each synthon is shown in Table 3.4-3.6.   
Table 3.4 Hydrogen-bond energies for each synthon in each respective group (P1-P12 against 10 
aliphatic acids and 6 aromatic acids).  
P1-P12 against 20 acids 
  Synthon I Synthon II Synthon III Synthon IV 
GROUP 1 Aliphatic acids (10) 37.21±0.57 32.54±1.14 28.36±1.75 N/A 
 Aromatic acids (6) 32.10±0.83 29.15±1.18 31.34±0.94 N/A 
GROUP 2 Aliphatic acids (10) 34.32±0.99 29.88±0.54 22.64±0.56 26.90±1.74 
 Aromatic acids (6) 29.02±1.10 26.23±0.91 24.96±1.23 29.26±1.89 
 
Table 3.5 Hydrogen bond energies for synthons I, II, III and IV in each respective group (P1-
P12 against aromatic acids with an additional donor group).  
 Synthon I Synthon II Synthon III Synthon IV 
GROUP 1 29.68±0.60 26.52±1.00 26.30±0.79 N/A 
GROUP 2 27.03±0.84 24.37±0.96 20.94±1.03 24.55±1.59 
 
Table 3.6 Hydrogen bond energies for synthon V, VII, VIII and X in each respective group (P1-
P12 against aromatic acids with an additional donor group).  
  Synthon V/VIII Synthon VI/IX Synthon VII/X 
GROUP 1 OH 20.64±1.25 31.75±0.96 N/A 
 NH2 13.35±0.81 20.53±0.62  
GROUP 2 OH 17.63±1.44 25.28±1.24 25.72±3.19 
 NH2 11.41±0.93 16.35±0.80 19.16±1.24 
 
3.3.2.3 Method 3: Propensities for synthon prediction in co-crystals 
Hydrogen-bond propensities were calculated for each group for different co-formers by looking at 
the heteromeric interactions in the propensity chart. The results of the propensity predictions are 
shown in the Table 3.7.  
Table 3.7 Synthon prediction using propensity method for group 1 and group 2.  
 Group 1(P1-P8) Group 2 (P9-P12) 
Aliphatic acid (10) Synthon I (NH(pyrazole)….C=O(acid)) Synthon IV 
Aromatic acids (w/o 
additional donor) 
Synthon I (NH(pyrazole)….C=O(acid)) Synthon IV 
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HydroxyBA Synthon III Synthon IV 
AminoBA Synthon IX Synthon X  
 
3.3.2.4 Method 4: Molecular complementarity for synthon prediction 
The molecular complementarity approach was used to determine which synthon is more likely to 
occur between synthon I and synthon II using CSD. The search was done by using fragments 






(a) Synthon I (b) Synthon I results 
 
 
(c) Synthon II (d) Synthon II results 
Figure 3.2 (a) Synthon I fragment used for search, (b) Bond angles distribution of 
NH(pyrazole)…O=C(acid) interaction in the CSD database, (c) Synthon II fragment used for 
search and (d)Bond angles distribution of NH(pyrazole)…O=C(acid) interaction in the CSD. 
3.3.3 Experimentally observed synthons   
The crystal structures are divided into three groups. Thirteen crystal structures (P1-PentaFBA, 
P2-Fum, P2-Suc, P2-Adi, P2-Pim, P3-3nitroBA, P3-4aminoBA, P3-PentaFBA, P4-Fum, P4-
Adi, P7-Sub, P8-Aze, and P8-Sub ) were obtained for group 1, and three crystal structures were 










Figure 3.3 Supramolecular trimer formed via 𝑹𝟐
𝟐(8) heterosynthons in (a) P2-Fum, (b) P2-Suc, 










Figure 3.5 Supramolecular dimer in (a) P1-PentaFBA, (b) P3-3nitroBA, (c) P3-4-aminoBA and 
(d) P3-PentaFBA.  
Four crystal structures were obtained in group 2 (P10-Fum, P10-Mal, P11-Aze and P11-dod) 
with di-aliphatic acids. No co-crystals were obtained with aromatic acids with and without 





Figure 3.6 Supramolecular trimer in (a) P10-Fum, (b) P10-Mal and (c) P11-Aze in 2:1 
stoichiometry. Synthon crossover in (d) P11-dod leading to 1:1 stoichiometry.  
 
3.4 Discussion 
3.4.1 Experimental co-crystal screening  
3.4.1.1 Group 1(co-crystallization of P9-P12 with 20 carboxylic acids) 
Target molecules P1-P8 formed co-crystals in 58 out of 80 (73% supramolecular yield) 
experiments with aliphatic acids and in 45 out of 80 experiments (56% supramolecular yield) with 
aromatic acids. Overall, all target molecules except P1(with 30% yields) and P6 (with 40% yields) 
has good success rate based on the grinding experiments with 20 co-formers (64% supramolecular 
yield). Adding a methyl group on P1 to form P6 increases the supramolecular yield from 30% to 
85%, whereas adding a methyl group on P5 to form P6 decreases the supramolecular yield from 
60% to 40%. Target molecules P2, P3 and P7 have the highest supramolecular yields in this group. 
The target molecules with an aliphatic side chain group (P1-P6) gave 73 out of 120 experimental 
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positive co-crystal outcomes indicating 61% success rate whereas the target molecules with an 
aromatic side group (P7-P8) gave 30 out of 40 positive co-crystal outcomes indicating 75% 
success rate. This indicates that aromatic group has higher probability of forming co-crystals 
compared to alkyl chains although the comparison might not be fair as the dataset of alkyl group 
molecules is larger compared to aromatic groups.  
 
3.4.1.2 Group 2(co-crystallization of P9-P12 with 20 carboxylic acids) 
Group 2: P9-P12 formed co-crystals in 40 out of 40 (100% supramolecular yield) experiments 
with aliphatic acids and in 26 out of 40 experiments (65% supramolecular yield) with aromatic 
acids. Overall, all target molecules, P9-P12 have good success rate based on the grinding 
experiments with 20 co-formers (83% supramolecular yield), Figure 4.1. Adding a methyl group 
on P9 and P11 increases the supramolecular yield by 5% in P10 and P12.  
Overall, the experimental screen produced co-crystals in 169 of the 240 experiments (70% 
supramolecular yield) between P1-P12 and 20 dicarboxylic acids, Table 4.2 (from IR). It is a rather 
high success rate considering the very limited scope of the experimental screen (only LAG from 
methanol was used to screen for co-crystals and only one solvent (methanol or nitromethane) was 
used to grow single crystals).  With further experimentation, it is reasonable to assume that some 
pairs that did not succeed in co-crystallizing in this screen could eventually form. Still, it is 
necessary to employ consistent experimental conditions when trying to elucidate the success or 






Figure 3.7 Graphs showing supramolecular yields with respect to each group.  
 
3.4.2 Experimental co-crystal screening vs energy prediction  
The multicomponent score for hydrogen-bond energies (MCE) was obtained by subtracting the 
best homo-meric interactions from the best hetero-meric interactions. The comparison between 
predicted and experimental co-crystal screen was made, Appendix G.  
 
In group 1, 160 experiments were performed, and the energy prediction was compared with the 
experimental co-crystal screening. 92 out of 160 co-crystal screens were true positive, 51 were 
false positive, 11 were false negative and 6 were true negative. In total, there was an 61% 
agreement (98 out of 160 combinations were either true positive or true negative) between the 
predicted and experimental results for P1-P8 with 20 acids, Figure 3.8a.  A low success rate is 
because 51 out of 160 combinations were predicted as false positives, indicating that the energy 
method predicted them to be positive co-crystal but experimentally, they were designated as 
negative co-crystal outcome. Therefore, an energy method could not predict which combinations 
does not form co-crystals in group 1.  
In group 2, 64 out of 80 experiments were true positive, 10 were false positive, 2 were false 

































80 combinations were either true positive or true negative) between the predicted and experimental 
results for P9-P12 with 20 acids.  The energy method predicted the experimentally co-crystal 






































98/160, 61% 68/80, 85% 
(a) Group 1(P1-P8) (b) Group 2 (P9-P12) 
Figure 3.8 Confusion matrices determined from multi-component energies, MCE results (cut off 
=-0.10) for P1-P12 molecules with co-formers, (a) Group 1(P1-P8) and (b) Group 2 (P9-P12). 
 
3.4.3 Experimental co-crystal screening vs propensity prediction  
The predictions made using the MCP model were compared to experimental co-crystal screening 
results, Appendix G. A confusion matrix was used to analyze the data as reported by Wood et. 
al.24  
The confusion matrices determined from MCP results using cut off =0.00 and -0.10 for P1-P12 
are shown in Figure 3.9-3.10. In total, the number of false negatives reduced from 142 to 66 by 
changing the cut off from 0.0 to -0.10. The agreement between experimental and predicted also 
increased from 35% (89 out of 240 combinations) to 57% (136 out of 240 combinations).  
 
MCE (P1-P8) 
Cut off = 0.0 
Predicted outcome 
MCE (P9-P12) 































71/160, 44% 12/80, 15% 
(a) Group 1(P1-P8) (b) Group 2 (P9-P12) 
Figure 3.9 Confusion matrices determined from multi-component propensity MCP results (cut off 





Cut off = -0.10 
Predicted outcome 
MCP(P9-P12) 






























88/160, 55% 48/80, 60% 
(a) Group 1(P1-P8) (b) Group 2 (P9-P12) 
Figure 3.10 Confusion matrices determined from multi-component propensity MCP results (cut 
off = -0.10) for P1-P12 molecules with co-formers, (a) Group 1(P1-P8) and (b) Group 2 (P9-P12).  
 
The prediction of co-crystal based on propensity in pyrazole-amide based molecules is difficult 
because of the presence of multiple donors and acceptors on the pyrazole. At-least two different 
interactions are possible in each co-crystal combination due to presence of two donor groups on 
the pyrazole molecules: both could be heteromeric interactions or one could be homomeric and 
other could be heteromeric interaction. The propensity MCP score is based on only best hetero and 
homo interaction observed. For examples, in group 1, The best homomeric interaction; 
NH(pyrazole)…C=O (amide) is a stronger interaction compared to the best heteromeric 
interaction; NH(pyrazole)…C=O(acid). Therefore, the outcome based on MCP is negative co-
crystal. However, experimentally it is a positive co-crystal and the best homomeric interaction is 
observed in the co-crystal. This indicated that we must consider all the possible homomeric and 
heteromeric interactions in the molecule. Similar is true for group 2 in which the best homomeric 
interaction NH(pyrazole)…N(pyridine) or NH(pyrazole)….C=O(amide) is observed in the 
experimentally observed crystal structures.  
 
3.4.4 Comparison between predicted and experimental co-crystal screening 
Two prediction methods were used to analyze the co-crystal grinding experiment results in this 
study, Table 3.8. The data was divided in two groups based on the number of functional groups 
present on the target molecules. 
Based on the MCE method, there was 61% agreement between prediction and experimental co-
crystal outcome for group 1 and 85% for group 2. The method did well on group 2 and didn’t do 
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that well on group 1. The possible reason for low success rate in group 1 could be due to the 
method not able to predict the experimentally observed negative co-crystal outcome. The best 
homomeric interaction is NH(pyr)...C=O(amide) and the best heteromeric interaction is 
OH(acid)…C=O(amide). The heteromeric interaction was stronger than homomeric interaction in 
most cases so gave positive MCE score. The method gave 51 false positives which means they 
were predicted as positive co-crystal outcome but experimentally formed negative co-crystal.  
Propensity method was used as an alternative to determine the MCP score which is determined by 
subtracting the best homomeric interaction from the best heteromeric interaction based on 
knowledge of Cambridge structural database. Based on MCP as 0.0 cut off, there was 44% and 15 
% agreement between predicted and experimental for group 1 and group 2 respectively. This poor 
agreement is because the propensity predicted homo-meric NH(pyr)…C=O(amide) interaction in 
group 1 and NH(pyr)…N(pyr) in group 2 as the best interactions. Therefore, the MCP score was 
negative and 142 out of 240 co-crystals (59%) were predicted as false negative means they were 
predicted negative by propensity but they do form co-crystal experimentally. Since pyrazole target 
molecules has multiple functional groups including two donor groups, it is likely that more than 
one interaction happens in the co-crystal and the propensity calculation method need to be 
modified to include all possible interaction. Based on MCP cut off value of -0.10, the agreement 
was improved to 55% for group 1 and 60% for group 2.  
 
Table 3.8 Summary of experimental co-crystal screening and energy and propensity prediction 
comparison for group 1 and group 2.  
 Experimental co-







Group 1 64% 98/160, 61% 71/160, 44% 88/160, 55% 
Group 2 83%  68/80, 85% 12/80, 15% 48/80, 60% 
 
PART 2: SYNTHON PREDICION STUDY 
Once, the co-crystal screen was done, synthon prediction studies were performed. There are two 
binding pockets in the pyrazole molecules, P1-P8. The acid functionality of carboxylic group (10 
aliphatic acids and 10 aromatic acids w/o additional donor) can either bind to pyrazole binding 
pocket forming synthon I, or amide binding pocket forming synthon II or it can undergo synthon 





(a) Group 1 (b) Group 2 
Scheme 3.8 Schematics showing different synthon possibilities.   
In P9-P12, the additional pyridyl acceptor group can lead to synthon IV. Therefore, in P1-P8, 
synthon I, II, and III are possible and in P9-P12, synthon I, II, III, and IV are possible. The 
synthon complexity increases as an additional donor group is introduced on the aromatic acids (an 
additional synthon V, VII and VIII for hydroxyBA and an additional synthon VIII, IX and X for 
aminoBA). To find out which of these synthons is more likely to happen in the crystal structure, 
predictions were made using electrostatics, energies and propensity method.  
 
3.4.5 Synthon prediction in group 1 
3.4.5.1 Method 1: Electrostatics 
Synthon I is predicted to be the most optimal synthon as the NH(pyrazole) is the best donor and N 
(pyrazole) is the second best acceptor compared to synthon II in which NH(amide) and 
N(pyrazole) will form synthon in aliphatic acids and aromatic acids without additional donor. 
Synthon VI is predicted to be the most likely synthon in hydroxyBA and synthon I is the best 
predicted synthon in aminoBA, Figure 3.11.  
 
3.4.5.2 Method 2: Energies 
In group 1, for aliphatic acids, synthon I was the most preferred synthon followed by synthon II. 
For aromatic acids without an additional donor group, I was the most preferred synthon followed 
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by synthon III and synthon II. In hydroxyBA, one-point synthon VI and two-point synthon I are 
most likely to happen. In aminoBA, synthon I is most likely to occur, Figure 3.11.  
 
Figure 3.11 Synthon predicted in group 1 using electrostatics and energies.  
 
3.4.5.3 Method 3: Propensities 
The best heteromeric interaction was selected from the propensity chart and the synthon based on 
that interaction was chosen to be the most preferred synthon based on propensity. The preferred 




Figure 3.12 Synthon predicted in group 1 using propensities.  
 
3.4.5.4 Molecular complementarity/geometrical constraints  
The main difference between synthon I and synthon II is that in the former, pyrazole NH is used 
as the hydrogen-bond donor for ligand and in the latter, amide NH is used as the hydrogen-bond 
donor. The bond analysis of crystal structures in the CSD was done for NH(pyrazole)…O=C(acid) 
and NH(amide)...O=C(acid) interactions.  Ten structures are reported in the CSD where pyrazole 
binding pocket binds to carboxylic acids via dimeric synthon I. 76 structures are reported in the 
CSD where amide pocket binds as dimer to the carboxylic acids visa synthon II. The bond angle 
analysis shows that most structures with NH(pyrazole)…O=C(acid) interaction has a bond angle 
of 138 ̊and NH(amide)…. O=C(acid) interactions has a bond angle of 172 ̊, Figure 3.13.  
 
Figure 3.13 Differences in angles of amide and pyrazole binding pocket.  
 
The second interaction OH(acid)…N(pyrazole) is common in both synthons and is almost linear. 
These results indicate that NH(amide)...O=C(acid) interaction is more linear compared to 
NH(pyrazole)…O=C(acid), therefore when a probe molecule has a choice between two binding 
pockets, it binds to the one which forms more linear hydrogen-bond interactions, i.e. the probe 
binds to pocket which is more geometrically favorable/compatible. In this study, amide binding 




Figure 3.14 Summary of synthon predictions by different methods in group 1.  
 
3.4.6 Synthon prediction in group 2 
3.4.6.1 Method 1: Electrostatics 
In group 2, synthon I is most likely to occur for two-point interaction and synthon IV based on 
one-point interaction. Note that the supramolecular chelate effect plays a role in the final 
determination of the synthon. For HydroxyBA, where additional single point interaction donor is 
present, synthon VII in group 2 are very likely to happen based on best donor-best acceptor Etter’s 




Figure 3.15 Synthon prediction in group 2 using electrostatics.  
3.4.6.2 Method 2: Energies 
In group 2, Synthon I was the most preferred synthon in aliphatic acids and synthon III was the 
most preferred synthon in aromatic acids (without additional donor group) followed by synthon I 
and synthon II. All synthons were close in energy; therefore, any synthon could be possible. In 
group 2 with hydroxyBA and aminoBA, there are seven synthon possibilities in each combination 
because of presence of an additional acceptor group on each target molecule. In hydroxyBA, 
synthon II (two-point interaction) and synthon IV (one-point interaction) are most likely to occur. 







Figure 3.16 Synthon prediction in group 2 using (a) energies and (b) propensities.  
 
3.4.6.3 Method 3: Propensities 
Synthon IV is the most preferred synthon in aliphatic acids and aromatic acids without an 
additional donor group. In hydroxyBA, synthon IV is the most optimal synthon in group 2. In 
aminoBA, synthon X are the most preferred synthons in group 2, Figure 3.16b.  
 
Figure 3.17 Summary of synthon predictions by different methods in group 2.  
 
 
3.4.7  Synthon observed in the crystal structures   
3.4.7.1 Crystal structures in group 1 
In group 1, nine crystal structures were obtained with di-aliphatic acids and four crystal structures 
were obtained with mono-aromatic acids. In seven out of nine cocrystals with di-aliphatic acids 
(78%), both ends of acids are involved in two complementary hydrogen bonds between carboxylic 
acid O-H(acid)…N(pyrazole) and N-H(amide)…O=C(acid) acid moieties gives rise to the robust 
𝑅2
2(8) hydrogen-bonded synthon II in a 2:1 crystallizing agent: acid stoichiometry. These 
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heteromeric synthons are propagated into 2-dimensional sheets via hydrogen bonding between 
pyrazole N-H and carbonyl oxygen of the target molecule, forming homo-meric synthon.  
There are two exceptions. The co-crystal of P4-Adi and P8-Sub forms dimeric synthon II on one 
side of acid (two-point interaction) but forms one point-interactions on the other end of acid; 
synthon III (OH(acid)…C=O(amide)) and half of synthon I (NH(pyrazole)….C=O(acid)) leading 
to synthon crossover. In aromatic acids without an additional donor group, three crystal structures 
were obtained and in all crystal structures, synthon II involving OH(acid)…N(pyrazole) and 
NH(amide)…O=C(acid) is the dominant interaction leading to 1:1 stoichiometry.  In aromatic 
acids with an additional donor group, one crystal was obtained with P3-4minoBA and synthon II 
was observed as predicted by molecular complementarity approach. Therefore, in eleven out of 
thirteen crystal structures (85%) in group 1, synthon II is preferred over synthon I or III. Synthon 
II was predicted based on molecular complementarity over synthon I even though the latter is 
predicted to more optimal synthon based on electrostatics, energies, and propensities in aliphatic 
diacids and aromatic acids with no additional donor, Figure 3.18.  
 
Figure 3.18 Summary of synthons observed in the crystal structures in group 1.  
 
3.4.7.2 Crystal structures in group 2 
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Four crystal structures were obtained in group 2 and in three out of four co-crystals (P10-Fum, 
P10-Mal, and P11-Aze) with di-aliphatic acids, synthon II was observed. The crystal structure of 
P11-Aze forms robust synthon II on one side of suberic acid whereas the opposite end of acid 
participates in the synthon IV and half of synthon I leading to synthon crossover. No co-crystals 
were obtained with aromatic acids with and without additional donor group, Figure 3.19.  
 
Figure 3.19 Summary of synthons observed in the crystal structures in group 2.  
 
In total, we obtained 13 co-crystals with aliphatic acids and 4 co-crystals with aromatic acids. 
Therefore, 10 out of 13 (77%) outcomes showed dimeric synthon II and 2 out of 13 (15%) showed 
synthon III, 1 out of 13 (7%) showed synthon IV as the most preferred supramolecular outcome 
irrespective of different groups. The structure determinations reveal that synthon II is the most 
desired synthon and the primary intermolecular interactions, the O-H(acid)…N(pyrazole) and N-
H(amide)…O=C(acid) hydrogen bonds, consistently remain intact. The supramolecular trimer was 
extended into 2-D sheets via one-point homomeric hydrogen bond between pyrazole N-H and 
carbonyl oxygen, N-H(pyrazole)…O=C(amide), resulting in homo-meric synthon.  In each case, 
dimeric synthon II is preferred over synthon I in a competitive environment. Therefore, having 
methyl group on pyrazole backbone or introducing bulky substituents such as methyl, ethyl, phenyl 
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or pyridyl groups next to amide functionality didn’t change the synthon preference in these co-
crystals but there is chance of synthon crossover.  
3.4.8 Comparison of experiment vs predictions 
Comparing the predicted synthons with the observed synthons, it was found that the synthons 
observed in the crystal structures matches with the second possibility of predicted synthon 
(Synthon II or III) instead of the first possibility (synthon I) based on all three prediction methods 
(electrostatics, energies and propensities). Synthon II was also predicted based on molecular 
complementarity.  Synthon I was the most preferred synthon based on prediction, but it wasn’t 
observed in any of the crystal structures because of geometric constraints associated with this 
synthon.  Based on CSD search, synthon II was more likely to occur compared to synthon I 
because in former, the hydrogen-bond angles are more linear compared to the former synthon. 
These results indicate that when a probe molecule has a choice between two binding pockets, it 
binds to the one which forms more linear hydrogen-bond interactions, i.e. the probe binds to pocket 
which is more geometrically favorable/compatible. Therefore, in this study even though synthon I 
is more energetically favored, synthon II is preferred because it is more geometrically compatible.  
 
Table 3.9 Summary of predicted vs experimental synthons observed in each group  
 













Group 1 Aliphatic acids Synthon I Synthon II 
 
Synthon II Synthon II (7/9) 
Synthon III (2/9) 
Aromatic acids Synthon I or III Synthon II (3/3) 
HydroxyBA Synthon VI, III Synthon I N/A 
AminoBA Synthon I, III, IX Synthon II Synthon II (1/1) 
Group 2 Aliphatic acids Synthon I, IV Synthon II Synthon II Synthon II (3/4) 
Synthon III (1/4) 
Aromatic acids Synthon I, IV N/A 
HydroxyBA Synthon I, VII, IV N/A 
AminoBA Synthon IV, I, X N/A 
 
3.5 Conclusions 
We attempted to co-crystallize the twelve target molecules (P1-P12) with twenty different 
carboxylic acids to probe the strength and stability of the homomeric interactions. 
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1. The homomeric interactions were broken to form heteromeric synthons via experimental co-
crystallization with 70% success rate.  
2.  Hydrogen bond energy and propensity were used as prediction methods to predict and 
compare the experimental co-crystal screening results comprising twelve target molecules and 
twenty carboxylic acids resulting in 240 data points.  Hydrogen-bond energy resulted in 69% 
agreement and hydrogen bond propensity resulted in only 35% agreement.  
3. Synthon prediction studies were done using electrostatics, energies, propensities and molecular 
complementarity. Synthon I was the preferred synthon over synthon II based on electrostatics, 
energies and propensities whereas Synthon II was preferred based on molecular 
complementarity.  
4. Synthon II was observed experimentally in 14 out 17 crystal structures with 82% success rate.  
These results indicated the solid state supramolecular synthesis25 depends not only upon the 
electrostatic or chemical environment around the binding site but also upon the size, shape, 
geometry and orientation of interacting molecular species to achieve robust and predictable 
supramolecular synthons.26  Effective molecular recognition occurs when both factors, 
electrostatics and molecular geometry are compatible between the interacting partners.27,28   
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Chapter 4 - Evaluating Homomeric Synthons in Thiazole based 
Molecules using Energies and Propensities 
4.1 Introduction 
Thiazole rings are present in many pharmaceutical compounds, and drugs such as FB,24 AMG 
517,25 meloxicam,26-27 and nitazoxanide,28-29 contain amide-substituted thiazoles as part of their 
chemical make-up.  This functionality has been successfully exploited to synthesize co-crystals of 
some of these active pharmaceutical ingredients (APIs). Knowing in advance which 
supramolecular pathways are accessible in molecular solids by themselves, and which of those 
possible options is the most likely route for a molecule, is thus clearly of importance for developing 
solid forms with optimum bulk properties.  
 








(a) Synthon A (b) Synthon B (c) Synthon C (d) Synthon D 
Scheme 4.2 Four postulated synthons in a generic thiazole-amide; (a) synthon A, N-H 
(amide)…(aromatic); (b) synthon B, N-H (amide)…S(aromatic); (c) synthon C, N-H 
(amide)…O=C(amide); and (d) synthon D, N-H (amide)…(pyridine N(R1=H, CH3; R2= methyl, 
ethyl, or benzyl).  
In this study, we want to establish what intermolecular preference, if any, the N-H group displays 
and whether we can rationalize this in a convincing manner. The target molecules T1-T12 (scheme 
4.2) are divided into two groups based on the number of functional groups present. T1-T8 belongs 
to group1 and T9-T12 belongs to group 2 molecules.  The interaction between the hydrogen-bond 
donor and the three possible acceptors in group1 would lead to three different synthons (synthon 
A, synthon B and synthon C) and an additional synthon (synthon D) in group 2, Scheme 4.3, taking 
into account only the trans C=O-NH isomer and disregarding any catemeric versions of synthons 
A and B.   We used structural informatics as a guideline to determine the most plausible 
conformation in these target molecules using data from the CSD.  The search was restricted to 
structures without disorder, and with an R-factor below 5%.  According to our CSD search (CSD 
database 5.38, Nov 2016 with updates from Feb and May 2017),30-33 we found 6335 relevant 
structures containing the amide functionality and only about 0.5% of these displayed a cis CO- 
NH isomer.  Therefore, we felt justified in focusing exclusively on the trans CO-NH geometry in 
these target molecules.  In addition, structural data complemented by geometry optimizations (see 




Scheme 4.3 An outline of prediction and experimental methods used in this study.  
The study is done to answer the following questions, 
1. Which method (MEPs, HBE, HBP or HBC) is successful in predicting the key hydrogen-
bond interactions? 
2. Is a combination of prediction methods preferred over individual methods? 
3. Which synthon is the most optimal synthon in group 1 (T1-T8) and how does adding an 




2-Amino-thiazole, 2-amino-5-methyl-thiazole, acetic anhydride, propionic anhydride, butyric 
anhydride, nicotinic acid, Isonicotinic acid and thionyl chloride and benzoyl chloride were 
purchased from commercial sources and utilized without further purification. Target molecules 
T1-T6 and T9-T12 are synthesized following procedures below. Target molecules T7-T8 are 
synthesized following literature methods.34 Melting points were measured using a Fisher-Johns 
melting point apparatus. Solution 1H NMR data were collected in DMSO-d6 on a Varian Unity 





4.2.2.1 Synthesis of 2-acetamido-thiazole, T1 
 
 
A solution of 2-amino-thiazole (2.46g, 24.6mmol) in 15ml of acetic anhydride was refluxed until 
acetylation was complete for approximately 6 hours. Thin layer chromatography (TLC) was 
performed to confirm the formation of only one product. Excess acetic anhydride and acetic acid 
were removed by rota-evaporation under vacuum. The product so obtained was washed with water 
and the solid precipitate was filtered. The solid was dissolved in a 1:1 ratio of methanol/diethyl-
ether and the solution was allowed to stand at room temperature. Crystals of pure product were 
obtained in a week. Yellow solid; yield: 2.75 g (79%); mp 200-205 ̊C (lit. 200-202 ̊C)35  1H NMR 
(δH; DMSO, 400MHz): 11.48 (s, 1H), 7.85 (d, 1H), 7.53 (d, 1H), 2.69 (s, 3H).  
 
4.2.2.2 Synthesis of 2-acetamido-5-methyl-thiazole, T2. 
 
A solution of 2-amino-5-methyl-thiazole (2.6g, 17.4mmol) in 10ml of acetic anhydride was 
refluxed at 70 ̊C for approximately 6 hours until acetylation was complete. TLC was performed to 
confirm the formation of only one product. Excess acetic anhydride and acetic acid were removed 
by rota-evaporation under vacuum. The product so obtained was washed with water and the solid 
precipitate was filtered. The solid was dissolved in a 1:1 ratio of methanol/diethyl-ether and the 
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solution was allowed to stand at room temperature. Crystals of pure product were obtained in a 
week. White solid; yield: 3.55 g (98%); mp 219-225 ̊C (lit. 225 ̊C)i H NMR (δH; DMSO, 
400MHz): 11.32 (s, 1H), 7.49 (s, 1H), 2.80 (s, 3H), 2.65 (s, 3H). 
 
4.2.2.3 Synthesis of 2-propamido-thiazole, T3. 
 
A solution of 2-amino-thiazole (2.46g, 24.6mmol) in 10ml of propionic anhydride was refluxed at 
65 ̊C for 2 hours. TLC was performed to confirm the formation of only one product. Excess 
propionic anhydride and propionic acid were removed by rota-evaporation under vacuum. The 
brown product so obtained was washed with water and the solid precipitate was isolated by 
filtration. The solid was dissolved in methanol and the solution was allowed to stand at room 
temperature. Crystals of pure product were obtained in 5 days. Brown solid; yield: 3.00 g (78%); 
mp 158-162 ̊C (lit. 157-159 ̊C)ii; 1H NMR (δH; DMSO, 400MHz): 12.05 (s, 1H), 7.44 (d, 1H), 
7.18(d, 1H), 2.42 (q, 2H), 1.08 (t, 3H).  
 
4.2.2.4 Synthesis of 2-propamido-5-methyl-thiazole, T4. 
 
A solution of 2-amino-5-methyl-thiazole (2.6g, 17.4mmol) in 10ml of propionic anhydride was 
refluxed at 65 ̊C for 2.5 hours. TLC was performed to confirm the formation of only one product. 
Excess propionic anhydride and propionic acid were removed by rota-evaporation under vacuum. 
The yellow product so obtained was washed with water and the solid precipitate was isolated by 
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filtration. The solid was dissolved in methanol and the solution was allowed to stand at room 
temperature. Crystals of pure product were obtained in a week. Yield: 3.89 g (88%); mp 196-
201 ̊C; 1H NMR (δH; DMSO, 400MHz): 11.84 (s, 1H), 7.10 (s, 1H), 2.32 (q, 2H), 2.32 (s, 3H), 
1.07 (t, 3H). 
 
4.2.2.5 Synthesis of 3-butyramido thiazole, T5 
 
 
2-Aminothiazole (0.601 g, 6.00 mmol) was dissolved in 30 mL of dichloromethane, 1.6 mL N-
methylmorpholine (14.6 mmol), and 1.49 mL butyryl chloride (14.0 mmol). After stirring for 16 
hours, the mixture was concentrated and the residue was dissolved in 30 mL methanol.  Then, 7 
mL of 2.5M sodium hydroxide was added dropwise, followed by 10 mL of tetrahydrofuran. The 
mixture was allowed to sit for 15 minutes before being concentrated again and suspended in water. 
The tan precipitate was filtered, air dried, and finally recrystallized in methanol to yield dark, 
golden crystals. 61% yield, m.p. 143-146°C, 1H NMR (400 MHz, DMSO-d6) δ ppm: 12.02 (1H), 
7.42 (1H), 7.16 (1H), 2.38 (2H), 1.60 (2H), 0.88 (3H). 
 




2-Amino-5-methylthiazole (0.685 g, 6.00 mmol) was dissolved in 30 mL of dichloromethane, 
1.6 mL N-methylmorpholine (14.6 mmol), and 1.49 mL butyryl chloride (14.0 mmol). After 
stirring for 16 hours, the mixture was concentrated and the residue was dissolved in 30 mL 
methanol.  Then, 7 mL of 2.5M sodium hydroxide was added dropwise, followed by 10 mL of 
tetrahydrofuran. The mixture was allowed to sit for 15 minutes before being concentrated again 
and suspended in water. The tan precipitate was filtered, air dried, and finally recrystallized in 
methanol to yield tan crystals. 45% yield, m.p. 126-135°C, 1H NMR (400 MHz, DMSO-d6) δ ppm: 
11.01 (1H), 6.28 (1H), 1.55 (2H), 1.51 (3H), 0.78 (2H), 0.07 (3H). 
 
4.2.2.7 Synthesis of 2-benzamido-thiazole, T7 
 
To a mixture of 2.5g of 2-amino-thiazole in 30ml acetone and 50ml brine solution (16.67g NaCl 
in 50ml water), 2.91ml of benzoyl chloride in 3ml acetone was added in increments over a period 
of 15 minutes with continuous stirring at room temperature. A total of 4.2g of sodium bicarbonate 
was dissolved in 50ml of water and the saturated solution was added to the mixture. The reaction 
mixture was further stirred for 15-30 minutes. The solid formed was separated by filtration and 
dried. It was dissolved in methanol and the solution was allowed to slowly evaporate at room 
temperature to grow single crystals.  White solid; yield: 3.06 g (60%); mp 150-152 ̊C (lit. 152 ̊C) 
1H NMR (δH; DMSO, 400MHz): 12.65 (s, 1H), 8.10 (d, 2H), 7.63 (t, 1H), 7.54 (d, 2H), 7.52 (s, 
1H), 7.29 (s, 1H).  
 




To a mixture of 1.42 g of 2-amino-5-methyl-thiazole in 15ml acetone and 25ml brine solution 
(8.34g NaCl in 50ml water), 1.45ml of benzoyl chloride in 1.5ml acetone was added in portions 
with continuous stirring during 15 minutes at room temperature. A total of 2.10 g of sodium 
bicarbonate was dissolved in 25ml of water and the saturated solution was added to the mixture. 
The reaction mixture was further stirred for 15-30 minutes. The solid formed was separated by 
filtration and dried. It was dissolved in methanol and the solution was allowed to slowly evaporate 
at room temperature to grow single crystals. White solid; yield: 2.01 g (73%); mp 160-162 ̊C; 1H 
NMR (δH; DMSO, 400MHz): 12.46 (s, 1H), 8.08 (d, 2H), 7.62 (t, 1H), 7.53 (d, 2H), 7.23 (s, 1H), 
2.37 (S, 3H).  
 
4.2.2.9 Synthesis of N-(thiazol-2-yl) nicotinamide, T9 
 
A solution of 3-pyridine-carboxylic acids (5 grams, 40.5 mmol) in thionyl chloride (50ml) was 
refluxed for 4 hours at 70-80 °C. Then, thionyl chloride was removed under vacuum to obtain 
white solid as nicotinoyl chloride (91.27%). 2-amino-thiazole (1.2g, 12 mmol) was added slowly 
into 50ml round bottom flask containing nicotinoyl chloride (1.70g, 12 mmole) and triethylamine 
(1.6 ml) in acetonitrile (20 ml). the mixture was stirred at room temperature overnight. The organic 
layer was washed with water and the solvent was removed by gravity filtration to yield a yellow 
powder as the crude product. The product was recrystallized from methanol. Yellow solid; yield 
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90%; mp 213-214 ̊C, 1H NMR (δH, 400 MHz, DMSO): 12.87 (br, 1H), 9.20 (s, 1H), 8.79 (s, 1H), 
8.42 (s, 1H), 7.57 (s, 2H), 7.32 (s, 1H).   
 
4.2.2.10 Synthesis of N-(5-methylthiazol-2-yl) nicotinamide, T10 
 
A solution of 3-pyridine-carboxylic acids (5 grams, 40.5 mmol) in thionyl chloride (50ml) was 
refluxed for 4 hours at 70-80 °C. Then, thionyl chloride was removed under vacuum to obtain 
white solid as nicotinoyl chloride (91.27%).2-amino-5methyl-thiazole (1.79g, 12 mmol) was 
added slowly into 50ml round bottom flask containing nicotinoyl chloride (1.70g, 12 mmole) and 
triethylamine (1.6 ml) in acetonitrile (20 ml). the mixture was stirred at room temperature 
overnight. The organic layer was washed with water and the solvent was removed by gravity 
filtration to yield a white powder as the crude product. white solid; yield 92%; mp 212-213 ̊C, 1H 
NMR (δH, 400 MHz, DMSO): 12.71 (br, 1H), 9.18 (s, 1H), 8.78 (s, 1H), 8.38 (s, 1H), 7.55 (s, 1H), 
7.24 (s, 1H), 2.38 (s, 3H).    
 
4.2.2.11  Synthesis of N-(thiazol-2-yl)isonicotinamide, T11 
 
A solution of 4-pyridine-carboxylic acids (5 grams, 40.5 mmol) in thionyl chloride (50ml) was 
refluxed for 4 hours at 70-80 °C. Then, thionyl chloride was removed under vacuum to obtain 
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white solid as nicotinoyl chloride (93%). 2-amino-thiazole (1.2g, 12 mmol) was added slowly into 
50ml round bottom flask containing isonicotinoyl chloride (1.70g, 12 mmole) and triethylamine 
(1.6 ml) in acetonitrile (20 ml). the mixture was stirred at room temperature overnight. The organic 
layer was washed with water and the solvent was removed by gravity filtration to yield a yellow 
powder as the crude product. The product was recrystallized from methanol. Yellow solid; yield 
89%; mp 199-201 ̊C,1H NMR (δH, 400 MHz, DMSO): 12.97 (br, 1H), 8.80 (s, 2H), 7.98 (s, 2H),  
7.59 (s, 1H), 7.32 (s, 1H).   
 
4.2.2.12 Synthesis of N-(5-methylthiazol-2-yl) isonicotinamide, T12 
 
2-Amino-5methyl-thiazole (1.79g, 12 mmol) was added slowly into 50ml round bottom flask 
containing nicotinoyl chloride (1.70g, 12 mmole) and triethylamine (1.6 ml) in acetonitrile (20 
ml). the mixture was stirred at room temperature overnight. The organic layer was washed with 
water and the solvent was removed by gravity filtration to yield a dark yellow powder as the crude 
product. Yellow solid; yield 85%; mp 213-214 ̊C,1H NMR (δH, 400 MHz, DMSO): 12.78 (s, 1H), 
8.79 (d, 2H), 7.97 (d, 2H), 7.26(d, 1H), 2.38 (s, 3H).  
 







Figure 4.1 (a) Amide functionality (both bonds are acyclic) used to perform the torsion angle 
search. (b) Scatterplot indicating number of structures with torsions for cis (red, ~32 structures) 
and trans (blue, ~6303 Structures) conformations.  
A search was done by drawing the amide group as shown in Figure 4.1 and CSD database 5.38 
(Nov 2016) with updates from Feb and May 2017 was used to perform the torsion angle search on 
CSD database. The following filters were applied to the search (No disordered, No errors, Not 
polymeric, No ions, No powder patterns and only organics). The torsion angle on four atoms 
(OCNH) was defined from -180° to +180°. A total of 6335 structures was obtained and 
approximately 32 (0.5%) of these structures have the cis-amide conformation and about 6303 
structures (99%) have trans-amide conformation.   
4.2.4 Geometry optimizations for T1-T12 
Geometry optimization was performed on each conformation of T1-T12 and the most stable 
conformation is given a value of 0 kJ/mol; all other conformations energies are presented relative 
to this, Table 4.1.  
Table 4.1 Energies of each trans conformation relative to most stable trans conformation is 
shown below in kJ/mol. Note: conformations of target molecules with methyl group on thiazole 
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T1 0 + 4     
T2 0 +4     
T3 
      
T3 0 +3 +3 +4 +7 +7 
T4 0 +3 +3 +4 +7 +7 
T5 
      
T5 0 +1 +2 +3 +4  
T6 0 +2 0 +3 +4  
       
T5 +5 +5 +6 +7 +9  
T6 +5 +5 +4 +7 +8  
T7 
  
    
T7 0 +7     





4.2.5 Molecular electrostatic potential (MEPs) calculations 
 
Molecular electrostatic potential surfaces (MEPS) of T1–T12 were generated with density 
functional B3LYP level of theory using 6-311++G** basis set in vacuum, see section 2.2.4 for 
details.  
 
4.2.6 Hydrogen-bond energies (HBE) for predicting structural outcomes 
 
See section 2.2.5 for detailed description of hydrogen-bond energy calculations. The results are 
shown in Table 4.2.   
Table 4.2 Electrostatics (in kJ/mol) and alpha and beta values for T1-T12 calculated using 






cyclic N β(N 
acceptor) 

















   
T1 246.00 3.35 -146.00 4.47 -76.00 1.55 -178.00 6.28 
  
T2 237.00 3.19 -153.00 4.84 -80.00 1.68 -184.00 6.65 
  
T3 239.00 3.22 -149.00 4.63 -78.00 1.61 -172.00 5.92 
  
T9 
     
 
T9 0 +4 +5 +8   
T10 +4 +8 0 +5   
T11 
    
  
T11 0 +5     
T12 0 +5     
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T4 231.00 3.09 -156.00 5.00 -88.00 1.95 -178.00 6.28 
  
T5 239.00 3.19 -150.00 4.84 -90.00 1.68 -173.00 6.65 
  
T6 232.00 3.22 -157.00 4.63 -70.00 1.61 -179.00 5.92 
  
T7 226.00 3.00 -149.00 4.63 -84.00 1.81 -172.00 5.92 
  
T8 221.00 2.92 -156.00 5.00 -82.00 1.74 -176.00 6.16 
  
T9 229.00 3.05 -143.00 4.32 -39.00 0.58 -152.00 4.79 -153.00 4.84 
T10 225.00 2.98 -147.00 4.52 -60.00 1.08 -156.00 5.00 -158.00 5.11 
T11 243.00 3.29 -134.00 3.87 -20.00 0.24 -149.00 4.63 -160.00 5.23 
T12 241.00 3.26 -141.00 4.21 -28.00 0.37 -157.00 5.06 -169.00 5.74 
 
4.2.7 Hydrogen-bond propensities (HBP) for predicting structural outcomes 
 
The detailed description of HBP calculations is described in section 2.2.6. The different amide 
substituents in targets T1/T2, T3/T4 and T5/T6 were modeled separately as shown in Table 4.3.  
 
Table 4.3 Functional groups used to determine the hydrogen-bond propensities for the twelve 
target molecules.  The labels in the figures can be explained as follows:  Tn = atom makes n 
bonds, c = atom is cyclic,  = bond is acyclic, and Hn = n bonded hydrogen atoms.  




T1/T2 T3/T4/T5/T6 T7-T12 T1-T12 T1-T12 T9-T12 
 
4.2.8 Crystal growth 
 
T1-T12 were kept in a vial for slow evaporation methanol solvent in order to obtain crystals 
suitable for single crystal X-ray diffraction. If suitable crystals were not obtained in methanol, then 
different solvents were tried to grow crystals.  X-ray experimental data and crystallographic data 






Table 4.4 Experimental details of crystals obtained  
 Molecules Solvent used Morphology Melting point 
Group1 T1 Methanol Block, colorless 200-205 ̊C 
T2 Methanol Plate, colorless 219-225 ̊C 
T3 Methanol Plate, colorless 158-162 ̊C 
T4 Methanol Block, colorless 196-201 ̊C 
T5 Methanol Blocks, colorless 143-146 ̊C 
T6 Methanol Blocks, colorless 126-135 ̊C 
T7 Methanol Plates, colorless 150-152 ̊C 
T8 Methanol Block, colorless 160-162 ̊C 
Group 2 T9 Methanol Plate, yellow 213-214 ̊C 
T10 Methanol Plate, yellow 212-213 ̊C 
T11 Methanol Blocks, colorless 199-201 ̊C 
T12 Methanol Blocks, colorless 213-214 ̊C 
 
4.3 Results 
4.3.1 Molecular electrostatic potentials (MEPs) 
The twelve custom-designed thiazoles used in this study all have hydrogen-bond acceptors (amide 
carbonyl O, thiazole S, and thiazole N) in T1-T8, an additional hydrogen-bond acceptor (pyridine 
N) in T9-T12 and one hydrogen-bond donor (an amide N-H). The ranking of the acceptor sites 
and a donor site is established using molecular electrostatic potential surfaces and the results from 
the density functional theory (DFT) calculations are shown in Figure 4.2 and 4.3. Higher negative 





Figure 4.2 Electrostatic potentials values (in kJ/mol); a) T1 b) T2 c) T3 d) T4 e) T5 f) T6 g) T7 
and h) T8 
 
 
Figure 4.3 Electrostatic potentials values (in kJ/mol); i) T9 j) T10 k) T11 and l) T12  
 
4.3.2 Hydrogen-bond energies (HBE) 




Table 4.5 Hydrogen-bond energies for monomeric (per hydrogen bond) and dimeric (per 
synthon) synthon A, synthon B, synthon C and Synthon D using equation 3.   
Target molecules 
(T1-T12) 
Synthon A Synthon B Synthon C synthon D 
Monomeric Dimeric Monomeric Dimeric Monomeric 
 
NH…N NH…N NH…S NH…S NH…C=O NH…N 
Group 1 T1 -14.96 -29.92 -5.19 -10.38 -21.02 N/A 
T2 -15.44 -30.88 -5.35 -10.71 -21.23 N/A 
T3 -14.92 -29.84 -5.20 -10.41 -19.09 N/A 
T4 -15.45 -30.89 -6.02 -12.03 -19.39 N/A 
T5 -15.44 -30.88 -5.35 -10.71 -21.23 N/A 
T6 -14.92 -29.84 -5.20 -10.41 -19.09 N/A 
T7 -13.89 -27.78 -5.44 -10.87 -17.77 N/A 
T8 -14.60 -29.19 -5.09 -10.18 -17.97 N/A 
AVG. -14.95 -29.90 -5.36 -10.71 -19.60 N/A 
 Std.dev 0.53 1.06 0.29 0.58 1.41 N/A 
Group 2 T9 -13.17 -26.35 -1.79 -3.57 -14.61 -14.78 
T10 -13.50 -26.99 -3.23 -6.47 -14.93 -15.26 
T11 -12.74 -25.48 -0.81 -1.61 -15.24 -17.21 
T12 -13.73 -27.47 -1.22 -2.44 -16.49 -18.71 
AVG. -13.29 -26.57 -1.76 -3.52 -15.32 -16.49 
Std.dev 0.43 0.86 1.06 2.12 0.82 1.82 
 
4.3.3 Hydrogen-bond propensities (HBP) 
The propensity calculations for the twelve target molecules consider all possible pairwise 
interactions that may take place between one of the three acceptors in group1 (four acceptors in 
group 2) and the sole hydrogen-bond donor, N-H (amide) are shown in Table 4.6.  
 
Table 4.6 Hydrogen-bond propensities (larger value indicates increased likelihood of formation) 
for each postulated synthon in T1-T12. All propensities are given for individual hydrogen bonds 
whereas hydrogen-bond energies are given per synthon.   
 Hydrogen-bond propensities (Lower bound, upper bound) 
  Synthon A Synthon B Synthon C Synthon D 
Group1 T1 0.66 (0.54, 0.76) 0.02 (0.01, 0.05) 0.50 (0.39, 0.61) N/A 
T2 0.60 (0.47, 0.71) 0.02 (0.01, 0.04) 0.47 (0.36, 0.59) N/A 
T3 0.65 (0.56, 0.74) 0.03 (0.01, 0.06) 0.42 (0.30, 0.55) N/A 
T4 0.61 (0.50, 0.71) 0.02 (0.01, 0.05) 0.43 (0.31, 0.56) N/A 
T5 0.66 (0.56, 0.74) 0.03 (0.01, 0.06) 0.37 (0.26, 0.51) N/A 
T6 0.60 (0.49, 0.70) 0.02 (0.01, 0.05) 0.37 (0.26, 0.51) N/A 
T7 0.46 (0.29, 0.64) 0.01 (0.00, 0.03) 0.12 (0.05, 0.24) N/A 
T8 0.42 (0.24, 0.61) 0.01 (0.00, 0.02) 0.12 (0.05, 0.24) N/A 
Group 2 T9 0.58 (0.43, 0.72) 0.02 (0.01, 0.06) 0.17(0.09, 0.32) 0.64 (0.45, 0.80) 
T10 0.50 (0.35, 0.65) 0.02 (0.01, 0.05) 0.17(0.08, 0.30) 0.63 (0.44, 0.78) 
T11 0.57 (0.42, 0.71) 0.02 (0.01, 0.06) 0.16 (0.08, 0.30) 0.67 (0.49, 0.81) 




4.3.4 Hydrogen-bond coordination (HBC) 
Hydrogen-bond coordination tool was used to determine the coordination of each functional group 
for the most optimal predicted synthon, Table 4.7. In group1, the most optimal motif is predicted 
to have synthon A and in group2, both synthon A and synthon D are possible, Figure 4.4.  
 
Table 4.7 Hydrogen-bond coordination for each functional group T1-T12.  













Group1 T1-T8 1 1 0 0 N/A Synthon A 
Group 2 T9-T12 1 1 0 0 0 Synthon A 
 
 




(a)  (b) 
 
Figure 4.4 Synthon predictions using hydrogen-bond coordination for (a) T2 (group 1) and (b) 
T9 (group 2).  
 
4.3.5 Experimentally observed crystal structures 
We obtained crystal structures for T2, T4 and T6  (crystal structures for T1 (YODJAD)39 and T5 
(NORLAI)40 have previously been reported) in group 1 and in all five cases, synthon A (with a 
graph-set notation of 𝑅2
2(8)) was observed, Figure 4.5.  The only conventional hydrogen-bond 
donor in this group of molecules, the N-H amide moiety, selects the N(thiazole) acceptor site as 
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its preferred partner.  In group 2, two types of synthons are observed, synthon D is observed for 





   
T1 T2 T4 T5 T6 
Figure 4.5 Synthon A appears in the crystal structures of T1-T2, T4, and T7-T8.  
 
Group 2 
   
T9 T10 T11 
Figure 4.6 Synthon D appears in the crystal structures of T9, T10 and synthon A appears in the 
crystal structure of T11.  
4.4  Discussion 
4.4.1 What are the predicted synthons?  
Based on four methods (MEPS, HBE, HBP, and HBC) used to predict synthons, three (HBE, HBP 
and HBC) out of four methods predicted synthon A in group1 (Figure 4.7a). In group 2, two out 
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of four methods (HBE and HBC) predicted synthon A and three out of four methods (MEPS, HBP 
and HBC) predicted synthon D as the most optimal synthons (Figure 4.7b).  
 
Group1 Group 2 
  
Figure 4.7 Synthon predictions by each method in (a) Group 1 and (b) Group 2.  
  
4.4.2 Predicted vs experimental data 
Group 1: In total, five out of eight crystal structures (T1, T2, T4, T7, and T8) of target molecules 
were obtained in group 1 and each crystal structure showed synthon A as the most preferred 
binding site. The preference for synthon A (NH(amide)….N(aromatic))over synthon B 
(NH(amide)…S(aromatic) in group 1 is readily explained on the basis of electrostatics.  As there 
is no geometric bias for either motif, the outcome appears to be determined by the fact that the 
sulfur acceptor atom with its significantly lower (less negative) electrostatic potential value, is not 
competitive relative to the thiazole ring nitrogen atom.  This is also born out in the propensity 
analysis which shows very a low probability for the occurrence of the hydrogen bonds in synthon 
B, implying that is not as frequently observed in crystal structures.  Even though individual N-
H…N interactions (in synthon A) are weaker than individual N-H…O=C hydrogen bonds (in 




























geometry and relative position of the donors/acceptors on these molecules which facilitates the 
appearance of two hydrogen bonds through a supramolecular ’chelate’ effect.  HBE, HBP and 
HBC predicted the observed synthon correctly (Figure 4.8).  
 
Figure 4.8 Predicted vs experimental comparison of homomeric synthons in group 1 molecules 
using different prediction methods. 
  
Group 2: Three out of four crystal structures (T9, T10, and T11) were obtained in this group. 
The meta substituted T9-T10 forms monomeric synthon D (predicted based on MEPS, HBP and 
HBC) and para substituted T10 molecule forms dimeric synthon A (predicted based on HBE and 
HBC).  Both synthon A (preferred due to supramolecular chelating effect) and synthon D 
(preferred due to strong pyridine site) are preferred over synthon B or C because of above reasons.  
Both synthons are predicted by four methods therefore, its wasn’t surprising to see these 




Figure 4.9 Predicted vs experimental comparison of homomeric synthons in group 2 molecules 
using different prediction methods. 
 
We hypothesize that such dimeric assemblies can most likely compensate for individually weaker 
interactions in a substantial number of cases but only if the electrostatic differences between the 
possible acceptors is not too large.  It is also possible that this energetic bias is most important 
during crystal growth, where a dimeric synthon A growth unit would be preferred over synthon C.  
It is of course not too surprising that a pair of weak interactions can overcome a single interaction 
that is thermodynamically more favorable.  However, it is a real challenge to predict exactly where 
the energetic ‘tipping point’ may reside and this is why a combined MEPS/HBP approach is 
potentially very powerful.  If/when both methods agree (i.e. they rank the order of interactions in 
the same manner), this likely means that combinations of interactions have limited ability to 
overcome the stabilization of isolated stronger interactions. If the HBP shows that weaker 
interactions are represented in the statistics, it would indicate that crystal packing forces can tilt 
the balance in favor of the weaker interactions. 
4.5 Conclusions 
The structural chemistry of twelve target molecules has been analyzed using MEPS, HBE, HBP 
and HBC as a way of predicting which intermolecular interactions are likely to appear in the solid 
state. The molecules were divided into two groups based on hydrogen-bond functionalities.  
 
1. In group 1, based on HBE, HBP and HBC, synthon A was predicted to be favored over 
synthons B and C. Based on group 2, synthon A and synthon D were predicted by combination 
of four methods.  
2. The combination of prediction methods is successful over individual methods.   
3. In group 1, Synthon A was observed experimentally in all five crystal structures. In group 2, 
both predicted synthons A and D were observed experimentally. The four methods accurately 
predicted the experimentally observed intermolecular hydrogen-bond interactions in three 




 Figure 4.10 Results of four prediction methods suggesting combination of atleast two methods 
is valuable in making predictions.   
 
The ability to make informed predictions about how different molecules recognize and bind to 
each other, and how they subsequently assemble into solid-state architectures is of critical 
importance in areas such as drug design and formulation, and the recently published guidance by 
the FDA on the regulatory classification of pharmaceutical co-crystals41 will continue to keep this 
fundamental science in sharp focus. Therefore, the successful use of structural informatics tools 
such as hydrogen-bond propensity and calculated molecular electrostatic potential surfaces for 
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Chapter 5 - Evaluating Competing Heteromeric Interactions 
through Electrostatics, Energies and Propensities in Thiazole based 
molecules 
5.1 Introduction 
In Chapter 4, we analyzed the possible homomeric interactions in the thiazole based molecules 
using four different methods to predict and compare the homomeric synthons in these molecules 
with the experimental crystal structures. In this chapter, we want to try to break the homomeric 
interactions (synthons A, D, E) by introducing a suitable carboxylic acid that may favor 
heteromeric interactions that can drive co-crystal formation (synthons F-I, Scheme 5.1). 
 
 
Scheme 5.1.  Three postulated heteromeric hydrogen-bond based synthons between a thiazole-




Our working strategy for the synthesis of co-crystals is based on optimizing the affinity between 
different molecules bearing complementary hydrogen-bonding moieties, thereby controlling the 
balance between homomeric (re-crystallization) and heteromeric (co-crystallization) outcomes.  
The complete sets of targets (thiazole amides) and probes (carboxylic acids) are listed in Scheme 
5.2 and 5.3. Molecules T1-T12 have systematically increasing molecular weight and they also 
display specific and controllable changes to the charge density on the synthon.  By exploring the 
structural landscape of this family of closely related molecules, we may be able to highlight the 
relative influence of small structural differences.  Likewise, for the co-formers, the aliphatic 
carboxylic acids show increasing chain length and molecular flexibility. Similarly, the aromatic 
acids explore the addition of competing hydrogen-bonding groups and the influence of substituent 




Scheme 5.2 Twelve thiazole amides used in this study.  
 
 
Scheme 5.3 Twenty carboxylic acid co-formers used in this study. 
 
The study is undertaken to answer three important questions.  
1. Can we find a reliable method for predicting co-crystallization in a set of target molecules 
T1-T12 with 20 carboxylic acids? 
2. Can we predict the correct heteromeric synthons in the co-crystals?  







The synthesis and characterization of target molecules (T1-T12) were described chapter 5. 
Carboxylic acids were purchased from commercial sources and used as received. Melting points 
were measured using a Fisher-Johns melting point apparatus. Solution 1H NMR data were 
collected in DMSO-d6 on a Varian Unity plus 400 MHz NMR spectrometer. IR spectra of co-
crystal screening experiments were recorded with a Nicolet 380 FT-IR spectrometer using ATR 
(attenuated total reflection) technique and ZnSe as the crystal.  
5.2.2 IR Co-crystal screening 
T1-T12 were put through a co-crystal screen as explained in section 3.2.5. The detailed IR 
analysis is provided in Appendix C. 
5.2.3 Molecular electrostatic potential (MEPs) calculations 
See section 2.2. for details of molecular electrostatic potential surfaces (MEPs) calculations. The 
results of MEPs of T1–T12 are shown in section 4.3.1. The electrostatics potentials of 20 
carboxylic acids are shown in appendix E.   
5.2.4 Hydrogen-bond propensities (HBP) for predicting co-crystal outcome 
The detailed description of HBP calculations of co-crystal screening is described in section 3.2.4. 
The description of functional groups used are shown in Table 5.1.  
Table 5.1 Functional groups used to determine the hydrogen-bond propensities for the six target 
molecules.  The labels in the figures can be explained as follows:  Tn = atom makes n bonds, c = 
atom is cyclic,  = bond is acyclic, and Hn = n bonded hydrogen atoms.  


















5.2.5 Hydrogen-bond energies (HBE) for predicting structural outcomes 
See section 2.2.5 for methodology for the hydrogen-bond energy calculation for synthon prediction 
and section 3.2.3 for co-crystal screen.  
5.2.6 Single crystal growth and X-ray crystallography 
All 240 combinations from the grinding experiments were dissolved in a minimum amount of 
methanol or nitromethane (1–2 ml, both reactants were readily soluble in these solvents) and kept 
in a vial for slow evaporation in order to obtain crystals suitable for single crystal X-ray diffraction. 
Of 240 LAG reactions, 151 produced co-crystals according to IR data and fourteen of those yielded 
crystals suitable for single-crystal X-ray diffraction (Table 5.2).  X-ray experimental data and 
crystallographic data are given in the Appendix. 
 
Table 5.2 Experimental details for crystal structures obtained.   
 Stoichiometric ratio Solvent Morphology/color Melting 
point 
T1-3HydroxyBA 1:1 Methanol Rod, bronze 135-138 C 
T2-4HydroxyBA 1:1 Methanol/ 
Nitromethane 
Plate, colorless 176-178 ̊ C 
T4-3NitroBA 1:1 Methanol Plate, colorless 126-128 ̊C 
T8-Suc 2:1 Methanol Plate, colorless 178-181 ̊C 
T8-Sub 2:1 Methanol Plate, colorless 121-123 ̊C 
T8-Seb 2:1 Methanol Plate, colorless 135-137 ̊C 
T8-Aze 2:1 Methanol Prism, colorless 99-102 ̊C 
T8-Dod 2:1 Methanol Prism, colorless 106-108 ̊C 
T9-3HydroxyBA 2:1 Methanol Plates, yellow  185-195 ̊C 






5.3.1 IR co-crystal screening experiments 
The experimental screen produced co-crystals in 151 of the 240 experiments between T1-T12 and 
aliphatic diacids and aromatic monoacids. The results of the IR grinding screen are tabulated in 
Table 5.3. An example of how the IR was analyzed by comparing the grinded mixture to the 
individual pure components is shown in Figure 5.1. 
Table 5.3 Attempted co-crystallizations using LAG (methanol) of T1-T12 with aliphatic and 
aromatic acids (red indicates negative co-crystal outcome and green indicates positive co-crystal 
outcome).   
 Group 1 Group 2  
ACID T1 T2 T3 T4 T5 T6 T7 T8 T9 T10 T12 T12 
Success 
rate 
Suc             58% 
Adi             58% 
Sub             58% 
Seb             50% 
Dod             50% 
Fum             67% 
Mal             75% 
Glu             58% 
Pim             50% 
Aze             42% 
3-HydroxyBA             100% 
4-HydroxyBA             83% 
3-AminoBA             92% 
4-AminoBA             67% 
3-NitroBA             100% 
4-NitroBA             50% 
BA             67% 
4-IodoBA             8% 
4-BromoBA             16% 
PentaFBA             100% 
Positive outcomes 7 8 4 5 6 11 19 18 19 18 18 18 151/240 





Figure 5.1 IR spectra of T1-3HydroxyBA and the component starting materials (T1 – top; T1-
3HydroxyBA co-crystal – middle; 3HydroxyBA – bottom).  
 
5.3.2 Hydrogen-bond propensities for co-crystal screening 
A hydrogen-bond propensity model was used to predict the outcome of co-crystal. The two highest 
propensity donor-acceptor interactions were taken into account for homomeric systems: N-HN 
for the target molecule designated as T:T (target donor : target acceptor) and O-HO=C or N-
HO=C (in the case of aminoBA) for the acid co-former designated as C:C (co-former donor : 
co-former acceptor). The interaction with the maximum propensity for heteromeric systems was 
designated as T:C (target donor : co-former acceptor) or C:T (co-former donor : target acceptor). 
An MC score (as described in section 2.4) is used to predict whether a reaction (in this case, co-
crystal formation) will or will not take place when two reactants are combined.  A summary of the 
multi-component hydrogen-bond propensity (HBP) screening results for T1-T12 with 20 co-































































































































































































































5.3.3 Using hydrogen-bond energies to predict heteromeric synthons 
The hydrogen-bond energy for synthon F, H and synthon I in each co-crystal combination (240 
combinations) was calculated and is tabulated in the appendix (only heteromeric interactions are 
considered) and the average energies are provided in Table 5.4. The larger (more negative) the 
hydrogen-bond energy, the stronger the interaction between the two different components favoring 
co-crystallization.   
Table 5.4 Hydrogen -bond energies of each hetero-synthon in T1-T12 combined with aliphatic 
and aromatic acids. 




 (a) Synthon F (b) Synthon H (c) Synthon I 
Group 1 (w/o additional h-bond donor) -35.54 ±0.63 -24.52±1.21 n/a 
Group 2 (w/o additional h-bond donor) -33.79±0.93  -19.94±1.26 -26.87±1.18 
Group 1 (with additional h-bond donor) -34.52±0.62 -21.53±1.06 n/a 





 (d) Synthon J (e) Synthon K (f) Synthon L 
Group 1 (with additional h-bond donor) 25.42 ± 1.72 19.43± 1.31 n/a 






 (g) Synthon M (i) Synthon N (j) Synthon O 
Group 1 (with additional h-bond donor) 17.27±1.36 13.20±1.04 n/a 
Group 2 (with additional h-bond donor) 14.05±1.11 11.36±0.90 15.53±1.23 
 
5.3.4 Using electrostatics to predict heteromeric synthons 
Based on Etter’s rule guidelines, the best donor of target molecule binds to best acceptor of acid 
and the best donor of acid binds to best acceptor of target molecule and, therefore following 
synthons are preferred in each group. The electrostatic potentials of target molecules are provided 
in Chapter 4 and acids are provided in the appendix. The details of synthon preferred in each group 
are listed in Table 5.5. 
Table 5.5 Synthon preferred in each group based on electrostatics.  
  Best acceptor of target Best donor of acid Preferred synthon 
Group 1 (w/o h-bond donor) C=O OH(acid) Synthon H 
 (hydroxyBA) C=O OH (Hydroxylic) Synthon J 
 (AminoBA) C=O OH(acid) Synthon H 
Group 2 (w/o h-bond donor) N pyridine OH(acid) Synthon I 
 (hydroxyBA) N pyridine OH (Hydroxylic) Synthon L 
 (AminoBA) N pyridine OH(acid) Synthon H 
 
5.3.5 Experimentally observed crystal structures 
5.3.5.1 Group 1: T1-T8 against 20 carboxylic acids 
In group 1, we obtained single-crystal XRD data for five co-crystals with aliphatic acids, and in 
all five crystal structures the carboxylic acid O-HN thiazole and amide N-HO=C acid moieties 
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give rise to the robust 𝑅2
2(8) hydrogen-bonded synthon F in a 2:1 target:acid stoichiometry, Figure 
5.2d-h.  Three crystal structures were obtained with aromatic acids with varying stoichiometry (1:2 
ratio for T1-3HydroxyBA, 2:1 for T2-4HydroxyBA and 1:1 for T4-3NitroBA). As with the 
aliphatic acid co-crystals, a robust 𝑅2
2(8) hydrogen-bonded synthon F is formed using O-HN 
and N-HO hydrogen bonds in each case (Figure 5.2a-c). In T1-3HydroxyBA, the additional 
hydrogen-bond donor on 3hydroxyBA binds to the carbonyl oxygen of the acid via homomeric 
interaction, OH(hydroxyl) O=C(acid), Figure 5.2a.  In T2-4HydroxyBA, the extra hydrogen-















Figure 5.2 Main hydrogen bonds in the crystal structures of (a) T1-3HydroxyBA, (b) T2-
4HydroxyBA, (c) T4-3NitroBA, (d) T8-Suc, (e) T8-Sub, (f) T8-Seb, (g) T8-Aze and (h) T8-
Dod.  
 
5.3.5.2 Group 2: T9-T12 against 20 carboxylic acids 
In group 2, we obtained single-crystal XRD data for four co-crystals with aliphatic acids, and in  
all four crystal structures, either one end or both ends of the carboxylic acid is involved in the  O-
HN thiazole and amide N-HO=C acid moieties giving rise to the robust 𝑅2
2(8) hydrogen-
bonded synthon F and in three out of four  crystal structures, one end of acid is also involved in 
OH---N pyridine hydrogen bond synthon I (Figure 6.3b, d, e, and f).  Two crystal structures were 
obtained with aromatic acids (2:1 ratio for T9-3HydroxyBA, 2:1 for T12-4HydroxyBA). As with 
the aliphatic acid co-crystals, a robust 𝑅2
2(8) hydrogen-bonded synthon F is formed using O-HN 
and N-HO hydrogen bonds in each case (Figure 5.3 a, c). In both T9-3HydroxyBA and T12-
4HydroxyBA, the extra hydrogen-bond donor interacts with a pyridine N of each target molecule 













Figure 5.3 Main hydrogen bonds in the crystal structures of (a) T9-3HydroxyBA, (b)T11-Sub, 
(c) T12-4HydroxyBA, (d) T12-Suc, (e) T12-dod, and (f) T12-Adi.  
 
5.4 Discussion 
5.4.1 Experimental vs predicted co-crystal screening 
The predictions made using the HBP model were compared to experimental co-crystal screening 
results. A confusion matrix was used to analyze the data as reported by Wood et. al.17 The entries 
in the matrix are labelled true positive (TP; positive for co-crystal via both prediction and 
experimental), false positive (FP; positive for co-crystal via prediction but negative via 
experimental), false negative (FN; negative for co-crystal via prediction but positive via 
experimental), and true negative (TN; negative for co-crystal via both prediction and 
experimental), Figure 5.4. Any MC value > 0.00 was considered as a prediction of co-crystal 
formation and an MC value below or equal to 0.00 was considered as a prediction against co-
crystal formation.   
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5.4.1.1 Group 1: T1-T8 against 20 carboxylic acids 
Hydrogen-bond propensity calculations were performed on T1-T8 against 20 co-formers giving a 
total of 160 prediction results. When compared to experimental screening results, 112 out of the 
160 combinations (70%), the HBP model accurately predicted the outcome of the reaction; 49 out 
of 112 combinations were true positive and 63 of the 112 combinations were true negative, 
respectively (Table 5.7, Figure 5.4). 
Experimentally, T1-T6 displayed a 15% and T7-T8 a 95% success rate of co-crystal formation 
with aliphatic acids.  Such a discrepancy between molecules that carry the same principle 
functionality is difficult to predict or foresee using chemical intuition, but we were delighted that 
the HBP model delivered predictions that reflected these highly unexpected experimental results 
very well.  Using an MCcutoff > 0.00, only twelve out of sixty reactions (20%) between an aliphatic 
diacid and T1-T6 was predicted to yield a co-crystal, whereas 18 of 20 combinations (90%) 
between a diacid and T7-T8 were predicted to produce a co-crystal. In T1-T6 with aliphatic acids, 
homomeric interactions; N-H(amide)N(thiazole) or O-H(acid) O=C(acid) are more probable 
than the heteromeric interaction, O-H(acid)N(thiazole), whereas in T7-T8, the heteromeric 
interaction, O-H(acid)N(thiazole), dominates over homomeric interactions which suggests that 
descriptors such as “steric density” and “aromaticity” play a significant role in the co-
crystallization outcome.  There was an 80% agreement (64 out of 80 combinations were either true 
positive or true negative) between the predicted and experimental results for aliphatic acids with 
T1-T8.  Among the sixteen unsuccessful predictions, nine were false positives (red box) and seven 
were false negatives (yellow box).  
The experimental co-crystal screening of ten aromatic acids against T1-T8 produced 49 positive 
results out of eighty attempts.  T5-T6 showed a higher success rate than T1-T6, but almost all 
target molecules were able to form co-crystals with a success rate greater than 50% (the one 
exception, T3, had a 40% success rate).  The HBP models predicted mostly negative outcomes for 
T1-T6, whereas reactions of T5-T6 were predicted as positive for co-crystal formation (3-
aminoBA and 4-aminoBA co-formers were always predicted to produce co-crystals, regardless of 
target).  Overall, the outcome of 47 of the 80 reactions (58%) was accurately predicted by the HBP 
model (either true positives or true negatives) using an MC > 0.00 cutoff.  Additionally, 24 of the 
80-aromatic acid/T1-T8 combinations were false negatives (yellow box) and nine were false 
positives (red box).   
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Overall, in group 1, in 112 out of 240 (70% success rate) combinations, there was agreement 
between experimental and predicted results, Table 5.8.  
5.4.1.2 Group 2: T9-T12 against 20 carboxylic acids 
Hydrogen-bond propensity calculations were performed on T9-T12 against 20 co-formers giving 
a total of 80 prediction results. When compared to experimental screening results, 55 out of the 80 
combinations (68%), the HBP model accurately predicted the outcome of the reaction; 48 out of 
55 combinations were true positive and 7 of the 55 combinations were true negative, respectively, 
Table 5.8, Figure 5.4. 
The experimental co-crystal screening of T9-T12 against 10 aliphatic acids produced 40 positive 
results out of 40 attempts (100%). The HBP model predicted 36 of 40 co-crystal screens (90%, 
either true positive or true negative) correctly using an MC>0.00 cutoff. There were 0 false 
positives and four were false negatives.  
The experimental co-crystal screening of T9-T12 against 10 aromatic acids produced 33 positive 
results out of 40 co-crystal attempts (83%). The HBP model predicted only 19 of them correctly 
(47%, either true positive or true negative). There were 0 false positives and 21 false negatives. 
Overall, in group 2, 55 out of 80 (69% success rate) combinations, there was agreement between 
experimental and predicted results, Table 5.6.  
Table 5.6 True positive, false positive, false negative and true negative propensity comparison 
results for each target molecule (T1-T12) against 20 carboxylic acids and the % yields  









TP/TN FP/FN % 




T2 2 0 6 12 14 6 
T3 1 1 3 15 16 4 
T4 1 2 4 13 14 6 
T5 3 5 4 8 11 9 
T6 5 6 6 3 8 12 
T7 19 1 0 0 19 1 
T8 16 2 2 0 16 4 
















T9 12 0 7 1 13 7 
T10 12 0 6 2 14 6 
T12 12 0 6 2 14 6 
T12 12 0 6 2 14 6 
Total 48 0 25 7 55 25 
 
As indicated by Wood et al17  false negatives are a concern with prediction tools when it comes to 
creating a list of potential co-formers for a systematic search for new solid forms, as these co-
formers will not be included in the experimental study for being seen as unlikely to co-crystallize.  
On the other hand, a false positive can also be detrimental as extensive experimental resources and 
time may then be wasted on a co-former that is expected to produce a co-crystal but does not.  
Although the predictions suggest that the pairs are favored to form co-crystals, they do not indicate 




























































Figure 5.4 Confusion matrices determined from multi-component HBP results for T1-T12 
molecules with co-formers, (a) explanation of matrix (b) MCcutoff: > 0.00.  
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5.4.2 Comparison of predicted vs experimental synthons in group 1 and group 2 
5.4.2.1  Group 1 (without an additional hydrogen-bond donor) 
Two synthons (synthon F and synthon H) are possible in aliphatic acids and aromatic acids without 
additional hydrogen-bond donor. The dimeric synthon F is favored over synthon H by 11 kJ/mol.  
 
Figure 5.5 Predicted vs experimental results of group 1 (without an additional hydrogen-bond 
donor).  
Six crystal structures (5 with aliphatic acids and 1 with aromatic acids) were obtained in this group, 
synthon F was observed experimentally irrespective of the aliphatic or aromatic acids. The energy 
results were also supported by propensity results, Table 5.7.  
 
5.4.2.2 Group 1(with an additional hydrogen-bond donor) 
 Based on hydrogen-bond energies, synthon F is favored for both hydroxybenzoic acid co-crystals 
(over synthons H, J and K) and aminobenzoic acid co-crystals (over synthons H, M, and N). Two 
crystal structures of hydroxybenzoic acid co-crystals were obtained; in T1-3HydroxyBA, synthon 
F was observed as predicted. The additional hydrogen-bond donor on 3hydroxyBA binds to the 
carbonyl oxygen of the acid, OH(hydroxyl)O=C(acid), Figure 5.2a.  In the crystal structure of 
T2-4HydroxyBA, both synthons F and synthon J were observed. In T2-4HydroxyBA, the extra 
hydrogen-bond donor interacts with a carbonyl oxygen atom of T2 to form 1-D chains.  All 
conventional hydrogen-bond donors and acceptors are involved in heteromeric interactions (thus 
following Etter’s rule). Without geometric constraints, the best donor of the acid (hydroxylic O-
H) binds to the best acceptor of T2 (C=O amide), the second-best donor of the acid (carboxylic O-
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H) binds to the second-best acceptor of T2 (aromatic N) and the best donor of T2 (N-H amide) 
binds to the best acceptor of the acid (O=C). Overall, the predictions made using electrostatics 
agree very well with the experimentally observed crystal structures, Table 5.7.  
  
Figure 5.6 Predicted vs experimental results of group 1 (with an additional hydrogen-bond 
donor).  
 
Moreover, all synthons observed in these crystal structures were either predicted by electrostatics 
or energy or propensity. Unfortunately, we have not been able to grow crystals suitable for single-
crystal X-ray diffraction for aminobenzoic acids, so we do not yet have the data to experimentally 
determine the synthons observed in this category.  
5.4.2.3  Group 2 (without an additional hydrogen-bond donor) 
Three synthons (synthon F, H and I) are possible in aliphatic and aromatic acids without an 
additional hydrogen-bond donor. The dimeric synthon F is favored over monomeric synthon I and 
synthon H by 8 kJ/mol and 14 kJ/mol respectively. Four crystal structures were obtained in this 
group. In the crystal structure of T11-Sub, synthon F was observed on the both side of acid. In the 
crystal structure of T12-suc and T12-Dod, one end of the acid forms a robust 𝑅2
2(8) hydrogen-
bonded synthon F using O-H(acid)N(thiazole) and N-H(amide)O=C(acid) hydrogen bonds in 





Figure 5.7 Predicted vs experimental results of group 2 (without an additional hydrogen-bond 
donor).  
 
In the crystal structure of T12-Adi, both synthon F and I are observed in the crystal structure, but 
both ends of same acid forms same synthon (either F or I). This type of interaction is different to 
what observed in the T12-Suc and T12-dod.  Both synthon F and synthon I only differs by 8 
kJ/mol in energy therefore both type of synthons are highly likely to happen as the pyridine N is a 
stronger acceptor compared to thiazole N based on electrostatics charges and therefore, taking into 
balance between electrostatics and energies, both synthon F and I are competitive and has equal 
chance to form the synthon. Synthon I was predicted to be the most optimal synthon according to 
hydrogen-bond propensity, Table 5.7. 
 
5.4.2.4 Group 2 (with an additional hydrogen-bond donor) 
Six different synthons (synthon F, H, I, J, K and L for hydroxybenzoic acids) and (synthon F, H, 
I, M, N and O for aminobenzoic acids) are possible for aromatic acids with additional hydrogen-
bond donors and in each category, synthon F is the most preferred synthon. Two crystal structures 
are observed with hydroxybenzoic acids; T9-3HydroxyBA and T12-4HydroxyBA. Two synthons 
(Synthon F and synthon L) were observed in each crystal structure. The best donor of the acid 
(hydroxylic O-H) binds to the best acceptor of T9 and T12(Pyridine N) following Etter’r rule. The 
second-best donor of the acid (carboxylic O-H) binds to the thiazole N and the C=O (best acceptor 
of acid) binds to the amide NH forming synthon F which is dominant due to its supramolecular 
chelating effect. Both synthon F and L are ranked 1 and 2 based on energies in this group out of 
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six different synthon possibilities and differs by about 10 kJ/mo based on hydrogen-bond energies. 
 
Figure 5.8 Predicted vs experimental results of group 2 (with an additional hydrogen-bond 
donor).  
 
The presence for additional donor group on the acid binds to best acceptor on the target molecule 
as expected based on electrostatics, Table 5.8. Unfortunately, we have not been able to grow 
crystals suitable for single-crystal X-ray diffraction for aminobenzoic acids, so we do not yet have 
the data to experimentally determine the synthons observed in this category.  
 
Table 5.7 Summary of predicted vs experimental synthons in co-crystals of T1-T12 with 20 
dicarboxylic acids.  
 Electrostatics  Energies  Propensities  Experimental 




(w/o h-bond donor) Synthon H Synthon F Synthon F Synthon F 6 
(HydroxyBA) Synthon J Synthon F Synthon F Synthon F and J 2 
(AminoBA) Synthon H Synthon F Synthon N N/A 0 
Group 2 
(w/o h-bond donor) Synthon I Synthon F Synthon I Synthon F and I 4 
(HydroxyBA) Synthon L Synthon F Synthon I Synthon F and L 2 





• The HBP model was used to predict and compare the experimental co-crystal screening results 
comprising twelve target molecules and twenty carboxylic acids resulting in 240 data points.  
An MC score produced from the HBP calculations using a cut-off value of > 0.0 resulted in a 
69% agreement between prediction and experiment (70% success for group 1 and 68% for 
group 2).  The HBP model made 80% and 90% predictions correctly for group 1 and group 2 
respectively with aliphatics acids. The HBP model made 58% and 47% predictions correctly 
for group 1 and group 2 respectively with aromatic acids.  
• The electrostatics and propensity along with hydrogen-bond energies were used to predict 
synthons in positive co-crystal outcomes. The HBE predicted synthon F to be more favorable 
in both groups. The HBP calculations also predicted synthon F to be more favorable in group 
1 but in the aminoBA co-crystals. Synthon N is favored over synthons F in aminoBA co-
crystals.  In group2, HBP predicted synthon I to be more favorable and synthon O is favored 
in aminoBA co-crystals. Based on electrostatics, synthon H was favored in group 1 but synthon 
J in hydroxyBA. In group 2, different synthons were predicted in each category.  




Figure 5.9 Summary of results obtained in this study. 
 
 The ability to make informed predictions about how different molecules recognize and bind to 
each other, and how they subsequently assemble into solid-state architectures is of critical 
importance in areas such as drug design and formulation, and the recently published guidance by 
the FDA on the regulatory classification of pharmaceutical co-crystals34 will continue to keep this 
fundamental science in sharp focus. Therefore, the successful use of structural informatics tools 
such as hydrogen-bond propensity and calculated molecular electrostatic potential surfaces for 
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Chapter 6 - Constructing Binary and Ternary Co-crystals Using 
Hydrogen and Halogen Bonds as Synthetic Vectors 
 
6.1 Introduction  
Intermolecular interactions such as hydrogen bonding,1-5 halogen bonding,6-9 or  interactions 
represent the primary tools in supramolecular chemistry and crystal engineering.2 It is important to 
have a better understanding of the fundamental nature of these interactions in order to successfully 
design complex supramolecular systems in a predetermined and effective manner. The hydrogen bond 
is a key synthetic tool in assembly of molecules into well-defined architectures.12 Hydrogen bonded 
binary co-crystals have been constructed through a variety of heterosynthons such as carboxylic 
acid…pyridine,10-12 oxime…N-heterocycles,13 and carboxylic acid….amide. 14-15  Halogen bonding is 
a relatively recent addition to the tool box of supramolecular chemistry.4 According to IUPAC, “A 
halogen bond R−X⋯Y−Z occurs when there is evidence of a net attractive interaction between an 
electrophilic region on a halogen atom X belonging to a molecule or a molecular fragment R–X (where 
R can be another atom, including X, or a group of atoms) and a nucleophilic region of a molecule, or 
molecular fragment, Y−Z” (Scheme 6.1).5 The halogen bond, due to its relative strength and highly 
directional nature, has been employed in a similar manner to hydrogen bonding for the assembly 
and synthesis of binary co-crystals.16   The most common halogen bonded synthons includes I…N 
type interactions.  
 
Scheme 6.1 Schematic diagram showing the formation of a halogen bond (X is a halogen atom 
and Y is a nucleophilic atom) 
 
The successful synthesis of multi-component supramolecular systems17 is challenging because of 
the relatively weak and reversible nature of non-covalent forces.  If the synthetic target contains 
more than two different molecules,  such as a ternary or quaternary co-crystal, the number of 
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binding sites also increases which expands the possibilities of unwanted synthon crossover.18 14 
As a result, the exact chemical composition of the product, as well as the relative orientation of 
the participating molecular constituents, becomes much less predictable.   Against this background, 
it is not surprising that it is still very challenging to produce ternary systems since the co-
crystallization process can lead to a very diverse set of outcomes; simple recrystallizations of all 
starting materials, binary co-crystals, solvates/hydrates of any of those combinations, or the 
targeted ternary co-crystal (Scheme 6.2).13  The role of the solvent can obviously play a key role 
in the outcome which means that both thermodynamic and kinetic factors need to be balanced,19 
in order  to successfully synthesize ternary co-crystals. 
 
 
Scheme 6.2 Different possibilities for an attempt to make ternary co-crystals.  
 
Clearly both hydrogen and halogen bonding offer effective synthetic avenues for binary systems20-
21 but only a relative limited number of examples of the assembly of ternary co-crystals have been 
reported.22-23  A variety of strategies have been pursued for ternary co-crystal synthesis many of 
which have been inspired by Etter’s observation that “the best hydrogen-bond donor and the best 
hydrogen-bond acceptor will preferentially form hydrogen bonds to one another,’’24 and Aakeröy 
and co-workers have employed molecular electrostatic potential calculations as a way of ranking 
acceptors/donors.  The combination of these ideas have been found to be of considerable practical 
use for determining the connectivity patterns in molecules with multiple binding pockets,24 as well 
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as for synthesizing ternary co-crystals with desired composition and intermolecular connectivity.3, 
19, 22  Desiraju and co-workers have presented size, shape and template based approaches to the 
synthesis of co-crystals, 25  and these protocols have also been modified and extended to the 
assembly of very rare examples of quaternary, quintenary co-crystals26-27 and six-component 
molecular solids.28 Recently, Rissanen and co-workers used the orthogonality of two 
supramolecular interaction modes: hydrogen bonding between crown ethers and thioureas, and 
halogen bonding between thioureas and perfluorohalocarbons to construct ternary co-crystals.29  
  The combination of hydrogen- and halogen bonding in the same supramolecular synthetic scheme 
may offer more efficient and reliable avenues for the preparation of complex multi-component 
assemblies as these two interactions, although similar in some ways, can be tailored independently 
in order to minimize synthon crossover.23, 30-32  
We have previously explored binding preferences of thiazole-based ligands with two competing 
binding pockets and shown that the N-H/N site is preferred over the N-HS site when the ligand 
is presented with a carboxylic acid, Scheme 6.3.  This selectivity is readily explained on the basis 
of a simple electrostatic argument which favors the nitrogen atom over the sulfur atom as a 
hydrogen-bond acceptor due to the higher negative electrostatic potential of the former 
 
 
Scheme 6.3 Hydrogen-bond preferences of a carboxylic acid vis-à-vis a thiazole-based ligand33 
 
In order to now build a new molecule capable of acting as an assembly point for ternary co-crystals, 
we decided to add a suitable acceptor capable of reliably forming halogen bonds with a suitable 




Scheme 6.4 Four target molecules for ternary co-crystals. 
 
6.1.1 Proposed hypothesis 
Our choice of acceptors, T9-T12 was guided by the fact that there is considerable structural data 
in the CSD to suggest that activated halogen atoms are prone to forming C-XN halogen bonds 
with pyridyl moieties.  Recognition point 1 is a two-point interaction designed for a suitable 
hydrogen-bond donor (Scheme 6.5a) and recognition point 2 is a one-point interaction designed 





Scheme 6.5 Schematics of hypothesized (a) hydrogen-bonding and (b) halogen-bonding 
interactions in T9-T12. 
 
Our strategy is that when binary hydrogen-bond co-crystallization is attempted, recognition point 
1 will be occupied by the donor due to supramolecular chelating effect leaving the recognition 
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point 2 vacant. One the other hand, when binary halogen-bond co-crystallization is attempted, 
recognition point 2 will be occupied by the suitable halogen-bon donor leaving the recognition 
point 1 vacant or form homomeric interactions. We also hypothesized that as the halogen-bond 
only involves a single-point interaction, whereas a carboxylic acid generates a heterosynthon with 
two hydrogen bonds with thiazole pocket, the halogen-bond donor would not be competitive for 
the thiazole nitrogen atom.  Similarly, we would not expect the self-complementary thiazole 
homosynthon to be disrupted in a binary halogen-bonded co-crystal.  These ideas form the basis 
for a synthetic strategy of ternary co-crystals driven by structurally independent hydrogen- and 
halogen bonds, Scheme 6.6.      
 
Scheme 6.6 Proposed supramolecular design strategy for the assembly of ternary co-crystals  
 
In this study we want to address following questions;   
1. Can we make hydrogen-bond binary co-crystals at recognition point 1 without using 
recognition point 2?  
2. Can we form halogen-bond binary co-crystals at recognition point 2 without using 
recognition point 1? 
3. Can we use both recognition points to form ternary co-crystals by using recognition point 
1 for hydrogen-bonding and recognition point 2 for halogen bonding?  
 
Fifteen different hydrogen-bond donors were chosen for this study (10 aliphatic acids and 5 






Scheme 6.7 Fifteen hydrogen-bond donors and one halogen-bond donor chosen for ternary co-
crystallization.  
 
To get a better understanding of how we may control not just synthon reproducibility but also the 
three-dimensional consequences thereof, we have also explored how the same type of molecular 
recognition events may lead to supramolecular architectures of different dimensionality and 
connectivity, Scheme 6.8 with hydrogen-bond donors. First talking about aliphatic diacids, three 
different synthons (synthon I, synthon II and synthon III) are possible, Scheme 6.8. Synthon I 
represent both ends of same acid binding to recognition point 1; N-H(amide)…O=C(acid) and O-
H(acid)…N(thiazole) hydrogen bonds. Synthon II represent both ends of same acids binds to 
recognition point 2; O-H(acid)…N(pyridine) hydrogen bonds. Synthon III represents one end of 
acids binds to recognition point 1 (N-H(amide)…O=C(acid), O-H(acid)…N(thiazole)) and other 
end binds to recognition point 2 (O-H(acid)…N(pyridine)).  A possible complication (synthon II 
and synthon III), would result if the carboxylic diacid were to bind to the thiazole pocket at one 
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end and to the pyridyl moiety (O-H…N(py) at the other end which could prevent the halogen-bond 
donor from being included in the product.  The most desired synthon with aliphatic diacids is 




Synthon I Synthon II 
 
 
Synthon III Synthon IV 
Scheme 6.8 Possible synthons with ditopic acceptors leading to either 0-D discrete or 1-D infinite 
chains in binary hydrogen bonded cocrystals with aliphatic and aromatic acids.  
 
In order to understand how having additional functional group on the co-former affects the 
resulting synthons, we included five aromatic acids with functional groups such as hydroxy, and 
nitro groups available.  We postulate that in the case of H11 and H12, the carboxylic acid group 
would bind to recognition point 1 via a two-point interaction and the hydroxy group would bind 
to recognition point 2 via one-point interaction, synthon IV. If synthon IV is to form in the 
hydrogen-bonding, then the formation of halogen bonding or ternary co-crystals would not be 
possible because the pyridyl nitrogen would be occupied. Therefore, co-formers H13-H15 would 
be ideal candidate for ternary co-crystallization.  
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6.2 Experimental  
6.2.1 Materials   
All precursors, solvents and aliphatic dicarboxylic acids, and halogen-bond donors were purchased 
from commercial sources and used without further purification. T9-T12 synthetic procedures are 
provided in chapter 4.  1H NMR spectra were recorded on a Varian Unity plus 400 MHz 
spectrometer. Infrared spectra were recorded with a Nicolet 380 FT-IR. Melting points were 
determined using Fischer-Johns Mel-Temp melting point apparatus and are uncorrected.  
 
6.2.2 Hydrogen-bonded co-crystals   
The binary hydrogen-bond synthesis of T9-T12 with 10 aliphatic acids and 5 aromatic acids is 
described in detail in chapter 5.  In all 40 combinations with aliphatics and 20 combinations with 
aromatics, the ditopic acceptors and donors were mixed in 2:1 and 1:1 stoichiometric ratio 
respectively and the solid resulting from each reaction was characterized using IR spectroscopy to 
determine if a co-crystal had formed. 
 
6.2.3 Halogen-bonded co-crystals 
Synthesis of halogen bonded co-crystals was performed by mixing each acceptor with the halogen-
bond donor in a 2:1 stoichiometric ratio in a drop of methanol solvent. The mixture was ground, 
and the mixture was analyzed using infra-red spectroscopy to determine if a co-crystal has formed. 
Once the co-crystal was confirmed, the grinded mixture was dissolved in the minimum amount of 
solvent to grow crystals using slow evaporation method. 
 
6.2.3.1 T9-D1 (2:1) 
N-(thiazol-2-yl) nicotinamide-1,4-diiodotetrafluorobenzene (2:1): T9 (41mg, 0.10 mmol) and 1,4-
diiodotetrafluorobenzene, D1 (40mg, 0.05mmol) were dissolved in minimum amount of methanol 
and the solution was allowed to evaporate. 
 
6.2.3.2 T10-D1 (2:1)  
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N-(5-methylthiazol-2-yl) nicotinamide-1,4-diiodotetrafluorobenzene (2:1): T10 (43mg, 0.10 
mmol) and 1,4-diiodotetrafluorobenzene, D1 (40mg, 0.05mmol) were dissolved in minimum 
amount of methanol and the solution was allowed to evaporate.  
 
6.2.3.3  T11-D1 (2:1) 
N-(thiazol-2-yl) isonicotinamide-1,4-diiodotetrafluorobenzene (2:1): T11 (41mg, 0.10 mmol) and 
1,4-diiodotetrafluorobenzene, D1 (40mg, 0.05mmol) were dissolved in minimum amount of 
methanol and the solution was allowed to evaporate.  
 
6.2.3.4  T12-D1 (2:1) 
N-(5-methylthiazol-2-yl) isonicotinamide-1,4-diiodotetrafluorobenzene (2:1): T12 (43mg, 0.10 
mmol) and 1,4-diiodotetrafluorobenzene, D1 (40mg, 0.05mmol) were dissolved in minimum 
amount of methanol and the solution was allowed to evaporate.  
 
6.2.4 Ternary co-crystals  
A total of 60 different combination experiments were performed using T9-T12, 15 hydrogen-bond 
donors (10 aliphatic diacids and 5 aromatic monoacids) and one halogen bond donor. A 2:1:1 
stoichiometric ratio of acceptor: hydrogen bond donor: halogen-bond donor was ground together 
in a mortar and pestle in a drop of methanol. Once confirmed positive via infra-red spectroscopy, 
the mixture was dissolved in the minimum amount of solvent to grow crystals using slow 
evaporation.  
 
Table 6.1 Stoichiometric ratios of each donor and acceptor and solvent used for ternary co-
crystallization attempts.  





T9-H1-D1 41mg, 0.10 mmol 6 mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T9-H2-D1 41mg, 0.10 mmol 7.3 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H3-D1 41mg, 0.10 mmol 8.7 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H4-D1 41mg, 0.10 mmol 10 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H5-D1 41mg, 0.10 mmol 12mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T9-H6-D1 41mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H7-D1 41mg, 0.10 mmol 5.8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H8-D1 41mg, 0.10 mmol 6.6mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
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T9-H9-D1 41mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H10-D1 41mg, 0.10 mmol  9.4mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H11-D1 41mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H12-D1 41mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H13-D1 41mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H14-D1 41mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T9-H15-D1 41mg, 0.10 mmol 21mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
     
T10-H1-D1 43mg, 0.10 mmol 6 mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T10-H2-D1 43mg, 0.10 mmol 7.3 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H3-D1 43mg, 0.10 mmol 8.7 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H4-D1 43mg, 0.10 mmol 10 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H5-D1 43mg, 0.10 mmol 12mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T10-H6-D1 43mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H7-D1 43mg, 0.10 mmol 5.8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H8-D1 43mg, 0.10 mmol 6.6mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H9-D1 43mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H10-D1 43mg, 0.10 mmol  9.4mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H11-D1 43mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H12-D1 43mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H13-D1 43mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H14-D1 43mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T10-H15-D1 43mg, 0.10 mmol 21mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
     
T11-H1-D1 41mg, 0.10 mmol 6 mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol 
T11-H2-D1 41mg, 0.10 mmol 7.3 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H3-D1 41mg, 0.10 mmol 8.7 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H4-D1 41mg, 0.10 mmol 10 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H5-D1 41mg, 0.10 mmol 12mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T11-H6-D1 41mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H7-D1 41mg, 0.10 mmol 5.8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H8-D1 41mg, 0.10 mmol 6.6mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H9-D1 41mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H10-D1 41mg, 0.10 mmol  9.4mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H11-D1 41mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H12-D1 41mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H13-D1 41mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H14-D1 41mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T11-H15-D1 41mg, 0.10 mmol 21mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
     
T12-H1-D1 43mg, 0.10 mmol 6 mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T12-H2-D1 43mg, 0.10 mmol 7.3 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H3-D1 43mg, 0.10 mmol 8.7 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H4-D1 43mg, 0.10 mmol 10 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H5-D1 43mg, 0.10 mmol 12mg, 0.05mmol  40mg, 0.05mmol Methanol, Ethanol  
T12-H6-D1 43mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H7-D1 43mg, 0.10 mmol 5.8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H8-D1 43mg, 0.10 mmol 6.6mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H9-D1 43mg, 0.10 mmol 8 mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H10-D1 43mg, 0.10 mmol  9.4mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
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T12-H11-D1 43mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H12-D1 43mg, 0.10 mmol 13mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H13-D1 43mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H14-D1 43mg, 0.10 mmol 16mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
T12-H15-D1 43mg, 0.10 mmol 21mg, 0.05mmol 40mg, 0.05mmol Methanol, Ethanol  
 
6.3 Results 
6.3.1 Hydrogen-bonding: Grinding   
The solvent-assisted grinding experiments of hydrogen-bonding were analyzed through IR 
spectroscopy and 60 of the 60 experiments resulted in a co-crystal formation, (the details of 
grinding experiment is provided in chapter 6 and appendix C). All co-crystals displayed broad 
bands in the 1,850 and 2,500 cm-1 region (as a result of O–H…N hydrogen bonds) and significant 
changes in the C=O stretch of the carboxylic acid, see chapter 6 for detailed results.  
 
 
Table 6.2 Grinding experiment results with aliphatic and aromatic hydrogen-bond donors.  
 Aliphatic diacids Aromatic monoacids Halogen bonding 
T9 10/10 5/5 1/1 
T10 10/10 5/5 1/1 
T11 10/10 5/5 1/1 
T12 10/10 5/5 1/1 
 
The energies of each possible synthon in the hydrogen-bonded binary systems is listed in the table 
6.3.  
Table 6.3 Hydrogen-bond energies for synthon I-IV in a binary system 
 Synthon I Synthon II Synthon III Synthon IV 
Energies 
(kJ/mol) 
-70.76±1.85 -67.81±2.21 -64.87±2.86 -55.28±2.93 
 
6.3.2 Halogen-bonding: Grinding and TGA analysis  
The solvent-assisted grinding experiments of halogen-bonding were analyzed through IR 
spectroscopy and 4 of the 4 experiments resulted in a co-crystal. The IR analysis for identifying 
co-crystal formation focused on the C−F and C-I stretch of the halogen-bond donor (Figure 6.1, 
Table 6.4). A shift of three wave numbers or more was considered to be significant and indicative 
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of a positive result, i.e., co-crystal formation (the subsequent single-crystal X-ray diffraction 
analyses confirmed that the assignment based on IR data was correct). 
 
 
Figure 6.1 IR spectra of T12:D1 and the respective starting materials (T12 – top; T12:D1 co-
crystal – middle; D1 – bottom).  
 
A TGA analysis was performed to confirm the formation of halogen-bond co-crystals (Figure 6.2).  
  
(a)T11-D1 (b) T12-D1 
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Table 6.4 Grinding experiment details and co-crystal assessment of halogen-bonded co-crystals.  
 Acceptor Halogen bond donor Grinded mixture Co-crystal? 
T9-D1 1668 1456 1648 Yes 
1598 1429 1548 
1549 938 1457 
1483 757 1295 
1427  913 
1298  745 
T10-D1 1670 1456 1681 Yes 
1541 1429 1548 
1292 938 1453 
1056 757 1283 
  889, 797 
T11-D1 1668 1456 1666 Yes 
1558 1429 1557 
1534 938 1452 
1311 757 1415 
1195  933, 750 
T12-D1 1672 1456 1670 Yes 
1556 1429 1553 
1412 938 1451 
1305 757 1310 
837  938 
  748 
 
 
6.3.3 Ternary co-crystal: Grinding and DSC analysis 
A total of 60 ternary co-crystallizations were performed and analyzed using infra-red spectroscopy 
and 44 out of 60 (73% success rate) showed positive outcome based on solid-state grinding 
analysis. All positive co-crystals displayed broad bands in the 1850 and 2500 cm-1 region (as a 
result of O–H…N hydrogen bonds) as well as significant shifts in the C-F and C-I stretch of the 
halogen-bond donor indicting both hydrogen and halogen bonding is observed (Figure 6.3, 
Appendix C). Also, The IR of ternary co-crystals was compared to binary hydrogen and halogen 
bonded IRs and pure components as well. The DSC analysis was also done on the crystals obtained 





Figure 6.3 IR spectra of T11-H5-D1 co-crystal and the respective starting materials (T11 – pink, 
H5-blue, T11-H5-D1 co-crystal – red; and D1 – green).  
 
The melting point was obtained for ternary co-crystals and compared with the melting point of 
individual and binary components, Table 6.5.   
 
Table 6.5 Melting point comparisons of ternary systems and corresponding individual and 







Binary XB Ternary 
system 
T11-H5-D1 199-201 ̊C 127-129 ̊C 107-109 ̊C 208-210 ̊C 155-157 ̊C 
T11-H13-D1 199-201 ̊C 139-141 ̊C 107-109 ̊C 208-210 ̊C 140-141 ̊C 
T11-H15-D1 199-201 ̊C 100-102 ̊C 107-109 ̊C 208-210 ̊C 150-152 ̊C 




















































































































































































































































































































































































































(a) T11-H5-D1 (b) T11-H15-D1 
 
 (c) T12-H14-D1 
Figure 6.4 DSC analysis of ternary systems representing single melting temperatures different 
from individual or binary systems. 
 
6.3.4 Crystal structures  
6.3.4.1  Hydrogen bonded co-crystals  
Although vibrational spectroscopy provides unambiguous information about whether a co-crystal 
has formed or not, it does not reveal which acceptor site(s) is/are involved and thus in order to 
examine any hydrogen-bond preferences, single crystal data is required. Four crystal structures 
were obtained from combinations of T9-T12 with ten aliphatic acids, one for T10-based co-
crystals, three for T12-based co-crystals (few highlights of crystal structures listed in Figure 6.5). 
Despite repeated efforts suitable crystals were not available for any co-crystal of T9 and T11, even 















structures were obtained from combinations of T9-T12 with five aromatic acids, one for T9 and 




(a)  (b)  (c)  
Pyridyl site is vacant  Both sites are occupied  Both sites are occupied 
Optimal for ternary systems  Less optimal for ternary systems  Less optimal for ternary systems  
Figure 6.5 Hydrogen-bonding in the crystal structures of (a) T11-Sub, (b) T12-Suc and (c) T9-
3HydroxyBA.  
6.3.4.2 Halogen bonded co-crystals  
Based on the values of MEPS for the acceptor atoms on T9-T12, the pyridine nitrogen atoms 
represent the best acceptors, while the thiazole nitrogen is the second-best acceptor.  Three crystal 
structures were obtained with D1. One crystal structure was obtained with T10-D1, where the 
pyridine nitrogen atom (best acceptor site) of T10 forms a halogen bond with D1 (Figure 6.6). The 
halogen bond formation takes place at both ends of D1, resulting in a supramolecular ribbon. The 
second-best acceptor site on T10 forms homomeric interactions with adjacent molecule via 
NH…N hydrogen bonding. Same interactions were observed with T11-D1 and T12-D1 leading to 
1D supramolecular ribbons (Figure 6.7 and 6.8). The ribbons were extended into 2D architecture 








Figure 6.6 (a) One-dimensional halogen-bonded (heteromeric) and hydrogen-bonded 
(homomeric) chain in the crystal structure of T10-D1, (b) crystal packing in T10-D1.  
 
 
Figure 6.7 One-dimensional halogen-bonded (heteromeric) and hydrogen-bonded (homomeric) 





Figure 6.8 One-dimensional halogen-bonded (heteromeric) and hydrogen-bonded (homomeric) 
chain in the crystal structure of T12-D1.  
6.3.4.3 Ternary co-crystals  
We were able to obtain good quality single crystals for two ternary co-crystals, T11-H5-D1 and 















The starting point of our design of a ternary cocrystal was to first obtain binary co-crystals of T9-
T12 with hydrogen-bond donors and halogen bond donors. If the hydrogen-bond donor binds to 
only recognition point 1 (synthon I), and the halogen bond donor can bind to recognition point 2, 
ternary co-crystals are possible. However, the following three possibilities could cause a possible 
complication towards the success of ternary systems:  
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1. If the hydrogen-bond donor binds to both recognition 1 and recognition 2 (synthon III), 
then the halogen bonding in a ternary system is unlikely.  
2. If the hydrogen-bond donor binds to only recognition point 2 on both sides of acid, then 
halogen bonding in a ternary system is unlikely.  
3. If one binary system is stronger than other or have lower solubility in solution than other, 
it will co-crystallize first, then only binary co-crystals are possible (hydrogen or halogen 
bonding) and ternary would be less likely. 
 
Aromatic acids with an additional donor group such as HydroxyBA were chosen as reference co-
formers which allowed us to include a monotopic donor, hydroxyl OH on the acid. Having a 
monotopic donor on the acid would mean it can bind to recognition point 2 while blocking the 
halogen bond donor from binding and not resulting in ternary co-crystals. 
 
6.4.1 Hydrogen-bonded binary co-crystals  
The binary co-crystals with hydrogen-bond donors were successfully obtained. There was 100% 
success rate with the chosen hydrogen-bond donors (60 grinding and solution experiments), and 
we were able to obtain crystal structures of six co-crystals (four with aliphatic acids and 2 with 
aromatic acids), Figure 6.11. All co-crystals are described in detail in chapter 5. 
 




 The results indicated that T11 might be better acceptor compared to T9, T10 and T12 to make 
ternary co-crystals because in hydrogen-bonding, the recognition point 2 (pyridine N) was vacant. 
6.4.2 Halogen-bonded binary co-crystals  
Three 2:1 stoichiometric binary halogen bonded co-crystals were obtained; T10-D1, T11-D1 and 
T12-D1. T9 also formed halogen-bond co-crystal with 1,4-diiodotetrafluorobenzene but the 
crystal quality wasn’t good for X-ray diffraction studies. The iodine of halogen bond donor, 1,4-
diiodotetrafluorobenzene binds to pyridine N via I…N single point interaction. The recognition 




bond interaction and the weak CH…F interactions expands the structure into 2-D architecture, 
Figure 7.12.  
 
 
Figure 6.12 Summary of halogen-bonded binary co-crystals.  
6.4.3 Ternary co-crystals  
Once the binary co-crystals were obtained, the next step was to use the combination of hydrogen 
and halogen bonding to form ternary co-crystals. Hydrogen bonding in acceptor T11 was most 
optimal for ternary system because the pyridine nitrogen site was vacant which means the halogen 
bond donor can bind to the pyridine nitrogen. Once the binary cocrystals were obtained with 
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hydrogen and halogen bond donors, we attempted ternary co-crystallization with all four target 
molecules, 15 hydrogen-bond donors and one halogen-bond donor giving 60 ternary grinding 
experiments. Based on grinding experiment results, 44 out of 60 co-crystallization attempts (74% 
success rate) formed ternary co-crystals as confirmed by IR spectroscopy by carefully looking at 
peak shifts of both donor groups. All 60 co-crystallizations were put through solution 
crystallization via slow solvent evaporation method in methanol and ethanol solvent. We were able 
to successfully obtain four ternary complexes crystals as confirmed by DSC. The melting point of 
ternary co-crystals was compared with the melting temperatures of individual and binary 
components (Figure 6.13) and it was found to be different from halogen-bonded co-crystals 
confirming IR results that it is indeed a three-component system.  
In ternary co-crystal T11-H5-D1, an aliphatic hydrogen-bond donor, dodecanedioic acid binds to 
recognition point 1 and the 1,4-diiodotetrafluorobenzene binds to the recognition point 2 on both 
ends of halogen bond donor. In ternary co-crystal T11-H13-D1, an aromatic hydrogen-bond donor, 
3-nitrobenzoic acid binds to recognition point 1 whereas the halogen-bond donor 1,4-
diiodotetrafluorobenzene binds to the recognition point 2 on one end and oxygen of OH of 
aromatic acid on the other end.  
 






























6.4.4 Ternary crystal growth issues 
The main criteria for co-crystal formation include comparable solubility, stable synthons, and 
shape/size mimicry among the co-formers29, 31, 34-36. Most solution crystal growth attempts in this 
study resulted in binary halogen-bonded co-crystals with few hydrogen-bond binary systems 
indicating that there were some issues with the formation of crystals of ternary complexes from 
solution.  
 
1. Relative solubility: The path toward crystal growth depends on the difference in solubility of 
the co-formers in a certain solvent. It is believed that the lower the solubility difference 
between the co-formers, the greater the probability of crystal formation with desired 
components34. However, if there is solubility differences between the individual components, 
or formation of binary systems, then it is possible that low solubility component will crystallize 
out first. In this study, halogen-bond binary co-crystal crystallizes out first indicating it was 
the less soluble co-crystal.  
2. Presence of multiple functional groups: The presence of multiple functional groups in the 
solution can cause competition between donor and acceptors groups to choose the right binding 
site and delay the nucleation and crystal growth phenomenon and could result in crystallization 
of either individual or binary components.   
3. Stoichiometric ratios: The different stoichiometric ratios of target molecules, hydrogen-bond 
donor and halogen-bond acceptor could play an important role in the outcome of binary or 
ternary systems. In this study, we have analyzed 2:1:1 (target: aliphatic hydrogen-bond donor: 
halogen-bond donor) and 1:1:0.5 (target: aromatic hydrogen-bond donor: halogen-bond donor) 
stoichiometries only. It is possible that varying stoichiometric ratios could give us more co-
crystals.  
6.5 Conclusions 
This study shows that ternary systems are easy to form with a well-defined design strategy of target 
molecules in solid state. We were successfully able to form binary hydrogen-bond co-crystals with 
target molecules (T9-T12) forming all four synthons in the crystal structures. Also, these target 
molecules were good candidates for halogen-bonding particularly with 1,4-
diiodotetrafluorobenzene (100% supramolecular yield). Finally, 60 out of 60 ternary co-
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crystallization attempts resulted in the crystal structure of two ternary co-crystal from solution 
state.  
1. We successfully made hydrogen-bond binary co-crystals and obtained six new co-crystals 
but only T11 target molecule has the optimal binding pattern at recognition point 1 without 
using the recognition point 2.  
2. We successfully formed crystal structure of three halogen-bond binary co-crystals at 
recognition point 2 without using the recognition point 1.  
3. We were able to make 60 ternary co-crystals and crystals of two of these ternary systems 
were obtained.   
 
 
Figure 6.14 Summary of re-crystallization, binary and ternary co-crystals.  
 
This system worked well in the solid-state, but it still raises questions about interaction strength 




of graded strength. If there are molecules T1, H1 and X1 where the interaction T1-X1 (say halogen 
bond) is stronger than the interaction T1-H1 (say hydrogen bond), then it is fair to expect that 
initial formation of T1X1 in solution can lead to the association of H1 to give an T1-H1-X1 
aggregate giving a ternary cocrystal. Yet, T1-X1 should not be too strong and/or the resulting 
binary cocrystal too insoluble, because then, it will be preferentially isolated36. A fine balance of 
interactions and solubilities is therefore needed to get a ternary cocrystal, the design of which 
remains one of the big synthetic challenges in crystal engineering of molecular organic solids. 
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Chapter 7 - Solid-State landscape of amide containing activated 
halogen bond donors 
7.1 Introduction 
Crystal packing is the result of the optimization of various possible intermolecular interactions 
between the molecules in the solid state.1 Identification of supramolecular synthons between 
various functional groups simplifies the understanding and prediction of crystal structures to some 
extent.2 Therefore, predicting supramolecular synthons3-5 is less complex if the given molecule has 
a small number of functional groups which are self-complementary to form predictable robust 
synthons. As the number of functional groups on a molecule increases, the interference between 
supramolecular synthons becomes a major concern leading to synthon polymorphism6-8 and 
synthon crossover,9-10 Chapter 3-5.   
 
Scheme 7.1 Supramolecular synthons formed by 1̊, 2̊ and 3̊ amides.1  
 
One approach to minimize synthon crossover11-13 and polymorphism14-15 is to incorporate into the 
molecule a small number of functional groups that can interact intermolecularly and to use these 
interactions to limit the possible arrangements of the molecules in space with respect to one 
another. The amide functionality serves as a building block in this context from which a variety of 
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supramolecular structures can be assembled based on the number of substituents on the nitrogen 
atom, scheme 7.1. The type of structure formed is dependent on various factors such as geometry 
of amide group, the number and type of substituents attached to nitrogen atom and the number of 
amide groups present in a molecule as well steric and electronic effects of neighboring functional 
groups in a molecule. 2̊ Amides tend to form repeated chains via NH(amide)….C=O interactions. 
However, this interaction can be easily disrupted if a stronger acceptor, such as pyridine is present 
in the molecule or due to supramolecular chelating effects associated with NH amide (see chapter 





Scheme 7.2 Two possible ways the amide…amide chain interaction is at risk of synthon crossover. 
  
In this context, a good synthetic strategy is needed to obtain desired synthons whilst keeping the 
amide…amide interaction intact. A good approach could be to introduce functional groups such 
as iodine and pyridine that can form halogen bonding, Scheme 7.3. Therefore, we want to design 
molecules in such a way to form both hydrogen and halogen bonding in a molecule without having 
synthon crossovers. Our design strategy includes two donors (hydrogen bond; NH amide and 
halogen bond donor, iodine) and two acceptors (pyridine and C=O) in a same molecule. There are 
two synthon possibilities; Synthon A includes amide disruption (preferred based on Etter’s rule) 






Scheme 7.3 Two types of synthons are possible in our design molecule.   
 
In order to keep the amide functionality intact, synthon B is the desired interaction. The desired 
interaction can be achieved via two methods.  
1. Activation of halogen atom: The first possibility is by activating the iodine atom on the 
molecule to make a strong halogen bond donor. Literature has shown that by introducing an 
sp-hybridized carbon atom1 or by incorporating a fluorinated backbone2 next to the halogen 
atom, the molecular electrostatic potential that determines the σ-hole is enhanced. In order to 
develop a new series of potent XB donors and keep amide functionality intact, we decided to 
activate the halogen bond donors by both methods; by incorporating fluorinated backbone next 




Scheme 7.4 Two possibilities to keep the amide functionality intact either by activating the 
halogen group or via hydrogen-bonded co-crystallization.  
 
2. Co-crystallization: The second possibility to keep the amide functionality intact is by finding 
a suitable stronger hydrogen bond donor than amide NH such as carboxylic acid OH which 
can bind to pyridine N via hydrogen-bond co-crystallization and leave the amide functionality 
intact (Scheme 7.4). Our hypothesis is that hydrogen-bonding will be possible in unactivated 
molecules whereas it might be challenging in activated molecules because all donors and 
acceptors will be already satisfied, Scheme 7.5.  




Scheme 7.5 Our hypothesis for hydrogen-bonded co-crystals with this group of molecules.  
 
Eight different molecules are designed for this study; 3N-IB and 4N-IB are considered unactivated 
molecules, whereas 3N-ITFB, 3N-EB, 3N-IEB, 4N-ITFB, 4N-EB and 4N-IEB are considered 
activated molecules.   
  
(a) (b) 




Scheme 7.7 Aliphatic and aromatic acids used in this study.   
 
 In this chapter we will examine/answer four different questions:  
1. Can we keep the amide functionality intact by activating the halogen-bond donors in 
homomeric synthons? 
2. Can we keep amide functionality intact via hydrogen-bonded co-crystallization? 
3. What is the tipping point for heteromeric vs homomeric hydrogen bond interactions in this 
series of molecules? 
4. Can ethynyl based H and iodoethynyl molecules based I; two atoms of radically different 




Scheme 7.8 An outline of this study 
7.2 Experimental 
7.2.1 General  
All precursors, solvents and donors were purchased from commercial sources and used without further 
purification. 1H NMR spectra and 13C NMR spectra were recorded on Varian Unity plus 400 MHz 
spectrometer. Melting points of target molecules and co-crystals were determined using a Fischer–
Johns Mel-Temp melting point apparatus and uncorrected. 
 
7.2.2 Synthesis 




To stirred ice bathed neat oxalyl chloride, nicotinic acid was added to form thick slurry. The reaction 
mixture was left at room temperature for one hour during which excess oxalyl chloride was allowed to 
evaporate in fume hood to yield white powder. After one hour, 4-iodoaninline (1.5g, 6.85 mmol) in 
acetone was added under vigorous stirring to the resulting powder under ice bath conditions. The 
reaction was subsequently warmed to room temperature and stirred for 15 minutes. The reaction was 
terminated by quenching with 5% aqueous NaHCO3 solution. The resulting crude product was washed 
with water and filtered to yield final compound as an off-white powder. Yield: 2.0g (90%); 1H NMR 
(400 MHz, DMSO) δ ppm: 7.57 (d, 2H), 7.61(m, 2H), 7.73 (m, 1H), 8.27(d, 1H), 8.76 (d,1H), 9.09 
(s, 1H), 10.52(m, 1H).  
 
7.2.2.2 Synthesis of N-(4-iodophenyl) isonicotinamide, 4N-IB18 
 
 
Isonicotinoyl chloride (2.00 g, 14.2 mmol) in 3 ml of triethylamine was added to 40ml of methylene 
chloride. The mixture was chilled to 0̊ C in an ice-bath for 5 minutes. Then, 4-iodoaniline (2.70g, 12 
mmol) was added slowly to the cold solution over a period of 15 minutes. The reaction mixture was 
stirred at room temperature overnight. The resulting precipitate was collected on a frit, recrystallized 
with methanol to afford the final product as an off-white powder. Yield: 3.5g (87%); 1H NMR (400 
MHz, DMSO) δ ppm: 7.63 (d, 2H), 7.71(d, 2H), 7.84 (d, 2H), 8.78(d, 2H), 10.57(m, 1H).  
 
 




1.194g (5.5 mmol) of yellow/orange HgO was added to a solution of 1.35g (8.2 mmol) of 2,3,5,6-
tetrafluoroaniline in 60 ml of ethanol. The mixture was stirred for 30 minutes and then 1.86 g (7.3g) 
of I2 was added. The mixture was stirred overnight. The compound was rota evaporated to remove the 
solvent, then the product was re-dissolved in dichloromethane and washed several times with saturated 
Na2S2O3 solution. The compound was dried over MgSO4 solution. It was rota evaporated to get dark 
brown crystalline solid as the desired product. The product was confirmed using 1H NMR. Yield: 2.2g 
(89%); 1H NMR (400 MHz, DMSO) δ ppm: 4.11 (d, 2H). 
 
 
7.2.2.4 Synthesis of N-(2,3,5,6-tetrafluoro-4-iodophenyl) nicotinamide, 3N-ITFB 
 
To an oven dried 50ml flask was added 3-nicotinic acid (2.46g, 20 mmol) under nitrogen atmosphere. 
An excess of thionyl chloride (2ml) was added via syringe to the reaction flask. The reaction mixture 
was refluxed at 90̊ C for 4-6 hours and excess thionyl chloride was removed under reduced pressure. 
The 3-nicotinoyl chloride (0.848g, 6 mmol) was used for next step without further purification. To 
another oven dried 100ml flask was added 4-iodotetrafluoroaniline (1.74g, 6 mmol)), 4-
Dimethylaminopyridine (0.366g, 3 mmol) and dry methylene chloride (~20ml) under nitrogen 
atmosphere. The reaction mixture was stirred at room temperature for 48 hours. The white precipitate 
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was filtered to yield a white crystalline solid. yield: 2.12g (90%); m.p. 285-286 ̊C, 1H NMR (400 
MHz, DMSO) δ ppm: 7.61 (m, 1H), 8.35(d, 1H), 8.82(d,1H), 9.15(s, 1H), 10.84(m, 1H).  
 
7.2.2.5 Synthesis of N-(2,3,5,6-tetrafluoro-4-iodophenyl) isonicotinamide, 4N-ITFB 
 
To an oven dried 50ml flask was added 4-nicotinic acid (2.46g, 20 mmol) under nitrogen atmosphere. 
An excess of thionyl chloride (20ml) was added via syringe to the reaction flask. The reaction mixture 
was refluxed at 90̊ C for 20 hours and excess thionyl chloride was removed under reduced pressure. 
The acid chloride was used without further purification. 4-nicotinoyl chloride (1.1375g, 8.06 mmol) 
was added into round bottom flask. Pyridine (10ml) was added to the mixture. After that, 4-
iodotetrafluoroaniline (1.76g, 6.04 mmol) was added to the above mixture in an ice-water bath. The 
reaction mixture was stirred in an ice-water bath for 30 minutes and then stirred at room temperature 
under nitrogen for overnight. The crude product was washed with water and dried to get the final 
product as white crystalline solid. Yield: 2.01g (84%); 1H NMR (400 MHz, DMSO) δ ppm: 7.80 (d, 
2H), 8.77(d,2H), 13.65(m, 1H). 
  




In a 250ml round bottom flask fitted with a stir bar, 20 ml of triethylamine was degassed and placed 
under nitrogen atmosphere. To this, 4-iodoaniline (2.4gm, 11mmol), copper(I) iodide (0.067gm, 
0.109mmol), and dichlorobis(triphenylphosphine) palladium (II) (0.038gm, 0.055mmol) were added. 
The reaction mixture was degassed again for 20 minutes and kept under nitrogen atmosphere. To this, 
trimethylsilyl acetylene (1.67ml, 11.8mmol) was added and the reaction mixture was stirred at room 
temperature for 2 days. After this, the solvent was removed from the reaction mixture under vacuum. 
The slurry was dissolved in 50 ml chloroform and washed with 2M ammonium chloride solution and 
further with 50ml 1M sodium chloride solution. The solvent was removed from the organic layer to 
obtain the product. Yield: 1.89g (98%); 1H NMR (400 MHz, DMSO) δ ppm: 0.24 (S, 9 H), 3.80 
(br, 2 H), 6.57 (d, 2 H), 7.24 (d, 2 H). 
 
The TMS protected alkyne (1g, 5.28mmol) was dissolved in methanol (15ml) and dichloromethane 
(5ml). Then, K2CO3 (2.07g, 15mmol) was added into the solution. The mixture was stirred at room 
temperature before being poured into water. The solution was extracted with ethyl acetate and washed 
with brine. After drying over magnesium sulfate (MgSO4), the solvent was evaporated to afford the 
product in dark brown color which forms needles. Yield: 0.66g (94%); 1H NMR (400 MHz, DMSO) 
δ ppm: 3.76 (s, 1 H), 5.48 (br, 2 H), 6.48 (d, 2 H), 7.09 (d, 2 H). 
 




In a 2-neck round bottom 50 ml flask, 0.5 g (4.2 mmol) of 4-ethynylaniline and 2.07ml of triethylamine 
was dissolved in 50 ml of dichloromethane. The solution was kept in an ice-water bath at 0̊ C under 
N2 atmosphere. Then 0.8g (5.6 mmol) of freshly prepared isonicotinoyl chloride was added into the 
reaction mixture. The mixture was allowed to stir in an ice-bath for 2 hours and then at room 
temperature. The reaction was monitored with TLC every 6-12 hours. After 24 hours, the 3-nicotinoyl 
chloride was added and the reaction was allowed to stir at room temperature. After 48 hours, the 
solution was rota-evaporated to get the crude product which was dissolved in ethanol. It was washed 
with saturated NaHCO3 solution and water twice to get rid of any unreacted acid chloride and the 
solution was rota-evaporated to get the pure product. Yield: 0.82g (87%); 1H NMR (400 MHz, 
DMSO) δ ppm: 4.12 (s, 1 H), 7.50 (d, 2 H), 7.59 (m, 1H), 7.82 (d, 2H), 8.28(d, 1H), 8.78(d, 
1H),9.10(s, 1H), 10.58 (br, 1H). 
 
 
7.2.2.8 Synthesis of N-(4-ethynylphenyl) isonicotinamide, 4N-EB 
 
In a 2-neck round bottom 50 flask, 0.5 g (4.2 mmol) of 4-ethynylaniline and 2.07ml of triethylamine 
were dissolved in 50 ml of dichloromethane. The solution was kept in an ice-water bath at 0̊ C under 
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N2 atmosphere. Then 0.8g (5.6 mmol) of freshly prepared isonicotinoyl chloride was added into 
reaction mixture. The mixture was allowed to stir in an ice-bath for 2 hours and then stir at room 
temperature. The reaction was monitored by TLC every 6-12 hours. After 24 hours, the 4-nicotinoyl 
chloride was added and the reaction was allowed to stir at room temperature. After 31 hours, the 
solution was rota-evaporated to get the crude product which was dissolved in ethanol. It was washed 
with saturated NaHCO3 solution and water twice to get rid of any unreacted acid chloride and the 
solution was rota-evaporated to get the pure product. Yield: 0.70g (75%); 1H NMR (400 MHz, 
DMSO) δ ppm: 4.13 (s, 1 H), 7.48 (d, 2 H), 7.80 (d, 2H), 7.85(d, 2H), 8.80(d, 2H), 10.65 (br, 1H). 
 
 
7.2.2.9 Synthesis of N-(4-(iodoethynyl) phenyl) nicotinamide, 3N-IEB 
 
 
To a solution of N-(4-ethynylphenyl) isonicotinamide (0.25 g, 1.08 mmol) dissolved in THF (50 
mL), were added dropwise simultaneously a concentrated solution of iodine in methanol (0.30 g, 
1.19 mmol) and a 10% sodium hydroxide solution over 30 min, vigorously stirring. The mixture 
was stirred overnight and quenched with 100 mL water upon which a light-yellow color precipitate 
formed. The filtered solid was washed with sodium bisulfite solution and afforded pure pale-
yellow color powder of 3N-IEB. Yield: 0.36g (92%); 1H NMR (400 MHz, DMSO) δ ppm: 7.43 
(d, 2 H), 7.59 (m, 1H), 7.80 (d, 2H), 8.29(d, 1H), 8.78(d, 1H),9.09(s, 1H), 10.57 (br, 1H). 
 




To a solution of N-(4-ethynylphenyl) isonicotinamide (0.2 g, 0.9 mmol) dissolved in THF (50 mL), 
added dropwise simultaneously a concentrated solution of iodine in methanol (0.30 g, 1.20 mmol) 
and a 10% sodium hydroxide solution over 30 min, vigorously stirring. The mixture was stirred 
overnight and quenched with 100 mL water upon which a light-yellow color precipitate forms. 
The filtered solid washed with sodium bisulfite solution afforded pure pale-yellow color powder 
of 4N-IEB. Yield: 0.27g (86%); 1H NMR (400 MHz, DMSO) δ ppm: 7.44 (d, 2 H), 7.78 (d, 2H), 
7.85(d, 2H), 8.80(d, 2H), 10.63 (br, 1H). 
 
 
7.2.3 Growing crystals of target molecules 
Crystals suitable for single crystal X-ray analysis for 3N-IB and 4N-IB were grown by slow 
evaporation in methanol. Crystals of 3N-ITFB and 4N-ITFB were obtained by slow evaporation from 
ethanol and nitromethane. Crystals of 3N-EB and 4N-EB were obtained from a mixture of 
methanol/water (1:1). Attempts to grow crystals of 3N-IEB and 4N-IEB were done in various solvents 
and binary solvents (methanol, ethanol, DCM, nitromethane, ethyl acetate, acetone, chloroform, 
methanol/water (1:1), methanol/DCM(1:1) and ethanol/DCM (1:1), but were unsuccessful.  
 
7.2.4 Molecular electrostatic potential calculations 
As mentioned in chapter 3 and 5, only trans amide conformations are considered for this study based 
on a CSD analysis which shows that more than 90% of structures with an amide functionality exist in 
a trans conformation rather than cis conformation. Therefore, the calculations are restricted to finding 
the most stable conformation of the trans form (using MMFF) and that calculating the molecular 
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electrostatic potentials on the most stable conformation geometrically optimized using density 
functional B3LYP level of theory with 6-311++G** basis set in vacuum as described in section 2.2.4.  
 
Table 7.1  Energies of trans amide conformation relative to the most stable trans conformation is for 
meta and para substituted molecules are shown below in kJ/mol.  


























kJ/mol 0 +3  0 
 
7.2.5 Co-crystal screening and crystallography 
Initial screening was carried out through solvent-assisted grinding using methanol. Target 
molecules were combined with each hydrogen-bond donor in stoichiometric ratios (2:1 for 
aliphatic and 1:1 for aromatic acids) leading to a total of 160 grinding experiments. In each 
experiment, 10 mg of the target molecule was used. Once the solvent had evaporated the ground 
mixtures were analyzed using IR spectroscopy to determine whether a co-crystal had formed or 
not. Successful interactions between the target molecules and donor were identified using the 
specific shifts of the peaks of the mixture compared to the starting compounds as well as well as 
the appearance of broad stretches around 2,300 and 1,800 cm-1 as a result of intermolecular O-
H…N hydrogen bonds were taken as an indication of co-crystal formation (such hydrogen bonds 
would not be possible in either of the pure compounds, see appendix). For each successful reaction, 
the resulting solid was dissolved in a minimum amount (2 mL) of methanol/dichloromethane (1:1) 
or methanol/acetone (1:1) or methanol/ethyl acetate (1:1) mixture and then left in a vial for slow 
evaporation in order to obtain crystals suitable for single crystal X-ray diffraction. Most solvents 
resulted in fine needle like crystals which were unsuitable for single crystal diffraction analysis. 
Good quality crystals were obtained for only three combinations.  Table 7.1 summarizes the 
experimental details. X-ray crystallographic data and all halogen-bond geometries are provided in 
the Appendix B.5. 
 
Table 7.2 Experimental details for the ten co-crystals obtained 
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Compound ID Solvent Crystal 
stoichiometry 
Color and morphology 
3N-IB Methanol N/A Colorless, blocks 
3N-ITFB Methanol N/A colorless, blocks 
4N-ITFB Ethanol N/A Colorless, blocks  
3N-EB Methanol/water (1:1) N/A Yellow, needles 
4N-EB Methanol/water (1:1) N/A Yellow, blocks 
3N-IEB Ethyl acetate N/A orange, plates 
3N-IB: Seb Methanol 2:1 Colorless, plate 
3N-EB: Fum Methanol/water (1:1) 2:1 Colorless, blocks  
3N-IEB: Adi Methanol 2:1 Yellow, plates  
 
7.3 Results 
7.3.1 Molecular electrostatic potentials  
The maximum value of the potential, corresponding to the depth of the σ-hole on each halogen 
atom, was determined for the eight donors (Figure 7.1). 
 
 
Figure 7.1 Molecular electrostatic potentials of unactivated and activated target molecules  
 
7.3.2 Experimental structures of halogen bond donors 
Once the compounds were successfully synthesized the next step was to analyze them with single 
crystal X-ray diffraction to determine the nature of their intermolecular interactions. Of the eight 
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target molecules that were synthesized, suitable crystals were obtained for five (3N-IB, 3N-ITFB, 
4N-ITFB, 3N-EB and 4N-EB) molecules. Single crystal X-ray experimental data and the halogen 
bond geometries for the solved structures are provided in the Appendix D. For comparison 
purposes, the crystal structure of 3N-BB is also presented from literature. 13  
The crystal structure of 3N-BB is shown in Figure 7.2. The NH of the amide group binds to the 
pyridine nitrogen disrupting the amide-amide chain. 
 
Figure 7.2 Main intermolecular interactions in the crystal structure 3N-BB (refcode:COFVUQ)21  
 
The crystal structure of 3N-IB is shown in Figure 7.3. The NH amide participates in the hydrogen 
bonding with the carbonyl oxygen of the neighboring molecule. The iodine participates in short 
contact interaction with pyridine N via halogen bonding.  
 
Figure 7.3 Main intermolecular interactions in the crystal structure 3N-IB  
 
 
The crystal structures of 3N-ITFB and 4N-ITFB are shown in Figure 7.4 and Figure 7.5 
respectively. The NH amide participates in the hydrogen bonding with the carbonyl oxygen of the 
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neighboring molecule. The activated iodine (via fluorinated aromatic ring) participates in halogen 
bonding with pyridine N.  
 
 
Figure 7.4 Main intermolecular interactions in the crystal structure 3N-ITFB  
 
Figure 7.5 Main intermolecular interactions in the crystal structure 4N-ITFB  
 
The crystal structure of 3N-EB and 4N-EB is shown in Figure 7.6 and Figure 7.7 respectively. 
The NH amide participates in the hydrogen bonding with the carbonyl oxygen of the neighboring 





Figure 7.6 Main intermolecular interactions in the crystal structure 3N-EB  
 
 
Figure 7.7 Main intermolecular interactions in the crystal structure 4N-EB 
 
In the crystal structure of 3N-IEB, amide…amide interaction is intact and activated iodine binds 
to pyridine.  
 




7.3.3 Grinding experiments and characterization by IR spectroscopy 
Solvent-assisted grinding experiments between each of the eight target molecules and 20 donors 
were analyzed using IR spectroscopy to identify notable interactions between the two potential co-
formers, Figure 7.9-7.10 and Table 7.3 summarize the outcomes. Detailed IR analysis for grinding 
based experiments is provided in Appendix C.   
 
Figure 7.9 An example of hydrogen-bond co-crystal formation based on appearance of broad 












Figure 7.10 An example of no hydrogen-bond co-crystal formation for activated halogen bond 
donors based on no appearance of broad hydrogen-bond stretches; (a) 3N-ITFB:4hydroxyBA 
and (b) 3N-IEB:4hydroxyBA.  
 
Table 7.3 Summary of grinding results. The green box indicates the positive co-crystal outcome 
and red box indicates negative co-crystal outcome. 
 
 Target molecules 
  3N-IB 4N-IB 3N-EB 4N-EB 3N-ITFB 3N-ITFB 3N-IEB 4N-IEB 
Suc              
Adi              
Sub              
Seb              
Fum              
Mal              
Glu              
Pim              
Aze              
Dod              
3OHBA              
4OHBA              
3AminoBA              


























3NitroBA              
4NitroBA              
BA              
4BromoBA              
4IodoBA              
PentaFBA              
% Success rate 17/20 10/20 16/20 16/20 0/20 0/20 3/20 3/20 
85% 50% 80% 80% 0% 0% 15% 15% 
 
 
7.3.4 Experimental structures of co-crystals 
The structure determination of 3N-IB: seb shows the expected trimer constructed from two 
symmetry related OH⋯N(py) hydrogen bonds, resulting in a trimer with a 2:1 stoichiometry of 
target molecule to the sebacic acid. The amide…amide interaction remains intact. 
 
Figure 7.11 Main intermolecular interactions in the crystal structure 3N-IB: Seb  
 
The structure determination of 3N-EB: fum shows the formation of a hydrogen bond between 
pyridine N on the target molecules and the OH on the acid. However, the amide…amide interaction 
was disrupted by a water molecule. The OH group of water binds to a carbonyl oxygen of the 










Figure 7.13 Main intermolecular interactions in the crystal structure 3N-EB: Fum  
 
The crystal structure of 3N-IEB: Adi involves hydrogen bonding between OH of the acid and the 
pyridine N as well as halogen bonding between the activated iodine and carbonyl oxygen of acid. 





Figure 7.14 Main intermolecular interactions in the crystal structure 3N-IEB: Adi 
7.4 Discussion  
7.4.1 Molecular electrostatic potentials of target molecules   
The premise for this study is the assumption that most conventional halogen bonds are dominated 
by electrostatics, a premise that means that a more pronounced σ-hole would produce a more 
effective XB donor. The unactivated halogen bond donor had the value for V(r) of 98 kJ/mol.  As 
we substituted the benzene ring with tetraflourinated ring, the halogen bond donor had the value 




Figure 7.15 From left to right: The eight target molecules are presented in increasing order of 
molecular electrostatics potential associated with the most positive σ hole among the halogen 
atoms in the molecules. Values are presented in kJ/mol.  
 
The second possibility is to add a sp-hybridized carbon next to halogen bond donor, the strong 
polarizing effect of the sp carbon atom allows the ethynyl-based hydrogen and iodine atom to 
display a σ-hole of higher magnitude of 154 kJ/mol and 168 kJ/mol respectively. The results show 
strong similarity between the σ hole on each donor and the resulting MEPs values. A less polarized 
iodine atom on 3N-IB and 4N-IB is more strongly affected by a sp triple bond iodine containing 
moiety than it is by the proximity of a sp2-perflourinated ring or sp-hybridized ethynyl group as 
shown by the increases in the electrostatic potential as we go from 3N/4N-IB<3N/4N-EB<3N/4N-
ITFB<3N/4N-IEB. Synthon B will be formed in all activated donors (3N-ITFB, 4N-ITFB, 3N-
EB, 4N-EB, 3N-IEB and 4N-IEB) 
 To summarize, the calculations have identified the iodoethynyl moiety in IEB as the top ranked 
halogen bond donor as shown in Figure 7.15. These results are in strong agreement with Aakerӧy 
et. al. research work published in 201322 where supramolecular hierarchy was established by 




7.4.2 Synthon prediction based on MEPs 
NH amide is the best donor and pyridine is the best acceptor, therefore, based on Etter’s rule NH 
amide will bind to N forming synthon A will be formed in the crystal structure of 3N-IB and 4N-
IB. In activated target molecules (3N-ITFB, 4N-ITFB, 3N-EB, 4N-EB, 3N-IEB and 4N-IEB), 
the iodine atom or activated ethynyl H are better donors compared to amide NH, therefore activated 
donor (I or H) will bind to pyridine and NH amide will bind to C=O forming synthon B.  
 
7.4.3 Homomeric synthon analysis in target molecules 
Synthon A was predicted in unactivated target molecules and synthon B was predicted in activated 
target molecules.  Six crystal structures of target molecules (3N-IB, 3N-ITFB, 4N-ITFB, 3N-EB, 
4N-EB and 3N-IEB) and one literature structure 3N-BB were analyzed and compared to predicted 
synthons based on electrostatics, Figure 7.16.  
 
Figure 7.16 Predicted (based on MEPs) vs experimental synthons in the target molecules 
 
In all six crystal structures obtained in this study, the amide functionality was intact irrespective 
of whether the halogen atom was activated or not. In 3N-IB, the halogen bond was weak between 
I…N (more of a short contact than a halogen bond) and could be easily disrupted if iodine is 
replaced with bromine atom as was seen in the crystal structure of 3N-BB, where based on Etter’s 
rule; the best donor NH amide binds to best acceptor pyridine N. These results are also supported 
by electrostatic potential values on 3N-IB and 3N-BB, where these molecules have weak σ-hole 
193 
 
value and can only form short contacts with the stronger acceptor group. On the other hand, in all 
activated crystal structures, amide…amide interaction is observed and strong halogen bonding 
interaction between activated iodine and pyridine N is also observed in 3N-ITFB, 4N-ITFB, 3N-
EB, 4N-EB and 3N-IEB molecules. These results were complemented by electrostatic potentials.  
  
7.4.4 Experimental co-crystal screening analysis  
 
7.4.4.1 Unactivated vs activated halogen bond donors 
 
Based on grinding experiment results, the unactivated halogen-bond donors (3N-IB and 4N-IB) 
showed 67% success rate with the 20 hydrogen-bond donors whereas the activated halogen-bond 
donors (3N-ITFB, 4N-ITFB, 3N-IEB, and 4N-IEB) showed only 7% success rate with hydrogen-
bonded co-crystallization, Figure 7.17.  
 
Figure 7.17 Co-crystallization vs re-crystallization summary of unactivated and activated class 
of halogen bond donors  
 
These results indicated that the weak homomeric interactions between Iodine and nitrogen in 
unactivated molecules were easy to break via suitable donors whereas in unactivated molecules, 
all donors and acceptors were involved in strong homomeric interactions and therefore, were 
difficult to break via co-crystallization. These results agree with out hypothesis and are supported 




7.4.4.2 Ethynyl vs iodoethynyl based target molecules  
Another comparison was done between ethynyl and iodoethynyl molecules, it was found that 
ethynyl molecules where only hydrogen bonding was involved in the molecules by themselves 
gave 80% positive co-crystal outcome whereas iodoethynyl molecules where strong halogen 
bonding is involved between activated iodine and nitrogen in homomeric system gave only 15% 
positive co-crystal outcome, Figure 7.18. 
  
Figure 7.18 Co-crystallization vs re-crystallization summary of ethynyl vs iodoethynyl halogen 
bonds 
Therefore, in this study, ethynyl based H and iodoethynyl molecules based I; two atoms of 
radically different size and chemical characteristics doesn’t behave similarly in solid state towards 
aliphatic and aromatic hydrogen-bond donors. It could be due to presence of hydrogen-bonding 


























































Figure 7.19 Comparison between supramolecular yield and electrostatic potentials of 
unactivated and activated molecules.  
 
7.4.5 Experimental structures of co-crystals  
 
Three crystal structures of co-crystals were obtained (3N-IB: Seb, 3N-EB-Fum and 3N-IEB: Adi) 
and in 2 out 3 crystal structures (67%), the amide…amide interaction was intact. In 3N-EB: Fum, 
it was disrupted because of presence of water molecule in the lattice. The summary of three crystal 
structures is provided in Table 7.4.  
 







What type of 
cocrystal? 
Neutral co-crystal Hydrate co-crystal Neutral cocrystal 
Amide functionality 
Intact? 
Yes No (disrupted) Yes 
Which interaction is 
observed? 
Only hydrogen bonding Only hydrogen bonding Hydrogen and halogen 
bonding 






Eight new compounds were synthesized in this study (six of them have halogen bond donor and 2 
contains hydrogen bond donor). Two of the six are unactivated and four of the six are activated 
halogen bond donors. The goal of keeping the amide functionality intact by activating the halogen 
bond donor either by introducing fluorinated ring or by sp-hybridized carbon was achieved.  
1. Both the hydrogen and halogen bonding was systematically controlled in the target molecules 
based on knowledge of stronger halogen bonding between I…. N and strong hydrogen bonding 
between neighboring amide functionality. In each crystal structure obtained for target 
molecules, the amide functionality was kept intact.   
2. The second goal of keeping the amide functionality was also achieved via co-crystallization as 
three crystal structures were obtained, and each crystal structure has amide functionality intact. 
3.  The unactivated halogen bonds donors had 67% supramolecular yield whereas activated 
halogen bond donors had only 7% success with the 20 di and mono acids, Figure 7.20. The 
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results were readily rationalized against calculated molecular electrostatic surface potentials 





Figure 7.20 Success rates of co-crystallization experiments; green-positive results and red 
negative results for (a) activated and (b) unactivated molecules.  
 
4. The ethynyl based ‘hydrogen’ and iodoethynyl based ‘Iodine’ do not display same 
supramolecular field in the solid state against 20 carboxylic acids studied as ethynyl based 
target molecules had 80% supramolecular yield and iodoethynyl based target molecules had 























Figure 7.21 Success rates of co-crystallization experiments; green-positive results and red 
negative results for (a) ethynyl and (b) iodoethynyl molecules.  
 
7.6 References 
1. Greenberg, A.; Breneman, C. M.; Liebman, J. F., The Amide Linkage: Structural 
Significance in Chemistry, Biochemistry, and Materials Science. Wiley: 2002. 
2. Sarma, J. A. R. P.; Desiraju, G. R., Crystal Growth & Design 2002, 2 (2), 93-100. 
3. R., D. G., Angewandte Chemie International Edition in English 1995, 34 (21), 2311-2327. 
4. Joel, B.; E., D. R.; Liat, S.; Ning‐Leh, C., Angewandte Chemie International Edition in 
English 1995, 34 (15), 1555-1573. 
5. Mirzaei, M.; Eshghi, H.; Akhlaghi Bagherjeri, F.; Mirzaei, M.; Farhadipour, A., Journal of 
Molecular Structure 2018, 1163, 316-326. 
6. Pogoda, D.; Janczak, J.; Videnova-Adrabinska, V., Acta Crystallographica Section B 2016, 
72 (2), 263-273. 
7. Mukherjee, A.; Desiraju, G. R., Chemical Communications 2011, 47 (14), 4090-4092. 
8. Mukherjee, A.; Tothadi, S.; Chakraborty, S.; Ganguly, S.; Desiraju, G. R., CrystEngComm 
2013, 15 (23), 4640-4654. 
9. B. Aakeröy, C.; D. Chopade, P.; Desper, J., Avoiding “Synthon Crossover” in Crystal 
Engineering with Halogen Bonds and Hydrogen Bonds. 2011; Vol. 11. 
10. Aakeroy, C. B.; Chopade, P. D.; Ganser, C.; Rajbanshi, A.; Desper, J., CrystEngComm 
2012, 14 (18), 5845-5853. 
11. Aakeröy, C. B.; Chopade, P. D.; Desper, J., Crystal Growth & Design 2011, 11 (12), 5333-
5336. 
12. Khavasi, H. R.; Esmaeili, M., CrystEngComm 2014, 16 (36), 8479-8485. 
13. Khavasi, H. R.; Tehrani, A. A., CrystEngComm 2013, 15 (29), 5813-5820. 
14. Moulton, B.; Zaworotko, M. J., Chemical Reviews 2001, 101 (6), 1629-1658. 
15. Rodrı́guez-Spong, B.; Price, C. P.; Jayasankar, A.; Matzger, A. J.; Rodrı́guez-Hornedo, N. 
r., Advanced Drug Delivery Reviews 2004, 56 (3), 241-274. 
16. Sandhu, B.; McLean, A.; Sinha, A. S.; Desper, J.; Sarjeant, A. A.; Vyas, S.; Reutzel-Edens, 
S. M.; Aakeröy, C. B., Crystal Growth & Design 2018, 18 (1), 466-478. 
17. Al-Sha’er, M. A., Pharma Chem. 2014 2014, 6, 261-291. 
198 
 
18. Mishra, A.; Jung, H.; Park, J. W.; Kim, H. K.; Kim, H.; Stang, P. J.; Chi, K.-W., 
Organometallics 2012, 31 (9), 3519-3526. 
19. Bushuyev, O. S.; Tomberg, A.; Friščić, T.; Barrett, C. J., Journal of the American Chemical 
Society 2013, 135 (34), 12556-12559. 
20. Chadwick, R. C.; Khan, U.; Coleman, J. N.; Adronov, A., Small 2013, 9 (4), 552-560. 
21. Taylor, R. G. D.; Yeo, B. R.; Hallett, A. J.; Kariuki, B. M.; Pope, S. J. A., CrystEngComm 
2014, 16 (21), 4641-4652. 
22. Aakeröy, C. B.; Baldrighi, M.; Desper, J.; Metrangolo, P.; Resnati, G., Chemistry – A 









Chapter 8 - Predicting the crystallization propensity of drug like 
molecules with diverse functionalities 
8.1 Introduction 
Predicting the crystallization propensity of drug-like molecules is one of the biggest challenges 
facing pharmaceutical scientists today.1 Specifically, understanding which molecules in a series of 
similar compounds will be the most difficult to crystallize would be extremely useful, as would 
any indication of the experimental conditions (such as temperature, solvent polarity, molar 
concentration, etc.) that might make crystallization take place more readily. When it comes to 
predictability, it is somewhat easier to predict synthons in molecules with similar functionalities 
but as complexity of molecules grows, synthon prediction becomes more difficult as we have seen 
in chapters 2-5. Crystallizability of a molecule is dependent on many factors such as molecular 
weight, rotatable bond, # of conformers, enthalpy, entropy, glass transition temperature; 
experimental, environmental conditions and hydrogen bond donors and acceptors, Figure 8.1.  
 




8.1.1 Current methodologies 
Despite the importance of being able to understand which structural features of a molecule (such 
as molecular size, polarity, etc.) and which experimental conditions (such as temperature, 
concentration, etc.) permit a molecule to readily crystallize, there has been very little work 
published in the literature focused on this topic. Different approaches have been taken in recent 
years to model and predict crystallization propensity. Machine learning approaches to 
understanding molecular crystallizability in terms of forming ‘good crystals’ have found key 
attributes the number of rotatable bonds and a ‘molecular connectivity index’ effectively 
describing molecular size.2 Statistical (Random Forest) modeling has also been used to model and 
predict crystallizability in terms of giving single crystals suitable for X-ray diffraction.3 In this 
study, descriptors of the relative energy, atom connectivity, conformation and flexibility (number 
of rotatable bonds) contributed to the 70% accuracy of the crystallizability prediction. Taylor, et 
al. have also investigated the crystallization tendency of organic molecules from both undercooled 
melts and supersaturated solutions, having shown that small, rigid molecules of low molecular 
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Figure 8.1 (a and b) Literature studies showing the correlation between molecular weight, 
rotatable bonds and crystallizing ability of molecules.  
 
A recent study found that amorphous stability is strongly correlated with multiple factors, 
including molecular weight, thermodynamic parameters (Tm, H, G) and molecular descriptors (# 
of H bond donors, carbon-to-heteroatom ratio).6 These varied approaches may not give a consistent 
picture of crystallizability, as the difficulty in nucleation does not necessarily correlate to slow 
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crystal growth rates or poor crystal quality.7 More importantly, these approaches do not provide a 
path forward for overcoming inherently poor crystallizability, i.e., crystallizing a molecule for the 
first time.  
In this study, cheminformatics tools such as hydrogen-bond propensity8-9 will be used to predict 
the polymorphs of drug molecules and then use this approach along with molecular descriptors to 
find a systematic way to predict crystallizability. We want to be able to predict if a given molecule 
will be easy to crystallize or not, i.e. the molecule's "crystallizability", Scheme 8.2.  
8.1.2 Outline 
The two main goals of this chapter are listed below: 
1. Apply solid-state informatics tools on drug molecules with diverse functionalities and 
compare/analyze the predicate propensities with the experimentally observed structures or 
polymorphs.   
2. Use solid state and chem informatics to determine a logistic regression model that can be useful 
in predicting the crystallizability of drug molecules.  
 
The second goal of chapter involve six different steps as shown in scheme 8.5.  
 




8.1.3 Defining crystallizability 
There is no simple way of defining crystallizability, and it is even questionable that it is a 
measurable physical quantity. If we ignore the ambiguity in the concept of crystallizability as a 
physically meaningful concept and instead limit ourselves to attempting to predict a probability of 
crystallization, it may be possible to re-phrase the problem in a meaningful way and to find a 
mathematical model for it. A probability is a real number in the interval [0; 1], and we are looking 
for an equation for calculating it, given a molecule and any external experimental factors as input. 
A crystallization experiment either yields crystals or not, it is a dichotomous outcome. We describe 
the outcome as a binary random variable that takes the values 1 (crystals formed) or 0 (no crystals). 
Experiments with a dichotomous outcome that (presumably) depends on several factors can often 
be modelled with a binomial logistic regression model.  
 
Scheme 8.2 Computational approach for prediction of crystallizability in drug-like molecules 
 
In order to determine crystallizability, large flexible drug molecules will be used as the training 
dataset. The chemical structure of list of drug molecules used in each classification is shown in 
scheme 8.3 and 8.4. Each molecule was classified into Class I as crystallizable or Class III as non-
crystallizable based on experimental classification established already in literature By Taylor et. 
al.4 The crystallization classification was done using differential scanning calorimetry (DSC) 
where each sample was heated to above the melting temperature, held isothermally for 3 min, 
cooled at a rate of 20̊C min-1 to -75̊C, and reheated at 108̊C min to just above the melting 
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temperature. The molecules were classified into three categories based on this classification, 
Figure 8.2, Table 8.1.  
The classification was done as follows:  
1. Class I (Rapid crystallizers): If a compound shows exotherm peak from the undercooled melt 
state prior to the Tg event, it was classified as class I molecule.  
2. Class II (intermediate crystallizers): If the compound shows no crystallization upon cooling 
from the undercooled melt state to below Tg, however, crystallization was observed during 
reheating above Tg, it is classified as class II molecule.  
3. Class III (Slow crystallizers): If no crystallization was observed upon either cooling to below 
Tg or upon subsequent reheating up to the melting point, it is classified as class III molecule.  
 
   
(a) Class I (b) Class II (c) Class III 
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Procaine Probucol Ritonavir  
Scheme 8.4 Chemical structures of class III molecules included in this study 
 
8.1.4 Logistic regression model 
The logistic regression model10 is a statistical model used to determine correlation between 
different variables and the response variable is categorical. The model involves three different 
methods to find the best correlation; backward elimination, forward selection and stepwise 
selection. The backward elimination method involves starting with all predictors in the model and 
removing the predictor with highest p-value greater than αcritical, repeating the steps to get the model 
that has all descriptors p-value less than αcritical. The αcritical here simply means “p-to-remove” and 
will be used as 0.10 cut off for this study. The forward selection method is reverse of backward 
elimination method. In this method, we start with no variables in the model and for all predictors 
not in the model, their p-value is checked if they are added to the model. The process is continued 
until descriptors with lowest p-value less than αcritical is chosen and no new descriptors can be 
added.  Stepwise regression is a combination of backward elimination and forward selection.11 It 
is similar to forward selection except that variables are removed from the model if they become 
nonsignificant as other predictors are added. Stepwise procedures are relatively cheap 
computationally, but they do have some drawbacks.  
 
The model does tend to overfit data and gives an equation based on input file. Few ways to check 
the quality of model includes: 
1. P-value= (correlation b/w descriptor and crystallizability), Less than 10% considered good  
2. R2 Value = Statistical measure of how close the data is to the fitted regression line (Above 50% 
considered good) 
3.  GOF= Tells us how good the model is (Above 75% considered good).  
 
The regression model is the logit function: 






Here, P is the predicted outcome, a number between 0 and 1, which can be interpreted as a 
probability, and t is called the 'linear predictor' and depends on the experimental factors. 
Let the factor levels that affect the experiment be denoted xi, i.e. the ith factor has level x. The 
importance of each factor (their regression coefficients) are denoted βn. We can then write t = β0 + 
β1x1. The first β0 is a constant, corresponding to the y-axis intercept in linear regression. If there 
are several factors, we write the 'linear predictor' as a scalar product 
                                      t = β0 + β1x1 + β2x2 + β3x3 ………………………………………………………….  Equation 8.2  
8.2 Experimental 
8.2.1 Hydrogen-bond propensity study 
Hydrogen-bond propensity8-9, 12 calculations (CSD Version 5.38 and Mercury 3.9) were used as a 
way of predicting the most likely interactions in the structures of the class I and class III molecules  
Each compound was sketched and auto-edited, functional groups were selected as suggested by 
Mercury, a training dataset (350-600 structures per functional group) was made and the 
propensities were calculated with an ROC curve higher than 0.800 (“good discrimination”).   
 
8.2.2 Logistic regression model 
The logistic regression model is used because the response variable in this study is categorical i.e. 
the output can take only two values, I and III and there are one or more independent variables that 
determine an outcome. The MINITAB13-14 software will be used to determine the regression 
model. Different methods of determining the model were used such as stepwise, forward selection 






Figure 8.3 (a) Representation of prediction and response variables, (b) different prediction 
methods.  
 
The logistic regression models were obtained using 36 molecules (half were classified as 
crystallizable and half were classified as non-crystallizable). The methods used to determine the 
model is stepwise selection and forward selection. Four different models were obtained (Figure 
8.4). The details of model 1 and model 2 is provided in Table 8.1, Figure 8.3 and Table 8.2, Figure 




Table 8.1 Summary of the model 1 obtained in this study 
Class I molecules  18 
Class II molecules 18 
Methods used Stepwise selection, Forward selection 
Significant descriptors MW, Tg, SA, RB, heteroatom 
GOF .99, .99, .95 
Model equation 33.5 -0.1508 MW+0.197Tg -0.282SA+1.84RB+3.25heteroatom 





• Forward selection  




Figure 8.4 Normal probability plot and histogram for the model 1 
 
The probability equation for crystallizability obtained from this model 2 is given below:  
 
𝑃 =  
𝒆𝒙𝒑(𝟑𝟑.𝟓−𝟎.𝟏𝟓𝟎𝟖𝑴𝑾+𝟎.𝟗𝟕𝟏𝑻𝒈−𝟎.𝟐𝟖𝟐𝑺𝑨+𝟏.𝟖𝟒𝑹𝑩+𝟑.𝟐𝟓𝒉𝒆𝒕𝒆𝒓𝒐𝒂𝒕𝒐𝒎)
𝟏+𝒆𝒙𝒑 (𝟑𝟑.𝟓−𝟎.𝟏𝟓𝟎𝟖𝑴𝑾+𝟎.𝟗𝟕𝟏𝑻𝒈−𝟎.𝟐𝟖𝟐𝑺𝑨+𝟏.𝟖𝟒𝑹𝑩+𝟑.𝟐𝟓𝒉𝒆𝒕𝒆𝒓𝒐𝒂𝒕𝒐𝒎)




Table 8.2 Summary of the model 2 obtained in this study 
Class I molecules  18 
Class II molecules 18 
Methods used Forward selection 
Significant descriptors MW, Tm, SA, RB, heteroatom 
GOF .99, .87, .97 
Model equation 15.53 - 0.1227 MW + 0.0891 Tm - 0.276 SA + 1.039 RB + 3.90 heteroatom 





Figure 8.5 Normal probability plot and histogram for the model 2 
 
The probability (crystallizability) equation obtained from this model 2 is given below: 
𝑃 =  
𝒆𝒙𝒑(𝟏𝟓.𝟓𝟑 − 𝟎.𝟏𝟐𝟐𝟕 𝐌𝐖 + 𝟎.𝟎𝟖𝟗𝟏 𝐓𝐦 − 𝟎.𝟐𝟕𝟔 𝐒𝐀 + 𝟏.𝟎𝟑𝟗 𝐑𝐁 + 𝟑.𝟗𝟎 𝐡𝐞𝐭𝐞𝐫𝐨𝐚𝐭𝐨𝐦)







Figure 8.6 Four different models and the significance of each descriptor. 
 
8.2.3 Training dataset 
Taylor’s approach based on DSC melt experiments was used to determine the final classification, 
Table 8.1. Taylor et. al classified molecules as class I, class II and class III but we can only have 
response variable as two outputs.  We combined class II and class III molecules together because 
based on initial co-relation studies between descriptors and crystallizability, we found that class II 
and class III were indistinguishable.  
 
Table 8.3 Classification of each molecule based on melt study and classification used for logistic 
regression model.  
 ID Based on melt   Final classification  
1 4-Biphenylcarboxylic acid  Class I  Class I  
2 4-Biphenylmethanol  Class I  Class I  
3 4-biphenylcarboxaldehyde Class I  Class I  
4 4-Phenylphenol  Class I  Class I  
5 Anthranilic acid  Class I  Class I  
6 Antipyrin Class I  Class I  
7 Atenolol Class I  Not included in the study  
8 Benzamide Class I  Class I  
9 Benzocaine Class I  Class I  
10 caffeine  Class I  Class I  
11 Carbamazepine Class I  Class I  
12 Chlorpropamide Class I  Class I  
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13 Chlorzoxazone Class I  Class I  
14 Felbinac Class I  Class I  
15 Flufenamic acid Class I  Class I  
16 Griseofulvin  Class I  Class I  
17 Haloperidol Class I  Class I  
18 Indoprofen Class I  Class I  
19 Lidocaine class I  Class I  
20 Phenacetin Class I  Class I  
21 Theophylline Class I  Class I  
22 Tolbutamide Class I  Class I  
23 Tolfenamic acid  Class I  Class I  
24 Acetaminophen Class II  Class III  
25 Bifonazole  Class II  Class III 
26 Celecoxib Class II  Class III  
27 cinnarizine Class II  Class III 
28 Clofoctol Class II  Class III 
29 Dibucaine Class II  Class III  
30 Droperidol Class II  Class III  
31 Flurbiprofen Class II  Class III 
32 Nifedipine class II Class III  
33 Salicin Class II  Class III  
34 Tolazamide Class II  Class III  
35 Aceclofenac Class III  Class III  
36 clotrimazole Class III  Class III  
37 Felodipine Class III  Class III  
38 Fenofibrate Class III  Class III  
39 Ibuprofen Class III  Class III  
40 Indomethacin Class III  Class III  
41 itraconazole Class III  Class III  
42 ketoconazole Class III  Class III  
43 Ketoprofen Class III  Class III  
44 loratadine Class III  Class III  
45 miconazole  Class III  Class III  
46 Nilutamide  Class III  Class III  
47 Nimesulide Class III  Class III  
48 Pimozide Class III  Class III  
49 Probucol  Class III  Class III  
50 Procaine  Class III  Class III  
51 Ritonavir  Class III  Class III  
 
8.2.4 Choice of descriptors  
Number of descriptors including physical parameters such as molecular weight, donors, acceptors, 
ratio of D/A, rotatable bond, polarizability, enthalpy etc were chosen for this study. The list of 
descriptors is shown in Figure 8.8. Descriptor Information for each molecule is provided in 




Figure 8.7 Various molecular, conformational, thermodynamic and intermolecular descriptors 
chosen for this study are shown here.    
 
8.3 Results 
8.3.1 Propensity comparison study  
 
Table 8.4 Representation of highest propensity interaction observed in each crystal structure and 
comparison with the known forms. White box indicates no more polymorphs, green box 
indicates experimental results match with prediction, red indicates experimental does not match 
with prediction and yellow indicates that the crystal structure was not available.   
   
Best propensity  
#  
polymorphs 
Form I Form II Form III Form IV Form V 
1 4-Biphenylcarboxylic acid  0.42 1      
2 4-Biphenylmethanol  0.27 1      
3 4-Phenylphoneol  0.17 2      
4 Anthranilic acid  0.92 3 Intra  Intra  Intra    
5 Atenolol 0.71 2      
6 Benzamide 0.73 3      
7 Benzocaine 0.56 3      
8 Carbamazepine 0.62 5 Dimer  Dimer  Dimer  Dimer  Catemer  
9 Chlorpropamide 0.67 5      
10 Chlorzoxazone 0.71 1      
11 Felbnac 0.39 1      
12 Flufenamic acid 0.91 8      
13 Haloperidol 0.38 1      
14 Indoprofen 0.3 1      
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15 Phenacetin 0.59 1      
16 Theophylline 0.38 3 C=O  C=O   
17 Tolbutamide 0.64 4      
18 Lidocaine  0.31 1      
19 Tolfenamic acid  0.91 2      
20 Acetaminophen 0.56 6      
21 Celecoxib 0.7 1      
22 Clofoctol 0.07 NO CS      
23 Dibucaine 0.25 1      
24 Droperidol 0.26 2      
25 Flurbiprofen 0.32 2      
26 Nifedipine 0.26 3      
27 Salicin 0.59 1      
28 Tolazamide 0.59 2      
29 Aceclofenac 0.94 1      
30 Felodipine 0.32 5      
31 Ibuprofen 0.37 2      
32 Indomethacin 0.36 2      
33 Nimesulide 0.68 2      
34 Ketoprofen 0.19 1      
35 Pimozide 0.27 No CS       
36 Probucol 0.02 1      
37 Procaine 0.59 2      
38 Ritonavir  0.4 2      
 
8.3.2  Influence of molecular descriptors on the crystallizability prediction  
Based on molecular weight, molecules with molecular weight less than 300 g/mol falls in Class I 
(21 out of 26 molecules, 81%) and above 300 g/mol falls in Class III (14 out of 23 molecules, 
61%), Figure 8.8a.  
Based on rotatable bond, 22 out of 26 (85%) of class I molecules have # of rotatable bonds less 
than 4 and 19 out of 23 molecules (82%) of class III molecules # of rotatable bonds ≥ 4, Figure 
8.8b.  
Based on heavy +hydrogen atom: 18 out of 26 (69%) of class I molecules have Heavy atom+ 
hydrogen atom < 35 and 18 out of 23 (78%) of class III molecules have Heavy atom+ hydrogen 
atom > 35, Figure 8.9a. 






Figure 8.8  (a) Molecular weight vs crystallizability, (b) Rotatable bond vs crystallizability. 
  
(a) (b) 
 Figure 8.9 (a) Heavy atom + hydrogen atom count and (b) surface area vs crystallizability 
classification of molecules.  
 
8.3.3  Influence of conformational descriptors on crystallizability prediction  
The number of conformations increases as we go from class I to class III molecules (Table 8.5).  
 
Table 8.5 # of conformers for each molecule in class I and class III  
ID Crystallizability conformers  ID Crystallizability conformers  
4-Biphenylcarboxylic acid  Class I  3 Tolazamide Class III 2000 
4-Biphenylmethanol  Class I  2 Flurbiprofen Class III 38 
4-Phenylphenol  Class I  2 Clofoctol Class III 384 
Anthranilic acid  Class I  2 Celecoxib Class III 72 
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Benzamide Class I  1 Dibucaine Class III 2000 
Benzocaine Class I  19 Droperidol Class III 2000 
Carbamazepine Class I  4 Nifedipine Class III 223 
Chlorpropamide Class I  1872 Salicin Class III 258 
Chlorzoxazone Class I  0 Aceclofenac Class III 2000 
Felbinac Class I  24 Felodipine Class III 546 
Flufenamic acid Class I  95 Ibuprofen Class III 46 
Haloperidol Class I  2000 Indomethacin Class III 384 
Indoprofen Class I  48 Nimesulide Class III 71 
Phenacetin Class I  40 Ketoprofen Class III 153 
Theophylline Class I  0 Pimozide Class III 2000 
Tolbutamide Class I  2000 Probucol Class III 174 
Lidocaine  Class I  2000 Procaine Class III 2000 
Tolfenamic acid  Class I  46 Ritonavir  Class III 2000 
 
8.3.4 Influence of intermolecular descriptors on crystallizability prediction  
Ratio of donor/acceptor: 14 out of 20 (70%) of class I molecules have ratio of donor/acceptor ≥ 
0.5 and 9 out of 12 (75%) of class III molecules have ratio of donor/acceptor < 0.5 (Figure 8.10).  
 
 
Figure 8.10 Ratio of donor/acceptor vs crystallizability 
 
Propensity: In class I: 11 out of 21molecules, 52% molecules have propensity higher than 0.5 and 





Figure 8.11 Propensity vs crystallizability 
 
# of competing interactions: In class I, 10 out of 22 molecules, 45% have 0 competing 
interactions and in class III, 3 of 10 molecules, 30% have 0 competing interactions (Figure 8.12).  
 




























































Risk of synthon polymorphism: The risk of synthon polymorphism is determined by # of 
competing interaction in the molecules using propensity chart. Anything below 0.10 was not 
considered a valid interaction for this comparison. In class I, 11 out of 19 molecules, 58% have 0 
competing interactions, Table 8.6 and in class III, 6 of 19 molecules, 32% have 0 competing 
interactions, Table 8.7.  
 






# of structures 
after cif. 
Insertion 





Risk of synthon 
polymorphism? 
1 4-Biphenylcarboxylic acid 1 1 yes No 
2 4-biphenylmethanol 1 1 yes No 
3 4-phenylphoneol 1 1 yes No 
4 Anthranilic acid 2 7 no Yes 
5 Atenolol 41 4 yes Yes 
6 Benzamide 1 2 yes No 
7 Benzocaine 2 3 yes No 
8 Carbamazepine 2 3 yes No 
9 Chlorpropamide 2 4 no Yes 
10 Chlorzoxazone 1 1 yes No 
11 Felbnac 1 1 yes No 
12 Flufenamic acid 2 1 no Yes 
13 Haloperidol 1 2 no Yes 
14 Indoprofen 2 2 no Yes 
15 Phenacetin 2 1 yes No 
16 Theophylline 6 6 yes Yes 
17 Tolbutamide 2 7 no Yes 
18 Lidocaine 1 4 no No 
























Risk of synthon 
polymorphism? 
1 Acetaminophen 2 2 no Yes 
2 Celecoxib 3 3 no Yes 
3 Clofoctol   N/A No 
4 Dibucaine 1 2 yes Yes 
5 Droperidol 2 3 yes Yes 
6 Flurbiprofen 1 3 no No 
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7 Nifedipine 0 1 Yes Yes 
8 Salicin >40 >20 no Yes 
9 Tolazamide 1 17 yes Yes 
10 Aceclofenac 1 4 yes Yes 
11 felodipine 2 2 yes Yes 
12 Ibuprofen 1 2 yes No 
13 Indomethacin 3 3 No Yes 
14 Nimusalide 2 3 no Yes 
15 Ketoprofen 2 2 yes Yes 
16 Pimozide   N/A No 
17 Probucol 1 3 no No 
18 Procaine 2 3 No No 











8.3.5  Logistic regression model results 
The model 1 was very good with 73% chances of predicting the unknown correctly. The five most 
significant descriptors were molecular weight (MW), glass transition temperature (Tg), surface 
area (SA), rotatable bond (RB) and heteroatom. The model 2 was based on molecular weight 
(MW), melting temperature (Tm), surface area (SA), rotatable bond (RB) and heteroatom with R2 
value of 69%. All the descriptors in model 2 can be easily determined except melting point, 
therefore an online software (https://www.epa.gov/tsca-screening-tools/epi-suitetm-estimation-
program-interface) was used to predict the melting temperature. The model 3 was based on 
molecular weight (MW), glass transition temperature (Tg), topological surface area (TPSA), 
small/large (S/L axis ratio) with R2 value of 76%.  The model 4 was based on molecular weight 
(MW), melting temperature (Tm), topological surface area (TPSA), S axis (Å) with R2 value of 
76%. 
 
8.3.6 Regression Output Analysis (training dataset)    
All four models were tested on the training dataset and the comparison between prediction and 





Figure 8.13 The probability of crystallizability prediction of training dataset using four different 
models and the resulting success rate with each model.  
 
8.3.7 External validation test datasets  
The model was then tested on the external unknown molecules where experimental 
crystallizability is already established. The prediction results were compared with the experimental 
results.  Three different test datasets were studied, and the results are shown in Figure 8.14-8.16. 
 




Figure 8.14 The probability of crystallizability prediction of bergstrom et.al. study15 using four 
different models and the resulting success rate with each model.  
 




Figure 8.15 The probability of crystallizability prediction of Kohrenon et.al. study16 using four 
different models and the resulting success rate with each model.  
 
8.3.7.3  Test datatset-3 (Taylor et.al. study (13 molecules) 
 
Figure 8.16 The probability of crystallizability prediction of Taylor et.al. study4 using four 
different models and the resulting success rate with each model.  
 
8.4 Discussion 
8.4.1 Influence of various descriptors on the crystallizability   
Based on comparison between various descriptors and crystallizability classification, it was found 
that molecular weight, rotatable bond, # of competing interactions, risk of synthon polymorphism, 
ratio of donor/acceptor affects whether a molecule crystallizes or not, Table 8.8. A low molecular 
weight molecule with less number of rotatable bonds and lower risk of synthon polymorphism is 
more prone to fall in class I (crystallizable) whereas high molecular weight compounds with higher 
number of rotatable bonds and high risk of synthon polymorphism are more prone to fall in class 






Table 8.8 Summary of correlation between descriptors and each classification 
 
Class I Class III 
Molecular weight Low (<300g/mol) High 
(>300g/mol) 
Rotatable bond Low (<4) High (≥4) 
Heavy +hydrogen atom low High 
Ratio of donor/acceptor High (>0.5) Low (<0.5) 
Propensity Medium Low 
# of competing interactions Medium High 
Risk of synthon polymorphism Low High 
  
8.4.2 Selection and validation of training and test datasets  
A logistic regression model was derived to predict drug crystallizability.  Acetaminophen was 
considered as an outlier on the model as it affected the model negatively when present in the dataset 
therefore, it was removed from the dataset. The chosen iterative procedure to select the optimal 
model algorithm and analysis criterion is illustrated in section 8.1.2. For each selection, the GOF, 
R2 value, graphs were carefully analyzed to choose the best fit model. The model predicts the 
crystallizability outcome as 0 for non-crystallizable and 1 for crystallizable. The 0.5 cut off was 
chosen to analyze the results and in 32 out of 36 molecules (89% success rate), there was agreement 
between prediction and experimental results using model 1. Out of 36 molecules, 16 were true 
positive,2 were false positives, 2 were false negatives and 16 were true negatives. The model 
suggested that five descriptors play an important role in the crystallizability; molecular weight, 
rotatable bond, surface area, glass transition temperature and number of heteroatoms present in the 
molecule. The model 2 was same model as model 1 but the glass transition temperature descriptor 
was replaced with melting point temperature. The complete analysis of four models and the 
resulting success rate is shown in Table 8.9.  
 












Taylor  89 83 75 89 89 
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Bergstrom 82 95 95 86 86 
Kohrenon  83 75 58 92 92 
Tay-remaining  85 92 38 67 75 
Overall  85% 88% 68% 84% 86% 
 
In all validation studies, all four models predicted the experimental crystallization above 75% 
indicating the applicability of these simple model equations outside the scope of the sample set 
due to its moderately high predictive power and its structural simplicity. In a drug discovery 
setting, this degree of accuracy would be of high utility.  
 
 
Figure 8.17 Summary of validation test results  
 
Combining both training and validation dataset, we have 85% agreement (70 out of 83 molecules) 
between predicted and experimental crystallizability outcome using model 1 and the confusion 
matrix showing TP (true positive), FN(false negative), FP(false positive) and TN(true negative) 
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t Yes  41 4 
No  9 29 
 
(a) (b) 
Figure 8.18 Confusion matrix of predicted vs experimental results for 83 molecules involved in 
this study is shown using model 1 
8.5 Conclusion 
This work demonstrates that crystallizability of drug molecules can be predicted with a good 
degree of confidence using a combination of easily calculated, predicted, or measured parameters. 
The correlations of various descriptors such as molecular weight, RB, surface area, heteroatom, 
melting temperature, glass transition temperature, molecular shape/volume with the 
crystallizability provide insight into the key factors that influence mechanisms which drive 
crystallization. Four different models were used to predict the crystallizability of 83 different 
molecules and the predictions were made successfully with above 85% success rate.6 This success 
rate is higher than what is reported in the literature with other predictive methods. Nevertheless, 
the predictive power of the selected models should be further validated on a larger external data 
set. Once successfully validated, such models could assist in faster and more cost effective decision 
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Chapter 9 - Modulating physical properties of solid forms of urea 
using co-crystallization technology 
 
9.1 Introduction  
Urea is an inexpensive fertilizer with the highest nitrogen content among commonly used solid 
fertilizers.  The solubility of urea in water is approx. 110-170 g/100 ml, in the 20-40 ˚C range, and 
it is rapidly hydrolyzed after application.1 The high solubility of urea in water and rapid moisture 
intake after application makes it susceptible to mobility and/or runoff from treated areas where it 
kills aquatic plants and animals causing environmental damage. Because of the mobility, higher 
concentrations of urea are oftentimes applied to seeds and plants to ensure that a sufficient amount 
of active ingredient is available for utilization by the plant. Excessive application results in 
inefficiencies and large loss of excess nitrogen to the environment which can impact air and water 
quality, biodiversity and human health.2 The high moisture content of urea at relative humidity of 




Scheme 9.1  An outline of co-crystallization event in the urea.  
 
Various slow-release fertilizer (SRF) technologies have been used, thus preventing problems 
related to leaching, volatization, denitrification and run-off.3 The uncoated slow release fertilizer 
(urea:formaldehyde,4 isobutylidene-diurea5 and inorganic salts6), coated slow-release fertilizers 
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(sulfur coated,7 polymer coated8 and hybrid coated urea9) as well as urease and nitrification  
bioinhibitors7, 10 have been used to tackle the issues.11These methods have disadvantages related 
to manufacture cost of production, and irregular nutrient release.  
 
 
Scheme 9.2  Four potential avenues for intermolecular ‘intervention’ on urea (A and D =  
hydrogen-bond acceptor and donor, respectively) and resulting choice of potential co-formers.  
 
Co-crystals has proven to be a powerful tool to alter the physiochemical properties of molecules 
of interest without modifying their biological properties. Therefore, by fine-tuning the crystalline 
environment of a compound without altering its molecular structure, we could potentially “dial-
in” desirable physical properties, which would be highly significant to manufacturers/consumers 
of organic specialty chemicals.12  It is able to do so using the strength of non-covalent 
intermolecular interactions, such as hydrogen bonding,13-14 halogen bonding,15 π···π, 16and other 
non-covalent interactions.17 Co-crystals have proven to show solubility advantage over various 
pharmaceutical compounds with diverse chemical and pharmacological nature which includes 
myricetin (anticancer flavonol),18 itraconazole (antifungal),19 adefovir (antiviral),20 aceclofenac 
(NSAID),21 gabapentine (anticonvulsant),22 aspirin(NSAID),23-24 norfloxacin (antibiotic),25  
 stanolone(API),26 caffeine(stimulant),27 efavirenz(antiviral)28  and mirtazapine (antidepressant)29 
displaying potential to improve solubility and hence bioavailability. The technique has also been 
used for creating less-sensitive explosives, as well as modifying and optimizing other properties 
of energetic materials, a class of materials including explosives, propellants and pyrotechnics. 
Cocrystals of TNT, HMX and CL-20 have clearly demonstrated the capacity for modifying 
materials properties through co-crystallization.30 Co-crystals have been used to stabilize volatile 
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liquid chemicals,31 make non-linear optic materials32-35 and are gaining interest in agro-
chemicals.36-37   
The study is done to address the following questions,  
1. Can co-crystallization technology be utilized for producing new solid forms of urea (Scheme 
9.1)? 
2. Can the physiochemical properties of new solid forms of urea be altered without affecting the 
biological properties? 
 2.1 Can we decrease solubility in a predetermined manner? 
2.2 Can we increase stability and hygroscopicity sensitivity?  
 
We hypothesize that if we can incorporate a suitable co-former within a series of crystalline solids 
characterized by considerable structural consistency, we may be able to fine-tune properties such 
as aqueous solubility and moisture sensitivity.  Changes to the physical properties will be achieved 
by varying the co-crystallizing agents in a systematic fashion without altering the precise nature 
of the molecular recognition events that drive the supramolecular assembly. This will allow us to 
modify physical properties and alter aqueous solubility, stability and hygroscopicity in order to 
optimize the performance and benefits of urea as a plant nutrient. It would be highly advantageous 
if it will be possible to alter/control the aqueous solubility in a predetermined manner.  
In this study, we present the results from a systemic co-crystallization study comprising 60 
experiments with selected co-formers intended to provide more details of new co-crystals of urea 
that can add value to the resulting solid form (Scheme 9.3).  The co-formers chosen for this study 
are relatively inexpensive, easily available, non-toxic, have no harmful effect on the soil, or can 
add nutritional benefit to the soil.  The choice of co-formers was also based on finding chemical 
functionalities that can bind in a complementary and effective manner with the molecular 













Scheme 9.3 List of co-formers used in this study 
 
9.2 Experimental  
 
9.2.1  Materials  
Urea and all co-formers were purchased from Aldrich and utilized without further purification.   
 




Melting points were measured using Fisher-Johns melting point apparatus. Solution 1H NMR data 
were collected on a Varian Unity plus 400 MHz spectrometer in DMSO. IR spectra were recorded 
with a Nicolet 380 FT-IR. An outline of experimental steps followed in this study is displayed in 
scheme 9.4 
 
9.2.2 Isostar and full interaction maps (FIMs) search 
The first phase of this study involves the use of several complementary approaches pursued in 
parallel.  In order to develop robust protocols for co-crystal synthesis of urea we combine a 
knowledge-based approach for mapping out the intermolecular interactions that are most likely to 
take place with different parts of the urea functionality.  To this end, a careful analysis of all 
relevant structural data from the Cambridge Crystallographic Data Centre will furnish a map of 
the most likely short contacts with the C=O and the N-H moieties.  The data is analyzed using 
Isostar which provides 3-D maps of intermolecular interactions based upon existing experimental 
structural data. In this work, an intermolecular contact was defined as any contact shorter than the 
sum of the van der Waals radii of the atoms involved. Two terminal urea compounds with cis and 
trans confirmation were studied. The FIMs were done using Mercury CSD database 5.38 (Nov 
2016) with updates from Feb and May 2017 with 2, 4, 6 and contour levels and using uncharged 
NH nitrogen, carbonyl oxygen and aromatic CH carbon.  
 
Figure 9.1 Flow chart of experimental strategy employed in this study 
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9.2.3  Co-crystal screening 
The co-crystal screening experiments were based on appropriate stoichiometric ratios of target:co-
former and all reactant combinations were put through slow solvent evaporation in different 
solvents to grow crystals suitable for single-crystal x-ray diffraction studies, (Table 9.1).  
 
Table 9.1 Stoichiometric ratio, solvents used in the solution co-crystallization 
 Conformers M.W. 
(g mol−1) 
Mass (g) mmole Solvent Ratio 
Co-former: urea 
Aliphatic acids 
1 Citric acid (CA) 192 0.0192 0.10 Methanol, Water 1:2 
2 Citramalic acid (CmA) 148.12 0.0148 0.10 Methanol, Ethanol 1:2 
3 Malonic acid (MA) 52.00 0.0052 0.05 Methanol, Ethanol 1:2 
4 Succinic acid (SA) 118.09 0.0059 0.05 Methanol, Ethanol 1:2 
5 Fumaric acid (FA) 116.07 0.0058 0.05 Methanol, Ethanol 1:2 
6 Glutaric acid (GA) 132.12 0.0066 0.05 Methanol, Ethanol 1:2 
7 Adipic acid (AA) 146.14 0.0073 0.05 Methanol, Ethanol 1:2 
8 Pimelic aid (PA) 160.17 0.0084 0.05 Methanol, Ethanol 1:2 
9 Suberic acid (SbA) 174.20 0.0087 0.05 Methanol, Ethanol 1:2 
10 Sebacic acid (SeA) 202.25 0.0101 0.05 Methanol, Ethanol 1:2 
11 Tartaric acid (TA) 150 0.0150 0.10 Methanol, Ethanol 1:2 
12 Maleic acid (MeA) 120 0.0120 0.10 Methanol, Ethanol 1:2 
13 Azelaic acid (AzA) 188.22 0.0094 0.05 Methanol, Ethanol 1:2 
Aromatic acids 
14 3-Hydroxy benzoic acid (3HBA) 138.12 0.0138 0.10 Methanol, Ethanol 1:1 
15 4-Hydroxy benzoic acid (4HBA) 138.12 0.0138 0.10 Methanol, Ethanol 1:1 
16 3-Amino benzoic acid (3ABA) 137.13 0.0137 0.10 Methanol, Ethanol 1:1 
17 4-Amino benzoic acid (4ABA) 137.13 0.0137 0.10 Methanol, Ethanol 1:1 
18 Phthalic acid (PtA) 166 0.0166 0.10 Methanol, Ethanol 1:2 
19 Pyrazine-2-carboxylic acid (Py2_CA) 124 0.0124 0.10 Methanol, Ethanol 1:2 
20 Pyrazine2,3-dicarboxylic acid 
(Py2,3_CA) 
168 0.0168 0.10 Methanol, Ethanol 1:2 
21 Pyridine2,5-dicarboxylic acid 
(Py2,5_CA) 
168 0.0168 0.10 Methanol, Ethanol 1:2 
22 Pyridine 2,6-dicarboxylic acid 
(Py2,6_CA) 
168 0.0168 0.10 Methanol, Ethanol 1:2 
23 Pyrazine3,5-dicarboxylic acid 
(Py3,5_CA) 
168 0.0168 0.10 Methanol, Ethanol 1:2 
24 Hippuric acid (HipA) 179 0.0179 0.10 Methanol, Ethanol 1:2 
25 2,5-Dihydroxybenzoic acid (2,5DHBA) 154 0.0154 0.10 Methanol, Ethanol 1:1 
26 3,4-Dihydroxybenzoic acid 
(3,4DHBA) 
154 0.0154 0.10 Methanol, Ethanol 1:1 
27 3,5-Dihydroxybenzoic acid 
(3,5DHBA) 
154 0.0154 0.10 Methanol, Ethanol 1:1 
Nitro substituents 
28 o-Nitrophenol (2NP) 140 0.028 0.20 DMF, Methanol 1:1 
29 m-Nitrophenol (3NP) 140 0.028 0.20 DMF, Methanol 1:1 
30 p-Nitrophenol (4NP) 140 0.028 0.20 DMF, Methanol 1:1 
31 1,2-Dinitrobenzene (1,2DNB) 168 0.0168 0.10 Methanol, Ethanol 1:2 
32 1,3-Dinitrobenzene (1,3DNB) 168 0.0168 0.10 Methanol, Ethanol 1:2 
33 1,4-Dinitrobenzene (1,4DNB) 168 0.0168 0.10 Methanol, Ethanol 1:2 
34 o-Nitrobenzoic acid (2NBA) 167 0.0167 0.10 Methanol, Ethanol 1:2 
35 m-Nitrobenzoic acid (3NBA) 167 0.0167 0.10 Methanol, Ethanol 1:2 
36 p-Nitrobenzoic acid (4NBA) 167 0.0167 0.10 Methanol, Ethanol 1:2 
Amino acids 
37 Lysine (Lys) 146 0.0146 0.10 Methanol/Water (1:1) 1:1 





60 different co-formers were chosen based on the Iso-star and FIMs search and urea was put 
through a co-crystal screen using liquid-assisted grinding (LAG) in a drop of methanol against 60 
co-formers in stoichiometric amounts. The solid resulting from each reaction was characterized 
using IR spectroscopy to determine if a co-crystal had formed (See Appendix C). A positive co-
crystal outcome was considered when peaks from both urea and co-former were present in the 
grinded mixture and shifted more than 7 wavenumbers as well as the appearance of broad stretches 
around 2,300 and 1,800 cm-1 as a result of intermolecular O-H…N hydrogen bonds were taken as 
an indication of co-crystal formation (such hydrogen bonds would not be possible in either of the 
pure compounds). Four new crystal structures of co-crystals were obtained, and the experimental 
details are provided in Table 9.2 
 
Table 9.2 Experimental details for new crystal structures of co-crystals obtained in this study 
 
 
39 Arginine (Arg) 170 0.017 0.10 Methanol/Water (1:1) 1:1 
40 Aspartic acid (Asp) 133 0.0133 0.10 Methanol/Water (1:1) 1:1 
41 Glutamic acid (Glu) 147 0.0147 0.10 Methanol/Water (1:1) 1:1 
42 Alanine (Ala) 89 0.0089 0.10 Methanol/Water (1:1) 1:1 
Nicotinamides 
43 Nicotinamide (N) 122 0.0122 0.10 Methanol, Ethanol 1:2 
44 N-methyl-nicotinamide (Me_N) 136 0.0136 0.10 Methanol, Ethanol 1:2 
45 2-chloro-nicotinamide (2Cl_N) 156 0.0156 0.10 Methanol, Ethanol 1:2 
46 6-chloro-nicotinamide (6Cl_N) 156 0.0156 0.10 Methanol, Ethanol 1:2 
N-Oxides 
47 Pyrazine N-oxide  (Py_NO ) 96 0.0096 0.10 Methanol, Ethanol 1:2 
48 Tetramethyl pyrazine N-oxide 
(TmPy_NO) 
110 0.011 0.10 Methanol, Ethanol 1:2 
49 Pyrazine-NN-oxide 
(Py_NNO) 
112 0.0112 0.10 Methanol, Ethanol 1:2 
50 Tetramethylpyrazine-NNoxide 
(TmPy_NNO) 
168 0.0168 0.10 Methanol, Ethanol 1:2 
51 Bipyridine-N-oxide (BiP_NO) 172 0.0172 0.10 Methanol, Ethanol 1:2 
Various 
52 Glucose (Gl) 180 0.018 0.10 Water 1:1 
53 Biuret (Biu) 103 0.0103 0.10 Methanol, Ethanol 1:2 
54 Imidazolidone (Im) 86 0.0086 0.10 Methanol, Ethanol 1:1 
55 Maleimide (Ma) 97 0.0097 0.10 Methanol, Ethanol 1:2 
56 Resorcinol (Re) 110 0.011 0.10 Acetone/Methanol (1:1) 1:1 
57 2,6-Lutidine (Lut) 107 0.010 0.10 Methanol, Ethanol 1:1 
58 Quinoline (Qui) 129 0.013 0.10 Methanol, Ethanol 1:1 
59 Uric acid (Ur) 168 0.0168 0.10 Methanol, Ethanol 1:2 




Co-crystals Co-former Solvent Stoic 
(urea:co-former ) 
M.P. (̊C) Morphology 
U1 
 
Ethanol 2:1 155-164 ̊C Plate, colorless 
U2 
 











1:1 70-72 ̊C Plate, colorless 
 
9.2.4 Large scale synthesis of co-crystals 
 
Supersaturated solutions of co-crystals of urea with phthalic acid, pimelic acid, and p-nitrophenol 
were prepared via a solvothermal method (Figure 9.2).1 After 10-20 min of heating at 40-50 °C, 
the resulting solution was cooled to 5° C. The precipitate was filtered, dried and analyzed using 
IR spectroscopy to confirm co-crystal formation. The PXRD pattern of bulk co-crystal and 
simulated single crystal pattern were compared to confirm the homogeneity of the bulk sample. 
  
Step1 Step 2 Step 3 Step 4 Step 5 
     




Suction filtration Solid co-crystal XRPD 
Figure 9.2 Stepwise synthesis and characterization of large scale co-crystallization 
 
 
9.2.4.1 Urea phthalic acid (2:1) 
Urea (1.212g, 20mmol) and phthalic acid (1.660 g, 10mmol) were dissolved in 20 ml of 95% 
ethanol in a 50 ml round bottom flask. The mixture was refluxed at 95oC for 10 minutes. After 10 
minutes, the resulting solution was left to slowly evaporate at room temperature. The solid phase 
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was harvested by vacuum filtration and dried at room temperature on a Fisherbrand filter paper for 
1 hour to remove loosely bound solvent (Melting point 85-89 °C). The PXRD of the experimental 




Figure 9.3  (a) Supramolecular synthon observed in the crystal structure of U: PhA, (b) 
Simulated and experimental XRD pattern comparison for U:PhA co-crystal 
 
9.2.4.2 Urea Pimelic acid (2:1) 
Urea (12.1g, 200 mmole) and pimelic acid (16.20 g, 100 mmole) were dissolved in 250 ml of 
ethanol in a 500ml round bottom flask. The mixture was refluxed at 40°C for 30 minutes, after 
which the resulting solution was cooled to 5° C using an ice bath. The solid was harvested by 
vacuum filtration and dried at room temperature on a Fisherbrand filter paper for 12 hours to 
remove loosely bound solvent. (Melting point 118-121 °C). The PXRD of the experimental co-





Figure 9.4 (a) Supramolecular synthon observed in the crystal structure of U:PA, (b) Simulated 
and experimental XRD pattern comparison for U:PA co-crystal. 
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9.2.4.3 Urea 4-nitrophenol (1:1) 
Urea (12.10g, 200 mmole) and 4-nitrophenol (28.52 g, 200 mmole) were dissolved in 250 ml of 
methanol in a 500 ml round bottom flask. The mixture was refluxed at 40oC for 45 minutes, after 
which the resulting solution was cooled to 5° C using ice bath. The solid (yellow crystals) was 
harvested by vacuum filtration and dried at room temperature on a fisherbrand filter paper for 12 
hours to remove loosely bound solvent. (Melting point 98-100 °C). The PXRD of the experimental 





Figure 9.5 (a) Supramolecular synthon observed in the crystal structure of U:4NP, (b) Simulated 
and experimental XRD pattern comparison for U:4NP co-crystal. 
 
9.2.5  Solubility studies  
9.2.5.1 Qualitative analysis 
The qualitative analysis was performed as follows: Control experiment:  ~1.00 gm of pure urea 
was added to the vial and dissolved in approximately 1ml of water. Test experiment: An amount 
containing ~1.00 gm of urea in each co-crystal was added into each vial and the water was added 
until the co-crystal was completely dissolved. The vials where more than 1 ml was needed to 
dissolve the solid were chosen as good candidates for initial solubility studies.  
 
9.2.5.2 Quantitative analysis  
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The solubility studies of pure urea and U:PA, U:4NP were done using a gravimetric method. Pure 
urea: A saturated solution of urea was prepared by dissolving a known amount of urea in 10ml of 
distilled water in a 25ml beaker in trial 1. The beaker was sealed with para-film and stirred in a 
water bath to maintain constant temperature (22-23°C) for 4 hours, 24 hours, 10 days and 1 month. 
After stirring for a given time, the remaining solid was filtered from the solution and dried 
overnight. The weight of the leftover solid was recorded. The average concentration of the filtrate 
was determined by the mass difference of urea in 10ml of the water and leftover solid after stirring.  
Three trials were performed at each 4 hours, 24 hours, 10 days and 1 month respectively. The same 
procedure was repeated for U:PA and U:4NP co-crystals. 
 
9.2.6 Hygroscopicity studies  
Hygroscopicity studies were performed at 43% (K2CO3) and 85% (KCl) humidity conditions using 
humidity chamber (Figure 9.6). A supersaturated solution was made for each solution and was 
maintained saturated for a period of 1 month. Urea and three new solid forms were kept inside the 
humidity chamber and the samples were analyzed every week using TGA and DSC analysis and 
the photographs were taken after every week to qualitatively assess the hygroscopicity effects.  
 
Figure 9.6 Humidity chamber used for hygroscopicity studies  
 
9.2.7 Powder X-ray diffraction (PXRD) 
The PXRD spectra were collected on a Bruker X-ray powder diffractometer using CuK (= 
1.54059A)˚ radiation obtained at 30 kV and 15 mA. The scans were run from 5.0˚ to 30.0˚ 2, 




9.2.8 Differential scanning calorimetry (DSC)  
The melting points were measured with a Mettler Toledo DSC 822e differential scanning 
calorimeter (Greifensee, Switzerland). Accurately weighed samples (∼3 mg) were prepared in a 
covered aluminum crucible having pierced lids to allow escape of volatiles. The sensors and 
samples were under nitrogen purge during the experiments. The temperature calibration was 
carried out using the melting point of highly pure indium in the medium temperature range. 
Heating rate of 5 ◦C/min was selected.  
 
9.2.9 Thermogravimetric analysis (TGA)  
TGA were performed on a Mettler-Toledo TGA/SDTA 851e instrument. Approximately 2 mg 
sample was heated from 25 to 300˚ C at 10˚ C/min under nitrogen purge.  
 
9.2.10  Qualitative plant effect test  
Three tomato plants were treated with exactly the same amount of Urea, U:PA and U:4NP along 
with potassium and phosphorus at three different time intervals.   
 
 
9.3 Results  
9.3.1  Iso-star search and FIMs results 
The FIMs results for urea are shown in Figure 9.7 displaying all potential hydrogen-bond donors 




Figure 9.7 FIMs for urea showing all conventional donors and acceptors fully available for 
hydrogen-bond interactions 
9.3.2  Grinding experiment results  
The IR analysis from the grinding experiments is shown in Table 9.3. The detailed description of 
how the ground mixture was compared to the pure components is shown in Figure 9.8.  
 
Table 9.3 Experimental outcome of grinding experiments for co-crystallizations of urea with co-
formers. Co-formers with subscripts are already reported in the literature.  
 Urea co-crystal Outcome  Urea co-crystal Outcome  Urea co-crystal Outcome 
 Aliphatic acids  Aromatic acids  Nitro substituents 
1 U:CA ✓ 14 U:3HBA ✓ 28 U:2NP  
2 U:CmA ✓ 15 U:4HBA ✓38 29 U:3NP ✓ 
3 U:MA ✓39 16 U:3ABA  30 U:4NP ✓40-41 
4 U:SA ✓42,43,44 17 U:4ABA ✓45 31 U:1,2DNB ✓ 
5 U:FA ✓46-47,43 18 U:PtA ✓45 32 U:1,3DNB ✓ 
6 U:GA ✓48, 49 19 U:Py2_CA ✓ 33 U:1,4DNB ✓ 
7 U:AA ✓50 20 U:Py2,3_DCA ✓45 34 U:2NBA ✓ 
8 U:PA ✓51 21 U:Py2,5_DCA  35 U:3NBA ✓52 
9 U:SbA ✓ 22 U:Py2,6_DCA ✓45 36 U:4NBA ✓ 
10 U:TA ✓53-54 23 U:Py3,5_DCA     
11 U:MeA ✓44 24 U:HipA     
12 U:AzA ✓ 25 U:2,5DHBA ✓38    
13 U:SeA ✓ 26 U:3,4DHBA ✓    
   27 U:3,5DHBA ✓38    
 Amino acids  Nicotinamides  N-oxides 
37 U:Lys ✓ 43 U:N ✓55 47 U:Py_NO ✓ 
38 U:His  44 U:Me_N ✓ 48 U:TmPy_NO ✓ 
39 U:Arg ✓ 45 U:2Cl_N  49 U:Py_NNO ✓ 
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40 U:Asp ✓ 46 U:6Cl_N  50 U:TmPy_NNO ✓ 
41 U:Ala     51 U:BiP_NO ✓ 
42 U:Glu ✓       
Various 
52 U:Gl ✓56 57 U:Lut ✓57   
53 U:Biu  58 U:Qui ✓58    
54 U:Im ✓59 59 U:Ur     
55 U:Ma ✓ 60 U:Phen ✓60    
56 U:Re ✓61       
 
 
Figure 9.8 Examples of IR spectra for a successful co-crystallization:  U(blue), U:CA (red) and 
CA (green) 
 
9.3.3 Crystal structures of co-crystals  
Four new crystal structures (U1, U2, U3 and U4) were obtained and different synthons were 
observed in each co-crystal (Figure 9.9). The expanded crystal packing for each crystal structure 
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Figure 9.10 Packing in the crystal structures of (a) U1, (b) U2, (c) U3 and (d) U4 in the unit cell 
 





9.3.4 Solubility studies   
9.3.4.1 Qualitative analysis 




Figure 9.11 Qualitative analysis of urea and urea-co-former co-crystals in distilled water 
 
9.3.4.2 Quantitative analysis  
The quantitative solubility analysis of urea and three co-crystals of urea were performed using a 
gravimetric method. The homogeneity test was performed using PXRD and the result of each co-





Figure 9.12 PXRD analysis of U:PhA after 4 hours, 24 hours 10 days and 1month 
 
Figure 9.13 PXRD analysis of U:PA after 4 hours, 24 hours 10 days and 1month 
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Figure 9.14 PXRD analysis of U:4NP after 4 hours, 24 hours 10 days and 1month 
 
The solubility was measured after 4 hours, 24 hours, 10 days and 1 month and results are shown 
in Table 9.4 and Figure 9.15.  
 
Table 9.4 Solubility of pure urea, U:PhA, U:PA and U:4NP after 4 hours, 24 hours, 10days and 
1 month.  
 
4 hours 24 hours 10 days 1month 
Pure urea 17.79±0.02 17.25±0.20 17.22±0.24 17.18±0.3 
Concentration of urea in U:PhA co-crystal 2.87± 0.08 3.28 ± 0.6 3.21±0.4 3.54±0.8 
Concentration of urea in U:PA co-crystal 0.84± 0.26 0.71±0.04 1.01±0.3 0.76±0.1 
Concentration of urea in U:4NP cocrystal 0.28±0.04 0.2±0.09 0.30±0.03 0.27±0.07 
 
 
Operations: Y Scale Add 542 | Y Scale Add 875 | Y Scale Add 1000 | Y Scale Add 1000 | Y Scale 
urea p-nitrophenol - File: Urea 4-nitrophenol large scale new.raw - Type: 2Th/Th locked - Start: 5.0
Operations: Smooth 0.150 | X Offset -0.158 | Y Scale Add 250 | Y Scale Add 800 | Y Scale Add 10
urea pimelic acid-10days - File: urea p-nitrophenol-10 days.raw - Type: 2Th/Th locked - Start: 5.00
Operations: Y Scale Add 542 | Y Scale Add 1000 | Y Scale Add 1000 | Y Scale Mul  0.708 | Y Scal
File: NITPOL01.raw - Type: 2Th/Th locked - Start: 5.000 ° - End: 50.000 ° - Step: 0.020 ° - Step ti
Operations: Y Scale Add -167 | Y Scale Add -583 | Y Scale Add -1000 | Y Scale Mul  0.917 | Y Sca
File: NITPOL.raw - Type: 2Th/Th locked - Start: 5.000 ° - End: 50.000 ° - Step: 0.020 ° - Step time:
Operations: Y Scale Add 167 | Y Scale Add -833 | Y Scale Add -1000 | Y Scale Add -1000 | Y Scal
urea p-nitrophenol-4 hours - File: Urea p-nitrophenol-4hour-trial1.raw - Type: 2Th/Th locked - Start
Operations: Smooth 0.150 | Y Scale Add 167 | Y Scale Add -458 | Y Scale Mul  1.042 | Y Scale Ad
urea p-nitrophenol - File: urea p-nitrophenol 24 hours.raw - Type: 2Th/Th locked - Start: 5.000 ° - E
Operations: Y Scale Add -1000 | Y Scale Add -1000 | Y Scale Add -208 | Y Scale Add 1000 | Y Sca
File: Urea 4-nitrophenol simulated.raw - Type: 2Th/Th locked - Start: 5.000 ° - End: 50.000 ° - Step
Operations: Y Scale Add -750 | Y Scale Add -1000 | Y Scale Add 1001 | Y Scale Add 1001 | Y Scal



































Figure 9.15 Solubility profile of urea co-crystals for 4 hours, 24 hours, 10 days and 1 month 
 
9.3.4.3 Qualitative hygroscopicity studies   
The qualitative hygroscopicity test was performed in a humidity chamber at 43% and 85% relative 
humidity on urea and two co-crystals (U:PA and U:4NP) (Figure 9.16). The pictures were taken 
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Figure 9.16 Response to 85% humidity of (a) urea, (b) U:PA co-crystal and (c) U:4NP co-
crystal 
 
9.3.4.4 Quantitative stability studies  
In order to quantitively confirm that each co-crystal remained solid after exposure to high 
humidity, the TGA and DSC analysis were performed on urea (Figure 9.17a) and two new co-









Figure 9.17 DSC-TGA profile of (a) Urea, (b) U:PA and (c) U:4NP co-crystal after 1month 
exposure to 80% humidity conditions. 
 
9.3.4.5  Plant study test 





Figure 9.18 Urea and the two new co-crystals tested on the tomato plant       
 
9.4 Discussion 
9.4.1 FIMs  
The structural landscape occupied by urea was explored using full interaction maps (FIMs).  As 
expected, a large number of short-contacts were found in close proximity of (i) both lone pairs on 
the carbonyl oxygen atom and (ii) the four N-H protons, leading to four avenues for synthesizing 
co-crystals of urea, Scheme 9.2.   
9.4.2 Synthon search in CSD 
The FIM provides an overview of short contacts to urea in the solid state, but to add more 
granularity to the map, an analysis of relevant data from the CSD30-32 was conducted.  The type of 
interactions that urea tends to engage in can be described by five different synthons, Scheme 9.5 
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(a) Synthon I (b) Synthon II (c) Synthon III 
 
 
(d) Synthon IV (e) Synthon V 
 
Scheme 9.5 Five likely synthons in co-crystals of urea  
 
Synthon I: In the first category of co-crystals, urea forms robust 𝑅2 
2 (8) self-complementary 
homosynthons and the suitable co-former (mostly hydrogen bond acceptors) binds to two N-H 
groups of urea via bifurcated hydrogen bond interactions forming synthon I. The following co-
formers forms synthon I with urea-2,2-bipyridine (refcode AMILEN)62 urea-1,10-phenanthroline 
(refcode AMILUD)62, urea-2,9-dimethyl-1,10-phenanthroline (refcode AMIMAK)62, urea-
picoline N-oxide (refcode BAQZOI),63 urea-4,4'-dicyanobiphenyl (refcode BAFSOQ),64 and urea-
4,4'-bipyridine N,N-dioxide (refcode BAFTEH)64, urea-2,6- or 3,5-lutidine (refcodes JOLCIY, 
JOLCOE, and LUTDUR)65, urea-dihydroxyalkane (refcodes OTIYUM, OTIZAT, OTIZEX, 
OTIZIB, OTIZOH, and OTIZUN)66.  
Synthon II:   In the crystal structures of urea of with 4,4'-Dinitobiphenyl, and 18-Crown-6 pentakis 
(CRWNUR), the cocrystals forms synthon II. The crystal structure of 2,7-dimethyl-1,8-
naphthyridine and urea (IDELIO)67  and 4-aminobenzoic acid with urea (NUHYEU) 68 forms 
synthon II.   
Synthon III: In the third category of co-crystals, a suitable ditopic coformer with a hydrogen bond 
donor and acceptor site binds to urea via robust 𝑅2 
2 (8) heterosynthon breaking the self-
complementary hydrogen bond interaction observed in category I. Synthon III is observed in the 
crystal structures of urea-adipic acid (refcode ERIWUY), urea-4,6-dimethyIpyrimidin-2-one 
(refcode JELSEY)69, Urea-tartaric acid (refcode NEHPIZ), Urea-5-nitrosalicyclic acid (refcode 
NUHXUJ), Urea-pyrazine-2,3-dicarboxylic acid (refcode NUHYOE)68,Urea-o-phthalic acid 
(refcodes NUHYIY, NUHYUK)68, urea-2-Methyl-5-nitraminotetrazole (refcode OTAZUF), urea-
fumaric acid (refcode TIPWIY), urea-glutaric acid (refcode TONGUS), urea-succinic acid 
(refcode UNIRIT)42 , urea-oxalic acid (refcode UROXAL), urea-lenalidomide (XODPOX).71  
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Synthon IV: In the fourth category of co-crystals, urea forms self-complementary bifurcated 
hydrogen bond with itself and the suitable coformer (symmetric or asymmetric acceptor) binds to 
the NH group of urea leading to 1D or 2D architectures.  Synthon IV is observed in the crystal 
structures of urea- dinitrile of the formula (CH2)nCN  when n = 3-5, 6,8,10, and 12 (refcodes 
HEZSIU, HEZSOU, HEZTAH, and HEZTEL), urea:4,4′-bipyridine (refcode KOPJUW)72, urea-
1,4-dioxane (refcode SIDJEW)and urea-morpholine (refcode SIDJIA).73 
Synthon V: In the fifth category of co-crystals, no self-complementary hydrogen bond 
homosynthons are observed. The NH, hydrogen bond donor group of urea binds to suitable 
acceptor whereas the carbonyl group of urea binds to suitable co-former with hydrogen bond donor 
groups. Synthon V is observed in the crystal structures of urea-estradiol, urea-2-Amino-4-
methylthio-5-cyano-6(1H)-pyrimidinethione (refcode GIGWOI), urea-12-tridecanedione (refcode 
MISNOR)74, and urea-2,6-bis(2-benzimidazolyl)pyridine (PERTOW, PERTUC).75  
 
9.4.3 New crystal structures  
In our study, 49 of the 60 experiments (82%), the IR analysis showed prominent new features or 
significant changes to the spectra of one or both reactants, indicative of the formation of a co-
crystal, Table 9.3 and Table 9.5.   
 
Table 9.5 Co-crystallization summary and synthons expected in the co-former used (summary of 
each synthon is shown below) 








Aliphatic acids 13 13/13 III, V 
Aromatic acids 14 10/14  II, III, V 
Nitro-substituents  9 8/9  I, III 
Amino acids 6 4/6 III, V  
Nicotinamides 4 2/4 II, III 
N-oxides 5 5/5 I  
Various 9 7/9 I-V 








(a) Synthon I (b) Synthon II (c) Synthon III (d) Synthon IV (e) Synthon V 
 
In our study, four crystals suitable for single-crystal XRD were obtained and analyzed using single 
crystal X-ray diffraction in order to study the details of binding interactions between urea and 
various co-formers, Figure 9.9 and Figure 9.10.  
Two crystal structures were obtained for urea with n-oxides (U1 and U2).  In both cases, urea 
forms bifurcated hydrogen bonds with the oxygen of nitrogen-oxides (Figure 9.8a and b). The urea 
molecules form a linear ribbon that is constituted with dimer synthons arranged in a zig-zag 
manner with syn N-H⋯O hydrogen bonds as described in synthon I. The Iso-star prediction of two 
N-H groups of trans-urea tend to form bifurcated hydrogen bond with terminal oxygen atom of 
the co-former agrees with the obtained results in case of N-oxides. In both cases, the bifurcated 
hydrogen bonding was observed (Figure 9.9). 
In the crystal structure of urea-citric acid (U3), each asymmetric unit contains one molecule of 
citric acid and two crystallographically unique molecules of urea.  The primary supramolecular 
synthons in this structure comprises three 𝑅2
2(8) hydrogen-bonded synthon III formed using O-H 
(acid)⋯O(urea) and N-H(urea) ⋯O(acid) hydrogen bonds resulting from the interactions between 
dicarboxylic acid and urea molecules (Figure 9.8c). All of the acidic hydrogens are engaged in 
hydrogen bonding. The Iso-star prediction agrees well with the urea-citric acid structure obtained. 
Both lone pairs on the carbonyl oxygen participate in hydrogen bond with O-H functional groups 
of citric acid. Also, the carbonyl oxygen of urea forms strong hydrogen-bonding with the O-H 
hydroxyl group of citric acid forming synthon V (Figure 9.9c). 
In the crystal structure of urea:m-nitrophenol, synthon I was observed (Figure 9.9d). The nitro 
group of m-nitrophenol forms bifurcated hydrogen-bond with the NH groups of urea. The urea 
molecules form a linear ribbon composed of dimer synthons arranged in a zig-zag manner with 
syn N-H⋯O hydrogen bonds as described in synthon I. 
 
9.4.4 Solubility studies 
Three of the co-crystals identified in the qualitative solubility screen test were selected for further 
solubility studies; urea:phthalic acid,76 (U:PhA) urea: pimelic acid,51 (U:PA) and urea:4-
nitrophenol41, 77-78 (U:4NP).  There was 6-fold decrease in the concentration of urea in the urea: 
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phthalic acid co-crystal as compared to the pure urea in water. On the other hand, the concentration 
of phthalic acid in the urea: phthalic acid cocrystal is considerably increased as compared to pure 
phthalic acid. The solubility of urea in U:PA decreased to 0.76 (±0.10) M and in U:4NP decreased 
to 0.27 (±0.07) M after 1 month. There is 23-fold decrease in U:PA and 64-fold decrease U:4NP 
co-crystal, Table 9.4. 
 
9.4.5 Hygroscopicity studies  
Another major concern with urea is its sensitivity to moisture, and in order to examine if these new 
solid formulations of urea, U:PhA, U:PA and U:4NP, are better equipped to tolerate moisture, 
humidity studies were performed. Urea becomes a transparent liquid in less than 24 hours at 85% 
humidity, whereas U:PhA remained solid for 10 days and then gained moisture and became sticky. 
Both U:PA and U:4NP remain solid for over one month, Figure 9.16. An additional thermal 
analysis (DSC and TGA) of the two co-crystals (U:PA and U:4NP) after having been exposed to 
85% humidity for a month demonstrate that there are no thermodynamic events in either case prior 
to their respective melting points (Figure 9.17), indicating that the two co-crystals are very tolerant 
of prolonged exposure to high humid conditions. 
 
9.4.6 Qualitative plant testing  
Three tomato plants were treated with exactly same amount of each co-crystal; urea, U:PA and 
U:4NP along with potassium and phosphorus at three different time intervals (Figure 9.18). All 
three plants were treated each with different nutrient, U:4NP for one, U:PA for second and U:4NP 
and the it was found that all plants had same growth and no visible changes were observed to the 
plants comparing the pure urea and the co-crystals indicating that the new solid forms doesn’t have 
any harmful effect on the plant shelf life or growth.  
 
 
9.4.7 Conclusions  
In conclusion, FIMs combined with the CSD analysis, guided the choice of sixty co-formers for 
co-crystallization resulting in 49 out of 60 positive results and four new co-crystals. Furthermore, 
solubility and stability studies of U:PA and U:4NP indicates that the two co-crystals were able to 
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reduce the solubility of urea to 23-fold (in U:PA) and 64-fold (in U:4NP) respectively as well as 
making the new solid forms of urea more tolerant toward 85% humidity conditions as confirmed 
using PXRD, DSC and TGA. These results indicate that systematic changes to the molecular 
structure of urea can be made by altering the way it packs in the crystal lattice via co-crystals.  The 
goal of reducing solubility and lowering hygroscopicity of the parent compound was achieved, 
which, in turn, offers new opportunities for a highly-efficient slow-release fertilizer with limited 
hygroscopicity thereby reducing problems of transport, handling, and storage of urea. And the 
physicochemical properties such as solubility, and stability of urea can be tuned in a predictable 
and desired manner to optimize the performance and benefits of urea as a plant nutrient. This 
technique can also be used to alter solubility problems associated with agrochemicals such as 
herbicides, pesticides, insecticides and hence, positively impact the environment.   
 
 
9.5 Conclusions  
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Chapter 10 - Conclusions 
This dissertation involved fundamental studies of crystal engineering of two main categories of 
small rigid molecules (12 pyrazole based and 12 thiazole based molecules) with multiple 
functional groups. This fundamental study was done to validate methods such as hydrogen-bond 
propensity (HBP), hydrogen-bond energies (HBE) and electrostatics for synthon prediction in 
these molecules. Based on our study, we found that in 14 out of 18 target molecules (78% success 
rate) where crystal structures were obtained, the synthon predictions correct using a combination 
of methods indicating that both HBP and HBE are suitable for synthons predictions (Figure 10.1). 
 
Figure 10.1 Summary of synthon prediction in 12 pyrazole based and 12 thiazole based target 
molecules 
In order to study the robustness of homomeric interactions and to determine whether it was 
possible to break these interactions, the experimental co-crystallization was performed on (12 
thiazole and 12 pyrazole based molecules) with 20 carboxylic acids leading to 480 co-
crystallization experiments. In each category, the molecules were sub-divided into two groups 
based on the number of functional groups present. Following information was achieved from this 
study (Figure 10.2), 
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1. When an additional strong acceptor group such as pyridine was introduced, the 
experimental co-crystallization success rate increased from 64% to 83% in pyrazole based 
molecules and from 49% to 91% in thiazole based molecules. 
2. In group1, changing pyrazole to thiazole moiety decreased the success rate from 64% to 
49% and in group 2, changing pyrazole to thiazole increases the success rate from 83% to 
91%.  
3. Overall, pyrazole showed a slightly higher success rate (69%) than thiazole based 
molecules (58%).  
 
 Figure 10.2 Summary of experimental co-crystal screen 
 
Different prediction methods were used to analyze and predict the experimentally observed co-
crystal screen. In the thiazole based molecules, hydrogen-bond propensity was used as the 
prediction method and 70% of group1 molecules and 68% of group 2 molecules were predicted 
correctly. In the pyrazole molecules, hydrogen-bond propensity and hydrogen bond energies were 
used as prediction methods. Based on HBP, 44% of group1 molecules and 15% of group 2 
molecules were predicted correctly. Because of poor prediction using HBP, HBE was used as an 
alternative method and it was found that 70% of group 1 and 85% of group 2 molecules were 
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predicted correctly using this method. In conclusion, a combination of both HBP and HBE are 
suggested for prediction studies.  The synthon prediction were done on each co-crystal 
combination and combinations where co-crystal was obtained, 82% and 100% success was 
obtained in predicting the correct synthon observed in the crystal structures of pyrazole and 
thiazole based molecules (Figure 10.3).   
 
Figure 10.3 Summary of experimental vs predicted comparison using HBE and HBP for co-
crystal screening  
 
The ability of pyridine-based molecules to form binary hydrogen-bonding was successfully studied 
before. The pyridine functionality was also used to study binary halogen-bonding. Because of 
100% supramolecular yield with both binary hydrogen and halogen bonding, we were successfully 
able to design ternary complexes with high supramolecular yield by carefully designing the target 
molecules with two-point interaction for hydrogen-bonding and one-point interaction for halogen 
bonding. In the end, we were able to obtain two crystal structures of ternary system showing both 




Figure 10.4 Summary of binary and ternary co-crystals of thiazole-pyridine based molecules   
 
These small rigid molecules were mostly acceptors either for hydrogen-bonding or halogen 
bonding. In order to include halogen bond donors on the target molecules while keeping amide 
functionality intact, the supramolecular hierarchy of activated and unactivated halogen bond 
donors was explored. Eight new halogen bond donors were synthesized, and it was found that 
iodoethynyl based target molecules were the best halogen bond donors followed by 
tetraflourinated iodine and ethynyl based molecules (Figure 10.5). Moreover, the activated 
molecules didn’t form co-crystals with the carboxylic acids whereas unactivated halogen did 




Figure 10.5 Summary of supramolecular hierarchy and co-crystallization results of target 
molecules 
 
The next part of thesis involved moving from small rigid molecules to large flexible molecules 
with diverse functionalities. The major concern with large diverse molecules was the ability to 
predict their crystallizability. A statistical logistic regression model was developed using easily 
defined, measured and experimental parameters to predict crystallizability of drug-like molecules. 
The model was tested on molecules where experimental crystallizability is already established and 
a success rate >85% was obtained as validation between prediction and experimental results 




Figure 10.6 Summary of successful prediction of crystallizability using statistical logistic 
regression model 
 
One of the most exciting aspects of this dissertation is that we were able to make a transition from 
basic and very fundamental research on structural chemistry, to new materials that may have wide-
ranging practical applications coupled to considerable environmental benefits.  
 
Figure 10.7 Summary of decreased solubility and increased stability of urea via co-
crystallization technology 
 
Urea has gained worldwide importance as a nitrogen rich fertilizer and is used globally on a multi-
ton scale each year. However, due to its high solubility in water it is also prone to mobility and 
run-off problems.  Farmers therefore tend to use more than required to meet the needs of plants 
and crops which, in turn, increases the amount of nitrogen in the environment thereby creating 
numerous unwanted environmental consequences such as eutrophication of lakes and rivers.  A 
simple and easily scalable protocol based on knowledge-based method was used to design new 
solid forms of urea with more appropriate solubility and much enhanced stability with respect to 




Appendix A - Hydrogen-bond propensity for solid state risk 
assessment 
 A.1 Introduction  
The identification of the most stable form of a drug candidate is a crucial step in the development 
of new active pharmaceutical ingredients. Experimental solid form screening is a protocol 
followed by industry to determine the most stable form and to identify any polymorphic forms1. 
This process is time consuming, non-exhaustive and at same time involves risk (“have we done 
enough experiments?”) and opportunity (“can we design a better material?”). Therefore, it is of 
considerable interest to acquire as much detailed knowledge as possible on the crystal form 
landscape of a compound in the course of research and development from a lead compound to a 
marketed product.2  
A new approach to modeling and predicting stable polymorphs and for finding the most stable 
form utilizes solid form informatics. The Cambridge Crystallographic Data Centre (CCDC), in 
partnership with the Solid Form Design Centre3, its predecessor the Pfizer Institute for Material 
Science, and more recently members of the Crystal Form Consortium (CfC), has developed 
hydrogen-bond propensity4-7 and hydrogen-bond coordination likelihood tools to augment solid 
form design and risk assessment (Figure A.1).  
  
(a) (b) 
Figure A.1 (a) Hydrogen-bond propensity and (b) hydrogen bond coordination likelihood charts.  
 
The knowledge-based tool allows information on molecular geometries and intermolecular 
interactions encapsulated in the Cambridge Structural Database8 (CSD), the world’s repository of 
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all published and patented small molecule crystal structures (900,000+), to be efficiently and 
thoroughly mined. The tools search for similar structures from CSD based on functional groups 
present in the molecule of interest, this is followed by a statistical survey to find the most likely 
hydrogen bonds considering functional groups, competition, aromaticity and steric density and 
calculates propensity values for the hydrogen bonds in the range 0 to 1 for the specific molecule. 
A form with high propensity values indicates optimal intermolecular bonding, whereas low 
propensity hydrogen bonds can indicate that alternative ways of packing might be preferable, 
suggesting likely polymorphism.  
The hydrogen-bond coordination likelihood tool produces a landscape of possible structures based 
on hydrogen-bonds derived by propensity tool.  When there is only one combination with high 
propensity bonds and all donors and acceptors being used (denoted as “high coordination”), the 
risk of polymorphism is ranked as low. On the other hand, when there are many combinations with 
similar propensity and coordination the risk of polymorphism is considered high. The analysis can 
be performed on a single molecule to assess the “risk” of polymorphs or on a combination of 
molecules to determine the likelihood of the formation of multicomponent crystal forms. 
In this study, we will cover basics of hydrogen-bond propensity and hydrogen-bond coordination 
likelihood, interpretation/comparison of different datasets, sensitivity of the model and limitations. 
Five main sections include following: 
 
• Sensitivity analysis- comparing sample sizes  
• Role of HBP in identifying stable polymorphs 
• Using HBP to understand H-bond competition and their strength 
• Importance of functional group definition when making comparisons 
• Limitations  
 
 A.2 Experimental 
A.2.1 Hydrogen-bond propensity calculations  
Hydrogen-bond propensity4-5, 9 calculations were employed using CSD Version 5.38 and Mercury 
3.9, each compound was sketched, and auto-edited, functional groups were selected as suggested 
by Mercury (Table A.1 represents functional groups used for each molecule), a training dataset 
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(350-600 structures per functional group) was made and the propensities were calculated with an 
ROC curve higher than 0.800 (“good discrimination”) unless otherwise indicated. The propensity 
calculations are done using outline shown in Figure A.2 to A.6.  
 
Table A.1 Functional groups used to determine the hydrogen-bond propensities of small rigid 
molecules.  The labels in the figures can be explained as follows:  Tn = atom makes n bonds, c = 
atom is cyclic,  = bond is acyclic, and Hn = n bonded hydrogen atoms. 
      
Isonicotinamide  4-Hydroxybenzamide Benzoic acid  Isonicotinic acid 
   
Step1: A default H-bond definition as shown in Figure A.2 is used but sometimes if a short contact 
is observed in the crystal structure, that can be avoided by changing the minimum H-bond distance 
range.  
 







Step 2: By default, the functional groups are chosen in this wizard, however if a different 
functional group is needed, click on the functional group chosen and either use the editing tool or 
the sketch tool to make the new functional group.  
 
 
Figure A.3 Hydrogen-bond propensity wizard showing fitting data information.  
 
Step 3: The fitting data is generated in this step. The number of structures in the fitting data can 
be changed by moving the blue slider. Alternatively, if there is specific data already generated 
that you wish to use, click on the load from existing file option.  
Step 4: The true and false data are generated, and any value shown in red should be ignored. 
Step 5: If the model fails this step, use the refine model option to delete descriptors that have 
significance code less than 2 one by one and select accept and continue.  The area under ROC 






Figure A.4 Hydrogen-bond propensity wizard showing how to refine the model.  
Step 6: Calculate the propensities and click on the chart to get the hydrogen-bond coordination 
likelihood table.  
 







Figure A.6 Hydrogen-bond coordination likelihood chart.   
 
A.2.2 Molecular electrostatic potentials  
Molecular electrostatic potential surfaces (MEPS) of molecules studied were generated with DFT 
B3LYP level of theory using 6-311++G** basis set in vacuum. All calculations were carried out 
using Spartan’08 software. All molecules were geometry optimized with the maxima and minima 
in the electrostatic potential surface (0.002 e/au isosurface) determined using a positive point 
charge in vacuum as a probe. The numbers indicate the interaction energy (kJ/mol) between the 




 A.3 Results 
A.3.1 Sensitivity analysis 
 A.3.1.1 Comparing sample of Isonicotinamide 
A “sensitivity” analysis was performed on isonicotinamide as it has two hydrogen-bond donors 
(amine NH2 group) and two hydrogen-bond acceptors (pyridine N and C=O). There are two 
possible hydrogen-bond synthons; NH(amine) can either bind to pyridine N or C=O (Scheme A.1). 
To find out which is more likely to happen, and whether choosing a certain dataset affects the 




Synthon A Synthon B 
 Scheme A.1 Two possible hydrogen-bond interactions in the isonicotinamide.  
The results of hydrogen-bond propensity are shown in Table A.1.  
Table A.1 ROC and hydrogen-bond propensity of each interactions obtained for each dataset for 
isonicotinamide.  
Total Dataset ROC NH(amine)…C=O NH(amine)…N 
351 0.66  0.62 (0.45, 0.77) 0.48(0.32, 0.64) 
551 0.64  0.62 (0.50, 0.73) 0.56 (0.45,0.66) 
800 0.64 0.64 (0.53, 0.73) 0.62 (0.53, 0.71) 
1045 0.63 0.65(0.55, 0.73) 0.67 (0.59, 0.74) 
3589 0.67 0.66 (0.60, 0.72) 0.78 (0.75, 0.81) 
5727 0.69 0.66 (0.62, 0.71) 0.82 (0.80, 0.84) 
 
A.3.2 Role of HBP in identifying stable polymorphs 




Isonicotinamide has two hydrogen-bond donors (amine NH2) and two acceptors (pyridine N and 




type NH(amine)…O=C(carbamoyl) hydrogen-bond interaction10 or one NH of amine binds to 
pyridine N forming NH(amine)…N(pyridine) and second NH amine binds to C=O forming 
NH(amine)…C=O(carbamoyl) hydrogen-bond interaction11. HBP was carried out to determine 
whether the model can predict the both experimental forms and determine which form is more 
favorable, Table A.2.  
 
Table A.2 Results of hydrogen bond propensity calculations on isonicotinamide and the observed 
hydrogen bonds in each known polymorph.  
 
Donor…Acceptor  Propensity Refcode10 Refcode11 
 
0.62 (0.45, 0.77) Yes Yes 
 
0.48 (0.32, 0.64) - Yes 
 
The hydrogen-bond coordination chart was compared to predicted hypothetical structures and 
experimentally observed synthons (Figure A.7 and table A.3).  
  
Hypothetical motif II 





Figure A.7 Propensity coordination chart of isonicotinamide showing (a) two predicted motifs and 
(b) experimental observed motifs overlapping with predicted motifs.  
 
Table A.3 Coordination chart for each motif predicted by propensity-coordination chart for 
isonicotinamide.  
Structure # Atom (D/A) 0 1 2 3 
Hypothetical motif I NH2 of carbamoyl (D) 0.00 0.05 0.87 0.08 
 
N(aromatic) (A) 0.12 0.79 0.09 0.00 
 
O=C of carbamoyl (A) 0.04 0.62 0.31 0.02 
Hypothetical motif II NH2 of carbamoyl (D) 0.00 0.05 0.87 0.08 
 
N(aromatic) (A) 0.12 0.79 0.09 0.00 
 
O=C of carbamoyl (A) 0.04 0.62 0.31 0.02 
  
 
 A.3.2.2 4-Hydroxybenzamide12 
4-Hydroxybenzamide has three hydrogen-bond donors (amine NH2 group and hydroxyl OH group) 
and two hydrogen-bond acceptors (C=O and hydroxyl O). Four different types of interactions are 
possible in 4-hydroxybenzamide, Table A.4 
The HBP calculations were performed to determine which is the most optimal interaction and if 
there is competition between interactions. To perform HBP calculations, carbamoyl and aromatic 
OH functionalities were chosen, the hits for training dataset was 485 with 368 structures containing 
both functionalities Table A.4. The area under the ROC curve was 0.79 signifying good 
discrimination. 
 
Table A.4 Results of Hydrogen bond propensity calculations on hydroxybenzamide and the 
observed hydrogen bonds in each experimental known polymorph.  
Rank Donor…Acceptor  Propensity Refcode12 Refcode13 
1 
 





0.39 (0.28, 0.51) Yes - 
3 
 
0.31 (0.22, 0.43) Yes - 
4 
 
0.14 (0.10, 0.20) - Yes 
The hydrogen-bond coordination chart was obtained for 4-hydroxybenzamide, Figure A.8 and 
Table A.5.  
  
(a) (b) 
Figure A.8 Propensity coordination chart of hydroxybenzamide showing (a) five predicted motifs 
and (b) experimental observed motifs overlapping with two most optimal predicted motifs.  
 
Table A.5 Coordination table for each hypothetical structure for 4Hydroxybenzamide.  
Structure Atom (D/A) 0 1 2 3 
Hypothetical structure I and I’ NH2 of carbamoyl (D) 0.01 0.12 0.81 0.07  
OH of hydroxyl (D) 0.02 0.93 0.05 0.00  
O of hydroxyl (A) 0.68 0.31 0.01 0.00  
O=C of carbamoyl (A) 0.00 0.14 0.79 0.07 
Hypothetical structure II NH2 of carbamoyl (D) 0.01 0.12 0.81 0.07  
OH of hydroxyl (D) 0.02 0.93 0.05 0.00  
O of hydroxyl (A) 0.68 0.31 0.01 0.00  
O=C of carbamoyl (A) 0.00 0.14 0.79 0.07 
Hypothetical structure III and III’ NH2 of carbamoyl (D) 0.01 0.12 0.81 0.07  
OH of hydroxyl (D) 0.02 0.93 0.05 0.00 
Hypothetical motif III 
Hypothetical motif I 




O of hydroxyl (A) 0.68 0.31 0.01 0.00  
O=C of carbamoyl (A) 0.00 0.14 0.79 0.07 
 
 
A.3.3 Using HBP to understand H-bond competition  
Benzoic acid is a simple molecule with one hydrogen-bond donor (carboxylic OH) and two 
hydrogen-bond acceptors (carbonyl C=O and O(acid). When another possible strong acceptor 
group is introduced such as pyridine nitrogen as in isonicotinic acid, it increased the competition 
between two strong acceptors (C=O and Pyridine N) to bind to single OH group. The hydrogen-
bond propensity value are shown in scheme A.2 and the molecular electrostatic potential values 
are shown in figure A.9.  
 
Scheme A.2 Chemical diagram of benzoic acid and isonicotinic acid showing the propensity. 
(the propensity score OH(acid)…C=O shown in red, and propensity score of 
OH(acid)…N(aromatic) is shown in purple.  
 
 




A.3.4 Importance of functional group definition when making comparisons 
  A.3.4.1 Replacing a functional group (isonicotinic acid to thioisonicotinic acid) 
 
Scheme A.3 Chemical diagram of isonicotinic and thioisonicotinic acid.   
 
To make comparisons of hydrogen bond propensity between two molecules, a careful attention 
must be paid to the functional group chosen to define each molecule.  
We illustrate this with an example of isonicotinic acid by replacing carbonyl (C=O) of acid to 
thionyl (C=S) group. The functional groups and corresponding hydrogen-bond propensity values 
are shown in Table A.6.    
1. When the isonicotinic acid is chosen for HBP, two functional groups are chosen, aromatic 
COOH and aromatic nitrogen.  
2. HBP was performed on isonicotinic acid by fragmenting the COOH group into C=O and OH 
groups along with aromatic nitrogen. 
3. Replacing C=O with C=S functional group and choosing aromatic C=SOH and aromatic N for 
thioisonicotinic acid, the regression failed because the aromatic C=SOH functionality does not 
have enough data in the CSD. 
4. For thioisonicotinic acid, aromatic nitrogen, acrylic hydroxyl and C=S were chosen as the 
functional groups.  
 
Table A.6 Functional groups chosen and resulting propensities for isonicotinic acid and 
















0.19 (0.08, 0.37) 0.64(0.42, 0.81) 
 
 







364 0.25 (0.17, 0.36) 0.63 (0.51, 0.73) 
 
 
Figure A.10 Molecular electrostatic potentials of (a) isonicotinic acid and (b)thioisonicotinic acid.  
  
 A.3.4.2 Role of choosing correct functional group 
In order to determine the right functional group choice for molecules where the fragmentation is 
possible such as in bis-urea substituents, we performed an analysis of bis-urea analogues by 
fragmenting each functional group into three different ways (Scheme A.4-Scheme A.6). The 
propensity for each molecule was calculated using each fragmented functional group and 
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compared to the experimental data to make conclusion regarding which fragmentation is the 
correct choice of functional group for such molecules (Table A.7 and Table A.8). Four molecules 
were chosen for this study.  
 









Scheme A.6 Three different fragmentations of functional group on 1,3-bis(pyridin-2-yl) urea and 
1,4-di(pyridin-2-yl) urea.  
 
Table A.7 Hydrogen-bond propensity score for each fragment in 1,3-bisphenylurea.  
Donor…. Acceptor Fragment 1 Fragment 2 Fragment 3 
NH(1)…O=C 0.60 (0.42, 0.56) 0.49(0.39, 0.59) 0.40 (0.26, 0.56) 
NH(2)…O=C 0.60 (0.42, 0.56) 0.49 (0.39, 0.59) 0.40 (0.26, 0.56) 
ROC 0.731 0.773 0.720 
 
 
Table A.8 Hydrogen-bond propensity score for each fragment in bis-urea analogues.  
1,2-bis(pyridin-2-yl) urea 
Donor…. Acceptor Fragment 1 Fragment 2 Fragment 3 
NH(I)…N(pyridine) intra 0.86 (0.86, 0.86) 0.86 (0.86, 0.86) 0.86 (0.86, 0.86) 
NH(II)…O=C 0.66 (0.48, 0.80) 0.29 (0.18, 0.44) 0.22 (0.11, 0.38) 
NH(I)…N(pyridine) inter 0.58 (0.43, 0.73) 0.25 (0.15, 0.40) 0.31 (0.18, 0.49) 
ROC 0.737 0.784 0.771 
1,3-bis(pyridin-2-yl) urea 
Donor…. Acceptor Fragment 1 Fragment 2 Fragment 3 
NH(II)…O=C 0.55 (0.35, 0.73) 0.39 (0.26, 0.54) 0.43 (0.31, 0.57) 
NH(I)…N(pyridine) inter 0.71 (0.56, 0.83) 0.34 (0.22, 0.49) 0.47 (0.36, 0.59) 
ROC 0.711 0.727 0.653 
1,4-bis(pyridin-2-yl) urea 
Donor…. Acceptor Fragment 1 Fragment 2 Fragment 3 
NH(II)…O=C 0.54 (0.35, 0.71) 0.38 (0.25, 0.53) 0.47 (0.30, 0.63) 
NH(I)…N(pyridine) inter 0.76 (0.63, 0.85) 0.36 (0.23, 0.51) 0.53 (0.38, 0.68) 
ROC 0.719 0.727 0.642 
 
A.3.5 Limitations 
  A.3.5.1 Differentiation of equivalent synthon polymorphs 




Figure A.11 Hydrogen bonded ribbons of (a) Form I, (b) Form II, and (c) Form III. The π-π 
interaction motifs are shown for (d) Form I along the b-axis, (e) Form II along the c-axis, and (f) 
Form III along a-axis. 




Figure A.12 Propensity coordination chart of benzamide showing (a) two predicted motifs and (b) 
all experimental observed motifs overlapping with the most optimal predicted motifs.  
 
 A.4 Discussion 
Hypothetical motif II 
Hypothetical motif I 
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A.4.1 Sensitivity analysis- comparing sample sizes 
 A.4.1.1 Isonicotinamide 
We chose six different datasets; 351, 551, 800, 1045, 3589 and 5727 hits for training dataset. The 
hydrogen-bond propensity was calculated for each dataset and the ROC was obtained (Table A.1).  
 
Figure A.13 Graph showing the propensity ranking for two interactions changes as we increases 
the dataset.  
As the number of hits for each training dataset is increased, more structures are added into the 
model. As the dataset gets bigger, the training dataset deviates from the molecule of interest in 
terms of functionalities present on them. The larger dataset includes molecules with either aromatic 
N or carbamoyl functionalities as well as having them on two separate molecules in a crystal (co-
crystals).  In the case of isonicotinamide, more molecules with NH(amine)…N interactions are 
included in the dataset as we increase the training set. The propensity of NH(amine)…N increased, 
and it became rank 1 in the propensity order after 1000 dataset. The propensity of 
NH(amine)….C=O hydrogen-bond interaction also increased by 0.04 going from 351 to 5727 
datasets.  
 
A.4.2 Role of HBP in identifying stable polymorphs 
 A.4.2.1 Isonicotinamide10 
The hydrogen-bond coordination table suggested that isonicotinamide has two hypothetical 
structures, both with similar propensity value but different coordination likelihood. Interestingly, 





















structure I resembles Form II and hypothetical structure II resembles form 1and the former is more 
likely structure compared to latter based on the satisfaction of each donor and acceptor group 







Figure A.14 Chemical diagram of isonicotinamide and two experimental known polymorphs.  
 
 A.4.2.2 4-Hydroxybenzamide 
Experimentally, two synthon polymorphs of 4-hydroxybenzamide are known. In form 1, synthons 
1, 2, and 3 ranked based on propensity were observed12. In form 2, synthon 1 and 4 were observed 
experimentally (Figure A.15)13. All conventional donors and acceptors are involved in the 
hydrogen-bonding and each donor and acceptor has same coordination in the both crystal 
structures. Based on hydrogen-coordination table, five hypothetical structures with different 
donor/acceptor coordination and propensity were predicted.  The two most optimal structures 
indicated as hypothetical structure I and II have the same coordination for each donor and acceptor 
(primary NH amine can donate two, OH hydroxyl can donate one, carbamoyl C=O can accept two, 
and O(hydroxyl) can accept one) but propensities are different. The HBP tool is able to distinguish 
















Does model predict the 
experimental polymorphs? 
Isonicotinamide 2 2 Yes (both were predicted) 
4-Hydroxybenzamide 5 2 Yes (both were predicted) 
 
A.4.3 Using HBP to understand H-bond competition and their strength 
The HBP of OH(acid)….C=O is 0.42 (0.25, 0.61) in benzoic acid. Experimentally, the interaction 
is observed in its structure14 where the OH(acid) forms head to head dimer with the carbonyl 
oxygen of acid via R22(8) OH(acid)….O=C(acid) synthon. When a strong acceptor group is 
introduced, the HBP of OH(acid)…C=O decreases to 0.19 (0.08, 0.37) due to the presence of H-
bond competition by a relatively stronger acceptor group. The maximum HBP value is 0.64 (0.42, 
0.81) for OH(acid)…N(pyridine) which agrees with the experimentally observed 




Figure A.16 Hydrogen-bonding synthon observed in the crystal structure of (a) benzoic acid and 
(b) isonicotinic acid.  
These HBP results were supported by electrostatic potential charges (Figure A.9). According to 
molecular electrostatic potentials, Pyridine N has the highest negative charge in isonicotinic acid 
making it better acceptor compared to carbonyl oxygen and therefore has higher chance of forming 
interaction with the OH of acid. Whereas in benzoic acid, there is no competition for the C=O, 
therefore, it forms hydrogen bond with the OH of acid. The HBP results were supported by MEPs 
and experimentally observed structures.  
A.4.4 Importance of functional group definition when making comparisons 
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 A.4.4.1 Replacing a functional group (isonicotinic acid to thioisonicotinic acid) 
In order to make comparisons of HBP between two molecules, both molecules should have same 
definition of functional groups, same # of dataset. An example shown here is for isonicotinic and 
thioisonicotinic acid and we want to study how replacing C=O with C=S affects the resulting 
propensity. The propensity results are shown in table A.6. The HBP comparison of isonicotinic 
acid and thioisonicotinic acid indicates that when a strong acceptor such as C=O is replaced with 
a weaker acceptor group such as C=S, the propensity of OH(acid)…C=S (thionyl) decreases 
comparing to OH(acid)…C=O because S is less electronegative compared to oxygen as shown by 
MEPs calculations and the propensity of OH(acid)…N(aromatic) increases because C=S group 
provides less competition to aromatic N compared to C=O.  
 
 A.4.4.2 Importance of choosing correct functional group 
The importance of choosing a correct functional group is discussed in this section.  
 A.4.4.2.1 Hydrogen bond propensity in 1,3-bisphenyl urea16 
1,3-bisphenyl urea was chosen as a control experiment with two hydrogen-bond donors (NH) and 
one hydrogen-bond acceptor (C=O). The NH groups have only one choice for the acceptor group 
and it was established using propensity tool that both NH groups binds to C=O via bifurcated 
hydrogen-bond interactions. The prediction results match the experimental crystal structure. The 
propensity score decreases as we go from fragment 1 to fragment 3 indicating fragment 1 to be the 
best choice.  
 A.4.4.2.2 Hydrogen bond propensity 1,2-bis(pyridin-2-yl) urea17 
Based on propensity all three fragments, 1,2-bis(pyridin-2-yl) urea is expected to have 
intramolecular hydrogen bonding between NH(I)…N(pyridine) intra which matches with the 
experimental observed interaction in the crystal structure. Fragment 1 and 2 predicts NH(II)…O=C 
to be the second-best interaction and it was also observed in the crystal structure as well. Fragment 
1 is preferred over fragment 2 because it clearly distinguish between two possible intermolecular 




(a)  (b) 
Figure A.17 Synthons observed in the crystal structures of (a) 1,3-bisphenyl urea, and (b) 1,2-
bis(pyridin-2-yl) urea17.   
 
 2.4.4.2.3 Hydrogen bond propensity 1,3-bis(pyridin-2-yl) urea18 and 1,4-bis(pyridin-2-yl) 
urea19 
Based on hydrogen-bond propensity, NH(I)…N(pyridine) intermolecular interaction was 
predicted to be the best interaction in both 1,3-bis(pyridin-2-yl) urea and 1,4-bis(pyridin-2-yl) urea 
via fragment 1 and 3. Experimentally, NH(I)…N(pyridine) is observed in both experimental 





Figure A.18 Synthons observed in the crystal structures of (a) 1,3-bis(pyridin-2-yl) urea18 and (b) 




Therefore, fragment 1 is the best fragment for this study as in 4 out of 4 molecules, it predicted the 
experimentally observed synthon correctly. These results also suggest that choosing functional 
group is a key step in the predicting the propensity and ranking as well as the magnitude of 
propensity can vary drastically based on choice of functional groups.  
 
Table A.9 Summary of functional fragmentations in bis urea molecules  
Molecules Experimentally observed synthon Which fragment predicted correctly? 
1,3-bisphenyl urea Bifurcated H-bond Fragment 1-3 
1,2-bis(pyridin-2-yl) urea Intra (NH…N) 
Inter (NH…O=C) 
Fragment 1 
1,3-bis(pyridin-2-yl) urea Inter (NH…N) Fragment 1 
1,4-bis(pyridin-2-yl) urea Inter (NH…N) Fragment 1 
 
 A.4.5 Limitation 
A.4.5.1 Differentiation of equivalent synthon polymorphs 
Benzamide has three known experimental forms. All three structures are built up by the same 
primary building unit, a dimer of benzamide. These ribbons are packed in three distinct patterns 
for each crystal structure. These significant differences in the observed packing motifs are 
triggered by the second-ranking intermolecular interactions, the π-π interactions of the benzyl 
moieties. Form I is dominated by shifted π stacks while in Form II and Form III a herringbone 
pattern like arrangement is observed.  
We used hydrogen-bond propensity model to determine if all three forms or the distinct differences 
in the second-ranked intermolecular interaction will be predicted by the HBP tool.  Since the 
propensity tool is solely based on hydrogen-bond interactions between conventional hydrogen-
bond donors and acceptors and same type of synthon is observed in all three crystal structures of 
benzamide. The NH(carbamoyl)….C=O hydrogen-bond interaction has same propensity score of 
0.73 (0.62, 0.82) and same coordination score (two for amine donor and two for C=O group 
acceptor) for all three structures. The software predicted all three forms to lie at same spot in the 
propensity-coordination chart. Therefore, it fails to predict the secondary interactions.  
 A.5 Conclusion  
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The object of this research was a proof of concept to test hydrogen bond propensity tool of 
Cambridge crystallographic database center. At the outset of this discussion, it is important to note 
that the propensity tool is not a means for predicting polymorphism.1 The choice of the term 
“propensity” is meant to give an indication of the possibility of multiple crystal forms; in that sense 
it can provide some guidance on the amount of “time and money”20 that might be expended in 
experimentally searching for multiple crystal forms. Nevertheless, it is a statistical tool, and there 
is no guarantee that any particular compound will adhere to the statistics. 
The tool is sensitive to the number of datasets chosen for analysis. In order to have chemical 
similarity in the training model as well have decent training model, the dataset between 300-500 
will be considered optimal. The role of HBP in identifying stable polymorphs was done 
(isonicotinamide and 4-hydroxybenxamide). In both molecules, the HBP model predicts the 
experimentally observed synthon polymorphs correctly. The tool is good to understand the H-bond 
competition between conventional donors and acceptors and determine the most optimal synthon 
and its strength. It is sensitive to functional group definition and plays an important role in the final 
outcome of propensity ranking. Therefore, careful analysis of functional group must be done to 
make comparisons between different molecules. The fragment 1 functional group was the right 
choice of functional groups in bis urea molecules as the predictions made by HBP matches 100% 
with the experimentally observed synthons in four molecules studied.  
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Appendix B - NMR of target molecules 
 B.1 1H NMR for pyrazole based target molecules 
 
3-Acetamido-1H-pyrazole, P1.esp











































































Figure B.1.1 1H NMR of 3-acetamido-1H-pyrazole, P1.  
3-acetamido-5methyl-1H-pyrazole, P2.esp






















































































Figure B.1.2 1H NMR of 3-acetamido-5methyl-1H-pyrazole, P2. 
3-Propamido-1H-pyrazole, P3.esp

























































































Figure B.1.3 1H NMR of 3-propamido-1H-pyrazole, P3. 
3-propamido-5methyl-1H-pyrazole, P4.esp





















































































Figure B.1.4 1H NMR of 3-propamid 
o-5methyl-1H-pyrazole, P4. 
3-butyramido pyrazole, P5.esp























































































































Figure B.1.5 NMR spectrum of 3-butyramido pyrazole, P5 
3-butyramido 5-methyl pyrazole, P6.esp










































































































Figure B.1.6 NMR spectrum of 3-butyramido 5-methyl pyrazole, P6 
 
3-bezamido-1H-pyrazole, P7.esp



































































































Figure B.1.7 1H NMR of 3-bezamido-1H-pyrazole, P7. 
3-benzamido-5methyl-1H-pyrazole, P8.esp

































































































Figure B.1.8 1H NMR of 3-benzamido-5methyl-1H-pyrazole, P8. 
 
N-(pyrazole-2-yl)nicotinamide, P9.esp





















































































































































































































Figure B.1.10 NMR spectrum of N-(5-methylpyrazol-2-yl)nicotinamide, P10 
N-(1H-pyrazol-3-yl)isonicotinamide. P11.esp








































































































































































































Figure B.1.12 NMR spectrum of N-(5-methylpyrazol-2-yl)isonicotinamide, P12 
 
B.2 1H NMR for thiazole based target molecules 
3-acetamido-thiazole, T1.esp







































































Figure B.2.1 NMR spectrum of 3-acetamido-thiazole, T1 
 
3-acetamido-5methyl-thiazole, T2.esp



































































Figure B.2.2 NMR spectrum of 3-acetamido-5methyl-thiazole, T2 
 
3-propamido-thiazole, T3.esp




























































































































































Figure B.2.4 NMR spectrum of 3-propamido-5methyl-thiazole, T4 
3-butyramido-Thiazole, T5.esp



































































































































































































































Figure B.2.6 NMR spectrum of 3-Butyramido-5methyl-thiazole, T6 
 
Benzamido-thiazole, T7.esp
















































































































































































































































































































































































































































































































































































Figure B.2.12 NMR spectrum of N-(5-methylthiazol-2-yl)isonicotinamide, T12 
 
 
 B.3 1H NMR for activated halogen-bond donors  
N-(4-iodophenyl) nicotinamide, 3N-EB.esp




































































































Figure B.3.1 NMR spectrum of N-(4-iodophenyl) nicotinamide, 3N-EB 
N-(4-iodophenyl) isonicotinamide, 4N-EB .esp





































































































































































































































































































Figure B.3.4 NMR spectrum of N-(2,3,5,6-tetrafluoro-4-iodophenyl)isonicotinamide, 4N-ITFB  
 
4-((trimethylsilyl)ethynyl)aniline.esp































































































































Figure B.3.6 1H NMR spectrum of 4-ethynylaniline. 
N-(4-ethynylphenyl)nicotinamide, 3N-EB.esp





































































































































































































































Figure B.3.8 1H NMR spectrum of N-(4-ethynylphenyl)isonicotinamide, 4N-EB 
N-(4-Iodoethynylphenyl)nicotinamide, 3N-IEB.esp


























































































































































































Figure B.3.10 1H NMR spectrum of N-(4-Iodoethynylphenyl)isonicotinamide, 4N-IEB 
Appendix-IR 
Appendix C - IR 
 C.1 IR analysis of pyrazole based molecules 












P1-Suc - No co-crystal P1-3-HydroxyBA 2588, 1885 Co-crystal 
P1-Adi - No co-crystal P1-4-HydroxyBA 2534, 1916 Co-crystal 
P1-sub - No co-crystal P1-3-AminoBA 2397, 1979 No co-crystal 
P1-Seb 2459, 1730 Co-crystal P1-4-AminoBA 2542, 1902 Co-crystal 
P1-Dod 2340, 1866 Co-crystal P1-3-NitroBA 2361,1883 Co-crystal 
P1-Fum - No co-crystal P1-4-NitroBA - No co-crystal 
P1-Mal - No co-crystal P1-BA - No co-crystal 
P1-Glu - No co-crystal P1-4-IodoBA - No co-crystal 
P1-Pim - No co-crystal P1-4-BromoBA - No co-crystal 
P1-Aze - No co-crystal P1-PentafluoroBA 2360,1851 co-crystal 
      
P2-Suc 2342, 1877 co-crystal P2-3-HydroxyBA 2574, 1959 co-crystal 
P2-Adi 2479, 1830 co-crystal P2-4-HydroxyBA 2502, 1803 co-crystal 
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P2-sub 2506, 1865 co-crystal P2-3-AminoBA  No co-crystal 
P2-Seb 2302, 1981 co-crystal P2-4-AminoBA 2348, 1929 No co-crystal 
P2-Dod 2434, 1864 co-crystal P2-3-NitroBA 2342,1847 co-crystal 
P2-Fum 2358, 1838 co-crystal P2-4-NitroBA - No co-crystal 
P2-Mal 2476, 1984 co-crystal P2-BA 2328,1894 co-crystal 
P2-Glu 2475, 1893 co-crystal P2-4-IodoBA - No co-crystal 
P2-Pim 2514, 1917 co-crystal P2-4-BromoBA - No co-crystal 
P2-Aze 2331, 1884 co-crystal P2-PentafluoroBA 2346,1854 co-crystal 
      
P3-Suc 2456, 1838 co-crystal P3-3-HydroxyBA - No co-crystal 
P3-Adi 2485, 1829 co-crystal P3-4-HydroxyBA - No co-crystal 
P3-sub 2502, 1860 co-crystal P3-3-AminoBA  no co-crystal 
P3-Seb - No co-crystal P3-4-AminoBA 2445,1881 co-crystal 
P3-Dod - No co-crystal P3-3-NitroBA 2334,1873 co-crystal 
P3-Fum 2440, 1804 co-crystal P3-4-NitroBA  no co-crystal 
P3-Mal 2438, 1895 co-crystal P3-BA 2523,1854 co-crystal 
P3-Glu 2574, 1909 co-crystal P3-4-IodoBA - No co-crystal 
P3-Pim 2532, 1893 co-crystal P3-4-BromoBA - No co-crystal 
P3-Aze - No co-crystal P3-PentafluoroBA 2380,1865 co-crystal 
      
P4-Suc 2467, 1917 Co-crystal P4-3-HydroxyBA - No co-crystal 
P4-Adi 2458, 1880 Co-crystal P4-4-HydroxyBA - No co-crystal 
P4-sub 2583, 1988 Co-crystal P4-3-AminoBA  No co-crystal 
P4-Seb 2366, 1885 No co-crystal P4-4-AminoBA - No co-crystal 
P4-Dod - No co-crystal P4-3-NitroBA 2358,1854 Co-crystal 
P4-Fum 2364, 1858 Co-crystal P4-4-NitroBA - No co-crystal 
P4-Mal 2427, 1953 Co-crystal P4-BA 2492,1868 Co-crystal 
P4-Glu 2452, 1872 Co-crystal P4-4-IodoBA - No co-crystal 
P4-Pim 2364, 1924 Co-crystal P4-4-BromoBA - No co-crystal 
P4-Aze 2565, 1984 Co-crystal P4-PentafluoroBA 2349,1864 Co-crystal 
      
      
P5-7-Suc - No co-crystal P5-3-HydroxyBA 1879, 2355 Co-crystal 
P5-8-Adi 1887, 2362 Co-crystal P5-4-HydroxyBA - No co-crystal 
P5-9-Sub 1883, 2512 Co-crystal P5-3-AminoBA 2001, 2294 Co-crystal 
P5-10-Seb - No co-crystal P5-4-AminoBA - No co-crystal 
P5-11-Dod - No co-crystal P5-3-NitroBA 1853, 2475 Co-crystal 
P5-12-Fum 1865, 2520 Co-crystal P5-4-NitroBA - No co-crystal 
P5-13-Mal 1860, 2357 Co-crystal P5-BA 1865, 2450 Co-crystal 
P5-14-Glu 1895, 2432 Co-crystal P5-4-IodoBA - No co-crystal 
P5-15-Pim 1884, 2364 Co-crystal P5-4-BromoBA - No co-crystal 
P5-16-Aze 1868, 2355 Co-crystal P5-PentafluoroBA 1871, 2417 Co-crystal 
      
P6-7-Suc - No co-crystal P6-3-HydroxyBA - No co-crystal 
P6-8-Adi - No co-crystal P6-4-HydroxyBA - No co-crystal 
P6-9-Sub 1899, 2326 Co-crystal P6-3-AminoBA 1891, 2346 Co-crystal 
P6-10-Seb 1882, 2360 Co-crystal P6-4-AminoBA - No co-crystal 
P6-11-Dod - No co-crystal P6-3-NitroBA 1894, 2367 Co-crystal 
P6-12-Fum - No co-crystal P6-4-NitroBA - No co-crystal 
P6-13-Mal 1892, 2359 Co-crystal P6-BA 1917, 2366 Co-crystal 
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P6-14-Glu 1918, 2304 Co-crystal P6-4-IodoBA - No co-crystal 
P6-15-Pim - No co-crystal P6-4-BromoBA - No co-crystal 
P6-16-Aze - No co-crystal P6-PentafluoroBA 1837, 2355 Co-crystal 
      
P7-Suc 2435, 1909 Co-crystal P7-3-HydroxyBA  No co-crystal 
P7-Adi 2517, 1877 Co-crystal P7-4-HydroxyBA  No co-crystal 
P7-sub 2480, 1874 Co-crystal P7-3-AminoBA 2358, 2004 No co-crystal 
P7-Seb 2317, 1886 Co-crystal P7-4-AminoBA 2361,1872 Co-crystal 
P7-Dod - No co-crystal P7-3-NitroBA 2367,1865 Co-crystal 
P7-Fum 2327, 1886 Co-crystal P7-4-NitroBA 2331,1879 Co-crystal 
P7-Mal 2537, 2024 Co-crystal P7-BA 2557, 1858 no co-crystal 
P7-Glu 2340, 1834 Co-crystal P7-4-IodoBA 2554, 1927 no co-crystal 
P7-Pim 2441, 1892 Co-crystal P7-4-BromoBA 2361, 1929 no co-crystal 
P7-Aze 2350, 1866 Co-crystal P7-PentafluoroBA 2348,1874 Co-crystal 
      
P8-Suc 2525, 2033 Co-crystal P8-3-HydroxyBA - No co-crystal 
P8-Adi - No co-crystal P8-4-HydroxyBA - No co-crystal 
P8-sub 2392, 1869 Co-crystal P8-3-AminoBA 2425,1969 Co-crystal 
P8-Seb 2482, 1901 Co-crystal P8-4-AminoBA - No co-crystal 
P8-Dod 2415, 1975 Co-crystal P8-3-NitroBA 2361,1886 Co-crystal 
P8-Fum 2354, 1871 Co-crystal P8-4-NitroBA - No co-crystal 
P8-Mal 2516, 1969 Co-crystal P8-BA 2239,1906 Co-crystal 
P8-Glu 2562, 1956 Co-crystal P8-4-IodoBA - No co-crystal 
P8-Pim - No co-crystal P8-4-BromoBA - No co-crystal 
P8-Aze 2342, 1869 Co-crystal P8-PentafluoroBA 2378,1771 Co-crystal 
      
P9-Suc 2492, 1929 Co-crystal P9-3-HydroxyBA 2516, 1877 No co-crystal 
P9-Adi 2525, 1895 Co-crystal P9-4-HydroxyBA 2314, 1873 No co-crystal 
P9-sub 2366, 1914 Co-crystal P9-3-AminoBA 2375, 2014 Co-crystal 
P9-Seb 2357, 1923 Co-crystal P9-4-AminoBA - No co-crystal 
P9-Dod 2522, 1874 Co-crystal P9-3-NitroBA 2329, 1910 Co-crystal 
P9-Fum 2446, 1889 Co-crystal P9-4-NitroBA - No co-crystal 
P9-Mal  Co-crystal P9-BA 2437, 1837 Co-crystal 
P9-Glu 2525, 1898 Co-crystal P9-4-IodoBA - No co-crystal 
P9-Pim - No co-crystal P9-4-BromoBA - No co-crystal 
P9-Aze 2443, 1926 Co-crystal P9-PentafluoroBA 2400, 1926 Co-crystal 
      
P10-Suc 2443, 1932 Co-crystal P10-3-HydroxyBA - No co-crystal 
P10-Adi 2342, 1896 Co-crystal P10-4-HydroxyBA - No co-crystal 
P10-sub 2375, 1929 Co-crystal P10-3-AminoBA 2411, 2070 Co-crystal 
P10-Seb 2482, 1895 Co-crystal P10-4-AminoBA - No co-crystal 
P10-Dod 2236, 2366 Co-crystal P10-3-NitroBA 2452, 1944 Co-crystal 
P10-Fum 2345, 1892 Co-crystal P10-4-NitroBA - No co-crystal 
P10-Mal See below Co-crystal P10-BA See below Co-crystal 
P10-Glu 2354, 1883 Co-crystal P10-4-IodoBA - No co-crystal 
P10-Pim - No co-crystal P10-4-BromoBA - No co-crystal 
P10-Aze 2354, 1914 Co-crystal P10-PentafluoroBA 2455, 1917 Co-crystal 
      
P11-Suc 2366, 1842 Co-crystal P11-3-HydroxyBA - No co-crystal 
P11-Adi 2360, 1895 Co-crystal P11-4-HydroxyBA - No co-crystal 
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P11-sub 2375, 1929 Co-crystal P11-3-AminoBA 2161, 1914 Co-crystal 
P11-Seb 2473, 1917 Co-crystal P11-4-AminoBA - No co-crystal 
P11-Dod 2366, 1962 Co-crystal P11-3-NitroBA 2513, 1929 Co-crystal 
P11-Fum 2323, 1941 Co-crystal P11-4-NitroBA - No co-crystal 
P11-Mal 2366, 1935 Co-crystal P11-BA 2440, 1871 Co-crystal 
P11-Glu 2363, 1871 Co-crystal P11-4-IodoBA - No co-crystal 
P11-Pim - No co-crystal P11-4-BromoBA - No co-crystal 
P11-Aze 2452, 1883 Co-crystal P11-PentafluoroBA 2366, 1877 Co-crystal 
      
P12-Suc 2470, 1862 Co-crystal P12-3-HydroxyBA - No co-crystal 
P12-Adi 2350, 1889 Co-crystal P12-4-HydroxyBA - No co-crystal 
P12-sub 2324, 1911 Co-crystal P12-3-AminoBA See below Co-crystal 
P12-Seb 2375, 1855 Co-crystal P12-4-AminoBA - No co-crystal 
P12-Dod 2461, 1910 Co-crystal P12-3-NitroBA 2378, 1950 Co-crystal 
P12-Fum 2356, 1865 Co-crystal P12-4-NitroBA 2409, 1956 No co-crystal 
P12-Mal 2370, 1889 Co-crystal P12-BA 2427, 1874 Co-crystal 
P12-Glu 2358, 1893 Co-crystal P12-4-IodoBA - No co-crystal 
P12-Pim - No co-crystal P12-4-BromoBA - No co-crystal 
P12-Aze 2372, 1920 Co-crystal P12-PentafluoroBA 2446, 1944 Co-crystal 
 
 Ligand Acid Grinded mixture Result 




1679, 1557, 1461, 
1284 
Co-crystal 




1661, 1592, 1488, 
1420, 1293 
Co-crystal 




1712, 1673, 1574, 
1484 
Co-crystal 
P10-BA 1662, 1587, 
1480, 1419 
 
1671, 1587, 1481, 
1313 
Co-crystal 
P12-3-AminoBA 1699, 1658, 
1589, 1481 
1623, 1388 




 C.2 IR analysis of thiazole based molecules 
Table C.2.1 IR analysis of thiazole based molecules with 20 carboxylic acids 
Mixture IR bands in 
mixture 
Result Mixture IR bands in 
mixture 
Result 
T1-Suc 2253, 1935 Co-crystal T1-3HydroxyBA 2358, 1865 Co-crystal 
T1-Adi - No Co-crystal T1-4HydroxyBA 2353, 1949 Co-crystal 
T1-Sub - No co-crystal T1-3AminoBA 2346, 1917 Co-crystal 
T1-Seb - No co-crystal T1-4AminoBA 2440, 1822 Co-crystal 
T1-Dod - No co-crystal T1-3NitroBA 2359, 1895 Co-crystal 
T1-Fum - No co-crystal T1-4NitrooBA - No co-crystal 
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T1-Mal - No co-crystal T1-BA - No co-crystal 
T1-Glut - No co-crystal T1-4BromoBA - No co-crystal 
T1-Pim - No co-crystal T1-4IodoBA - No co-crystal 
T1-Aze - No co-crystal T1-PentaBA 2360, 1865 Co-crystal 
      
T2-Suc - No co-crystal T2-3HydroxyBA 2513, 2033 Co-crystal 
T2-Adi - No co-crystal T2-4HydroxyBA 2461, 1841 Co-crystal 
T2-Sub - No co-crystal T2-3AminoBA 2351, 1926 Co-crystal 
T2-Seb - No co-crystal T2-4AminoBA 2354, 1910 Co-crystal 
T2-Dod - No co-crystal T2-3NitroBA 2349, 1927 Co-crystal 
T2-Fum 2311, 1926 Co-crystal T2-4NitrooBA - No co-crystal 
T2-Mal 2381, 1877 Co-crystal T2-BA - No co-crystal 
T2-Glut - No co-crystal T2-4BromoBA - No co-crystal 
T2-Pim - No co-crystal T2-4IodoBA - No co-crystal 
T2-Aze - No co-crystal T2-PentaBA 2567, 1870 Co-crystal 
      
T3-Suc - No co-crystal T3-3HydroxyBA 2468, 1870 Co-crystal 
T3-Adi - No co-crystal T3-4HydroxyBA - No co-crystal 
T3-Sub - No co-crystal T3-3AminoBA 2363, 2005 Co-crystal 
T3-Seb - No co-crystal T3-4AminoBA - No co-crystal 
T3-Dod - No co-crystal T3-3NitroBA 2366, 1759 Co-crystal 
T3-Fum - No co-crystal T3-4NitrooBA - No co-crystal 
T3-Mal - No co-crystal T3-BA - No co-crystal 
T3-Glut - No co-crystal T3-4BromoBA - No co-crystal 
T3-Pim - No co-crystal T3-4IodoBA - No co-crystal 
T3-Aze - No co-crystal T3-PentaBA 2504, 1917 Co-crystal 
      
T4-Suc - No co-crystal T4-3HydroxyBA 2363, 1899 Co-crystal 
T4-Adi - No co-crystal T4-4HydroxyBA 2301, 1845 Co-crystal 
T4-Sub - No co-crystal T4-3AminoBA - No Co-crystal 
T4-Seb - No co-crystal T4-4AminoBA - No co-crystal 
T4-Dod - No co-crystal T4-3NitroBA 2366, 1759 Co-crystal 
T4-Fum - No co-crystal T4-4NitrooBA - No co-crystal 
T4-Mal - No co-crystal T4-BA 2358, 1825 Co-crystal 
T4-Glut - No co-crystal T4-4BromoBA - No co-crystal 
T4-Pim - No co-crystal T4-4IodoBA - No co-crystal 
T4-Aze - No co-crystal T4-PentaBA 2504, 1917 Co-crystal 
      
T5-Suc - No co-crystal T5-3HydroxyBA 1865,2367 Co-crystal 
T5-Adi - No co-crystal T5-4HydroxyBA - No co-crystal 
T5-Sub - No co-crystal T5-3AminoBA 1977, 2365 Co-crystal 
T5-Seb - No co-crystal T5-4AminoBA 1906,2305 No co-crystal 
T5-Dod - No co-crystal T5-3NitroBA 1870,2357 Co-crystal 
T5-Fum - No co-crystal T5-4NitroBA - No co-crystal 
T5-Mal 1878, 2314 Co-crystal T5-BA - No co-crystal 
T5-Glut - No co-crystal T5-4BromoBA - No co-crystal 
T5-Pim - No co-crystal T5-4IodoBA - No co-crystal 
T5-Aze - No co-crystal T5-PentaBA 1902,2492 Co-crystal 
      
T6-Suc - No co-crystal T6-3HydroxyBA 1840,2375 Co-crystal 
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T6-Adi 1866, 2400 Co-crystal T6-4HydroxyBA 1854,2543 Co-crystal 
T6-Sub 1918, 2284 Co-crystal T6-3AminoBA 1985,2305 Co-crystal 
T6-Seb - No co-crystal T6-4AminoBA - No co-crystal 
T6-Dod - No co-crystal T6-3NitroBA 1839,2306 Co-crystal 
T6-Fum 1862, 2371 Co-crystal T6-4NitroBA - No co-crystal 
T6-Mal 1942, 2369 Co-crystal T6-BA 1846,2357 Co-crystal 
T6-Glut 1877, 2361 Co-crystal T6-4BromoBA - No co-crystal 
T6-Pim - No co-crystal T6-4IodoBA - No co-crystal 
T6-Aze - No co-crystal T6-PentaBA 1897,2567 Co-crystal 
      
T7-Suc 2455, 1898 Co-crystal T7-3HydroxyBA 2468, 1870 Co-crystal 
T7-Adi 2336, 1907 Co-crystal T7-4HydroxyBA 2361, 1769 Co-crystal 
T7-Sub 2339, 1892 Co-crystal T7-3AminoBA 2406, 1983 Co-crystal 
T7-Seb 2366, 1929 Co-crystal T7-4AminoBA - No co-crystal 
T7-Dod 2378, 1969 Co-crystal T7-3NitroBA 2360, 1849 Co-crystal 
T7-Fum 2348, 1871 Co-crystal T7-4NitroBA 2364, 1897 Co-crystal 
T7-Mal 2363, 1865 Co-crystal T7-BA 2364, 1906 Co-crystal 
T7-Glut 2360, 1904 Co-crystal T7-4BromoBA 2337, 1909 Co-crystal 
T7-Pim 2339, 1886 Co-crystal T7-4IodoBA 2320, 1906 Co-crystal 
T7-Aze -  T7-PentaBA 2328, 1866 Co-crystal 
      
T8-Suc 2345, 1868 Co-crystal T8-3HydroxyBA 2489, 1852 Co-crystal 
T8-Adi 2360, 1880 Co-crystal T8-4HydroxyBA 2539, 1900 Co-crystal 
T8-Sub 2354, 1912 Co-crystal T8-3AminoBA 2367, 1977 Co-crystal 
T8-Seb 2357, 1862 Co-crystal T8-4AminoBA 2364, 1891 Co-crystal 
T8-Dod 2370, 1854 Co-crystal T8-3NitroBA 2334, 1885 Co-crystal 
T8-Fum 2345, 1914 Co-crystal T8-4NitroBA 2547, 1815 Co-crystal 
T8-Mal 2363, 1892 Co-crystal T8-BA 2408, 1875 Co-crystal 
T8-Glut 2362, 1885 Co-crystal T8-4BromoBA - No co-crystal 
T8-Pim 2326, 1898 Co-crystal T8-4IodoBA - No co-crystal 
T8-Aze 2345, 1900 Co-crystal T8-PentaBA 2359, 1892 Co-crystal 
      
T9-Suc 1871, 2433 Co-crystal T9-3HydroxyBA 1950, 2556 Co-crystal 
T9-Adi 1901, 2363 Co-crystal T9-4HydroxyBA 1849, 2492 Co-crystal 
T9-Sub 1840, 2339 Co-crystal T9-3AminoBA 1788, 2323 Co-crystal 
T9-Seb 1944, 2541 Co-crystal T9-4AminoBA 1898, 2495 Co-crystal 
T9-Dod 1880, 2345 Co-crystal T9-3NitroBA 1892, 2369 Co-crystal 
T9-Fum 1868, 2357 Co-crystal T9-4NitroBA 1956, 2363 Co-crystal 
T9-Mal 1929, 2259 Co-crystal T9-BA 1898, 2348 Co-crystal 
T9-Glut 1914, 2357 Co-crystal T9-4BromoBA 1935, 2357 Co-crystal 
T9-Pim 1929, 2259 Co-crystal T9-4IodoBA - No Co-crystal 
T9-Aze - No Co-crystal T9-PentaBA 1944, 2412 Co-crystal 
      
T10-Suc 1842, 2366 Co-crystal T10-3HydroxyBA 1935, 2397 Co-crystal 
T10-Adi 1886, 2354 Co-crystal T10-4HydroxyBA 1898, 2336 Co-crystal 
T10-Sub 1865, 2354 Co-crystal T10-3AminoBA 1914, 2161 Co-crystal 
T10-Seb 1941, 2213 Co-crystal T10-4AminoBA 1904, 2336 Co-crystal 
T10-Dod 1920, 2339 Co-crystal T10-3NitroBA 1929, 2513 Co-crystal 
T10-Fum 1871, 2363 Co-crystal T10-4NitroBA 1953, 2430 Co-crystal 
T10-Mal 1825, 2329 Co-crystal T10-BA 1871, 2440 Co-crystal 
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T10-Glut 1825, 2329 Co-crystal T10-4BromoBA - No Co-crystal 
T10-Pim 1751, 2360 Co-crystal T10-4IodoBA - No Co-crystal 
T10-Aze 1883, 2452 Co-crystal T10-PentaBA 1877, 2366 Co-crystal 
      
T11-Suc 1865, 2427 Co-crystal T11-3HydroxyBA 1889, 2345 Co-crystal 
T11-Adi 1889, 2516 Co-crystal T11-4HydroxyBA 1895, 2342 Co-crystal 
T11-Sub 1889, 2369 Co-crystal T11-3AminoBA 1947, 2351 Co-crystal 
T11-Seb 1881, 2475 Co-crystal T11-4AminoBA 2014, 2336 Co-crystal 
T11-Dod 1889, 2420 Co-crystal T11-3NitroBA 2516, 1929 Co-crystal 
T11-Fum 1825, 2339 Co-crystal T11-4NitroBA 2427, 1950 Co-crystal 
T11-Mal 2372, 1828 Co-crystal T11-BA 2351, 1910 Co-crystal 
T11-Glut 2357, 2005 Co-crystal T11-4BromoBA - No Co-crystal 
T11-Pim 1843, 2354 Co-crystal T11-4IodoBA - No Co-crystal 
T11-Aze 1874, 2342 Co-crystal T11-PentaBA 2437, 1883 Co-crystal 
      
T12-Suc 1863, 2466 Co-crystal T12-3HydroxyBA 1849, 2357 Co-crystal 
T12-Adi 1929, 2506 Co-crystal T12-4HydroxyBA 1892, 2336 Co-crystal 
T12-Sub See below Co-crystal T12-3AminoBA See below  Co-crystal 
T12-Seb 2384, 1856 Co-crystal T12-4AminoBA 1846, 2357 Co-crystal 
T12-Dod See below  Co-crystal T12-3NitroBA 1950, 2378 Co-crystal 
T12-Fum 2356, 1865 Co-crystal T12-4NitroBA 2409, 1956 Co-crystal 
T12-Mal 1889, 2370 Co-crystal T12-BA 2427, 1874 Co-crystal 
T12-Glut 1893, 2358 Co-crystal T12-4BromoBA - No co-crystal 
T12-Pim 1907, 2358 Co-crystal T12-4IodoBA - No co-crystal 
T12-Aze 1923, 2372 Co-crystal T12-PentaBA 2446, 1944 Co-crystal 
 
 Ligand Acid Grinded mixture Co-crystal? 
T9-3AminoBA 1549, 1593 1623, 1388 1633, 1543, 1392, 
1590 
Co-crystal 
T9-4AminoBA 1549, 1668 1420 1423, 1543, 1670 Co-crystal 
T10-4HydroxyBA 1679 1286 1294, 1673 Co-crystal 
T10-3AminoBA 1543 1388, 1623 1385, 1546, 1635 Co-crystal 
T10-4AminoBA 1153, 1301, 
1543, 1679 
1285 1159, 1294, 1558, 
1689 
Co-crystal 
T12-sub 1305, 1538, 
1556 
1187, 1248 1183, 1244, 1309, 
1544, 1562 
Co-crystal 
T12-dod 1538, 1556, 
1672 
1222, 1686 1220, 1548, 1561, 
1676 
Co-crystal 
T12-3AminoBA 1538 1623 1627, 1541 Co-crystal 
T12-4AminoBA 1412, 1597 1285 1603, 1408 Co-crystal 
 
 C.3 IR of co-crystals of ternary systems   
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Table C.3.1 IR analysis of thiazole based molecules with 15 carboxylic acids and one halogen 





Grinded mixture Ternary Co-crystal? 
T9-H1-D1 1678, 1410, 1306 1883, 2519, 1453, 1415, 937, 756 Yes 
T9-H2-D1 1683, 1406, 1272 1904, 2455, 1461, 1418, 939 Yes 
T9-H3-D1 1684, 1404, 1248 1886, 2287, 1464, 1409, 940 Yes 
T9-H4-D1 1686, 1405, 1297, 1232 2366, 1950, 1680, 1543, 1455  Yes 
T9-H5-D1 1686, 1427, 1408, 1279 1941, 2492, 1463, 1408, 937 Yes 
T9-H6-D1 1657, 1421, 1270 2339, 1956, 1673, 1595, 1522 Yes 
T9-H7-D1 1693, 1433 2329, 1880, 1670, 1559, 1460 Yes 
T9-H8-D1 1682, 1406, 1301 2314, 1819, 1556, 1486, 1303 Yes 
T9-H9-D1 1683, 1407, 1267 1681, 1544, 1455, 1407  No (only binary XB) 
T9-H10-D1 1682, 1408, 1250 1681, 1542, 1456, 1407, 1292  No (only binary XB) 
T9-H11-D1 1695, 1552, 1493, 1457  1456, 1429, 1862, 1460, 1427 (Only 
XB) 
No (only binary XB) 
T9-H12-D1 1668, 1592, 1286 1865, 2357, 1460, 1427, 938 Yes 
T9-H13-D1 1686, 1528, 1351 1461, 1422, 1870, 2424 (Only XB) No (only binary XB) 
T9-H14-D1 1685, 1599, 1536, 1275 2332, 1956, 1463, 1420, 939 Yes 
T9-H15-D1 1708, 1650 2427, 1883, 1678, 1531 Yes 
    
T10-H1-D1 1678, 1410, 1306 1883, 2342, 1458, 1410, 939 Yes 
T10-H2-D1 1683, 1406, 1272 1883, 2489, 1458, 1424, 939 Yes 
T10-H3-D1 1684, 1404, 1248 1889, 2467, 1457, 1423, 934 Yes 
T10-H4-D1 1686, 1405, 1297, 1232 1458, 1434, 939 (Only XB) No (only binary XB) 
T10-H5-D1 1686, 1427, 1408, 1279 2342, 1914, 1457, 1426, 936 Yes 
T10-H6-D1 1657, 1421, 1270 1455, 1434, 939 (Only XB) No (only binary XB) 
T10-H7-D1 1693, 1433 1455, 1434, 939 (Only XB) No (only binary XB) 
T10-H8-D1 1682, 1406, 1301 1455, 1434, 939 (Only XB) No (only binary XB) 
T10-H9-D1 1683, 1407, 1267 1655, 1553, 1451, 1553, 1411, 1134 
(Only XB) 
No (only binary XB) 
T10-H10-D1 1682, 1408, 1250 2366, 1962, 1683, 1520, 1465  Yes 
T10-H11-D1 1695, 1552, 1493, 1457  1867, 2268, 1458, 1409, 940, 1215 Yes 
T10-H12-D1 1668, 1592, 1286 2402, 1872, 1459, 1429, 938 Yes 
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T10-H13-D1 1686, 1528, 1351 1940, 2321, 1461, 1438, 940 Yes 
T10-H14-D1 1685, 1599, 1536, 1275 2357, 1858, 1664, 1598, 1572 Yes 
T10-H15-D1 1708, 1650 1957, 2360, 1465, 1421, 940 Yes 
    
T11-H1-D1 1678, 1410, 1306 1910, 2476, 1455, 1413, 935 Yes 
T11-H2-D1 1683, 1406, 1272 1456, 142, 937, 1907, 2489 Yes 
T11-H3-D1 1684, 1404, 1248 1892, 2363, 1458, 1424, 933 Yes 
T11-H4-D1 1686, 1405, 1297, 1232 1950, 2319, 1458, 1421, 936 Yes 
T11-H5-D1 1686, 1427, 1408, 1279 1910, 2371, 1682, 1544, 1457  Yes 
T11-H6-D1 1657, 1421, 1270 1681, 1544, 1455, 1289, 939 (only XB) No (only binary XB) 
T11-H7-D1 1693, 1433 1681, 1543, 1455, 1291, 939 (Only 
XB) 
No (only binary XB) 
T11-H8-D1 1682, 1406, 1301 2143, 1846, 1681, 1540, 1455 Yes 
T11-H9-D1 1683, 1407, 1267 2354, 1846, 1665, 1572 Yes 
T11-H10-D1 1682, 1408, 1250 2339, 1895, 1680, 1552, 1460  Yes 
T11-H11-D1 1695, 1552, 1493, 1457  1456, 976, 1996, 2447(Only XB) No (only binary XB) 
T11-H12-D1 1668, 1592, 1286 1875, 2472, 939, 1455, 1429 Yes 
T11-H13-D1 1686, 1528, 1351 1894, 2340, 1456, 936 Yes 
T11-H14-D1 1685, 1599, 1536, 1275 1953, 2363, 1465, 1421, 940 Yes 
T11-H15-D1 1708, 1650 946, 1466, 1684(Only XB) No (only binary XB) 
    
T12-H1-D1 1678, 1410, 1306 1898, 2482, 1458, 1409, 940 Yes 
T12-H2-D1 1683, 1406, 1272 1887, 2487, 1460, 1435, 941 Yes 
T12-H3-D1 1684, 1404, 1248 1946, 2533, 1461, 1426, 940 Yes 
T12-H4-D1 1686, 1405, 1297, 1232 1897, 2267, 1230, 1435, 941 Yes 
T12-H5-D1 1686, 1427, 1408, 1279 1461, 1430, 938, 1890, 2325 (Only 
XB) 
No (only binary XB) 
T12-H6-D1 1657, 1421, 1270 2366, 1966, 1522, 1467, 1424 Yes 
T12-H7-D1 1693, 1433 2492, 1920, 1672, 1568, 1450 Yes 
T12-H8-D1 1682, 1406, 1301 2357, 1709, 1579, 1409 Yes 
T12-H9-D1 1683, 1407, 1267 2305, 1941, 1681, 1540, 1455 Yes 
T12-H10-D1 1682, 1408, 1250 2396, 1946, 1677, 1492, 1326  Yes 
T12-H11-D1 1695, 1552, 1493, 1457  1463, 1419 (Only XB) No (only binary XB) 
T12-H12-D1 1668, 1592, 1286 1833, 2490 1450, 1412, 1429 Yes 
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T12-H13-D1 1686, 1528, 1351 1458, 938, 1938, 2360 (Only XB) No (only binary XB) 
T12-H14-D1 1685, 1599, 1536, 1275 1960, 2363, 1455, 1424, 940 Yes 
T12-H15-D1 1708, 1650 1946, 2396, 1469, 1417, 941 Yes 
 
 C.4 IR of co-crystals of halogen bond donors    
Table C.4.1 IR analysis of 10 halogen bond donors with 20 carboxylic acids  
Mixture IR bands in 
mixture 
Result Mixture IR bands in 
mixture 
Result 
3N-EB-Suc 2525, 1901 Co-crystal 3N-IB-3OHBA 2363, 1901 Co-crystal 
3N-EB-Adi 2468, 1907 Co-crystal 3N-IB-4OHBA 2485, 1901 Co-crystal 
3N-EB-Sub 2482, 1907 Co-crystal 3N-IB-3AminoBA 2461, 2005 Co-crystal 
3N-EB-Seb 2498, 1889 Co-crystal 3N- IB -4AminoBA 2556, 1898 Co-crystal 
3N-EB-Dod 2351, 1901 Co-crystal 3N- IB -3NitroBA 2476, 1938 Co-crystal 
3N-EB-Fum 2534, 1901 Co-crystal 3N- IB -4NitroBA 2387, 1896 Co-crystal 
3N-EB-Mal 2580, 1938 Co-crystal 3N- IB -BA 2351, 1895 Co-crystal 
3N-EB-Glut 2553, 1920 Co-crystal 3N- IB -4BromoBA 2498, 1895 Co-crystal 
3N-EB-Pim 2537, 1901 Co-crystal 3N- IB -4IodoBA - No co-crystal 
3N-EB-Aze 2510, 1904 Co-crystal 3N- IB -PentaFBA 2333, 1907 Co-crystal 
      
4N-EB-Suc 2504, 1907 Co-crystal 4N-IB-3OHBA 2332, 1904 Co-crystal 
4N-EB-Adi - No co-crystal 4N-IB-4OHBA See below Co-crystal 
4N-EB-Sub - No co-crystal 4N- IB -3AminoBA See below Co-crystal 
4N-EB-Seb - No co-crystal 4N- IB -4AminoBA 2340, 1903 Co-crystal 
4N-EB-Dod - No co-crystal 4N- IB -3NitroBA 2316, 1901 Co-crystal 
4N-EB-Fum 2360, 1895 Co-crystal 4N- IB -4NitrooBA 2364, 1886 Co-crystal 
4N-EB-Mal 2556, 1898 Co-crystal 4N- IB -BA  No co-crystal 
4N-EB-Glut - No co-crystal 4N- IB -4BromoBA  No co-crystal 
4N-EB-Pim - No co-crystal 4N- IB-4IodoBA  No co-crystal 
4N-EB-Aze - No co-crystal 4N- IB -PentaFBA 2345, 1886 Co-crystal 
      
3N-ITFB-Suc - No co-crystal 3N-ITFB:3OHBA - No co-crystal 
3N-ITFB-Adi - No co-crystal 3N-ITFB:4OHBA - No co-crystal 
3N-ITFB-Sub - No co-crystal 3N-ITFB-3AminoBA - No co-crystal 
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3N-ITFB-Seb - No co-crystal 3N-ITFB-4AminoBA - No co-crystal 
3N-ITFB-Dod - No co-crystal 3N-ITFB-3NitroBA - No co-crystal 
3N-ITFB-Fum - No co-crystal 3N-ITFB-4NitrooBA - No co-crystal 
3N-ITFB-Mal - No co-crystal 3N-ITFB-BA - No co-crystal 
3N-ITFB-Glut - No co-crystal 3N-ITFB-4BromoBA - No co-crystal 
3N-ITFB-Pim - No co-crystal 3N-ITFB-4IodoBA - No co-crystal 
3N-ITFB-Aze - No co-crystal 3N-ITFB-PentaBA - No co-crystal 
      
4N-ITFB-Suc - No co-crystal 4N-ITFB-3HydroxyBA - No co-crystal 
4N-ITFB-Adi - No co-crystal 4N-ITFB-4HydroxyBA - No co-crystal 
4N-ITFB-Sub - No co-crystal 4N-ITFB-3AminoBA - No co-crystal 
4N-ITFB-Seb - No co-crystal 4N-ITFB-4AminoBA - No co-crystal 
4N-ITFB-Dod - No co-crystal 4N-ITFB-3NitroBA - No co-crystal 
4N-ITFB-Fum - No co-crystal 4N-ITFB-4NitrooBA - No co-crystal 
4N-ITFB-Mal - No co-crystal 4N-ITFB-BA - No co-crystal 
4N-ITFB-Glut - No co-crystal 4N-ITFB-4BromoBA - No co-crystal 
4N-ITFB-Pim - No co-crystal 4N-ITFB-4IodoBA - No co-crystal 
4N-ITFB-Aze - No co-crystal 4N-ITFB-PentaBA - No co-crystal 
    - No co-crystal 
3N-EB-Suc 2522, 1907 Co-crystal 3N-EB-3HydroxyBA 2364, 1886 Co-crystal 
3N-EB-Adi 2482, 1907 Co-crystal 3N-EB-4HydroxyBA 2498, 1882 Co-crystal 
3N-EB-Sub 2525, 1914 Co-crystal 3N-EB-3AminoBA - No co-crystal 
3N-EB-Seb - No co-crystal 3N-EB-4AminoBA 2369, 1923 Co-crystal 
3N-EB-Dod - No co-crystal 3N-EB-3NitroBA 2354, 1950 Co-crystal 
3N-EB-Fum 2357, 1917 Co-crystal 3N-EB-4NitroBA - No co-crystal 
3N-EB-Mal 2354, 1959 Co-crystal 3N-EB-BA 2559, 1920 Co-crystal 
3N-EB-Glut 2485, 1914 Co-crystal 3N-EB-4BromoBA 2458, 1907 Co-crystal 
3N-EB-Pim 2516, 1920 Co-crystal 3N-EB-4IodoBA 2544, 1920 Co-crystal 
3N-EB-Aze 2366, 1898 Co-crystal 3N-EB-PentaBA 2342, 1932 Co-crystal 
      
4N-EB-Suc 2501, 1969 Co-crystal 4N-EB-3HydroxyBA 2362, 1906 Co-crystal 
4N-EB-Adi 2369, 1929 Co-crystal 4N-EB-4HydroxyBA 2350, 1985 Co-crystal 
4N-EB-Sub 2366, 1926 Co-crystal 4N-EB-3AminoBA 2446, 1956 Co-crystal 
4N-EB-Seb See below Co-crystal 4N-EB-4AminoBA 2544, 2097 Co-crystal 
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4N-EB-Dod 2320, 1932 Co-crystal 4N-EB-3NitroBA 2492, 1947 Co-crystal 
4N-EB-Fum 2498, 1920 Co-crystal 4N-EB-4NitroBA 2562, 1956 Co-crystal 
4N-EB-Mal  Co-crystal 4N-EB-BA 2437, 1959 Co-crystal 
4N-EB-Glut 2372, 1941 Co-crystal 4N-EB-4BromoBA 2550, 1932 Co-crystal 
4N-EB-Pim 2534, 1926 Co-crystal 4N-EB-4IodoBA 2544, 1914 Co-crystal 
4N-EB-Aze 2550, 1920 Co-crystal 4N-EB-PentaBA 2421, 1923 Co-crystal 
      
3N-IEB-Suc   3N-IEB-3HydroxyBA - No co-crystal 
3N-IEB-Adi 2348, 1926 Co-crystal 3N-IEB-4HydroxyBA - No co-crystal 
3N-IEB-Sub - No co-crystal 3N-IEB-3AminoBA - No co-crystal 
3N-IEB-Seb - No co-crystal 3N-IEB-4AminoBA - No co-crystal 
3N-IEB-Dod - No co-crystal 3N-IEB-3NitroBA 2291, 1951 Co-crystal 
3N-IEB-Fum - No co-crystal 3N-IEB-4NitroBA - No co-crystal 
3N-IEB-Mal 2362, 1931 Co-crystal 3N-IEB-BA - No co-crystal 
3N-IEB-Glut - No co-crystal 3N-IEB-4BromoBA - No co-crystal 
3N-IEB-Pim - No co-crystal 3N-IEB-4IodoBA - No co-crystal 
3N-IEB-Aze - No co-crystal 3N-IEB-PentaBA 2505, 1892 Co-crystal 
 - No co-crystal  - No co-crystal 
4N-IEB-Suc - No co-crystal 4N-IEB-3HydroxyBA - No co-crystal 
4N-IEB-Adi - No co-crystal 4N-IEB-4HydroxyBA - No co-crystal 
4N-IEB-Sub - No co-crystal 4N-IEB-3AminoBA - No co-crystal 
4N-IEB-Seb - No co-crystal 4N-IEB-4AminoBA - No co-crystal 
4N-IEB-Dod - No co-crystal 4N-IEB-3NitroBA 2511, 1912 Co-crystal 
4N-IEB-Fum - No co-crystal 4N-IEB-4NitroBA - No co-crystal 
4N-IEB-Mal 2513, 1886 Co-crystal 4N-IEB-BA - No co-crystal 
4N-IEB-Glut - No co-crystal 4N-IEB-4BromoBA - No co-crystal 
4N-IEB-Pim - No co-crystal 4N-IEB-4IodoBA - No co-crystal 
4N-IEB-Aze - No co-crystal 4N-IEB-PentaBA 2483, 1884 Co-crystal 
 
 Ligand Acid Grinded mixtures Co-crystal? 




1653, 1589, 1509, 
1389, 1311 
Co-crystal 




1654, 1507, 1388, Co-crystal 
4N-EB-Seb 1657, 1586, 
1514, 1405, 
1317 




 C.5 IR of co-crystals of urea  










Urea CA U:CA  Urea CmA U:CmA  
1708, 1672 1694 1697 
Co-crystal 
1708, 1672 1732 1701 
Co-crystal 
1587, 1555 1571 1569, 1527 1587, 1555 - 1611, 1554 
1455 1408 1427 1455 1471, 1426 1456 
- 1262 1258 - 1369, 1325 1338, 1304 
1145, 1038 1113, 1094 1142, 1079 1145, 976 1189, 1115 1175, 1127 
976 - 951 1038 - 1024 
- 882 876  961 966 
Urea MA U:MoA  Urea SA U:ScA  
3429, 3333 2989, 2906 3456, 3198 
Co-crystal 
3429, 3333 2956 3464, 3323 
Co-crystal 
2354  2487, 1857 2354  2373, 1908 
1708, 1672 1693 1658 1708, 1672 1678 1615 
1587 - 1580 1587 - - 
1455 1433 1463, 1404 1455 1410, 1459 
- 1300 - - 1306 1326 
1145 1214, 1167 1291, 1162 1145 1197 1197 
976 916 935, 876 976 635 1005 
788, 699 767, 652 747 788, 699 - 906 
Urea FA U:FA  Urea GA U:GA  
3429, 3333  3472, 3218 
Co-crystal 
3429, 3333  3325 
Co-crystal 
2354 2910, 2843 2362, 1869 2354 2911, 2823 2362, 1975 
1708, 1672 1686 1617 1708, 1672 1686 1701, 1623 
1587  1521 1587 1427 1575 
1455 1427, 1405 1460 1455 1332 1463 
- 1350 1300 - 1279, 1222  
 1297, 1232 - 1145 1185 1138 
1145 1186 1146, 1013 976 922 970 
976 923 936 788, 699 680 782 
788, 699 676 773, 621    
Urea AA U:AdA  Urea PA U:PA  
3429, 3333 2950 3472, 3225 
Co-crystal 
3429, 3333  3468, 3210 
Co-crystal 
2354  2389, 1898 2354 2911, 2823 2420, 1889 
1708, 1672 1683 1687, 1636 1708, 1672 1686 1693, 1658 
1587 1461 1563 1587 1427 1572 
1455 1406 1495 1455 1332 1434, 1407 
- 1314 1338 - 1279, 1222 1349, 1264 
1145 1272, 1189 1258, 1182 1145 1185 1189, 1091 
976  971 976 922 976 
788,699 733 731, 680 788, 699 680 778, 615 
Urea SbA U:SbA  Urea AzA U:AzA  
3429, 3333  3338, 3203 
Co-crystal 
3429, 3333  3464, 3222 
Co-crystal 
2354 2934, 2868 2353, 1818 2354 2911, 2823 2483, 1904 
1708, 1672 1684 1702, 1649 1708, 1672 1686 1786, 1657 
1587 1422, 1407 1592 1587 1427 1591, 1435 
1455 1330 1487 1455 1332 1314 
- 1248 1331 - 1279, 1222 1242   
1229 1145 1185 1162 
1145, 976 1187 1186 976 922 983, 904 
788, 699 922 953 788, 699 680 771, 613 
Urea TA U:TA  Urea MeA U:MeA  
1708 1736, 1716 1712 
Co-crystal 
1708, 1672 1686 1709 
Co-crystal 
1587 - 1622 1587  1611 
1301,1252 1219 1300, 1233 1455 1427, 1405 1463 
1038 1085 1098 - 1350 1396 
979 936 976 1145 1186 1194, 1110 
699 685 702 976 923 982 
Urea SeA U:SeA      
3429, 3333  3343, 3206 
Co-crystal 
    
2354 2910, 2843 1830     
1708, 1672 1686 1693, 1650     





Table C.5.2 IR results of grinding experiments for co-crystallizations with aromatic acids. 
1145 1186 1189     










Urea 3HBA U:3HBA  Urea 4HBA U:3HBA  
3429, 3333 3350 3432, 3320 
Co-crystal 
3429, 3333 3368 3421, 3347 
Co-crystal 
2354  2589 2354  2502, 1893 
1708, 1672 1678 1702 1708, 1672 1668, 1606 1663, 1631 
1587 1594 1597 1587 1592 1584 
1455 1459 1452 1455 1446 1467 
- 1226 1269 - 1286 1374, 1254 
1145, 976  1157, 1106 1145, 976  1154 
788, 699 753 751 788, 699 767 841, 743 
Urea 3ABA U:3ABA  Urea 4-ABA U:4ABA  




3429, 3333 3460, 3355 3480, 3362 
Co-crystal 
1672 1622 1619 2354  2549, 1924 
- 1553 1533, 1514 1708, 1672 1658,1623 1618 
- 1386 1378 1587 1597 1588 
 1223 1217 1455 1420 1408 
1145 - 1138 - 1309 1313 
788 786, 757 786, 755 1145, 976 1285 1271, 1166 
699 666 673 788, 699 768 912, 837, 771 
Urea PtA  U:PtA  Urea Py2_CA U:Py2_CA  
3429, 3333   
Co-crystal 
1672  1666 
Co-crystal 
2354 1667 1636 1587, 1455  1582, 1450 
1587 1583 1541  1386 1395 
1455 1399 1370  1309, 1270 1310, 1269 
1145 1268 1286 1145 1152 1152 
976   1038 1052 1049 
788, 699   715 715 715 
   699 698 690 
Urea Py2,3_DCA U:Py2,3_DCA  Urea Py2,5_DCA U:Py2,5_DCA  
1672 2437, 1865 2418, 1865 
Co-crystal 
3429, 3333 1696  
No co-
crystal 
1587, 1455 1711 1716 2354    
1687 1644 1708, 1672 1605 1707  
1576 1298 1587   
1145 1258 109 1455 1451  
1038 1094  - 1241, 1173 1234 
Urea Py2,6_DCA U:SbA  Urea Py3,5_DCA U:Py3,5_DCA  
3429, 3333  2361, 1865 
Co-crystal 
3429, 3333  1721 
No co-
crystal 
2354   2354   
1708, 1672 1697 1687 1708, 1672 1697, 1637 1669 
1587 1637, 1583 1646 1587 1583 1602 
1455  1455 - 1244 1152 
- 1244 1254    








1678 1587 1593 1520  
1596 1596 1455 1453 1453 
1555 1552 1553 
 
1219 1220 
1455 1489 1463 
 
  
1145 1175 1173 Urea 2,5-DHBA U-2,5-DHBA 
































1587 1667 1678 
Co-crystal 
1672 1680, 1605 1680 Co-crystal 
1455 1596 1594 1587, 1455 1479 1587 
 1289 190 1145 1158 1149 








Urea 2NP U:2NP  Urea 3NP U:3NP  
2354   
No co-
crystal  
 1672 1676 
Co-crystal 
1708, 1672  1671 1587 1594 1585 
1587 1583 1584 1455 1463 1477 
1455 1473 1473 1145, 976 1144 1148 
      
1145, 976 1131 1131 788, 699 811, 791 808, 772 
788, 699 868 866 788, 699 811, 791 808, 772 
Urea 4NP U:4NP  Urea 1,2DNB U:1,2DNB  
3429  3120 
Co-crystal  
1672 1526 1674, 1523 
Co-crystal 
1672 1457 1445 1587 1353 1585, 1350 
- 1328 1334 1455 790 1461, 787 
- 1110 1109    
 850, 816 844, 825    
Urea 1,3DNB U:1,3DNB  Urea 1,4DNB U:1,4DNB  
1672 1639, 1611 1596 
Co-crystal 
1672 1548 1602 
Co-crystal 
1587 1521 1504 1587 1526 1545 
1455 1424 
 
1455 1341, 1105 1338  
1326 1336    
Urea 2NBA U:2NBA  Urea 3NBA U:3NBA  









1133, 1290 1145 1257 788 792 789 
Urea 4NBA U:4NBA      
1587 1684, 1599 1680, 1598 
Co-crystal 
   
 1455 1423 1419     
1274 1275    












































Urea His U: His  Urea Arg U: Arg  
1672 1628 1676, 1620 
Co-crystal 
1587 1602 1607 
Co-crystal 
1587 1580 1597 1455 1471 1455 
1455 1453 1463  1344 1327 
 1340 1342 1133 1142 1145 
 1246 1244    
Urea Ala U: Ala  Urea Asp U: Asp  
1587 1586 1581 
No Co-
crystal 
 1504 1509 
No Co-
crystal 
1455 1455 1458 1455 1469 1459 
 1235 1226  1244 1242  
788 781 788 792 789 
 678, 659 680, 659    
Urea Glu U: Glu  Urea Lys U: Lys  
1708 - 1716 
Co-crystal 
1587  1681, 1623 Co-crystal  
1455 - 1462  1574 1583 
- 1255 1256 1455  1450 
- 864 864 1133   
 
Urea Co-former Grounded 
mixture 
Results Urea Co-former Grounded 
mixture 
Results 
Urea Py_NO U: Py_NO  Urea TmPy U: 
TmPy_NO 
 
1672 1649 1615 Co-crystal 1587 1581 1618 Co-crystal 
1587 1592 1597 1455 1472 1451 
1455 1467, 1430 1467  1382,1318 1382, 1310 
 1308 1385 1133 1136 1130 
1145 1211, 1002 1091  1010 1029 
 884 858 803  811 
Urea Py_NNO U: Py_NNO  Urea TmPy_NNO U: 
TmPy_NNO 
 
1587 1588 1662, 1598 Co-crystal  1523 1509 Co-crystal 
1455 1481, 1440 1459  1455 1444, 1427 1459 
 1255 1298  1387, 1333 1242 
1145 1027 1108, 1090  1303  
 859 803 788 1113 789 
788 796 669  864  
Urea BiP_NO U: BiP_NO      
1708 1728 1857, 1666 Co-crystal     
1455 1585, 1530 1576, 1474    
- 1405     
- 1217 1237    
 1074, 988 1176, 1033    





Table C.5.6 IR results of grinding experiments for co-crystallization of nicotinamides. 
 



















Urea IN U:IN  Urea Me_N U:Me_N  
 1660, 1619 1656, 1621 
Co-crystal 
1587 1585 1595 
Co-crystal 
 1550 1550 1555 1548 1558 
1455  1457 1455  1466 
 1407, 1389 1408, 1391 1038 1026 1021 
788  783    
Urea 2Cl_N U:2Cl_N  Urea 6Cl_N U:6Cl_N  







1587 1576 1585  1397 1402 
1455 - 1450 1145 1142 1142 
 1385 1383  1017 1018  
1156 1158 803, 788 807, 783 805, 779 
 1070 1070    







Urea Biu U: Biu  Urea Ur U:Ur  
1672 1569 1695 No co-
crystal 
 





1587 1555 1574 1557 
1455 - 1457 - 1345, 
1297 
1326 
 1406, 1356 1412, --1356 - 1117 1115 
 1221 1218  987 987 
1145  1135    
 761, 708 762, 709    
Urea Ma U: Ma 
 
Urea Glu U: Glu 
 
 1826 1828 Co-crystal 1672  1682, 1630 Co-crystal 
1672 
 









1459  1332 1339 
 1373 1378   1021 
 1134 1140 1145  994 
Urea Im U: Im  Urea Re U: Re  
1672 1649 1647 Co-crystal 1672 1604 1598 Co-crystal 
1587   1587  1578 
1455 1505 1507, 1448 1455 1486 1480 
 1268 1270  1166, 
1143 
1168, 1147 
      
Urea Lut U: Lut  Urea Phen U: Phen  
1672 1691 1683 Co-crystal 1672 1644  Co-crystal 
1587 1596 1627, 1605 1587 1502, 
1420 
1500 
1455 1447  1455  1418 
 1383   1343 1342 




Appendix D - Single Crystal X-ray diffraction data 
 D.1 Chapter 2-Pyrazole target molecules  
D.1.1Experimental details 
All datasets except those previously reported were collected on a Bruker Kappa APEX II system 
using MoKα radiation. Data were collected using APEX25 software. Initial cell constants were 
found by small widely separated “matrix” runs. Data collection strategies were determined using 
COSMO6. Scan speed and scan widths were chosen based on scattering power and peak rocking 
curves. 
The unit cell constants and orientation matrix were improved by least-squares refinement of 
reflections thresholded from the entire dataset. Integration was performed with SAINT7, using this 
improved unit cell as a starting point. Precise unit cell constants were calculated in SAINT from 
the final merged dataset. Lorenz and polarization corrections were applied. Multi-scan absorption 
corrections were performed with SADABS8.  
Data were reduced with SHELXTL9. The structures were solved in all cases by direct methods 
without incident. Except as noted, hydrogen atoms were located in idealized positions and were 
treated with a riding model. All non-hydrogen atoms were assigned anisotropic thermal 
parameters. Refinements continued to convergence, using the recommended weighting schemes. 
 
D.1.2 Hydrogen bond geometries 
Co-crystal D-H...A/A° D-H/ A° H…A// A° D…A// A° D-H…O/ ° 
P1 N1-H1…O17 0.97(3) 1.90(4) 2.862(3) 171.(3) 
 N6-H6…N11 0.88(3) 2.15(3) 3.033(3) 173.(3) 
 N10-H10…O8 0.91(3) 2.03(3) 2.930(3) 169.(3) 
 N15-H15…N2 0.83(3) 2.26(3) 3.087(4) 175.(3) 
P2 N1-H1…O18 0.96(4) 1.82(4) 2.771(3) 170.(3) 
 N6 -H6 …N12 0.92(4) 1.99 (4) 2.903(4) 173.(3) 
 N11- H11… O8 0.91(3) 1.91(3) 2.787(3) 161.(3) 
 N16 -H16 …N2 0.90(3) 2.12(3) 3.014(4) 170.(3) 
P3 N1 -H1… O22 0.95(3) 1.91(3) 2.831(3) 161.(2) 
 N6 -H6 …N16 0.93(3) 2.12(3) 3.041(3) 171.(2) 
 N15- H15 …O8 0.88(3) 2.20(3) 2.866(3) 133.(2) 
 N20 -H20 …N2 0.93(3) 2.07(3) 2.981(3) 168.(3) 
P4 N11 -H11 …O21 0.913(18) 1.937(18) 2.8103(14) 159.7(16) 
 N13 -H13 …N12 0.886(18) 2.045(18) 2.9225(14) 170.2(15) 
327 
 
P7 N1 -H1 …O20 0.91(5) 1.89(7) 2.755(16) 159.(12) 
 N7 -H7 …N13 0.91(5) 2.21(8) 2.946(15) 138.(8) 
 N12 -H12 …O9 0.91(5) 1.86(6) 2.755(15) 168.(12) 
 N18 -H18… N2 0.88(10) 2.06(11) 2.939(15) 174.(9) 
P10 N1 -H1 …N2 0.89(6) 2.19(7) 3.047(9) 163.(13) 
 N7 -H7 …N12 0.91(9) 2.23(10) 3.112(9) 164.(8) 
P11 N1 -H1… N12 0.92(2) 2.13(2) 2.910(2) 142.3(16) 
 N6 -H6 …N2 0.869(19) 2.15(2) 3.0002(19) 166.6(16) 
 
D.1.3 Crystallographic data 
Code P1 P2 P3 P4 P7 P10 P11 










Molecular weight 125.14 139.16 187.20 306.37 306.37 3 202.22 
37.35 
188.19 












Crystal system Monoclinic orthorhombi
c 
orthorhombic monoclinic Monoclinic orthorhomb
ic 
monoclinic 
Space group, Z P2(1)/c, 8 pbca, 16 pbca, 16 C 1 c 1, 4 C-2yc, 4 Pna21, 4 C-2yc, 8 
a, Å 15.212(4) 9.962(4) 10.586(3) 7.570(2) 7.570(2) 21.043(11) 11.261(3) 
b, Å 11.424(3) 10.024(4) 14.558(4) 21.799(6) 21.799(6) 8.832(5) 11.476(3) 
c, Å 7.214(2) 28.792(12) 25.523(7) 10.659(3) 10.659(3) 5.500(3) 13.654(3) 
α, º 90.00 90.00 90.00 90 90.00 90.00 90 
β, º 102.42(2) 90.00 90.00 108.247(17) 108.247(17) 90.00 103.67(2) 
γ, º 90.00 90.00 90.00 90 90.00 90.00 90 
Volume, Å3 1224.3(6) 2875.(2) 3933.4(19) 1670.5(8) 1670.5(8) 1022.2(10) 1714.5(7) 
Density, g/cm3 1.358 1.286 1.265 1.218 1.218 1.426 1.458 
T, ºK 296(2) 296 (2) 200 (2) 130(2) 120(2) 180.(2) 130(2) 
Crystal size, 















X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.100 0.092 0.086 0.086 0.086 0.091 0.102 
Trans min / max 0.97/0.99 0.97, 0.99 0.97/0.99 0.98, 0.99 0.98/ 0.99 0.96/ 0.99 0.96/0.99 
θmin, º 2.25 2.83 2.50 1.87 1.87 1.94 2.57 
θmax, º 21.98 21.20 22.05 25.39 25.39 25.30 24.88 
Reflections        
collected 30410 30040 69812 1523 1523 23993 21370 
independent 2263 2543 3486 998 1523 1800 1565 
observed 1384 1534 2093 219 998 1184 1260 
Rint 0.1016 0.1286 0.1294 0.1197 0.0000 0.4966 0.0487 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 181 200 270 219 219 145 135 
No. restraints 0 0 0 5 0 0 0 
R1 (observed) 0.0650 0.0580 0.0518 0.1197 0.1197 0.0883 0.0381 
wR2 (all) 0.1730 0.1555 0.1518 0.2232 0.2557 0.2194 0.1037 
Goodness of fit (all) 1.051 1.034 1.037 1.075 1.075 0.976 1.073 






Completeness to 2θ 
limit 
0.972 0.993 0.988 0.989 0.989 0.976 0.987 
 





P2-Fum P2-Suc P2-Adi P2-Pim P3-3NitroBA P3-4-amino 
BA 
Formula moiety C7 H F5 O2, C5 





(C6 H9 N3 O)2 
(C6 H10 O4) 
(C6 H9 N3 O)2 
(C7 H12 O4) 
C7 H5 N O4, C6 
H9 N3 O 
C6 H9 N3 O, 
C7 H7 N O2 
Empirical formula C12 H8 F5 N3 O3 C16 H22 N6 O6 C16 H24 N6 O6 C18 H28 N6 O6 C19 H30 N6 O6 C13 H14 N4 O5 C13 H16 N4 
O3 
Molecular weight 337.21 394.40 396.41 424.46 438.49 306.28 276.30 








Crystal system monoclinic Triclinic Triclinic Monoclinic monoclinic Monoclinic orthorhombic 
Space group, Z P2(1)/c, 4 Pī, 4 Pī, 1 P2(1)/n, 2 'C 2/c', 4 P21/n, 4 P b c a, 8 
a, Å 7.729(2) 10.649(2) 14.103(3) 5.2338(5) 14.1481(9) 8.484(4) 13.764(6) 
b, Å 14.281(4) 14.078(3) 16.797(4) 13.6144(12) 13.1406(9) 11.985(6) 8.082(3) 
c, Å 11.865(3) 13.409(3) 20.357(5) 14.8734(14) 12.4456(8) 14.344(7) 24.375(10) 
α, º 90 90.00 94.460(3) 90.00 90 90.00 90.00 
β, º 93.293(14) 112.837(19) 90.011(3) 100.113(3) 99.494(2) 106.86(3) 90.00 
γ, º 90 90.00 93.296(4) 90.00 90 90.00 90.00 
Volume, Å3 1307.5(6) 1852.6(7) 4800(2) 1043.34 (17) 2282.1(3) 1395.8(11) 2711.5(19) 
Density, g/cm3 130.(2) 1.414 1.371 1.351 1.276 1.457 1.354 
T, ºK 130.(2) 120(2) 120(2) 120(2) 120(2) 130.(2) 130.(2) 
Crystal size, min x 
mid x max 
0.14 x 0.37 x 0.54 0.18 x 0.24 x 
0.28 
0.12 x 0.30 x 
0.42 
0.12 x 0.26 x 
0.46 
0.20 x 0.24 x 
0.32 
0.08 x 0.26 x 
0.29 
0.10 x 0.16 x 
0.27 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 0.71073 0.7107 0.7107 
µ, mm-1 0.170 0.110 0.107 0.103 0.096 0.114  





0.9542/ 0.9878 0.681/ 0.981 0.97 / 0.99 0.97 / 0.99 
θmin, º 2.64 2.08 6.13 3.16 2.129 2.26 2.23 
θmax, º 25.88 32.07 30.15 31.39 31.081 26.02 22.76 
Reflections        
collected 35456 23564 122238 12032 7114 13782 55537 
independent 2568 5910 27543 3334 7114 2167 2543 
observed 2183 3947 14260 2570 5633 1507 1725 
Rint 0.0209 0.0307 0.0991 0.0354 0.0360 0.0725 0.0409 
Threshold 
expression 
> 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 221 275 1261 147 153 212 202 
No. restraints 0 0 0 0 0 0 1 
R1 (observed) 0.0395 0.0532 0.1017 0.0463 0.1495 0.0816 0.0866 
wR2 (all) 0.0789 0.1763 0.2694 0.1304 0.1747 0.1360 0.1190 
Goodness of fit (all) 1.031 1.185 1.303 1.096 1.138 1.002 1.037 
ρmax, ρmin, e Å−3 0.242, -0.244 0.435, -0.383 1.297, -0.548 0.343, -0.288 0.280, -0.290 0.218, -0.216 0.181, -0.229 
2θ limit, º 26.08 30.00 30.00 31.47 67.50 30.00  
Completeness to 2θ 
limit 
0.989 0.998 0.980 0.960 0.96 0.789  
 
Code P3-pentafluoroB P4-Fum P4-adi P7-sub P8-Aze P8-sub 
Formula moiety C7 H F5 O2, C6 
H9 N3 O 
C7 H11 N3 O, 
0.5(C4 H4 O4) 
(C12H10N4O) 
(C3H4O4) 
(C6H9N3O)2 (C4 H6 
O4) 
(C11 H11 N3 O),2 C9 
H16 O4 
(C11 H11 N3 O), C8 H14 
O4 
Empirical formula C13 H10 F5 N3 
O3 
C9 H13 N3 O3 C16 H22 N6 O6 C16 H24 N6 O6 C31 H38 N6 O6 C19 H25 N3 O5 
Molecular weight 351.24 211.22 394.40 396.41 590.67 375.42 
Color, Habit  Colorless, 
Rhombohedral 
Colorless, Plate Colorless, Plate Colorless, needles  
Crystal system triclinic Monoclinic Triclinic Triclinic orthorhombic Monoclinic 
Space group, Z P -1, 4 P21/c, 4 Pī, 4 Pī, 1 P c a 21, 4 P21/c, 4 
a, Å 11.563(3) 8.391(3) 10.649(2) 14.103(3) 27.095(5) 9.247(4) 
b, Å 12.171(3) 14.273(5) 14.078(3) 16.797(4) 5.0230(9) 22.132(8) 
c, Å 12.261(3) 9.443(4) 13.409(3) 20.357(5) 22.862(4) 10.159(4) 
α, º 70.680(11) 90 90.00 94.460(3) 90.00 90.00 
β, º 77.235(12) 111.223(19) 112.837(19) 90.011(3) 90.00  
γ, º 62.474(11) 95.615(3) 90.00 93.296(4) 90.00 90.00 
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Volume, Å3 1439.2(5) 1054.2(6) 1852.6(7) 4800(2) 3111.5(10) 1867.3(12) 
Density, g/cm3 1.621 1.331 1.414 1.371 1.261 1.335 
T, ºK 130.(2) 130.(2) 120(2) 120(2) 130.(2) 120(2) 
Crystal size, min x 
mid x max 
0.14 x 0.28 x 
0.436 
0.176 x 0.303 x 
0.458 
0.18 x 0.24 x 
0.28 
0.12 x 0.30 x 
0.42 
0.12 x 0.15 x 0.41 0.12 x 0.32 x 0.42 
X-ray wavelength, Å 0.71073 0.7107 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.158 0.102 0.110 0.107 0.089 0.098 
Trans min / max 0.94/0.98 0.95 / 0.98 0.9698/ 0.9804 
 
0.9566/ 0.9873 0.96/0.99  
θmin, º 2.26 2.60 2.08 6.13 2.33 6.29 
θmax, º 25.68 26.57 32.07 30.15 25.26 30.92 
Reflections       
collected 43427 37645 23564 122238 26807 8600 
independent 5566 11890 5910 27543 6268 4910 
observed 4295 7481 3947 14260 4578 3653 
Rint 0.0326 0.0410 0.0307 0.0991 0.0739  
Threshold 
expression 
> 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 459 548 275 1261 414 257 
No. restraints 2 0 0 0 6 0 
R1 (observed) 0.0367 0.0580 0.0532 0.1017 0.0812 0.0563 
wR2 (all) 0.0961 0.1839 0.1763 0.2694 0.1025  
Goodness of fit (all) 1.029 
 
1.023 1.185 1.303 1.066 1.081 
ρmax, ρmin, e Å−3  0.243, -0.228 0.435, -0.383 1.297, -0.548 0.197, -0.235  
2θ limit, º  30.00 30.00 30.00 26.26  
Completeness to 2θ 
limit 
 0.98 0.998 0.980 0.999  
 
Code P10-Fum P10-Mal P11-Aze P11-Dod 
Formula moiety C10 H10 N4 O, 
C5 H8 O4, H2 O 
C10 H10 N4 O, 
0.5(C4 H4 O4 
2(C9 H8 N4 O), 
C9 H16 O4 
(C9H8N4O) (C12 
H22 O4) 
Empirical formula C15 H20 N4 O6 C12 H12 N4 O3 C27 H32 N8 O6 C21 H30 N4 O5 
Molecular weight 352.35 260.26 564.61 418.49 





Crystal system monoclinic triclinic monoclinic orthorhombic 
Space group, Z P21/c,4 P -1,4 P21/c,4 P n a 21, 8 
a, Å 11.9858(2) 5.44270(10) 16.106(5) 19.5258(4) 
b, Å 13.3594(2) 6.8606(2) 17.267(5) 5.14640(10) 
c, Å 10.7736(2) 17.4166(4) 10.260(3) 42.2729(10) 
α, º 90 89.5020(10) 90 90 
β, º 90.7100(10) 89.0240(10) 100.303(17) 90 
γ, º 90 70.6290(10) 90 90 
Volume, Å3 1724.97(5) 613.43(3) 2807.3(15) 4247.90(16) 
Density, g/cm3 1.357 1.409 1.336 1.309 
T, ºK 296.(2) 296.(2) 130.(2) 200(2) 
Crystal size, min x 
mid x max 
0.04x 0.050x 
0.050 
0.020x0.05x0.06 0.12X0.24X0.43 0.02 x 0.04 x 0.06 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.899 0.877 0.097 0.776 
Trans min / max 0.96, 0.96 0.95, 0.98 0.96, 0.99 0.65/ 0.98 
θmin, º 3.69 5.08 1.28 2.09 
θmax, º 69.86 69.70 26.63 70.42 
Reflections     
collected 20722 8530 17199 28297 
independent 3229 2170 5122 7413 
observed 2752 1959 3035 6268 
Rint 0.0367   0.0689 
Threshold 
expression 
> 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 251 185 394 573 
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No. restraints 0 1 5 4 
R1 (observed) 0.0376 0.0388 0.0531 0.0522 
wR2 (all) 0.1042 0.1000 0.1236 0.1279 
Goodness of fit (all) 1.051 1.073 0.970 1.057 
ρmax, ρmin, e Å−3 0.357, -
0.0194 
0.219, -0.231 0.290, -
0.380 
0.223, -0.261 
2θ limit, º 30.00 30.00 30.00 30.00 
Completeness to 
2θ limit 





Co-crystal D-H...A/A° D-H/ A° H…A// A° D…A// A° D-H…O/ ° 
P1-PentafluoroBA N1 H1 O8 0.89(2) 1.85(2) 2.7201(18) 166.0(18) 
 N6 H6 O17 0.845(18) 2.005(19) 2.8407(17) 169.7(16) 
 O18 H18 N2 0.93(2) 1.72(2) 2.6522(16) 177.(2) 
P2-Fum N11 H11 O21 0.864(17) 1.896(17) 2.6958(16) 153.3(14) 
 N13 H13 O52 0.902(16) 1.986(16) 2.8829(15) 173.1(14) 
 N31 H31 O41 0.842(17) 1.956(17) 2.7674(16) 161.6(15) 
 N33 H33 O55 0.902(16) 1.955(16) 2.8498(14) 171.7(14) 
 O51 H51 N12 0.989(18) 1.624(19) 2.6106(14) 174.5(15) 
 O54 H54 N32 0.930(19) 1.69(2) 2.6153(14) 173.5(15) 
P2-Suc N11_1 H11_1O26_1 0.88 1.95 2.765(3) 152.4 
 N11_2 H11_2 O26_2 0.88 1.94 2.745(3) 152.3 
 N11_3 H11_3 O26_3 0.88 1.95 2.768(3) 153.7 
 N11_4 H11_4 O26_4 0.88 1.96 2.785(3) 154.8 
 N11_5 H11_5 O26_5 0.88 1.96 2.771(3) 153.6 
 N21_1 H21_1 O16_1 0.88 1.94 2.753(3) 152.3 
 N21_2 H21_2 O16_2 0.88 1.94 2.746(3) 152.1 
 N21_3 H21_3 O16_3 0.88 1.96 2.773(3) 152.6 
 N21_4 H21_4 O16_4 0.88 1.96 2.779(3) 154.3 
 N21_5 H21_5 O16_5 0.88 1.96 2.778(3) 155.0 
 N13_1 H13_1 O32_1 0.88 2.00 2.865(3) 168.7 
 N13_2 H13_2 O32_2 0.88 2.01 2.875(3) 169.5 
 N13_3 H13_3 O32_3 0.88 2.00 2.873(3) 168.2 
 N13_4 H13_4 O32_4 0.88 2.00 2.862(3) 167.4 
 N13_5 H13_5 O32_5 0.88 2.01 2.867(3) 165.5 
 N23_1 H23_1 O35_1 0.88 1.99 2.864(3) 169.4 
 N23_2 H23_2 O35_2 0.88 2.02 2.885(3 169.2 
 N23_3 H23_3 O35_3 0.88 2.01 2.874(3) 168.3 
 N23_4 H23_4 O35_4 0.88 2.00 2.860(3) 165.8 
 N23_5 H23_5 O35_5 0.88 1.99 2.860(3) 169.2 
 O31_1 H31_1 N12_1 0.84 1.80 2.639(3) 176.6 
 O31_2 H31_2 N12_2 0.84 1.80 2.638(3) 176.2 
 O31_3 H31_3 N12_3 0.84 1.80 2.643(3) 176.9 
 O31_4 H31_4 N12_4 0.84 1.80 2.640(3) 176.0 
 O31_5 H31_5 N12_5 0.84 1.82 2.657(3) 177.3 
 O34_1 H34_1 N22_1 0.84 1.80 2.640(3) 177.1 
 O34_2 H34_2 N22_2 0.84 1.79 2.629(3) 175.7 
 O34_3 H34_3 N22_3 0.84 1.82 2.656(3) 177.1 
 O34_4 H34_4 N22_4 0.84 1.80 2.644(3) 176.7 
 O34_5 H34_5 N22_5 0.84 1.80 2.637(3) 175.9 
P2-Adi N11 H11 O21 0.890(18) 1.893(18) 2.7655(14) 166.3(14) 
 N13 H13 O32 0.888(16) 2.039(17) 2.9142(13) 168.3(15) 
 O31 H31 N12 0.930(18) 1.785(18) 2.7134(13) 175.7(16) 
 
P2-Pim O31 H31 N12 0.96(2) 1.80(2) 2.7590(14) 175.1(18) 
 N11 H11 O21 0.883(19) 1.87(2) 2.7419(16) 168.1(18) 
 N13 H13 O32 0.936(19) 1.874(19) 2.8051(14) 172.9(16) 
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P3-3NitroBA O19 H19 N2 0.90(3) 1.74(3) 2.641(3) 173.(3) 
 N6 H6 O18 0.90(3) 1.90(3) 2.789(3) 171.(3) 
 N1 H1 O8 0.96(3) 1.82(3) 2.770(3) 172.(3) 
P3-4-amino BA N1 H1 O8 0.94(3) 1.77(3) 2.714(3) 176.(2) 
 N6 H6 O18 0.95(3) 1.95(3) 2.893(3) 170.(2) 
 O19 H19 N2 0.98(3) 1.68(3) 2.655(2) 174.(3) 
 N20 H20A O18 0.92(3) 2.25(3) 3.127(3) 160.(3) 
P3-pentafluoroB N1 H1 O18 1_565 0.89(2) 1.87(2) 2.755(2) 170.(2) 
 N6 H6 O42 1_465 0.82(2) 2.04(2) 2.849(2) 167.5(19) 
 N11 H11 O8 1_554 0.87(2) 1.87(2) 2.739(2) 173.(2) 
 N16 H16 O28 1_554 0.87(2) 2.03(2) 2.889(2) 170.9(19) 
 O29 H29 N12 1_556 0.96(2) 1.67(2) 2.6272(19) 174.(2) 
 O43 H43 N2 1_645 0.93(2) 1.71(2) 2.6478(19) 178.(2) 
P4-Fum O14 H14 N2 0.92(2) 1.77(2) 2.6882(16) 179.(2) 
 N6 H6 O15 0.916(16) 2.121(16) 3.0229(16) 167.8(15) 
 N1 H1 O10 0.902(19) 1.865(19) 2.7624(17) 173.3(16) 
P4-adi O21 H21 N2 0.90(3) 1.79(3) 2.683(4) 173.(4) 
 O13 H13 O9 0.87(3) 1.77(4) 2.636(4) 175.(6) 
 N7 H7 O20 0.91(4) 2.01(4) 2.909(4) 167.(3) 
 N1 H1 O12 0.88(5) 1.94(5) 2.811(4) 167.(5) 
P5-sub N11H11 O27 0.896(17) 1.908(18) 2.7212(16) 149.9(15) 
 N27H27 O52 0.910(15) 2.024(16) 2.9154(15) 166.1(14) 
 N31H31 O47 0.881(17) 1.924(17) 2.7421(15) 153.8(15) 
 N47H47 O59 0.904(15) 2.086(15) 2.9744(15) 167.1(13) 
 O51H51 N12 0.965(19) 1.756(19) 2.7205(16) 177.7(17) 
 O58H58 N32 0.966(17) 1.756(18) 2.7150(15) 171.6(15) 
P6-Aze N1 H1 O24 0.87(4) 1.89(4) 2.747(5) 165.(5) 
 N7 H7 O43 0.94(4) 2.00(4) 2.940(5) 175.(5) 
 N16 H16 O9 0.89(5) 1.99(5) 2.826(5) 157.(4) 
 N22 H22 O32 0.88(4) 2.11(4) 2.962(5) 165.(5) 
 31 H31 N17 0.81(4) 1.82(4) 2.622(5) 170.(8) 
 O42 H42 N2 0.86(4) 1.79(4) 2.654(5) 176.(6) 
P6-sub N13 H13 O32 0.90(2) 2.00(2) 2.8819(19) 166.0(17) 
 O31 H31 N12 0.92(2) 1.76(2) 2.6757(18) 175(2) 
 O38 H38 O27 0.91(2) 1.77(2) 2.6738(17) 176(2) 
P10-Fum N1 H1 N12 0.92(2) 1.96(2) 2.8701(17) 169.9(17) 
 N7 H7 O16 0.855(18) 2.040(19) 2.8839(16) 168.9(16) 
 O17 H17 N2 0.93(2) 1.72(2) 2.6501(16) 173.(2) 
 O24 H24 O25 0.95(3) 1.63(3) 2.5714(18) 171.(3) 
 O25 H25A O23 0.88(3) 1.91(3) 2.772(2) 168.(3) 
 O25 H25B O9 0.86(3) 1.90(3) 2.7396(17) 165.(3) 
P10-Mal N1 H1 N26 0.90(2) 1.95(2) 2.850(3) 175.(2 
 N6 H6 O29 0.89(2) 2.00(3) 2.882(3) 169.(2) 
 N15 H15 O8 0.92(2) 1.89(2) 2.790(3) 165.(3) 
 N20 H20 O41 0.903(19) 2.03(2) 2.911(3) 166.(2) 
 O30 H30 N2 0.92(2) 1.76(2) 2.673(3) 172.(3) 
 O40 H40 N16 0.92(2) 1.77(2) 2.685(3) 175.(3) 
P11-Aze N1 H1 N26 0.90(2) 1.95(2) 2.850(3) 175.(2) 
 N6 H6 O29 0.89(2) 2.00(3) 2.882(3) 169.(2) 
 N15 H15 O8 0.92(2) 1.89(2) 2.790(3) 165.(3) 
 N20 H20 O41 0.903(19) 2.03(2) 2.911(3) 166.(2) 
 O30 H30 N2 0.92(2) 1.76(2) 2.673(3) 172.(3) 
 O40 H40 N16 0.92(2) 1.77(2) 2.685(3) 175.(3) 
P11-Dod O60 H60 N16 0.81(6) 1.88(6) 2.682(5) 170.(6) 
 O45 H45 N12 0.95(5) 1.77(5) 2.701(5) 165.(5) 
 O43 H43 N26 0.89(7) 1.81(7) 2.695(5) 169.(7) 
 O30 H30 N2 0.89(5) 1.79(6) 2.675(5) 169.(8) 
 N20 H20 O59 0.81(6) 2.35(6) 3.131(5) 164.(6) 
 N17 H17 O44 0.97(5) 1.96(5) 2.801(5) 144.(5) 
 N6 H6 O29 0.81(6) 2.28(7) 3.070(5) 164.(6) 




 D.3 Chapter 4-Thiazole target molecules 
 
Code T2 T4 T6 T10 T11  
Formula moiety C6H8N2OS C7H10N2OS C11H10N2OS C10 H9 N3 O S' C9 H7 N3 O S 
Empirical formula C6H8N2OS C7H10N2OS C11H10N2OS C10 H9 N3 O S' C9 H7 N3 O S 
Molecular weight 156.20 170.23 218.27 219.26 205.24 
Habit, color  Plate, colorless Blocks, colorless Blocks, colorless Plate, yellow  Blocks, colorless  
Crystal system Monoclinic orthorhombic monoclinic monoclinic monoclinic 
Space group, Z P2(1)/c, 4 Ccca, 16 I 1 2/a 1 P21 C 2/c 
a, Å 5.2743(9) 14.260(4) 21.635(6) 3.8482(5) 21.258(12) 
b, Å 10.6364(19) 16.783(5) 3.9315(13) 9.8509(14) 3.7982(19) 
c, Å 12.652(2) 13.999(6) 25.555(10) 12.6883(17) 23.045(12) 
α, º 90.00 90.00 90.00 90 90 
β, º 101.689(4) 90.00 109.975(14) 95.494(7) 115.72(3) 
γ, º 90.00 90.00 90.00 90 90 
Volume, Å3 695.1(2) 3350.(2) 2042.9(12) 478.781 1676.4(1 
Density, g/cm3 1.493 1.350 1.419 1.521 1.626 
T, ºK 120(2) 296 (2) 180 (2) 120(2) 180.(2) 
Crystal size, 
min x mid x max 
0.08X0.20X0.44 0.08X0.18X0.26 0.18X0.33X0.34 0.06x0.18x0.44 0.158x0.378x0.392 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.390 0.330 0.288 0.311 0.349 
Trans min / max 0.8471/0.9695 0.92, 0.97 0.91/0.95 0.875/0.982 0.88, 0.95 
θmin, º 3.29 2.37 1.70 2.62 3.46 
θmax, º 31.95 25.10 25.84 27.28 25.03 
Reflections      
collected 8738 27503 26731 4952 7943 
independent 2191 1498 1951 2543 1473 
observed 1937 910 1679 1930 1173 
Rint 0.0241 0.0973 0.0501 0.0650 0.0754 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 96 106 141 136 131 
No. restraints 0 0 0 1 1 
R1 (observed) 0.0317 0.0568 0.0336 0.0642 0.0934 
wR2 (all) 0.0859 0.1381 0.1018 0.1688 0.2333 
Goodness of fit (all) 1.048 1.071 1.149 0.995 1.221 
ρmax, ρmin, e Å−3 0.363, -0.241 0.176, -0.196 0.313, -0.346 0.676, -0.492 0.748, -0.415 
Completeness to 2θ 
limit 
0.997 1.000 0.990 0.979 0.969 
 
 
Co-crystal D-H...A/A° D-H/ A° H…A// A° D…A// A° D-H…O/ ° 
T2 − () () () () 
T4 − () () () () 
T6 − () () () () 
T10 N12 H12 N21 0.88 2.10 2.946(6) 162.1 
T11 N6 H6 N3 0.84(4) 2.16(4) 2.986(9) 167.(6) 
 
 Chapter 5-Thiazole co-crystals 
 
Code T1-3HydroxyBA T2-4HydroxyBA T4-3NitroBA T8-Suc T8-Sub T8-Seb 
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Empirical formula C12H12N2O4S C13H14N2O4S C14H15N3O5S C26H26N4O6S2 C15H17N2O3S2 C32H38N4O6S2 
Molecular weight 280.30 294.32 337.35 554.63 305.37 638.78 
Color, Habit Bronze, Rod Colorless, Plate Colorless, Plate Colorless, Plate Colorless, Plate Colorless, Plate 
Crystal system Monoclinic monoclinic Triclinic Monoclinic Monoclinic Triclinic 
Space group, Z P2(1)/n, 4 P 21/n, 4 Pī, 2 P 21/c,2 P2(1)/n, 4 P-1, 2 
a, Å 12.482(6) 8.4638(16) 7.845(3) 11.0595(16) 15.206(2) 8.529(2) 
b, Å 5.082(3) 4.9284(9) 9.389(4) 6.7428(10) 5.7250(8) 8.887(2) 
c, Å 19.848(9) 32.056(6) 12.093(5) 17.931(3) 17.016(3) 11.214(3) 
α, º 90.00 90 98.623(13) 90 90.00 77.662(6) 
β, º 101.265(9) 94.963(7) 106.647(13) 107.426(4) 90.591(7) 76.190(6) 
γ, º 90.00 90 107.590(13) 90 90.00 89.982(6) 
Volume, Å3 1234.6(10) 1332.1(4) 785.7(6) 1275.8(3) 1481.2(4) 805.2(3) 
Density, g/cm3 1.508 1.468 1.426 1.444 1.369 1.373 
T, ºK 120(2) 120(2) 130.(2) 120(2) 120(2) 120 (2) 
Crystal size, 
min x mid x max 
0.08X0.14X0.38 0.100X0.24X0.48 0.12x0.22x0.22 0.08X0.38X0.42 0.12X0.38X0.44 0.14X0.38X0.46 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.274 0.258 0.235 0.259 0.230 0.215 
Trans min / max 0.9029/ 0.9784 0.746/0.975 0.95/ 0.97 0.906/0.980 0.91/0.97 0.911/0.983 
θmin, º 3.33 2.444 2.36 1.930 2.39 2.35 
θmax, º 30.98 30.848 25.35 32.618 31.44 31.11 
Reflections       
collected 18533 14370 11385 30608 16744 13784 
independent 3784 4023 2907 4371 4618 4861 
observed 3066 3313 2454 3940 3646 4161 
Rint 0.0479 0.0387 0.0384 0.0249 0.0328 0.0398 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 182 192 218 179 197 206 
No. restraints 0 0 0 0 1 0 
R1 (observed) 0.0415 0.0445 0.0344 0.0331 0.0431 0.0554 
wR2 (all) 0.1107 0.1247 0.0904 0.0934 0.1255 0.1639 
Goodness of fit (all) 1.124 1.023 1.051 1.044 1.077 1.270 
ρmax, ρmin, e Å−3 0.472, -0.368 0.595, -0.370 0.268,-0.231 0.463, -0.217 0.480, -0.321 0.738, -0.445 
Completeness to 2θ 
limit 
0.986 0.984 0.970 0.988 0.929 0.987 
 
Code T8-Aze T8-Dod T11-Sub T12-adi  T9-
3HydroxyBA 
T12-Suc T12-Dod 










(C10 H9 N3 O 
S) (C4 H6 O4) 




C31H36N4O6S2 C17H21N2O3S C13H14N3O3S C16H19N3O5S C16H13N3O4S C14 H15 N3 
O5 S 




624.76 333.42 292.33 365.40 343.35 337.35 449.56 










Bronze, prism  Colorless, 
needles  
Crystal system Monoclinic Triclinic Monoclinic Monoclinic Monoclinic monoclinic monoclinic 
Space group, Z Cc, 4 P-1, 2 P21/n P21/c P21/n P 21/n, 4 P21/c,  
a, Å 36.965(3) 8.8618(10) 14.1486(3) 12.429(5) 8.362(3) 4.9540(8) 19.249(11) 
b, Å 5.0868(4) 10.0557(11) 5.35660(10) 19.565(7) 7.421(3) 15.979(3) 5.092(3) 
c, Å 16.1184(12) 11.7950(13) 18.7308(4) 7.212(2) 24.785(8) 19.468(3) 23.614(14) 
α, º 90.00 113.637(4) 90 90 90 90 90 
β, º 94.167(3) 94.054(4) 109.0480(10) 104.506(16) 95.097(17) 93.103(5) 107.475(12) 
γ, º 90.00 112.682(4) 90 90 90 90 90 
Volume, Å3 3022.8(4) 856.28(17) 1341.85(5) 1697.9(10) 1531.9(9) 1538.9(4) 2208(2) 
Density, g/cm3 1.508 1.293 1.447 1.429 1.489 1.456 1.353 






















0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.227 0.205 0.71073 0.224 0.238 0.240 0.186 
Trans min / max 0.904/ 0.969 0.92/0.97 0.58, 0.88 0.93, 0.98 0.89, 0.93 0.906, 0.972 0.916, 0.985 
θmin, º 2.210 2.34 3.43 2.68 2.51 2.45  
θmax, º 32.030 31.01 70.01 25.70 25.82 31.61  
Reflections        
collected 17769 11911 9188 25849 32415 19679 9292 
independent 8258 5137 2466 3214 2972 4879 5795 
observed 7484 4198 2410 2668 2562 4091 4000 
Rint 0.0294 0.0236 0.0349  
0.0462 
0.0404 0.0329 0.0364 
Threshold 
expression 
> 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 402 217 190 239 229 218 290 
No. restraints 0 0 0 0 2 0 0 
R1 (observed) 0.0417 0.0479 0.0355 0.035 0.0545 0.0375 0.0524 
wR2 (all) 0.0959 0.1448 0.0888 0.0847 0.1049 0.1057 0.1623 
Goodness of fit 
(all) 
1.008 1.056 1.098 1.044 1.190 1.079 0.972 




0.382, -0.286 0.659, -0.529 
Completeness to 
2θ limit 
0.976 0.939 0.965 0.989 0.889 0.901  
 
Co-crystal D-H...A/A° D-H/ A° H…A// A° D…A// A° D-H…O/ ° 
T1-3HydroxyBA − () () () () 
 − () () () () 
 −  () () () () 
T2-4HydroxyBA − ( () () () 
 − ( () ( () 
 − () () ( () 
T4-3NitroBA − () () () () 
 − () () () () 
T8-Suc − () () () () 
 − () () () () 
T8-Sub − () () () () 
 − () () () () 
T8-Seb − () () () () 
 − () () () ( 
T8-Aze − () () () () 
 − () () () () 
 − () () () () 
 − () () () () 
T8-Dod − () () () () 
 − () () () () 
T12-Suc N12 H12 O32   0.851(15) 2.020(15) 2.8620(13) 169.8(14) 
 O31 H31 N13   0.900(18) 1.761(18) 2.6589(14) 176.3(17) 
 O34 H34 N21   0.918(17) 1.762(17) 2.6795(13) 178.4(15) 
T12-Dod N12 H12 O32   0.85(2) 2.10(2) 2.931(2) 168(2) 
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 O31 H31 N13   0.89(3) 1.75(3) 2.633(2) 173(2) 
 O42 H42 N21   0.86(3) 1.87(3) 2.697(2) 163(2) 
 
 D.4 Chapter 7 (ternary) 
Code T10-D1 T12-D1 T11-H10-D1 T11-D1 
Formula moiety C10H9N3OS, 0.5(C6F4I2) C10 H9 N3 O S, 
0.5(C6 F4 I2)' 
 
C27 H27 F3 I1.50 
N4.50O4.50 S1.50 
C9 H7 N3 O S, 0.5(C6 F4 I2 
Empirical formula C13H9F2IN3OS C13 H9 F2 I N3 O S' C27 H27 F3 I1.50 
N4.50O4.50 S1.50 
C12 H7 F2 I N3 O S 
Molecular weight 420.19 420.19 781.97 406.17 
Color, Habit Colorless, rectangular Colorless, 
Parallelepiped 
Colorless, blocks Colorless, plates 
Crystal system Triclinic Triclinic triclinic monoclinic 
Space group, Z P-1, 2 P-1, 2 P -1, 4 P21/n, 4 
a, Å 4.8363(5) 6.4078(7) 14.350(3) 9.334(3) 
b, Å 9.6588(10) 8.7487(9) 14.558(4) 7.392(3) 
 
c, Å 15.5868(16) 13.1516(14) 
 
15.377(3) 19.794(8) 
α, º 92.7220(10) 93.4920(10) 71.972(5) 90 
β, º 96.3790(10) 92.6420(10) 74.463(6) 102.19(2) 
γ, º 91.0120(10) 103.0880(10) 80.417(6) 
 
90 
Volume, Å3 722.59(13) 715.43(13) 2925.9(10) 1334.9(8) 
Density, g/cm3 1.931 1.951 1.775 2.021 
T, ºK 228 (2) 228.(2) 130.(2) 130.0(2) 
Crystal size, 
min x mid x max 
0.128X0.208X0.278 0.120x0.220x0.450 0.07x0.228x0.272 0.128x0.298x0.332 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 0.100 2.407 1.792 2.577 
Trans min / max 0.97/0.99 0.41, 0.76 0.64, 0.89 0.48, 0.73 
θmin, º 2.25 2.40  2.26 
θmax, º 21.98 32.93  25.60 
Reflections     
collected 30410 9970 57433 2535 
independent 2263 5074 11979 2535 
observed 1384 4333 3846 2217 
Rint 0.1016 0.0287 0.0527 0.00 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 181 195 781 185 
No. restraints 0 1 6 1 
R1 (observed) 0.0650 0.0641 0.0938 0.2210 
wR2 (all) 0.1730 0.0689 0.1604 0.2369 
Goodness of fit (all) 1.051 1.028 0.803 1.198 
ρmax, ρmin, e Å−3 0.215,-0.241 0.765, -0.987 0.690, -0.886 3.143, -2.549 
Completeness to 2θ limit 0.972 0.913 0.985 0.975 
 
Co-crystal D-H...A/A° D-H/ A° H…A// A° D…A// A° D-H…O/ ° 
37-D7 N7 H7 N5 0.82(2) 2.12(2) 2.942(3) 179.(3) 
38-D4 N7 H7 N5 0.82(2) 2.12(2) 2.936(2) 169.(3) 
BS1603 N6 H6 O43 0.81(4) 2.10(4) 2.891(7) 165.(7) 
 N20 H20 O60 0.80(3) 2.14(4) 2.892(8) 156.(6) 
 N34 H34 O57 0.90(4) 1.98(4) 2.866(8) 168.(7) 
 O44 H44 N5 0.84(4) 1.84(4) 2.673(8) 175.(6) 
 O58 H58 N33 0.85(5) 1.80(5) 2.646(8) 171.(10) 
 O59 H59 N19 0.84(5) 2.16(14) 2.662(7) 118.(14) 
BS1615 N6 H6 N3 0.88(5) 2.13(5) 2.99(10) 165.(8) 




 D.5 Chapter 8 (Activated halogens) 
 
 
Code 3N-ITFB 3N-EB:Fum 3N-EB 4N-EB 
Formula moiety C12H5F4IN2O C16 H12 N2 O3.50 C14 H10 N2 O C14 H10 N2 O 
Empirical formula C12 H5 F4 I N2 O C16 H12 N2 O3.50 C14 H10 N2 O' C14 H10 N2 O 
Molecular weight 396.08 288.28 222.24 222.24 
Color, Habit Colorless, blocks  Yellow, needles Yellow, blocks 
Crystal system orthorhombic monoclinic monoclinic monoclinic 
Space group, Z P 21 21 21, 4 P 1 21/c, 4 C 1 2/c, 8 P 1 21/n, 4 
a, Å 4.8009(17) 8.444(3) 25.764(5) 15.117(4) 
b, Å 9.695(3) 9.231(3) 5.3338(9) 5.2846(15) 
c, Å 26.315(9) 17.275(7) 16.701(3) 16.102(4) 
α, º 90 90 90 90 
β, º 90 97.74(2) 103.011(14) 114.406(9) 
γ, º 90 90 90 90 
Volume, Å3 1224.8(7) 1334.3(8) 2236.1(8) 1171.4(6) 
Density, g/cm3 2.148 1.435 1.320 1.260 
T, ºK 293(2) 130.(2) 296.(2) 296.(2) 
Crystal size, 
min x mid x max 
 0.114x0.228x0.402 0.135x0.262x0.324 0.126x0.194x0.261 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 2.661 0.103 0.085 0.082 
Trans min / max  0.96, 0.99 0.97, 0.99 0.98, 0.99 
θmin, º 2.239 2.38 2.5033 2.41 
θmax, º 25.996 26.13 24.7894 25.04 
Reflections     
collected 21062 32167 14333 21569 
independent 2380 2641 2010 2067 
observed 2225 1995 1488 1145 
Rint  0.0609 0.0508 0.0972 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 182 204 158 158 
No. restraints  1 0 0 
R1 (observed)  0.0546 0.0450 0.0605 
wR2 (all)  0.1704 0.1298 0.1686 
Goodness of fit (all)  1.045 1.042 1.020 
ρmax, ρmin, e Å−3  1.367, -0.241 2.5033, 24.7894 0.144, -0.186 
Completeness to 2θ limit  0.989 0.982 1.020 
 
Code 3N-IB 4N-ITFB 3N-IEB 3N-IB: Sub 
Formula moiety C12 H9 I N2 O C12H5F4IN2O C14H9IN2O C10 H9 N3 O S, 
C7 H6 O3 
Empirical formula C12 H9 I N2 O C12H5F4IN2O C14H9IN2O C17 H15 N3 O4 S' 
Molecular weight 324.11 396.08 348.13 357.38 
Color, Habit Colorless, blocks Colorless, blocks  Colorless, plate 
Crystal system monoclinic triclinic monoclinic monoclinic 
Space group, Z C 1 2/c, 8 'P -1, 6 Pc, 2 P 1 21/n, 4 
a, Å 19.262(4) 10.377(4) 11.5898(6) 20.9506(4) 
b, Å 5.3201(10) 13.547(5) 6.1640(3) 3.78608(5) 
c, Å 22.246(4) 14.302(6) 9.1027(6) 22.5283(4) 
α, º 90 93.78(2) 90 90 
β, º 95.545(10) 92.66(2) 99.225(6) 112.879(2) 
γ, º 90 103.28(2) 90 90 
Volume, Å3 2269.0(8) 1948.7(13) 641.88(6) 1646.36(5) 
 
Density, g/cm3 1.898 2.025 1.801 1.442 
337 
 
T, ºK 296.(2) 130(2) 296(2) 100.00(10) 
Crystal size, 
min x mid x max 
0.077x0.232x0.303 0.056x0.228x0.494  0.06x0.176x0.182 
X-ray wavelength, Å 0.71073 0.71073 0.71073 0.71073 
µ, mm-1 2.801 2.509 2.483 2.003 
Trans min / max 0.48, 0.81 0.370, 0.872  1.000, 0.570 
θmin, º 2.67 1.430 4.237 4.2670 
θmax, º 24.24 25.500 32.635 73.4990 
Reflections     
collected 18437 40986 7187 7722 
independent 2185 6952 3841 2846 
observed 1602 1904 3367 2994 
Rint 0.0468 0.1431 0.0249 0.0198 
Threshold expression > 2σ(I) > 2σ(I) > 2σ(I) > 2σ(I) 
No. parameters 149 231 164 230 
No. restraints 1 0 2 0 
R1 (observed) 0.0337 0.1201 0.0301 0.0833 
wR2 (all) 0.0693 0.3896 0.0649 0.0843 
Goodness of fit (all) 1.053 0.964 1.034 1.090 
ρmax, ρmin, e Å−3 0.425, -0.709 3.142, -3.405 0.681, -0.428 0.250, -0.245 
Completeness to 2θ limit 0.995 0.959 0.918 0.997 
 
 
Co-crystal D-H...A/A° D-H/ A° H…A// A° D…A// A° D-H…O/ ° 
3N-EB:Fum O19 H19 N4 0.94(3) 1.68(3) 2.599(2) 163.(3) 
 N9 H9 O18 0.91(3) 2.43(3) 3.326(3) 170.(2) 
3N-IB: Sub N9 H9 O11 0.85(2) 2.33(2) 3.135(2) 157.6(16) 
4N-EB N9 H9 O8 0.88(3) 2.26(3) 3.096(3) 157.(2) 
 C17 H17 N4 0.93 2.44 3.352(5) 166.7 
3N-IB N9 H9 O8 0.80(3) 2.37(3) 3.145(4) 162.(4) 
3N-IEB N1 H1N O1 0.84 2.08 2.921(5) 175.6 
 C7 H7 O1 0.93 2.42 2.900(6) 112.3 
 C13 H12 I1 0.93 3.17 3.889(5) 135.9 
 C14 H14 O1 0.93 2.50 3.255(6) 138.9 
 
Appendix E- Hydrogen-bond energies of co-crystal synthons 
 E.1 Molecular electrostatic potentials for 20 acids  
Table E.1.1 Electrostatics (in kJ/mol) and alpha ranked as (I) and (II) and beta ranked as (I) and 
(II) values for aliphatic acids calculated using equations 1 and 2 for donor and acceptor group. 
Each aliphatic acid has two acceptors; C=O ranked as (I) and (II) and two donors; O-H ranked as 









Alpha(2) beta(2) Eacid1 Eacid2 
Succinic -177.00 306.00 -131.00 283.00 4.46 6.22 4.02 3.72 27.75 14.97 
Adipic -157.00 268.00 -157.00 263.00 3.74 5.06 3.65 5.06 18.93 18.47 
Suberic -164.00 264.00 -164.00 262.00 3.67 5.45 3.63 5.45 20.00 19.80 
Sebacic -186.00 294.00 -161.00 261.00 4.23 6.78 3.61 5.28 28.67 19.09 
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Fumaric -162.00 282.00 -159.00 270.00 4.00 5.34 3.78 5.17 21.36 19.53 
Malonic -154.00 286.00 -154.00 284.00 4.08 4.89 4.04 4.89 19.95 19.77 
Glutaric -162.00 272.00 -153.00 265.00 3.82 5.34 3.69 4.84 20.37 17.85 
Pimelic -167.00 261.00 -164.00 260.00 3.61 5.62 3.60 5.45 20.33 19.61 
Azelaic -169.00 262.00 -160.00 258.00 3.63 5.74 3.56 5.23 20.86 18.60 
Dodeca -197.00 296.00 -164.00 260.00 4.27 7.50 3.60 5.45 31.99 19.61 
 
Table E.1.2 Electrostatics (in kJ/mol) and alpha ranked as (I) and (II) and beta ranked as (I) and 
(II) values for aromatic acids calculated using equations 1 and 2 for donor and acceptor group. 
Each aliphatic acid has two acceptors; C=O ranked as (I) and O(OH)/N(NH2) ranked as (II) and 




C=O (I) β (I) OH (I) α (I) O(OH) β (II) OH/NH2 
(II) 
α (II) 
3HydroxyBA -154 4.89 267 3.72 -116 3.04 276 3.89 
4HydroxyBA -169 5.74 255 3.51 -106 2.62 297 4.28 
3AminoBA -168 5.68 251 3.44 -117 3.08 203 2.62 
4AminoBA -184 6.65 236 3.17 -98 2.31 222 2.93 
3NitroBA -138 4.06 299 4.32 
    
4NitroBA -126 3.49 304 4.42 
    
BA -162 5.34 245 3.33 
    
4BromoBA -152 4.79 275 3.87 
    
4IodoBA -152 4.79 274 3.85 
    
PentafluroBA -136 3.97 305 4.44 




 E.2 Chapter-3: Pyrazole heteromeric interactions 
Table E.2.1 Hydrogen bond energies (kJ/mol) of synthon I in P1-P12 aliphatic acid co-crystals   
    
synthon I 
      
 
SUC ADI SUB SEB FUM MAL GLU PIM AZE DOD 
P1 34.02 36.79 37.21 36.74 38.57 36.61 36.98 37.50 37.63 35.84 
P2 34.86 37.40 37.73 37.21 39.27 37.50 37.65 38.05 38.10 36.35 
P3 34.14 36.85 37.25 36.77 38.65 36.74 37.06 37.55 37.66 35.88 
P4 35.52 38.02 38.33 37.78 39.94 38.21 38.29 38.66 38.68 36.93 
P5 34.08 36.74 37.12 36.63 38.54 36.67 36.95 37.42 37.52 35.75 
P6 35.15 37.61 37.91 37.37 39.50 37.81 37.87 38.24 38.25 36.52 
P7 33.82 36.59 37.02 36.55 38.36 36.40 36.78 37.30 37.44 35.65 
P8 34.86 37.40 37.73 37.21 39.27 37.50 37.65 38.05 38.10 36.35 
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P9 31.42 34.13 34.58 34.16 35.75 33.81 34.28 34.83 35.01 33.29 
P10 30.67 33.40 33.86 33.46 34.97 33.01 33.53 34.10 34.30 32.60 
P11 32.85 35.35 35.70 35.22 37.09 35.34 35.56 35.99 36.07 34.39 
P12 31.63 34.23 34.63 34.19 35.88 34.04 34.40 34.90 35.03 33.35 
 
Table E.2.2 Hydrogen bond energies (kJ/mol) of synthon I in P1-P12 aromatic acid co-crystals   



















P1 31.32 29.34 29.13 26.79 32.23 31.68 29.09 31.93 28.79 34.14 31.31 29.15 
P2 32.26 30.21 29.96 27.53 33.65 33.22 29.82 32.96 30.00 35.54 32.53 29.99 
P3 31.47 29.48 29.27 26.91 32.50 31.98 29.20 32.10 29.01 34.40 31.53 29.28 
P4 32.93 30.84 30.57 28.09 34.50 34.11 30.40 33.67 30.74 36.41 33.31 30.61 
P5 31.45 29.46 29.23 26.88 32.54 32.05 29.15 32.09 29.05 34.43 31.55 29.25 
P6 32.59 30.52 30.25 27.80 34.16 33.77 30.08 33.32 30.44 36.05 32.97 30.29 
P7 31.12 29.16 28.96 26.63 32.00 31.44 28.91 31.72 28.59 33.90 31.09 28.97 
P8 32.26 29.96 29.96 27.53 33.65 33.22 29.82 32.96 30.00 35.54 32.53 29.93 
 29.68±0.60 32.10±0.83   
P9 28.83 26.84 26.84 24.69 29.42 28.84 26.85 29.35 26.31 31.22 28.66 26.80 
P10 28.10 26.18 26.18 24.08 28.55 27.95 26.20 28.58 25.55 30.33 27.86 26.13 
P11 30.34 28.19 28.19 25.92 31.48 31.02 28.09 30.97 28.09 33.29 30.49 28.16 
P12 29.10 27.08 27.08 24.90 29.91 29.39 27.04 29.66 26.72 31.69 29.07 27.04 
 27.03±0.84 29.02±1.10   
Table E.2.3 Hydrogen bond energies (kJ/mol) of synthon II in P1-P12 aliphatic acid co-crystals   
 
 
    
synthon II 
      
 
SUC ADI SUB SEB FUM MAL GLU PIM AZE DOD 
P1 30.05 32.07 32.30 31.82 33.70 32.32 32.31 32.58 32.57 31.12 
P2 31.49 33.40 33.56 33.04 35.14 33.86 33.68 33.88 33.80 32.35 
P3 30.12 32.08 32.28 31.79 33.72 32.40 32.33 32.57 32.53 31.10 
P4 31.93 33.75 33.88 33.33 35.53 34.33 34.06 34.21 34.09 32.66 
p5 30.55 32.55 32.75 32.26 34.21 32.86 32.80 33.05 33.01 31.56 
P6 32.03 33.90 34.04 33.50 35.68 34.44 34.20 34.37 34.27 32.81 
P7 28.71 30.52 30.69 30.22 32.10 30.88 30.77 30.98 30.93 29.58 
P8 30.21 31.88 31.98 31.46 33.57 32.48 32.18 32.30 32.17 30.83 
P9 27.83 29.87 30.13 29.72 31.35 29.94 30.06 30.39 30.43 29.03 
P10 27.08 29.13 29.42 29.02 30.57 29.14 29.31 29.66 29.72 28.34 
P11 28.64 30.35 30.49 30.01 31.94 30.79 30.61 30.78 30.70 29.39 
P12 28.18 30.13 30.36 29.92 31.65 30.31 30.34 30.62 30.63 29.25 
Table E.2.4 Hydrogen bond energies (kJ/mol) of synthon II in P1-P12 aromatic acid co-crystals   
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Synthon II 
    
 
3-hydroxy 4-hydroxy 3-amino 4-amino 3-nitro 4-nitro ba 4-bromo 4iodo pentaF 
P1 27.91 26.14 25.89 23.79 29.39 29.10 25.72 28.56 26.17 30.98 
P2 29.37 27.50 27.21 24.99 31.23 31.03 26.97 30.10 27.78 32.86 
P3 28.03 26.24 25.98 23.87 29.62 29.36 25.79 28.70 26.36 31.20 
P4 29.85 27.95 27.64 25.38 31.93 31.77 27.36 30.63 28.37 33.55 
P5 28.42 26.61 26.35 24.21 30.01 29.75 26.16 29.10 26.72 31.62 
P6 29.91 28.01 27.70 25.44 31.92 31.74 27.44 30.68 28.37 33.56 
P7 26.74 25.04 24.79 22.77 28.34 28.12 24.59 27.39 25.21 29.84 
P8 28.27 26.47 26.17 24.02 30.32 30.19 25.89 29.02 26.93 31.84 
 26.52±1.00 24.37±0.96 
P9 25.75 24.12 23.91 21.98 26.85 26.50 23.81 26.31 23.94 28.36 
P10 25.02 23.44 23.25 21.37 25.98 25.62 23.16 25.54 23.18 27.47 
P11 26.73 25.02 24.76 25.31 28.46 28.29 24.53 27.40 25.31 29.94 
P12 26.14 24.48 24.26 24.44 27.44 27.14 24.12 26.74 24.44 28.95 
 29.15±1.18 26.23±0.91 
Table E.2.5 Hydrogen bond energies (kJ/mol) of synthon III in P1-P12 aliphatic acid co-crystals   
    
Synthon III 
      
 
SUC ADI SUB SEB FUM MAL GLU PIM AZE DOD 
P1 29.41 28.93 28.30 27.51 30.88 31.54 29.57 28.77 27.98 27.35 
P2 30.44 29.29 29.29 28.47 31.96 32.64 30.61 29.78 28.96 28.31 
P3 28.65 26.80 27.56 26.80 30.08 30.72 28.81 28.03 27.25 26.64 
P4 29.67 31.14 28.54 27.75 31.14 31.81 29.83 29.02 28.22 27.59 
p5 29.18 30.63 28.07 27.29 30.63 31.29 29.34 28.54 27.76 27.14 
P6 29.97 31.46 28.83 28.03 31.46 32.13 30.13 29.31 28.51 27.87 
P7 27.65 29.02 26.60 25.86 29.02 29.64 27.80 27.05 26.30 25.71 
P8 28.65 30.08 27.56 26.80 30.08 30.72 28.81 28.03 27.25 26.64 
P9 24.75 25.98 23.81 23.15 25.98 26.53 24.88 24.21 23.54 23.01 
P10 22.00 23.10 21.17 20.58 23.10 23.59 22.12 21.52 20.93 20.46 
P11 23.35 24.52 22.47 21.84 24.52 25.04 23.48 22.85 22.22 21.72 
P12 22.90 24.04 22.03 21.42 24.04 24.55 23.02 22.40 21.78 21.30 
 
Table E.2.6 Hydrogen bond energies (kJ/mol) of synthon III in P1-P12 aromatic acid co-crystals   



















P1 28.77 26.89 26.27 24.02 34.07 34.93 25.36 30.06 29.90 35.11 31.57 26.49 
P2 29.78 27.83 27.19 24.86 35.26 36.16 26.25 31.11 30.95 36.34 32.68 27.42 
P3 28.03 26.19 25.59 23.39 33.19 34.03 24.70 29.28 29.12 34.20 30.75 25.80 
P4 29.02 27.12 26.50 24.23 34.37 35.24 25.58 30.32 30.16 35.41 31.85 26.72 
p5 28.54 26.67 26.06 23.83 33.80 34.66 25.16 29.82 29.66 34.83 31.32 26.28 
P6 29.31 27.39 26.77 24.47 34.71 35.59 25.84 30.62 30.46 35.77 32.16 26.98 
P7 27.05 25.27 24.70 22.58 32.02 32.84 23.84 28.26 28.10 33.00 29.68 24.90 
P8 28.03 26.19 25.59 23.39 33.19 34.03 24.70 29.28 29.12 34.20 30.75 25.80 
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 26.61±0.67 31.34±0.94   
P9 24.21 22.62 22.10 20.21 28.66 29.39 21.34 25.29 25.15 29.54 26.56 22.29 
P10 21.52 20.11 19.65 17.97 25.48 26.13 18.97 22.49 22.36 26.26 23.62 19.81 
P11 22.85 21.35 20.86 19.07 27.05 27.74 20.14 23.87 23.74 27.88 25.07 21.03 
P12 22.40 20.93 20.45 18.70 26.52 27.20 19.74 23.40 23.28 27.33 24.58 20.62 
 20.94±1.03 24.96±1.23   
Table E.2.7 Hydrogen bond energies (kJ/mol) of synthon IV in P1-P12 aliphatic acid co-crystals   
     
Synthon IV 
    
 
 SUC ADI SUB SEB FUM MAL GLU PIM AZE DOD 
P9 27.49 27.04 26.45 25.71 28.86 29.48 27.64 26.89 26.15 25.57 
P10 25.47 25.05 24.50 23.82 26.74 27.31 25.61 24.92 24.23 23.69 
P11 29.59 29.11 28.47 27.68 31.06 31.73 29.75 28.95 28.15 27.52 
P12 26.47 26.04 25.47 24.76 27.79 28.38 26.62 25.90 25.18 24.62 
 



















P9 26.89 25.13 24.56 22.45 31.85 32.65 23.71 28.10 27.95 32.82 29.51 24.76 
P10 24.92 23.28 22.75 20.80 29.50 30.25 21.96 26.03 25.89 30.40 27.34 22.94 
P11 28.95 27.05 26.43 24.16 34.28 35.15 25.51 30.24 30.08 35.32 31.76 26.65 
P12 25.90 24.20 23.65 21.62 30.66 31.44 22.82 27.05 26.91 31.60 28.42 23.84 
 24.55±1.59 29.26±1.89  
 
Table E.2.9 Hydrogen bond energies (kJ/mol) of synthon V/VI/VIII/IX in P9-P12 aromatic acid 
co-crystals   
    
Synthon 
V/VIII 






















P1 18.26 20.38 11.70 13.29 15.91 P1 30.22 33.73 19.36 21.99 
P2 20.16 22.50 12.92 14.67 17.56 P2 31.28 34.91 20.04 22.76 
P3 18.68 20.84 11.97 13.59 16.27 P3 29.44 32.85 18.86 21.42 
P4 21.04 23.47 13.48 15.31 18.32 P4 30.48 34.02 19.53 22.18 
p5 18.89 21.08 12.10 13.74 16.45 p5 29.98 33.46 19.21 21.82 
P6 20.86 23.28 13.37 15.18 18.17 P6 30.79 34.36 19.73 22.41 
P7 18.06 20.15 11.57 13.14 15.73 P7 28.41 31.70 18.20 20.67 
P8 20.16 22.50 12.92 14.67 17.56 P8 29.44 32.85 18.86 21.42 
 17.00±1.03  26.14±0.79 
P9 16.06 17.93 10.29 11.69 13.99 P9 25.43 28.38 16.29 18.50 
P10 15.30 17.07 9.80 11.13 13.32 P10 22.61 25.23 14.49 16.45 
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P11 18.47 20.61 11.83 13.44 16.09 P11 24.00 26.78 15.38 17.46 
P12 16.85 18.80 10.79 12.26 14.68 P12 23.53 26.26 15.08 17.12 
 14.52±1.18  20.81±1.02 
 
  E.3 Chapter 5: Thiazoles heteromeric interactions  
Table E.3.1 Hydrogen bond energies (kJ/mol) of synthon F in T1-T12 aliphatic acid co-crystals   
Ligands---
Acid 
   
Synthon  F 
     
suc adi sub seb fum mal glut pim aze dod 
T1 -40.76 -33.66 -34.65 -41.60 -35.75 -34.60 -34.92 -34.98 -35.45 -44.17 
T2 -41.43 -34.25 -35.15 -42.10 -36.40 -35.35 -35.50 -35.44 -35.90 -44.57 
T3 -40.70 -33.63 -34.56 -41.43 -35.73 -34.65 -34.87 -34.86 -35.32 -43.92 
T4 -41.52 -34.34 -35.19 -42.09 -36.50 -35.51 -35.57 -35.45 -35.90 -44.50 
T5 -41.43 -34.25 -35.15 -42.10 -36.39 -35.34 -35.49 -35.44 -35.90 -44.57 
T6 -40.68 -33.61 -34.54 -41.41 -35.71 -34.63 -34.85 -34.85 -35.31 -43.90 
T7 -39.31 -32.50 -33.34 -39.92 -34.54 -33.55 -33.68 -33.61 -34.04 -42.25 
T8 -40.47 -33.48 -34.26 -40.94 -35.59 -34.68 -34.66 -34.50 -34.93 -43.23 
T9 -37.73 -31.12 -32.14 -38.67 -33.05 -31.88 -32.33 -32.49 -32.95 -41.18 
T10 -39.06 -32.24 -33.22 -39.91 -34.25 -33.12 -33.46 -33.55 -34.01 -42.41 
T11 -38.51 -31.77 -32.81 -39.50 -33.73 -32.52 -33.00 -33.18 -33.65 -42.07 
T12 -40.21 -33.20 -34.19 -41.06 -35.26 -34.11 -34.45 -34.53 -34.99 -43.62     
average -36.47 1.08 
   
 
 
Table E.3.2 Hydrogen bond energies (kJ/mol) of synthon H in T1-T12 aliphatic acid co-crystals   
Ligands-
--Acid 
   
synthon H 
       
suc adi sub seb fum mal glut pim aze dod 
 
T1 -28.02 -23.50 -23.04 -26.56 -25.13 -25.61 -23.96 -22.70 -22.82 -26.80 -24.81 
T2 -29.68 -24.90 -24.90 -28.14 -26.62 -27.13 -25.39 -24.05 -24.17 -28.39 -26.34 
T3 -26.40 -22.15 -21.71 -25.03 -23.68 -24.13 -22.58 -21.39 -21.50 -25.26 -23.38 
T4 -28.02 -23.50 -23.04 -26.56 -25.13 -25.61 -23.96 -22.70 -22.82 -26.80 -24.81 
T5 -29.66 -24.88 -24.40 -28.12 -26.61 -27.11 -25.37 -24.04 -24.16 -28.37 -26.27 
T6 -26.41 -22.15 -21.72 -25.03 -23.69 -24.13 -22.59 -21.40 -21.50 -25.26 -23.39 
T7 -26.40 -22.15 -21.71 -25.03 -23.68 -24.13 -22.58 -21.39 -21.50 -25.26 -23.38 
T8 -27.47 -23.05 -22.60 -26.04 -24.64 -25.11 -23.50 -22.26 -22.37 -26.28 -24.33 
T9 -20.65 -17.32 -16.99 -19.58 -18.53 -18.87 -17.66 -16.73 -16.82 -19.76 -18.29 
T10 -22.57 -18.93 -18.56 -21.40 -20.25 -20.63 -19.30 -18.29 -18.38 -21.59 -19.99 
T11 -23.06 -19.34 -18.97 -21.86 -20.69 -21.08 -19.72 -18.69 -18.78 -22.06 -20.42 
T12 -24.04 -20.17 -19.77 -22.79 -21.57 -21.97 -20.56 -19.48 -19.58 -23.00 -21.29     
AVERAGE -23.06 2.547277 
   
  
 
Table E.3.3 Hydrogen bond energies (kJ/mol) of synthon I in T9-T12 aliphatic acid co-crystals   
Ligands---
Acid  
    
Synthon I  
      
suc adi sub seb fum mal glut pim aze dod 
 
T9 -32.53 -26.46 -28.51 -35.46 -27.92 -25.60 -27.92 -29.42 -30.03 -39.22 -30.31 
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T10 -35.33 -28.73 -30.97 -38.52 -30.32 -27.80 -30.32 -31.95 -32.61 -42.59 -32.91 
T11 -35.70 -29.04 -31.29 -38.92 -30.64 -28.10 -30.64 -32.29 -32.96 -43.04 -33.26 
T12 -35.70 -29.04 -31.29 -38.92 -30.64 -28.10 -30.64 -32.29 -32.96 -43.04 -33.26           
average  -32.44 
 




   
Synthon F 



















T1 -32.99 -34.90 -34.39 -36.43 -32.90 -31.44 -32.76 -33.33 -33.24 -33.13 
T2 -33.61 -35.30 -34.77 -36.56 -33.86 -32.53 -33.15 -34.01 -33.92 -34.16 
T3 -32.98 -34.75 -34.23 -36.11 -33.08 -31.71 -32.63 -33.35 -33.26 -33.35 
T4 -33.71 -35.28 -34.75 -36.39 -34.15 -32.89 -33.15 -34.15 -34.05 -34.47 
T5 -33.60 -35.30 -34.77 -36.56 -33.86 -32.53 -33.15 -34.01 -33.91 -34.15 
T6 -32.97 -34.73 -34.22 -36.09 -33.07 -31.70 -32.61 -33.34 -33.25 -33.34 
T7 -31.89 -33.47 -32.97 -34.63 -32.18 -30.93 -31.44 -32.28 -32.19 -32.46 
T8 -32.88 -34.31 -33.78 -35.26 -33.46 -32.30 -32.24 -33.34 -33.24 -33.80 
T9 -30.48 -32.47 -32.00 -34.15 -30.08 -28.59 -30.46 -30.74 -30.66 -30.24 
T10 -31.60 -33.49 -33.00 -35.02 -31.42 -29.99 -31.43 -31.91 -31.82 -31.63 
T11 -31.11 -33.16 -32.68 -34.90 -30.66 -29.12 -31.10 -31.36 -31.28 -30.82 
T12 -32.54 -34.45 -33.95 -36.00 -32.40 -30.94 -32.33 -32.86 -32.78 -32.62     
average -33.09 1.07 
    
 





   
synthon H 



















T1 -23.37 -22.05 -21.61 -19.91 -19.91 -27.14 -27.76 -20.92 -
24.18 
-27.89 
T2 -24.75 -23.36 -22.89 -21.09 -21.09 -28.75 -29.41 -22.16 -
25.62 
-29.54 
T3 -22.02 -20.78 -20.36 -18.76 -18.76 -25.57 -26.16 -19.71 -
22.79 
-26.28 
T4 -23.37 -22.05 -21.61 -19.91 -19.91 -27.14 -27.76 -20.92 -
24.18 
-27.89 
T5 -24.74 -23.34 -22.88 -21.08 -21.08 -28.73 -29.39 -22.14 -
25.60 
-29.53 
T6 -22.02 -20.78 -20.36 -18.77 -18.77 -25.57 -26.17 -19.71 -
22.79 
-26.28 
T7 -22.02 -20.78 -20.36 -18.76 -18.76 -25.57 -26.16 -19.71 -
22.79 
-26.28 
T8 -22.91 -21.62 -21.19 -19.52 -19.52 -26.61 -27.22 -20.51 -
23.71 
-27.35 





T10 -18.82 -17.76 -17.41 -16.04 -16.04 -21.86 -22.37 -16.85 -
19.48 
-22.47 
T11 -19.23 -18.15 -17.78 -16.39 -16.39 -22.33 -22.85 -17.22 -
19.90 
-22.95 
T12 -20.05 -18.92 -18.54 -17.09 -17.09 -23.28 -23.82 -17.95 -
20.75 
-23.93 




   
 
 




    
Synthon I  



















T9 -19.46 -18.36 -17.99 -16.58 -22.59 -23.12 -17.42 -20.24 -20.14 -23.22 
T10 -21.13 -19.94 -19.54 -18.01 -24.54 -25.11 -18.91 -21.98 -21.87 -25.22 
T11 -21.35 -20.15 -19.75 -18.20 -24.80 -25.37 -19.11 -22.21 -22.10 -25.49 




   
 
 
Table E.3.7 Hydrogen bond energies (kJ/mol) of synthon J, K and L in T1-T12 aromatic acid 
co-crystals   
 
Table E.3.8 Hydrogen bond energies (kJ/mol) of synthon M, N and L in T1-T12 aromatic acid 
co-crystals   
 
 Synthon J Synthon K Synthon L 
E 3HydroxyBA 4HydroxyBA 3HydroxyBA 4HydroxyBA 3HydroxyBA 4HydroxyBA 
T1 24.43 26.88 17.39 19.13 N/A N/A 
T2 25.88 28.48 18.83 20.72 N/A N/A 
T3 23.02 25.33 18.00 19.80 N/A N/A 
T4 24.43 26.88 19.46 21.42 N/A N/A 
T5 25.87 28.46 18.83 20.72 N/A N/A 
T6 23.03 25.34 18.01 19.82 N/A N/A 
T7 23.02 25.33 18.00 19.80 N/A N/A 
T8 23.96 26.36 19.46 21.42 Synthon L 
T9 18.01 19.82 15.05 16.56 20.34 22.38 
T10 19.68 21.66 16.38 18.02 22.10 24.31 
T11 20.11 22.13 15.25 16.78 22.33 24.57 
T12 20.97 23.07 17.00 18.70 22.33 24.57 
 Synthon M Synthon N Synthon O 
E 4AminoBA 3AminoBA 4AminoBA 3AminoBA 3HydroxyBA 4HydroxyBA 
T1 16.46 18.40 11.71 13.10 N/A N/A 
T2 17.43 19.50 12.68 14.18 N/A N/A 







T4 16.46 18.40 13.11 14.66 N/A N/A 
T5 17.42 19.48 12.68 14.18 N/A N/A 
T6 15.51 17.35 12.13 13.57 N/A N/A 
T7 15.51 17.34 12.12 13.56 N/A N/A 
T8 16.14 18.05 13.11 14.66 Synthon O 
T9 12.13 13.57 10.14 11.34 13.70 15.32 
T10 13.26 14.83 11.03 12.34 14.88 16.64 
T11 13.55 15.15 10.27 11.49 15.04 16.82 
T12 14.12 15.79 11.45 12.80 15.04 16.82 
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Appendix F: Descriptors  
Table F.1 Information for molecular descriptors.  



















c acid  198 15 10 6.50 2 13 3.27 167 37 2 24 1.28 Yes  
4-
Biphenylmethanol  184 14 12 13.00 1 13 3.13 169 20 2 23 1.25 Yes  
4-Phenylphenol  170 13 10 12.00 1 12 3.32 153 20 1 21 1.24 Yes  
Anthranilic acid  147 10 7 2.33 3 7 0.79 104 63 1 15 1.42 Yes  
Benzamide 121 9 7 3.50 2 7 0.65 108 43 1 14 1.18 Yes  
Benzocaine 165 12 11 3.00 3 9 1.39 146 52 3 19 1.21 Yes  
Carbamazepine 236 18 12 5.00 3 15 2.93 186 46 0 28 1.34 Yes  
Chlorpropamide 276 17 13 1.43 7 10 1.78 207 83 4 26 1.42 Yes  
Chlorzoxazone 169 11 4 1.75 4 7 1.72 114 38 0 15.5 1.65 Yes  
Felbinac 212 16 12 7.00 2 14 3.21 182 37 3 25 1.23 Yes  
Flufenamic acid 281 20 10 2.33 6 14 3.98 201 49 3 27 1.48 Yes  
Haloperidol 376 26 23 4.20 5 21 3.49 303 41 6 40 1.31 Yes  
Indoprofen 281 21 15 4.25 4 17 2.84 215 58 3 31 1.32 Yes  
Phenacetin 180 13 13 3.33 3 10 1.56 163 38 3 20 1.23 Yes  
Theophylline 180 13 8 1.17 6 7 -0.06 123 69 0 17 1.49 Yes  
Tolbutamide 270 18 18 2.00 6 12 2.13 228 84 5 28 1.25 Yes  
Lidocaine  234 17 22 4.67 3 14 2.41 228 32 5 29 1.09 Yes  
Tolfenamic acid  262 18 12 3.50 4 14 4.1 196 49 3 29 1.33 Yes  
Celecoxib 381 26 14 1.89 9 17 4.34 266 86 3 36 1.52 No  
Clofoctol 365 24 26 7.00 3 21 8.19 324 20 5 41 1.22 No  
Dibucaine 343 25 29 4.00 5 20 3.77 320 55 10 41 1.15 No  
Droperidol 379 28 22 3.67 6 22 3.77 299 53 6 41 1.31 No  
Flurbiprofen 244 18 13 5.00 3 15 3.94 204 37 3 26 1.29 No  
Nifedipine 346 25 18 2.13 8 17 2.31 272 110 5 35 1.38 No  
Salicin 286 20 18 1.86 7 13 -0.77 190 120 4 28 1.41 No  
Tolazamide 311 21 21 2.00 7 14 1.41 241 87 3 32 1.34 No  
Aceclofenac 354 23 13 2.29 7 16 3.65 243 76 7 35 1.51 No  
Felodipine 384 25 19 2.57 7 18 2.24 301 65 6 38 2.24 No  
Ibuprofen 206 15 18 6.50 2 13 3.75 200 37 4 24 1.18 No  
Indomethacin 358 25 16 3.17 6 19 3.58 270 69 4 37 1.41 No  
Nimesulide 308 21 12 1.63 8 13 3.08 212 110 4 30 1.48 No  
Ketoprofen 254 19 14 5.33 3 16 3.31 212 54 4 28 1.28 No  
Pimozide 461 34 29 4.67 6 28 5.34 377 36 7 51 1.23 No  
Probucol 517 35 48 7.75 4 31 11.62 481 91 8 63 1.05 No  
Procaine 236 17 20 3.25 4 13 1.32 219 56 7 27 1.17 No  
Ritonavir  720 50 46 2.85 13 37 5.98 582 202 18 79 1.25 No  
 
 
Table F.2 Information for conformational descriptors. 
ID conformers  crystallizability 
4-Biphenylcarboxylic acid  3 Yes  
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4-Biphenylmethanol  2 Yes  
4-Phenylphenol  2 Yes  
Anthranilic acid  2 Yes  
Benzamide 1 Yes  
Benzocaine 19 Yes  
Carbamazepine 4 Yes  
Chlorpropamide 1872 Yes  
Chlorzoxazone 0 Yes  
Felbinac 24 Yes  
Flufenamic acid 95 Yes  
Haloperidol 2000 Yes  
Indoprofen 48 Yes  
Phenacetin 40 Yes  
Theophylline 0 Yes  
Tolbutamide 2000 Yes  
Lidocaine  2000 Yes  
Tolfenamic acid  46 Yes  
Tolazamide 2000 No  
Flurbiprofen 38 No  
Clofoctol 384 No  
Celecoxib 72 No  
Dibucaine 2000 No  
Droperidol 2000 No  
Nifedipine 223 No  
Salicin 258 No  
Aceclofenac 2000 No  
Felodipine 546 No  
Ibuprofen 46 No  
Indomethacin 384 No  
Nimesulide 71 No  
Ketoprofen 153 No  
Pimozide 2000 No  
Probucol 174 No  
Procaine 2000 No  
Ritonavir  2000 No  
 
Table F.3 Information for thermodynamic descriptors.  
ID Tm Tg TmTg Enthalpy  entropy  crystallizability 
4-Biphenylcarboxylic acid  227 69 158 32.26 0.06 Yes  
4-Biphenylmethanol  99 -22 121 25.06 0.07 Yes  
4-Phenylphenol  166 21 145 31.5 0.07 Yes  
Anthranilic acid  147 5 142 22.86 0.05 Yes  
Benzamide 127 -10 137 21.69 0.05 Yes  
Benzocaine 89 -31 120 22.55 0.06 Yes  
Carbamazepine 192 61 131 25.54 0.06 Yes  
Chlorpropamide 124 16 108 27.44 0.07 Yes  
Chlorzoxazone 191 38 153 25.62 0.06 Yes  
Felbinac 164 24 140 29.76 0.07 Yes  
Flufenamic acid 135 17 118 27.13 0.07 Yes  
Haloperidol 152 33 119 54.26 0.13 Yes  
Indoprofen 212 50 162 36.04 0.07 Yes  
Phenacetin 136 2 134 31.49 0.08 Yes  
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Theophylline 272 94 178 29.61 0.05 Yes  
Tolbutamide 129 4 125 26.24 0.07 Yes  
Lidocaine  68 -39 107 16.7 0.05 Yes  
Tolfenamic acid  213 63 150 38.83 0.08 Yes  
Celecoxib 163 58 105 37.42 0.09 No  
Clofoctol 88 -4 92 35.15 0.10 No  
Dibucaine 68 -39 107 29.23 0.09 No  
Droperidol 143 29 114 29.23 0.09 No  
Flurbiprofen 115 -6 121 27.41 0.07 No  
Nifedipine 173 45 128 38.19 0.09 No  
Salicin 201 58 143 52.76 0.11 No  
Tolazamide 172 18 154 43.44 0.10 No  
Aceclofenac 153 10 143 42.25 0.10 No  
Felodipine 147 45 102 30.98 0.07 No  
Ibuprofen 77 -45 122 26.48 0.08 No  
Indomethacin 162 45 117 37.56 0.09 No  
Nimesulide 150 21 129 33.38 0.08 No  
Ketoprofen 95 -3 98 28.31 0.08 No  
Pimozide 219 54 165 42.74 0.09 No  
Probucol 127 27 100 34.22 0.09 No  
Procaine 62 -39 101 26.2 0.08 No  
Ritonavir  126 49 77 65.34 0.16 No  
 
Table F.4 Information for intermolecular descriptors.  
ID Donor  Acceptor  Ratio Propensity crystallizability 
4-Biphenylcarboxylic acid  1 1 1 0.38 Yes  
4-Biphenylmethanol  1 1 1.00 0.16 Yes  
4-Phenylphenol  1 1 1.00 0.16 Yes  
Anthranilic acid  2 3 0.67 0.57 Yes  
Benzamide 1 1 1.00 0.7 Yes  
Benzocaine 1 3 0.33 0.65 Yes  
Carbamazepine 1 1 1.00 0.788 Yes  
Chlorpropamide 2 3 0.67 0.677 Yes  
Chlorzoxazone 1 2 0.50 0.722 Yes  
Felbinac 1 2 0.50 0.375 Yes  
Flufenamic acid 2 6 0.33 0.399 Yes  
Haloperidol 1 4 0.25 0.39 Yes  
Indoprofen 1 3 0.33 0.3 Yes  
Phenacetin 1 2 0.50 0.65 Yes  
Theophylline 1 3 0.33 0.38 Yes  
Tolbutamide 2 3 0.67 0.71 Yes  
Lidocaine  1 2 0.50 0.36 Yes  
Tolfenamic acid  2 3 0.67 0.91 Yes  
Celecoxib 1 7 0.14 0.7 No  
Clofoctol 1 1 1.00 0.09 No  
Dibucaine 1 4 0.25 0.3 No  
Droperidol 1 4 0.25 0.26 No  
Flurbiprofen 1 3 0.33 0.32 No  
Nifedipine 1 7 0.14 0.26 No  
Salicin 5 7 0.71 0.59 No  
Tolazamide 2 4 0.50 0.7 No  
Aceclofenac 2 5 0.40 0.57 No  
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Felodipine 1 5 0.20 0.32 No  
Ibuprofen 1 2 0.50 0.37 No  
Indomethacin 1 4 0.25 0.36 No  
Nimesulide 1 6 0.17 0.68 No  
Ketoprofen 1 3 0.33 0.19 No  
Pimozide 1 4 0.25 0.27 No  
Probucol 2 4 0.50 0.02 No  
Procaine 1 4 0.25 0.59 No  
Ritonavir  4 9 0.44 0.4 No  
 
Table F.5 Information for intermolecular descriptors.  




S axis (Å) S/L axis ratio crystallizability 
4-Biphenylcarboxylic acid 122.8 37.3 4.608666667 0.337666667 Yes 
4-Biphenylmethanol 86.97 20.23 4.9148 0.3732 Yes 
4-Phenylphenol 86.56 20.23 4.227333333 0.342666667 Yes 
Anthranilic acid 94 75.63 4.74425 0.54275 Yes 
Benzamide 81.22 43.09 3.4 0.359 Yes 
Benzocaine 66.17 63.32 4.818666667 0.386 Yes 
Carbamazepine 162 52.32 7.252 0.631 Yes 
Chlorpropamide 179.9 48.02 6.1579 0.4188 Yes 
Chlorzoxazone 93 86.36 5.4946 0.39255 Yes 
Felbinac 130 83.65 5.4945 0.39255 Yes 
Flufenamic acid 139 46 6.67225 0.521 Yes 
Haloperidol 194 20.23 6.49175 0.38165 Yes 
Indoprofen 198 54.46 6.56155 0.42705 Yes 
Phenacetin 115 58.1 5.02925 0.38155 Yes 
Theophylline 193 37.3 4.161 0.424 Yes 
Tolbutamide 182 64.63 6.62595 0.4787 Yes 
Lidocaine 144 49.33 6.4858 0.4933 Yes 
Tolfenamic acid 150 37.3 6.88925 0.5488 Yes 
Celecoxib 212 40.54 6.532222222 0.405111111 No 
Clofoctol 171 37.3 7.95265 0.524 No 
Dibucaine 217 68.53 7.6447 0.45505 No 
Droperidol 229 57.61 6.74135 0.3273 No 
Flurbiprofen 133 54.37 6.33635 0.46205 No 
Nifedipine 176 32.34 9.05515 0.7494 No 
Salicin 208 110.45 6.8581 0.5697 No 
Tolazamide 203 109.6 6.89295 0.4738 No 
Aceclofenac 200 38.33 7.9244 0.58995 No 
Felodipine 166 41.03 9.2632 0.7568 No 
Ibuprofen 94 55.56 6.48265 0.52055 No 
Indomethacin 219 119.61 6.77875 0.4188 No 
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Nimesulide 191 72.68 6.6523 0.5263 No 
Ketoprofen 149 86.89 6.7587 0.5162 No 
Pimozide 252 83.65 8.6274 0.44765 No 
Probucol 245 49.33 4.193 0.231 No 
Procaine 113 91.06 6.6091 0.4563 No 
Ritonavir 349 202.26 4.381 0.246 No 
 
 
Table F.6 Information for intermolecular descriptors for bergstrom study 










Bucetin 223 158 149 58.56 -3 58 5 4 5.6122 0.3522 Yes 
Bufexamac 223 167 161 58.56 2 59 6 4 6.13385 0.38085 Yes 
Diflunisal 250 213 169 57.53 43 57 2 5 5.57575 0.4335 Yes 
Fenbufen 254 186 162 54.37 28 54 5 3 5.6306 0.353 Yes 
Flumequine 261 258 167 59.3 78 58 1 5 5.9036667 0.534 Yes 
Mefenamic acid 241 231 152 49.33 51 49 3 3 7.04445 0.5566 Yes 
Naproxen 230 153 137 46.53 -3 46 3 3 6.3718 0.4626 Yes 
Pindolol 248 169 145 57.28 14 57 6 4 6.4751 0.45105 Yes 
Primidone 218 283 195 58.2 72 58 2 4 5.849 0.513 Yes 
Saccharin 183 226 159 71.62 20 72 0 5 3.751 0.389 Yes 
Spiperone 395 207 238 52.65 106 53 6 6 7.24255 0.40845 Yes 
Sulfamethoxazole 253 169 172 106.6 16 107 3 7 5.222 0.359 Yes 
Trimethoprim 290 197 189 105.51 51 106 5 7 6.6568 0.4368 Yes 
Tyramine 137 161 60 46.25 -37 46 2 2 5.057 0.4815 Yes 
Zoxazolamine 168 183 93.8 52.05 11 52 0 4 3.5 0.319 Yes 
Acetohexamide 324 190 211 100.72 26 101 4 7 6.5139 0.432 No 
Bezafibrate 361 184 230 75.63 73 76 7 6 6.7565 0.32955 No 
Testosterone 288 153 144 37.3 42 37 0 2 4.381 0.295 No 
Glafenine 372 164 229 91.68 63 92 7 7 6.2761 0.4086 No 
Hydrochlorothiazide 297 263 202 135.12 110 135 1 10 4.955 0.451 No 
Hydrocortisone 362 211 214.5 94.83 86 95 2 5 7.60525 0.51875 No 
Warfarin 308 162 197 67.51 68 64 4 4 7.7584 0.58205 No 
Table F.7 Information for intermolecular descriptors for Kohrenon study 
 
ID MW Tm Tm 
from 
source 




Tg SA RB heteroatom crystallizability 
Nabumetone 228 81 107.84 26.3 5.8124 0.3766 51 26 4 2 Yes  
Salcylamide 137 140 118 63.32 4.742 0.50075 123 63 1 3 Yes  
Salicyclic acid 138 159 93 57.53 4.74925 0.54325 107 58 1 3 Yes  
Thiosalycyclic acid  154 164 85.72 76.1 4.979333 0.567333 146 76 1 3 Yes  
Sulfanilamide 172 164 124 94.56 3.6 0.315 128 95 1 5 Yes  
Pyrazinecarboxamide 123 189 106.77 68.87 3.464 0.373 178 69 1 4 Yes  
Sulfamerazine 264 237 184.38 106.35 5.712667 0.381667 174 106 3 7 Yes  
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Acetylsalicylic acid 180 136 93 63.6 5.6951 0.56335 
-
26.92 64 3 4 Yes  
Sulfadimidine 278 197 189 106.35 6.61255 0.4355 78.12 106 3 7 No  
Perphenazine 404 94 223 59.88 7.3087 0.45585 15.31 55 6 6 No  
Cimetidine 252 139 194 114.19 6.69895 0.52875 46.52 114 8 7 No  
Pyridoxine 169 157 124 73.58 5.220167 0.54 66.26 74 2 4 No  
 
 
Table F.8 Information for intermolecular descriptors for Taylor remaining dataset study 
ID MW Tm Tm using 
software 










Antipyrin 188 111 119 -22 5.83975 0.489 26.93 3 24 1 yes 
Caffeine 194 237 180 -31 4.164 0.429 61.82 6 58 0 yes 
4-Biphenyl 
carboxaldehyde 
182 59 73 -50 4.382667 0.333667 17.07 1 17 2 Yes 
Griseofulvin 353 218 189 89 9.553 0.688333 71.06 7 71 3 yes 
Nilutamide 317 155 202 33 6.924875 0.522 95.23 10 95 3 No 
Bifonazole 310 151 197 17 7.45185 0.49655 17.82 2 18 4 No 
Felodipine 384 147 166 45 8.4902 0.6496 64.63 7 65 6 No 
Cinnarizine 368 121 198 7 7.7209 0.4385 6.48 2 6 6 No 
Loratadine 382 136 201 37 7.46815 0.45445 42.43 5 42 2 No 
Clotrimazole 345 145 206.55 30 3.5 0.283 17.82 3 18 4 No 
Itraconazole 705 168 349.84 58 7.9829 0.27455 104.7 14 101 11 No 
Ketoconazole 531 150 291.82 45 7.81685 0.33825 69.06 10 69 7 No 






Appendix-G: HBP and HBE results of co-crystal screens 
 G.1 Chapter 3-Pyrazole with 20 carboxylic acids  
Table G.3.1 The multicomponent energy (MCE) score of P1-P12 with 20 co-formers.  
Co-crystal  
MCE 
Score  Co-crystal 
MCE 
Score  Co-crystal 
MCE 
Score  Co-crystal 
MCE 
Score  
P1-Suc 2.17 P2-Suc 3.82 P3-Suc 2.56 P4-Suc 3.94 
P1-Adipic 1.75 P2-Adipic 3.38 P3-Adipic 2.15 P4-Suc 3.52 
P1-Seb 1.20 P2-Seb 2.81 P3-Seb 1.61 P4-Adipic 2.97 
P1-Sub 0.52 P2-Sub 2.10 P3-Sub 0.95 P4-Seb 2.28 
P1-Dod 0.38 P2-Dod 1.96 P3-Dod 0.81 P4-Sub 2.14 
P1-Fum 3.43 P2-Fum 5.12 P3-Fum 3.79 P4-Dod 5.22 
P1-Mal 4.00 P2-Mal 5.71 P3-Mal 4.34 P4-Fum 5.79 
P1-Glut 2.31 P2-Glut 3.96 P3-Glut 2.69 P4-Mal 4.08 
P1-Pim 1.62 P4-Pim 3.24 P3-Pim 2.02 P4-Glut 3.38 
P1-Aze 0.93 P2-Aze 2.53 P3-Aze 1.34 P4-Pim 2.69 
P1-3OHBA 2.88 P2-3OHBA 0.00 P3-3OHBA 3.24 P4-Aze 4.65 
P1-4OHBA 5.83 P2-4OHBA 7.60 P3-4OHBA 6.12 P4-3OHBA 7.63 
P1-3AminoBA -0.53 P2-3AminoBA 1.02 P3-3AminoBA -0.07 P4-4OHBA 1.22 
P1-4AminoBA -2.57 P2-4AminoBA -1.10 P3-4AminoBA -2.06 P4-3AminoBA -0.84 
P1-3NitroBA 6.13 P2-3NitroBA 7.92 P3-3NitroBA 6.41 P4-4AminoBA 6.41 
P1-4NitroBA 6.89 P2-4NitroBA 8.70 P3-4NitroBA 7.15 P4-3NitroBA 8.70 
P1-BA -1.36 P2-BA 0.16 P3-BA -0.88 P4-4NitroBA 0.38 
P1-4-IodoBA 2.57 P2-4-IodoBA 4.23 P3-4-IodoBA 2.95 P4-BA 4.35 
P1-4-bromoBA 2.73 P2-4-bromoBA 4.39 P3-4-bromoBA 3.10 P4-4-IodoBA 4.50 
P1-PentaBA 7.04 P2-PentaBA 8.86 P3-PentaBA 7.30 P4-4-bromoBA 8.85 
        
P5-Suc 2.43 P6-Suc 3.94 P7-Suc 3.94 P8-Suc 2.04 
P5-Adipic 2.02 P6-Adipic 3.52 P7-Adipic 3.52 P8-Adipic 1.65 
P5-Seb 1.48 P6-Seb 2.97 P7-Seb 2.97 P8-Seb 1.13 
P5-Sub 0.80 P6-Sub 2.28 P7-Sub 2.28 P8-Sub 0.48 
P5-Dod 0.67 P6-Dod 2.14 P7-Dod 2.14 P8-Dod 0.36 
P5-Fum 3.67 P6-Fum 5.22 P7-Fum 5.22 P8-Fum 3.22 
P5-Mal 4.23 P6-Mal 5.79 P7-Mal 5.79 P8-Mal 3.75 
P5-Glut 2.56 P6-Glut 4.08 P7-Glut 4.08 P8-Glut 2.17 
P5-Pim 1.88 P6-Pim 3.38 P7-Pim 3.38 P8-Pim 1.52 
P5-Aze 1.21 P6-Aze 2.69 P7-Aze 2.69 P8-Aze 0.87 
P5-3OHBA 3.12 P6-3OHBA 4.65 P7-3OHBA 2.70 P8-3OHBA 4.27 
P5-4OHBA 6.02 P6-4OHBA 7.63 P7-4OHBA 5.47 P8-4OHBA 7.15 
P5-3AminoBA -0.22 P6-3AminoBA 1.22 P7-3AminoBA -0.50 P8-3AminoBA 0.96 
P5-4AminoBA -2.23 P6-4AminoBA -0.84 P7-4AminoBA -2.41 P8-4AminoBA -1.03 
P5-3NitroBA 6.32 P6-3NitroBA 7.94 P7-3NitroBA 5.75 P8-3NitroBA 7.44 
P5-4NitroBA 7.06 P6-4NitroBA 8.70 P7-4NitroBA 6.46 P8-4NitroBA 8.18 
P5-BA -1.04 P6-BA 0.38 P7-BA -1.28 P8-BA 0.15 
P5-4-IodoBA 2.82 P6-4-IodoBA 4.35 P7-4-IodoBA 2.41 P8-4-IodoBA 3.98 
P5-4-bromoBA 2.97 P6-4-bromoBA 4.50 P7-4-bromoBA 2.56 P8-4-bromoBA 4.13 
P5-PentaBA 7.21 P6-PentaBA 8.85 P7-PentaBA 6.60 P8-PentaBA 8.33 
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P9-Suc 3.59 P10-Suc 2.46 P11-Suc 3.92 P12-Suc 2.28 
P9-Adipic 3.18 P10-Adipic 2.10 P11-Adipic 3.53 P12-Adipic 1.94 
P9-Seb 2.64 P10-Seb 1.62 P11-Seb 3.02 P12-Seb 1.50 
P9-Sub 1.98 P10-Sub 1.03 P11-Sub 2.38 P12-Sub 0.96 
P9-Dod 1.84 P10-Dod 0.92 P11-Dod 2.25 P12-Dod 0.85 
P9-Fum 4.82 P10-Fum 3.55 P11-Fum 5.09 P12-Fum 3.28 
P9-Mal 5.37 P10-Mal 4.04 P11-Mal 5.62 P12-Mal 3.74 
P9-Glut 3.72 P10-Glut 2.58 P11-Glut 4.05 P12-Glut 2.39 
P9-Pim 3.05 P10-Pim 1.98 P11-Pim 3.40 P12-Pim 1.83 
P9-Aze 2.38 P10-Aze 1.39 P11-Aze 2.76 P12-Aze 1.28 
P9-3OHBA 3.07 P10-3OHBA 4.58 P11-3OHBA 2.84 P12-3OHBA 3.64 
P9-4OHBA 5.62 P10-4OHBA 7.32 P11-4OHBA 5.19 P12-4OHBA 6.09 
P9-3AminoBA 0.13 P10-3AminoBA 1.41 P11-3AminoBA 0.12 P12-3AminoBA 0.82 
P9-4AminoBA -1.63 P10-4AminoBA -0.49 P11-4AminoBA -1.51 P12-4AminoBA -0.88 
P9-3NitroBA 5.88 P10-3NitroBA 7.60 P11-3NitroBA 5.44 P12-3NitroBA 6.34 
P9-4NitroBA 6.53 P10-4NitroBA 8.31 P11-4NitroBA 6.04 P12-4NitroBA 6.97 
P9-BA -0.59 P10-BA 0.63 P11-BA -0.54 P12-BA 0.13 
P9-4-IodoBA 2.81 P10-4-IodoBA 4.29 P11-4-IodoBA 2.60 P12-4-IodoBA 3.39 
P9-4-bromoBA 2.94 P10-4-bromoBA 4.44 P11-4-bromoBA 2.72 P12-4-bromoBA 3.52 
P9-PentaBA 6.66 P10-PentaBA 8.45 P11-PentaBA 6.16 P12-PentaBA 7.10 
 
Table G.3.2 The multicomponent propensity (MCP) score of P1-P12 with 20 co-formers.  
Co-crystal  
MCP 
Score  Co-crystal 
MCP 
Score  Co-crystal 
MCP 
Score  Co-crystal 
MCP 
Score  
P1-Suc -0.09 P2-Suc -0.10 P3-Suc -0.15 P4-Suc -0.15 
P1-Adipic -0.09 P2-Adipic -0.10 P3-Adipic -0.18 P4-Suc -0.18 
P1-Seb -0.09 P2-Seb -0.10 P3-Seb -0.17 P4-Adipic -0.17 
P1-Sub -0.09 P2-Sub -0.09 P3-Sub -0.19 P4-Seb -0.18 
P1-Dod -0.08 P2-Dod -0.09 P3-Dod -0.18 P4-Sub -0.18 
P1-Fum -0.11 P2-Fum -0.09 P3-Fum -0.05 P4-Dod -0.05 
P1-Mal -0.08 P2-Mal -0.10 P3-Mal -0.12 P4-Fum -0.12 
P1-Glut -0.09 P2-Glut -0.10 P3-Glut -0.16 P4-Mal -0.17 
P1-Pim -0.09 P4-Pim -0.09 P3-Pim -0.17 P4-Glut -0.17 
P1-Aze -0.09 P2-Aze 2.97 P3-Aze -0.18 P4-Pim -0.18 
P1-3OHBA -0.19 P2-3OHBA -0.17 P3-3OHBA -0.19 P4-Aze -0.16 
P1-4OHBA -0.20 P2-4OHBA -0.17 P3-4OHBA -0.17 P4-3OHBA -0.17 
P1-3AminoBA 0.02 P2-3AminoBA 0.04 P3-3AminoBA -0.10 P4-4OHBA 0.03 
P1-4AminoBA 0.02 P2-4AminoBA 0.05 P3-4AminoBA -0.02 P4-3AminoBA 0.04 
P1-3NitroBA -0.16 P2-3NitroBA -0.17 P3-3NitroBA -0.09 P4-4AminoBA -0.10 
P1-4NitroBA -0.11 P2-4NitroBA -0.13 P3-4NitroBA 0.05 P4-3NitroBA -0.03 
P1-BA -0.14 P2-BA -0.13 P3-BA -0.07 P4-4NitroBA -0.10 
P1-4-IodoBA -0.14 P2-4-IodoBA -0.14 P3-4-IodoBA -0.10 P4-BA -0.15 
P1-4-bromoBA -0.11 P2-4-bromoBA -0.11 P3-4-bromoBA -0.16 P4-4-IodoBA -0.11 
P1-PentaBA -0.11 P2-PentaBA -0.10 P3-PentaBA -0.04 P4-4-bromoBA -0.05 
        
P5-Suc -0.11 P6-Suc -0.12 P7-Suc 0.05 P8-Suc 0.05 
P5-Adipic -0.13 P6-Adipic -0.14 P7-Adipic 0.04 P8-Adipic 0.06 
P5-Seb -0.14 P6-Seb -0.14 P7-Seb 0.04 P8-Seb 0.07 
P5-Sub -0.14 P6-Sub -0.14 P7-Sub 0.05 P8-Sub 0.06 
P5-Dod -0.15 P6-Dod -0.15 P7-Dod 0.07 P8-Dod 0.06 
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P5-Fum -0.04 P6-Fum -0.03 P7-Fum 0.00 P8-Fum 0.06 
P5-Mal -0.09 P6-Mal -0.08 P7-Mal 0.04 P8-Mal 0.06 
P5-Glut -0.13 P6-Glut -0.13 P7-Glut 0.05 P8-Glut 0.07 
P5-Pim -0.14 P6-Pim -0.14 P7-Pim 0.04 P8-Pim 0.07 
P5-Aze -0.14 P6-Aze -0.15 P7-Aze 0.06 P8-Aze 0.07 
P5-3OHBA -0.09 P6-3OHBA -0.09 P7-3OHBA -0.20 P8-3OHBA -0.16 
P5-4OHBA -0.08 P6-4OHBA -0.07 P7-4OHBA -0.19 P8-4OHBA -0.15 
P5-3AminoBA 0.02 P6-3AminoBA 0.02 P7-3AminoBA 0.05 P8-3AminoBA 0.09 
P5-4AminoBA 0.03 P6-4AminoBA -0.01 P7-4AminoBA 0.07 P8-4AminoBA 0.10 
P5-3NitroBA 0 P6-3NitroBA 0 P7-3NitroBA -0.09 P8-3NitroBA -0.06 
P5-4NitroBA 0.01 P6-4NitroBA 0.01 P7-4NitroBA 0.05 P8-4NitroBA 0.08 
P5-BA -0.11 P6-BA -0.12 P7-BA -0.07 P8-BA -0.04 
P5-4-IodoBA -0.09 P6-4-IodoBA -0.1 P7-4-IodoBA -0.08 P8-4-IodoBA -0.02 
P5-4-bromoBA -0.07 P6-4-bromoBA -0.06 P7-4-bromoBA -0.03 P8-4-bromoBA 0.01 
P5-PentaBA -0.05 P6-PentaBA -0.06 P7-PentaBA -0.05 P8-PentaBA -0.01 
        
P9-Suc -0.10 P10-Suc -0.08 P11-Suc -0.09 P12-Suc -0.08 
P9-Adipic -0.10 P10-Adipic -0.08 P11-Adipic -0.10 P12-Adipic -0.08 
P9-Seb -0.10 P10-Seb -0.08 P11-Seb -0.09 P12-Seb -0.08 
P9-Sub -0.09 P10-Sub -0.08 P11-Sub -0.09 P12-Sub -0.07 
P9-Dod -0.10 P10-Dod -0.07 P11-Dod -0.09 P12-Dod -0.07 
P9-Fum -0.16 P10-Fum -0.14 P11-Fum -0.16 P12-Fum -0.13 
P9-Mal -0.09 P10-Mal -0.07 P11-Mal -0.09 P12-Mal -0.07 
P9-Glut -0.10 P10-Glut -0.09 P11-Glut -0.10 P12-Glut -0.08 
P9-Pim -0.10 P10-Pim -0.08 P11-Pim -0.10 P12-Pim -0.08 
P9-Aze -0.10 P10-Aze -0.08 P11-Aze -0.09 P12-Aze -0.07 
P9-3OHBA -0.17 P10-3OHBA -0.15 P11-3OHBA -0.16 P12-3OHBA -0.14 
P9-4OHBA -0.17 P10-4OHBA -0.15 P11-4OHBA -0.16 P12-4OHBA -0.14 
P9-3AminoBA 0.03 P10-3AminoBA 0.05 P11-3AminoBA 0.03 P12-3AminoBA 0.05 
P9-4AminoBA 0.04 P10-4AminoBA 0.06 P11-4AminoBA 0.03 P12-4AminoBA 0.06 
P9-3NitroBA -0.19 P10-3NitroBA -0.17 P11-3NitroBA -0.16 P12-3NitroBA -0.16 
P9-4NitroBA -0.19 P10-4NitroBA -0.16 P11-4NitroBA -0.16 P12-4NitroBA -0.14 
P9-BA -0.22 P10-BA -0.19 P11-BA -0.20 P12-BA -0.19 
P9-4-IodoBA -0.19 P10-4-IodoBA -0.17 P11-4-IodoBA -0.18 P12-4-IodoBA -0.16 
P9-4-bromoBA -0.19 P10-4-bromoBA -0.08 P11-4-bromoBA -0.09 P12-4-bromoBA -0.08 
P9-PentaBA -0.18 P10-PentaBA -0.08 P11-PentaBA -0.10 P12-PentaBA -0.08 
 
Table G.3.3 Comparison of MCE score for P1-P12 with 20 co-formers with the actual outcome 
of the experimental co-crystal screening (check mark means co-crystal formation and a cross 
means no co-crystal formation). The green box shows true positive, yellow box shows true 
negatives, the red box shows false positives and blue box shows true negatives. 
 
 MCE Exp. Matc
h? 
 MCE Exp. Matc
h? 
 MCE Exp. Match? 
P1-Suc 2.17  No P2-Suc 3.82 ✓ yes P3-Suc 2.56 ✓ yes 
P1-Adipic 1.75  No P2-Adipic 3.38 ✓ yes P3-Adipic 2.15 ✓ yes 
P1-Seb 1.20  No P2-Seb 2.81 ✓ yes P3-Seb 1.61 ✓ yes 
P1-Sub 0.52  No P2-Sub 2.10 ✓ yes P3-Sub 0.95 ✓ yes 
P1-Dod 0.38  No P2-Dod 1.96 ✓ yes P3-Dod 0.81 ✓ yes 
P1-Fum 3.43  No P2-Fum 5.12 ✓ yes P3-Fum 3.79 ✓ yes 
P1-Mal 4.00  No P2-Mal 5.71 ✓ yes P3-Mal 4.34 ✓ yes 
P1-Glut 2.31  No P2-Glut 3.96 ✓ yes P3-Glut 2.69 ✓ yes 
P1-Pim 1.62  No P4-Pim 3.24 ✓ yes P3-Pim 2.02 ✓ yes 
P1-Aze 0.93  No P2-Aze 2.53 ✓ yes P3-Aze 1.34 ✓ yes 
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P1-3OHBA 2.88 ✓ yes P2-3OHBA 0.00  yes P3-3OHBA 3.24  no 
P1-4OHBA 5.83 ✓ yes P2-4OHBA 7.60 ✓ yes P3-4OHBA 6.12  no 
P1-3AminoBA -0.53 ✓ no P2-3AminoBA 1.02 ✓ yes P3-3AminoBA -0.07 ✓ no 
P1-4AminoBA -2.57 ✓ no P2-4AminoBA -1.10 ✓ no P3-4AminoBA -2.06 ✓ no 
P1-3NitroBA 6.13 ✓ yes P2-3NitroBA 7.92 ✓ yes P3-3NitroBA 6.41 ✓ yes 
P1-4NitroBA 6.89  no P2-4NitroBA 8.70 ✓ yes P3-4NitroBA 7.15 ✓ yes 
P1-BA -1.36  yes P2-BA 0.16 ✓ yes P3-BA -0.88 ✓ no 
P1-4-IodoBA 2.57  no P2-4-IodoBA 4.23  no P3-4-IodoBA 2.95  no 
P1-4-bromoBA 2.73  no P2-4-bromoBA 4.39  no P3-4-bromoBA 3.10  no 
P1-PentaBA 7.04 ✓ yes P2-PentaBA 8.86 ✓ yes P3-PentaBA 7.30 ✓ yes 
 MCE Exp. Matc
h? 
 MCE Exp. Matc
h? 
 MCE Exp. Match? 
P4-Suc 3.94 ✓ yes P5-Suc 2.43  No P6-Suc 3.94  no 
P4-Adipic 3.52 ✓ yes P5-Adipic 2.02 ✓ No P6-Adipic 3.52  no 
P4-Seb 2.97 ✓ yes P5-Seb 1.48 ✓ yes P6-Seb 2.97 ✓ yes 
P4-Sub 2.28 ✓ yes P5-Sub 0.80  No P6-Sub 2.28 ✓ yes 
P4-Dod 2.14 ✓ yes P5-Dod 0.67  no P6-Dod 2.14  no 
P4-Fum 5.22 ✓ yes P5-Fum 3.67 ✓ yes P6-Fum 5.22  no 
P4-Mal 5.79 ✓ yes P5-Mal 4.23 ✓ yes P6-Mal 5.79 ✓ yes 
P4-Glut 4.08 ✓ yes P5-Glut 2.56 ✓ yes P6-Glut 4.08 ✓ yes 
P4-Pim 3.38 ✓ yes P5-Pim 1.88 ✓ yes P6-Pim 3.38  no 
P4-Aze 2.69 ✓ yes P5-Aze 1.21 ✓ yes P6-Aze 2.69  no 
P4-3OHBA 4.65 ✓ yes P5-3OHBA 3.12 ✓ yes P6-3OHBA 4.65  no 
P4-4OHBA 7.63 ✓ yes P5-4OHBA 6.02  no P6-4OHBA 7.63  no 
P4-3AminoBA 1.22 ✓ yes P5-3AminoBA -0.22 ✓ no P6-3AminoBA 1.22 ✓ yes 
P4-4AminoBA -0.84 ✓ no P5-4AminoBA -2.23  yes P6-4AminoBA -0.84  yes 
P4-3NitroBA 6.41 ✓ yes P5-3NitroBA 6.32 ✓ yes P6-3NitroBA 7.94 ✓ yes 
P4-4NitroBA 8.70  no P5-4NitroBA 7.06  no P6-4NitroBA 8.70  no 
P4-BA 0.38 ✓ yes P5-BA -1.04 ✓ no P6-BA 0.38 ✓ yes 
P4-4-IodoBA 4.35  no P5-4-IodoBA 2.82  no P6-4-IodoBA 4.35  no 
P4-4-bromoBA 4.50  no P5-4-bromoBA 2.97  no P6-4-bromoBA 4.50  no 
P4-PentaBA 8.85 ✓ yes P5-PentaBA 7.21 ✓ yes P6-PentaBA 8.85 ✓ yes 
 MCE Exp. Matc
h? 
 MCE Exp. Matc
h? 
 MCE Exp. Match? 
P7-Suc 3.94 ✓ yes P8-Suc 2.04 ✓ yes P9-Suc 3.59 ✓ yes 
P7-Adipic 3.52 ✓ yes P8-Adipic 1.65  no P9-Adipic 3.18 ✓ yes 
P7-Seb 2.97 ✓ yes P8-Seb 1.13 ✓ yes P9-Seb 2.64 ✓ yes 
P7-Sub 2.28 ✓ yes P8-Sub 0.48 ✓ yes P9-Sub 1.98 ✓ yes 
P7-Dod 2.14  no P8-Dod 0.36 ✓ yes P9-Dod 1.84 ✓ yes 
P7-Fum 5.22 ✓ yes P8-Fum 3.22 ✓ yes P9-Fum 4.82 ✓ yes 
P7-Mal 5.79 ✓ yes P8-Mal 3.75 ✓ yes P9-Mal 5.37 ✓ yes 
P7-Glut 4.08 ✓ yes P8-Glut 2.17 ✓ yes P9-Glut 3.72 ✓ yes 
P7-Pim 3.38 ✓ yes P8-Pim 1.52  no P9-Pim 3.05 ✓ yes 
P7-Aze 2.69 ✓ yes P8-Aze 0.87 ✓ yes P9-Aze 2.38 ✓ yes 
P7-3OHBA 2.70  no P8-3OHBA 4.27  no P9-3OHBA 3.07 ✓ yes 
P7-4OHBA 5.47  no P8-4OHBA 7.15 ✓ yes P9-4OHBA 5.62 ✓ Yes 
P7-3AminoBA -0.50 ✓ no P8-3AminoBA 0.96 ✓ yes P9-3AminoBA 0.13 ✓ yes 
P7-4AminoBA -2.41  yes P8-4AminoBA -1.03  yes P9-4AminoBA -1.63  yes 
P7-3NitroBA 5.75 ✓ yes P8-3NitroBA 7.44 ✓ yes P9-3NitroBA 5.88 ✓ yes 
P7-4NitroBA 6.46  no P8-4NitroBA 8.18 ✓ yes P9-4NitroBA 6.53  no 
P7-BA -1.28 ✓ no P8-BA 0.15 ✓ yes P9-BA -0.59 ✓ no 
P7-4-IodoBA 2.41  no P8-4-IodoBA 3.98  no P9-4-IodoBA 2.81  no 
P7-4-bromoBA 2.56  no P8-4-bromoBA 4.13  no P9-4-bromoBA 2.94 ✓ yes 
P7-PentaBA 6.60 ✓ yes P8-PentaBA 8.33 ✓ yes P9-PentaBA 6.66 ✓ yes 
 MCE Exp. Matc
h? 
 MCE Exp. Matc
h? 
 MCE Exp. Match? 
P10-Suc 2.46 ✓ yes P11-Suc 3.92 ✓  P12-Suc 2.28 ✓ yes 
P10-Adipic 2.10 ✓ yes P11-Adipic 3.53 ✓  P12-Adipic 1.94 ✓ yes 
P10-Seb 1.62 ✓ yes P11-Seb 3.02 ✓  P12-Seb 1.50 ✓ yes 
P10-Sub 1.03 ✓ yes P11-Sub 2.38 ✓  P12-Sub 0.96 ✓ yes 
P10-Dod 0.92 ✓ yes P11-Dod 2.25 ✓  P12-Dod 0.85 ✓ yes 
P10-Fum 3.55 ✓ yes P11-Fum 5.09 ✓  P12-Fum 3.28 ✓ yes 
P10-Mal 4.04 ✓ yes P11-Mal 5.62 ✓  P12-Mal 3.74 ✓ yes 
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P10-Glut 2.58 ✓ yes P11-Glut 4.05 ✓  P12-Glut 2.39 ✓ yes 
P10-Pim 1.98 ✓ yes P11-Pim 3.40 ✓  P12-Pim 1.83 ✓ yes 
P10-Aze 1.39 ✓ yes P11-Aze 2.76 ✓  P12-Aze 1.28 ✓ yes 
P10-3OHBA 4.58 ✓ yes P11-3OHBA 2.84   P12-3OHBA 3.64 ✓ yes 
P10-4OHBA 7.32 ✓ yes P11-4OHBA 5.19   P12-4OHBA 6.09  no 
P10-3AminoBA 1.41 ✓ yes P11-3AminoBA 0.12   P12-3AminoBA 0.82  no 
P10-4AminoBA -0.49 ✓ no P11-4AminoBA -1.51   P12-4AminoBA -0.88  yes 
P10-3NitroBA 7.60 ✓ yes P11-3NitroBA 5.44 ✓  P12-3NitroBA 6.34 ✓ yes 
P10-4NitroBA 8.31 ✓ yes P11-4NitroBA 6.04 ✓  P12-4NitroBA 6.97  no 
P10-BA 0.63 ✓ yes P11-BA -0.54   P12-BA 0.13 ✓ yes 
P10-4-IodoBA 4.29  no P11-4-IodoBA 2.60 ✓  P12-4-IodoBA 3.39 ✓ yes 
P10-4-bromoBA 4.44  no P11-4-bromoBA 2.72 ✓  P12-4-bromoBA 3.52 ✓ yes 
P10-PentaBA 8.45 ✓ yes P11-PentaBA 6.16 ✓  P12-PentaBA 7.10 ✓ yes 
            
 
 
Table G.3.4 Comparison of MCP score for P1-P12 with 20 co-formers with the actual outcome 
of the experimental co-crystal screening (check mark means co-crystal formation and a cross 
means no co-crystal formation). The green box shows true positive, yellow box shows true 

















P1-Suc -0.09   P2-Suc -0.10 ✓  P3-Suc -0.15 ✓  
P1-Adipic -0.09   P2-Adipic -0.10 ✓  P3-Adipic -0.18 ✓  
P1-Seb -0.09   P2-Seb -0.10 ✓  P3-Seb -0.17 ✓  
P1-Sub -0.09   P2-Sub -0.09 ✓  P3-Sub -0.19 ✓  
P1-Dod -0.08   P2-Dod -0.09 ✓  P3-Dod -0.18 ✓  
P1-Fum -0.11   P2-Fum -0.09 ✓  P3-Fum -0.05 ✓  
P1-Mal -0.08   P2-Mal -0.10 ✓  P3-Mal -0.12 ✓  
P1-Glut -0.09   P2-Glut -0.10 ✓  P3-Glut -0.16 ✓  
P1-Pim -0.09   P4-Pim -0.09 ✓  P3-Pim -0.17 ✓  
P1-Aze -0.09   P2-Aze 2.97 ✓  P3-Aze -0.18 ✓  
P1-3OHBA -0.19 ✓  P2-3OHBA -0.17   P3-3OHBA -0.19   
P1-4OHBA -0.20 ✓  P2-4OHBA -0.17 ✓  P3-4OHBA -0.17   
P1-3AminoBA 0.02 ✓  P2-3AminoBA 0.04 ✓  P3-3AminoBA -0.10 ✓  
P1-4AminoBA 0.02 ✓  P2-4AminoBA 0.05 ✓  P3-4AminoBA -0.02 ✓  
P1-3NitroBA -0.16 ✓  P2-3NitroBA -0.17 ✓  P3-3NitroBA -0.09 ✓  
P1-4NitroBA -0.11   P2-4NitroBA -0.13 ✓  P3-4NitroBA 0.05 ✓  
P1-BA -0.14   P2-BA -0.13 ✓  P3-BA -0.07 ✓  
P1-4-IodoBA -0.14   P2-4-IodoBA -0.14   P3-4-IodoBA -0.10   
P1-4-
bromoBA -0.11 






















P4-Suc -0.15 ✓  P5-Suc -0.11    P6-Suc -0.12    
P4-Adipic -0.18 ✓  P5-Adipic -0.13 ✓   P6-Adipic -0.14    
P4-Seb -0.17 ✓  P5-Seb -0.14 ✓   P6-Seb -0.14 ✓   
P4-Sub -0.18 ✓  P5-Sub -0.14    P6-Sub -0.14 ✓   
P4-Dod -0.18 ✓  P5-Dod -0.15    P6-Dod -0.15    
P4-Fum -0.05 ✓  P5-Fum -0.04 ✓   P6-Fum -0.03    
P4-Mal -0.12 ✓  P5-Mal -0.09 ✓   P6-Mal -0.08 ✓   
P4-Glut -0.17 ✓  P5-Glut -0.13 ✓   P6-Glut -0.13 ✓   
P4-Pim -0.17 ✓  P5-Pim -0.14 ✓   P6-Pim -0.14    
P4-Aze -0.18 ✓  P5-Aze -0.14 ✓   P6-Aze -0.15    
P4-3OHBA -0.16 ✓  P5-3OHBA -0.09 ✓   P6-3OHBA -0.09    
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P4-4OHBA -0.17 ✓  P5-4OHBA -0.08    P6-4OHBA -0.07    
P4-3AminoBA 0.03 ✓  P5-3AminoBA 0.02 ✓   P6-3AminoBA 0.02 ✓   
P4-4AminoBA 0.04 ✓  P5-4AminoBA 0.03    P6-4AminoBA -0.01    
P4-3NitroBA -0.10 ✓  P5-3NitroBA 0 ✓   P6-3NitroBA 0 ✓   
P4-4NitroBA -0.03   P5-4NitroBA 0.01    P6-4NitroBA 0.01    
P4-BA -0.10 ✓  P5-BA -0.11 ✓   P6-BA -0.12 ✓   
P4-4-IodoBA -0.15   P5-4-IodoBA -0.09    P6-4-IodoBA -0.1    
P4-4-
bromoBA -0.11 
  P5-4-bromoBA 
-0.07 
   
P6-4-
bromoBA 
-0.06    
















P7-Suc 0.05 ✓  P8-Suc 0.05 ✓  P9-Suc -0.10 ✓  
P7-Adipic 0.04 ✓  P8-Adipic 0.06   P9-Adipic -0.10 ✓  
P7-Seb 0.04 ✓  P8-Seb 0.07 ✓  P9-Seb -0.10 ✓  
P7-Sub 0.05 ✓  P8-Sub 0.06 ✓  P9-Sub -0.09 ✓  
P7-Dod 0.07   P8-Dod 0.06 ✓  P9-Dod -0.10 ✓  
P7-Fum 0.00 ✓  P8-Fum 0.06 ✓  P9-Fum -0.16 ✓  
P7-Mal 0.04 ✓  P8-Mal 0.06 ✓  P9-Mal -0.09 ✓  
P7-Glut 0.05 ✓  P8-Glut 0.07 ✓  P9-Glut -0.10 ✓  
P7-Pim 0.04 ✓  P8-Pim 0.07   P9-Pim -0.10 ✓  
P7-Aze 0.06 ✓  P8-Aze 0.07 ✓  P9-Aze -0.10 ✓  
P7-3OHBA -0.20   P8-3OHBA -0.16   P9-3OHBA -0.17 ✓  
P7-4OHBA -0.19   P8-4OHBA -0.15 ✓  P9-4OHBA -0.17 ✓  
P7-3AminoBA 0.05 ✓  P8-3AminoBA 0.09 ✓  P9-3AminoBA 0.03 ✓  
P7-4AminoBA 0.07   P8-4AminoBA 0.10   P9-4AminoBA 0.04   
P7-3NitroBA -0.09 ✓  P8-3NitroBA -0.06 ✓  P9-3NitroBA -0.19 ✓  
P7-4NitroBA 0.05   P8-4NitroBA 0.08 ✓  P9-4NitroBA -0.19   
P7-BA -0.07 ✓  P8-BA -0.04 ✓  P9-BA -0.22 ✓  
P7-4-IodoBA -0.08   P8-4-IodoBA -0.02   P9-4-IodoBA -0.19   
P7-4-
bromoBA -0.03 





-0.19 ✓  
















P10-Suc -0.08 ✓  P11-Suc -0.09 ✓  P12-Suc -0.08 ✓  
P10-Adipic -0.08 ✓  P11-Adipic -0.10 ✓  P12-Adipic -0.08 ✓  
P10-Seb -0.08 ✓  P11-Seb -0.09 ✓  P12-Seb -0.08 ✓  
P10-Sub -0.08 ✓  P11-Sub -0.09 ✓  P12-Sub -0.07 ✓  
P10-Dod -0.07 ✓  P11-Dod -0.09 ✓  P12-Dod -0.07 ✓  
P10-Fum -0.14 ✓  P11-Fum -0.16 ✓  P12-Fum -0.13 ✓  
P10-Mal -0.07 ✓  P11-Mal -0.09 ✓  P12-Mal -0.07 ✓  
P10-Glut -0.09 ✓  P11-Glut -0.10 ✓  P12-Glut -0.08 ✓  
P10-Pim -0.08 ✓  P11-Pim -0.10 ✓  P12-Pim -0.08 ✓  
P10-Aze -0.08 ✓  P11-Aze -0.09 ✓  P12-Aze -0.07 ✓  
P10-3OHBA -0.15 ✓  P11-3OHBA -0.16   P12-3OHBA -0.14 ✓  
P10-4OHBA -0.15 ✓  P11-4OHBA -0.16   P12-4OHBA -0.14   
P10-
3AminoBA 0.05 





0.05   
P10-
4AminoBA 0.06 





0.06   
P10-3NitroBA -0.17 ✓  P11-3NitroBA -0.16 ✓  P12-3NitroBA -0.16 ✓  
P10-4NitroBA -0.16 ✓  P11-4NitroBA -0.16 ✓  P12-4NitroBA -0.14   
P10-BA -0.19 ✓  P11-BA -0.20   P12-BA -0.19 ✓  









-0.16 ✓  
P10-PentaBA -0.17 ✓  P11-PentaBA -0.18 ✓  P12-PentaBA -0.16 ✓  
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Table G.5.1 MC score of T1-T12 against 20 carboxylic acids (HBP for T1-T8 were determined 
manually whereas HBP for T9-T12 were determined using new automated HBP tool, HBP tool is 
very sensitive to the method and number of data used and therefore, MC score could change as the 
CCDC updates in the future)  
Reactants  
MC 
Score  Reactants 
MC 
Score  Reactants 
MC 
Score  Reactants 
MC 
Score  
T1-Suc -0.06 T4-Suc 0 T3-Suc -0.03 T10-Suc 0.01 
T1-Adipic -0.05 T4-Adipic 0 T3-Adipic -0.03 T4-Suc 0 
T1-Seb -0.04 T4-Seb 0 T3-Seb -0.02 T4-Adipic 0 
T1-Sub -0.05 T4-Sub -0.01 T3-Sub -0.03 T4-Seb 0 
T1-Dod -0.04 T4-Dod 0 T3-Dod -0.03 T4-Sub -0.01 
T1-Fum -0.05 T4-Fum -0.01 T3-Fum -0.03 T4-Dod 0 
T1-Mal -0.03 T4-Mal 0.01 T3-Mal 0 T4-Fum -0.01 
T1-Glut -0.05 T4-Glut -0.01 T3-Glut -0.03 T4-Mal 0.01 
T1-Pim -0.05 T4-Pim -0.01 T3-Pim -0.02 T4-Glut -0.01 
T1-Aze -0.05 T4-Aze 0 T3-Aze -0.03 T4-Pim -0.01 
T1-3OHBA -0.12 T4-3OHBA -0.04 T3-3OHBA -0.05 T4-Aze 0 
T1-4OHBA -0.11 T4-4OHBA -0.04 T3-4OHBA -0.07 T4-3OHBA -0.04 
T1-3AminoBA 0.08 T4-3AminoBA 0.15 T3-3AminoBA 0.11 T4-4OHBA -0.04 
T1-4AminoBA 0.07 T4-4AminoBA 0.15 T3-4AminoBA 0.13 T4-3AminoBA 0.15 
T1-3NitroBA -0.14 T4-3NitroBA -0.04 T3-3NitroBA -0.05 T4-4AminoBA 0.15 
T1-4NitroBA -0.11 T4-4NitroBA -0.02 T3-4NitroBA -0.05 T4-3NitroBA -0.04 
T1-BA -0.14 T4-BA -0.05 T3-BA -0.07 T4-4NitroBA -0.02 
T1-4-IodoBA -0.13 T4-4-IodoBA -0.05 T3-4-IodoBA -0.06 T4-BA -0.05 
T1-4-bromoBA -0.12 T4-4-bromoBA -0.03 T3-4-bromoBA -0.03 T4-4-IodoBA -0.05 
T1-PentaBA -0.1 T4-PentaBA -0.02 T3-PentaBA -0.04 T4-4-bromoBA -0.03 
        
T5-Suc 0.01 T6-Suc 0.01 T7-Suc 0.06 T8-Suc 0.02 
T5-Adipic -0.01 T6-Adipic 0.01 T7-Adipic 0.06 T8-Adipic 0.01 
T5-Seb 0 T6-Seb 0.01 T7-Seb 0.04 T8-Seb -0.01 
T5-Sub 0 T6-Sub 0.02 T7-Sub 0.05 T8-Sub 0.01 
T5-Dod 0.01 T6-Dod 0.02 T7-Dod 0.02 T8-Dod -0.01 
T5-Fum -0.02 T6-Fum 0 T7-Fum 0.05 T8-Fum 0.07 
T5-Mal 0.01 T6-Mal 0.01 T7-Mal 0.05 T8-Mal 0.03 
T5-Glut -0.01 T6-Glut 0 T7-Glut 0.05 T8-Glut 0.03 
T5-Pim 0 T6-Pim 0.01 T7-Pim 0.06 T8-Pim 0.02 
T5-Aze 0 T6-Aze 0.01 T7-Aze 0.05 T8-Aze 0.02 
T5-3OHBA -0.06 T6-3OHBA -0.03 T7-3OHBA 0.01 T8-3OHBA 0.05 
T5-4OHBA -0.06 T6-4OHBA -0.03 T7-4OHBA 0.02 T8-4OHBA 0.06 
T5-3AminoBA 0.14 T6-3AminoBA 0.26 T7-3AminoBA 0.22 T8-3AminoBA 0.24 
T5-4AminoBA 0.15 T6-4AminoBA 0.17 T7-4AminoBA 0.24 T8-4AminoBA 0.25 
T5-3NitroBA -0.02 T6-3NitroBA 0 T7-3NitroBA 0.01 T8-3NitroBA 0.05 
T5-4NitroBA -0.02 T6-4NitroBA 0 T7-4NitroBA 0.01 T8-4NitroBA 0.05 
T5-BA -0.06 T6-BA -0.03 T7-BA 0.03 T8-BA 0.01 
T5-4-IodoBA -0.06 T6-4-IodoBA -0.04 T7-4-IodoBA 0.07 T8-4-IodoBA 0.09 
T5-4-bromoBA -0.02 T6-4-bromoBA -0.02 T7-4-bromoBA 0.09 T8-4-bromoBA 0.1 
T5-PentaBA -0.02 T6-PentaBA 0.01 T7-PentaBA 0.07 T8-PentaBA 0.1 
        
T9-Suc 0.04 T10-Suc 0.01 T11-Suc 0.01 T12-Suc 0.04 
T9-Adipic 0 T10-Adipic 0.05 T11-Adipic 0.04 T12-Adipic 0.05 
T9-Seb 0.01 T10-Seb 0.05 T11-Seb 0.05 T12-Seb 0.02 
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T9-Sub 0.05 T10-Sub 0.05 T11-Sub 0.05 T12-Sub 0.05 
T9-Dod 0.05 T10-Dod 0.06 T11-Dod 0.05 T12-Dod 0.02 
T9-Fum 0.04 T10-Fum -0.01 T11-Fum -0.04 T12-Fum -0.01 
T9-Mal -0.04 T10-Mal 0.05 T11-Mal 0.01 T12-Mal 0.05 
T9-Glut 0.04 T10-Glut 0.04 T11-Glut 0 T12-Glut 0.01 
T9-Pim 0 T10-Pim 0.05 T11-Pim 0.04 T12-Pim 0.02 
T9-Aze 0.05 T10-Aze 0.01 T11-Aze 0.05 T12-Aze 0.05 
T9-3OHBA -0.06 T10-3OHBA -0.05 T11-3OHBA -0.05 T12-3OHBA -0.04 
T9-4OHBA -0.03 T10-4OHBA -0.02 T11-4OHBA -0.05 T12-4OHBA -0.04 
T9-3AminoBA 0.13 T10-3AminoBA 0.15 T11-3AminoBA 0.12 T12-3AminoBA 0.14 
T9-4AminoBA 0.14 T10-4AminoBA 0.15 T11-4AminoBA 0.13 T12-4AminoBA 0.15 
T9-3NitroBA -0.07 T10-3NitroBA -0.04 T11-3NitroBA -0.03 T12-3NitroBA -0.03 
T9-4NitroBA -0.03 T10-4NitroBA -0.07 T11-4NitroBA -0.03 T12-4NitroBA -0.07 
T9-BA -0.06 T10-BA -0.05 T11-BA -0.07 T12-BA -0.04 
T9-4-IodoBA -0.05 T10-4-IodoBA -0.01 T11-4-IodoBA -0.02 T12-4-IodoBA -0.01 
T9-4-bromoBA -0.03 T10-4-bromoBA -0.02 T11-4-bromoBA -0.02 T12-4-bromoBA -0.02 
T9-PentaBA 0.01 T10-PentaBA 0.02 T11-PentaBA 0.01 T12-PentaBA 0.02 
 
Table G.5.2 Comparison of hydrogen-bond propensity MC score for T1-T8 with aliphatic and 
aromatic acid co-crystals with the actual outcome of the experimental co-crystal screening (check 
mark means co-crystal formation and a cross means no co-crystal formation). The green box shows 
true positive, the blue box shows true negatives, the red box shows false positives and yellow box 
shows false negatives.  
Group 1 
MC score  
MC 
Score  experimental match?  MC score  
MC 
Score  experimental  match ? 
T1-Suc -0.06 ✓   T4-Suc 0    
T1-Adipic -0.05    T4-Adipic 0    
T1-Seb -0.04    T4-Seb 0    
T1-Sub -0.05    T4-Sub -0.01    
T1-Dod -0.04    T4-Dod 0    
T1-Fum -0.05    T4-Fum -0.01    
T1-Mal -0.03    T4-Mal 0.01    
T1-Glut -0.05    T4-Glut -0.01    
T1-Pim -0.05    T4-Pim -0.01    
T1-Aze -0.05    T4-Aze 0    
T1-3OHBA -0.12 ✓   T4-3OHBA -0.04 ✓   
T1-4OHBA -0.11 ✓   T4-4OHBA -0.04    
T1-3AminoBA 0.08 ✓   T4-3AminoBA 0.15 ✓   
T1-4AminoBA 0.07 ✓   T4-4AminoBA 0.15    
T1-3NitroBA -0.14 ✓   T4-3NitroBA -0.04 ✓   
T1-4NitroBA -0.11 ✓   T4-4NitroBA -0.02    
T1-BA -0.14    T4-BA -0.05 ✓   
T1-4-IodoBA -0.13    T4-4-IodoBA -0.05    
T1-4-bromoBA -0.12    T4-4-bromoBA -0.03    
T1-PentaBA -0.1 ✓   T4-PentaBA -0.02 ✓   
        
T2-Suc -0.04    T7-Suc 0.06 ✓   
T2-Adipic -0.03    T7-Adipic 0.06 ✓   
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T2-Seb -0.03    T7-Seb 0.04 ✓   
T2-Sub -0.03    T7-Sub 0.05 ✓   
T2-Dod -0.03    T7-Dod 0.02 ✓   
T2-Fum -0.06 ✓   T7-Fum 0.05 ✓   
T2-Mal -0.01 ✓   T7-Mal 0.05 ✓   
T2-Glut -0.03    T7-Glut 0.05 ✓   
T2-Pim -0.03    T7-Pim 0.06 ✓   





  T7-3OHBA 0.01 ✓   
T2-4OHBA -0.08 ✓   T7-4OHBA 0.02 ✓   
T2-3AminoBA 0.08 ✓   T7-3AminoBA 0.22 ✓   
T2-4AminoBA 0.12 ✓   T7-4AminoBA 0.24 ✓   
T2-3NitroBA -0.12 ✓   T7-3NitroBA 0.01 ✓   
T2-4NitroBA -0.02    T7-4NitroBA 0.01 ✓   
T2-BA -0.18    T7-BA 0.03 ✓   
T2-4-IodoBA -0.11    T7-4-IodoBA 0.07 ✓   
T2-4-bromoBA -0.11    T7-4-bromoBA 0.09 ✓   
T2-PentaBA -0.09 ✓   T7-PentaBA 0.07 ✓   
        
T3-Suc -0.03    T8-Suc 0.02 ✓   
T3-Adipic -0.03    T8-Adipic 0.01 ✓   
T3-Seb -0.02    T8-Seb -0.01 ✓   
T3-Sub -0.03    T8-Sub 0.01 ✓   
T3-Dod -0.03    T8-Dod -0.01 ✓   
T3-Fum -0.03    T8-Fum 0.07 ✓   
T3-Mal 0    T8-Mal 0.03 ✓   
T3-Glut -0.03    T8-Glut 0.03 ✓   
T3-Pim -0.02    T8-Pim 0.02 ✓   
T3-Aze -0.03    T8-Aze 0.02 ✓   
T3-3OHBA -0.05 ✓   T8-3OHBA 0.05 ✓   
T3-4OHBA -0.07    T8-4OHBA 0.06 ✓   
T3-3AminoBA 0.11 ✓   T8-3AminoBA 0.24 ✓   
T3-4AminoBA 0.13    T8-4AminoBA 0.25 ✓   
T3-3NitroBA -0.05 ✓   T8-3NitroBA 0.05 ✓   
T3-4NitroBA -0.05    T8-4NitroBA 0.05 ✓   
T3-BA -0.07    T8-BA 0.01 ✓   
T3-4-IodoBA -0.06    T8-4-IodoBA 0.09    
T3-4-bromoBA -0.03    T8-4-bromoBA 0.1    
T3-PentaBA -0.04 ✓   T8-PentaBA 0.1 ✓   
        
T5-Suc 0.01   T6-Suc 0.01   
T5-Adipic -0.01   T6-Adipic 0.01 ✓  
T5-Seb 0   T6-Seb 0.01 ✓  
T5-Sub 0   T6-Sub 0.02   
T5-Dod 0.01   T6-Dod 0.02   
T5-Fum -0.02   T6-Fum 0 ✓  
T5-Mal 0.01 ✓  T6-Mal 0.01 ✓  
T5-Glut -0.01   T6-Glut 0 ✓  
T5-Pim 0   T6-Pim 0.01   
T5-Aze 0   T6-Aze 0.01   
T5-3OHBA -0.06 ✓  T6-3OHBA -0.03 ✓  
T5-4OHBA -0.06   T6-4OHBA -0.03 ✓  
T5-3AminoBA 0.14 ✓  T6-3AminoBA 0.26 ✓  
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T5-4AminoBA 0.15 ✓  T6-4AminoBA 0.17   
T5-3NitroBA -0.02 ✓  T6-3NitroBA 0 ✓  
T5-4NitroBA -0.02   T6-4NitroBA 0   
T5-BA -0.06   T6-BA -0.03 ✓  
T5-4-IodoBA -0.06   T6-4-IodoBA -0.04   
T5-4-bromoBA -0.02   T6-4-bromoBA -0.02   
T5-PentaBA -0.02 ✓  T6-PentaBA 0.01 ✓  
 
Table G.5.3 Comparison of hydrogen-bond propensity MC score for T9-T12 with aliphatic and 
aromatic acid co-crystals with the actual outcome of the experimental co-crystal screening (check 
mark means co-crystal formation and a cross means no co-crystal formation). The green box shows 
true positive, the blue box shows true negatives, the red box shows false positives and yellow box 
shows false negatives. 
Group 2  
MC score 
MC 
Score experimental match? MC score 
MC 
Score experimental match ? 
T9-Suc 0.04 ✓  T10-Suc 0.01 ✓   
T9-Adipic 0 ✓  T10-Adipic 0.05 ✓   
T9-Seb 0.01 ✓  T10-Seb 0.05 ✓   
T9-Sub 0.05 ✓  T10-Sub 0.05 ✓   
T9-Dod 0.05 ✓  T10-Dod 0.06 ✓   
T9-Fum 0.04 ✓  T10-Fum -0.01 ✓   
T9-Mal -0.04 ✓  T10-Mal 0.05 ✓   
T9-Glut 0.04 ✓  T10-Glut 0.04 ✓   
T9-Pim 0 ✓  T10-Pim 0.05 ✓   
T9-Aze 0.05 ✓  T10-Aze 0.01 ✓   
T9-3OHBA -0.06 ✓  T10-3OHBA -0.05 ✓   
T9-4OHBA -0.03 ✓  T10-4OHBA -0.02 ✓   
T9-3AminoBA 0.13 ✓  T10-3AminoBA 0.15 ✓   
T9-4AminoBA 0.14 ✓  T10-4AminoBA 0.15 ✓   
T9-3NitroBA -0.07 ✓  T10-3NitroBA -0.04 ✓   
T9-4NitroBA -0.03 ✓  T10-4NitroBA -0.07 ✓   
T9-BA -0.06 ✓  T10-BA -0.05 ✓   
T9-4-IodoBA -0.05   T10-4-IodoBA -0.01    
T9-4-bromoBA -0.03 ✓  T10-4-bromoBA -0.02    
T9-PentaBA 0.01 ✓  T10-PentaBA 0.02 ✓   
        
T1-Suc 0.01 ✓  T12-Suc 0.04 ✓   
T12-Adipic 0.04 ✓  T12-Adipic 0.05 ✓   
T12-Seb 0.05 ✓  T12-Seb 0.02 ✓   
T12-Sub 0.05 ✓  T12-Sub 0.05 ✓   
T12-Dod 0.05 ✓  T12-Dod 0.02 ✓   
T12-Fum -0.04 ✓  T12-Fum -0.01 ✓   
T12-Mal 0.01 ✓  T12-Mal 0.05 ✓   
T12-Glut 0 ✓  T12-Glut 0.01 ✓   
T12-Pim 0.04 ✓  T12-Pim 0.02 ✓   
T12-Aze 0.05 ✓  T12-Aze 0.05 ✓   
T12-3OHBA -0.05 ✓  T12-3OHBA -0.04 ✓   
T12-4OHBA -0.05 ✓  T12-4OHBA -0.04 ✓   
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T12-3AminoBA 0.12 ✓  T12-3AminoBA 0.14 ✓   
T12-4AminoBA 0.13 ✓  T12-4AminoBA 0.15 ✓   
T12-3NitroBA -0.03 ✓  T12-3NitroBA -0.03 ✓   
T12-4NitroBA -0.03 ✓  T12-4NitroBA -0.07 ✓   
T12-BA -0.07 ✓  T12-BA -0.04 ✓   
T12-4-IodoBA -0.02   T12-4-IodoBA -0.01    
T12-4-bromoBA -0.02   T12-4-bromoBA -0.02    







                                                 
